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General introduction
In this thesis, the harms and benefits of lung cancer screening using low-dose computed 
tomography were investigated. Data of the Dutch-Belgian NELSON trial were used to 
quantify its harms and benefits and develop strategies to improve the balance between 
them. If the NELSON trial demonstrates that low-dose CT screening is an effective 
method to reduce mortality from lung cancer, balance between harms and benefits is 
a perquisite for the implementation of a lung cancer screening program. Background 
information on relevant aspects of epidemiology, medical ethics, pulmonary medicine, 
radiology, and pathology are essential for the interpretation of the studies in this thesis. 
In this chapter an overview of relevant background information is presented, as well as a 
description of the design of the NELSON trial.
AETIOLOGY
Lung cancer has been studied thoroughly in the past decades, which has given insight 
in its aetiology. The single most important cause of lung cancer is tobacco smoking.1-3 
Smokers have a 15-fold to 30-fold increased risk of developing lung cancer compared to 
non-smokers.4 Other causative factors of lung cancer are: second-hand tobacco smoke 
exposure,5,6 ionising radiation,7 indoor and outdoor air pollution,8 soot,9 radon,10-12 asbes-
tos,13,14 tar,15 arsenic,15 chromium15 and nickel.15 
Besides these causative factors, a number of risk indicators have been identified: older 
age,13,16 family history of lung cancer,16,17 acquired lung disease such as COPD,18-21 HIV 
infection22 and occupational exposures such as silica dust.13 Physical activity and fruit 
and vegetable intake have consistently shown to be associated with a decreased risk of 
lung cancer.3
EPIDEMIOLOGY
Since tobacco smoking is the predominant causative agent of lung cancer, lung cancer in-
cidence is strongly correlated with patterns of smoking prevalence.8,23,24 The characteristic 
long latency period of smoking-induced lung cancer, which is the period from the start 
of smoking to lung cancer diagnosis, causes a delay in lung cancer incidence of 20 to 30 
years.8 In the United States, Australia, New Zealand and many countries in North-West 
Europe, lung cancer incidence rapidly increased from the 1930’s onwards and peaked 
in the 1980’s,  and has been declining since.8,23 In contrast, in Southern and Eastern 
European countries, China, and Japan lung cancer incidence still increases or is stable.8 
Moreover, the lung cancer incidence is predicted to increase substantially throughout 
Asia and Africa in the future, due to the uptake of western smoking habits.8 Variations in 
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lung cancer incidence across countries or between males and females are largely reflected 
in the differences in the stage and degree of the tobacco epidemic.25
PUBLIC HEALTH
Currently, lung cancer is the second most common cancer; accounting for 14% of all 
cancer cases in the U.S. in both men and women.23 Moreover, lung cancer causes most 
cancer-related deaths; 28% of the cancer related deaths in men and 26% in women.23 
Lung cancer causes more deaths than prostate cancer, breast cancer, colon cancer and 
pancreatic cancer combined, which makes lung cancer a major public health problem.9,23
DISEASE CHARACTERISTICS
Lung cancer is such a major public health problem because of its high incidence and 
high case-fatality. The latter is partly caused by the fact that lung cancer often causes no 
symptoms at early stages of disease. As result, lung cancer is commonly diagnosed at 
stages wherein disease has advanced to regional (22%) or distant (56%) spread.23 Hence, 
only a minority is diagnosed with localised lung cancer, wherein surgical resection of 
the entire tumour is still feasible.10 In this group, the chance to be alive five years after 
diagnosis is 52%.23 Which is substantially higher than the five-year survival of regionally 
and distantly metastasised disease; respectively 25% and 4%.23 At these more advanced 
stages, surgical resection of the primary tumour is often not curative, and therapy is often 
only aimed at improving survival and quality of life.11,12
CLINICAL CARE
The advances in treatment of lung cancer have been substantial over the past decades and 
have improved survival of lung cancer patients. For example: several new chemotherapy 
regimens have been developed, some specifically directed at histological subtype,26 
and the increased use of chemotherapy as adjuvant therapy.27,28 More recently, targeted 
therapies at somatic mutations in receptors or signal proteins  have become available.26 
Further, advances in radiotherapy, such as stereotactic body radiotherapy, contributed 
to improved survival.29,30 The combination of chemotherapy and radiation therapy has 
evolved from sequential to concomitant, which further improved overall survival.31-33 
Pre-operative patient selection has improved as result of the use of validated comorbidity 
indices, multidisciplinary decision-making, and more accurate staging.34-36 Finally, bet-
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ter adoption to standard care treatment guidelines, and a greater proportion of patients 
receiving any treatment, contributed to the survival of lung cancer patients.37
Clearly, many improvements in the treatment of lung cancer have been made, but only 
modest improvement in the survival of lung cancer patients could be observed over the 
last decades.8 In the United States, the overall five-year relative survival of lung cancer 
patients has improved from 12% in 1975-1977 to 17% in 2002-2008.23 The overall five-
year survival of lung cancer patients in Canada improved from 15.7% in 1995-1999 to 
18.4% in 2005-2007.38 In Australia, an improvement from 13.9% in 1995-1999 to 17.0% 
in 2005-2007 was observed.38 The overall five-year survival in Europe improved from 9% 
to 11%, on average.39 In the United Kingdom, overall survival was substantially lower, 
7.0% in 1995-1999, as also the improvement in survival; 1.8% to 8.8% in 2005-2007.38 In 
North-West Europe, where high-quality registries with national coverage are available, 
similar small improvements in survival were observed; in the periods from 1995-1999 
and 2005-2009 respectively: from 8.0% to 10.9% in Denmark, 11.0% to 14.4% in Norway, 
12.7% to 16.3% in Sweden. In the Netherlands, the overall five-year survival increased 
from 14.8% in 1989-1993 to 17.4% in 2009.31 
PREVENTION
Improvements in the treatment of lung cancer are continued to be made, and will 
undoubtedly contribute to an improved survival of lung cancer patients in the future. 
However, the fact that lung cancer is mostly diagnosed at an incurable, advanced stage 
limits treatment options to improving survival and reducing morbidity. In contrary, pre-
vention may be able to reduce the burden of lung cancer in a different way. As presented 
in Box 1, three forms of prevention can be distinguished: primary, secondary and tertiary 
prevention.
Text box 1. Definitions prevention
Prevention and clinical care are the main methods in medicine to improve health. 
Prevention can be sub-classified in primary, secondary and tertiary prevention. 
•	 Primary prevention aims to prevent the occurrence of disease by elimination or 
reduction of the causes of disease.
•	 Secondary prevention aims to prevent progression of disease by detecting and 
treating disease at an early stage. 
•	 Tertiary prevention aims to prevent or limit the unfavorable outcomes of dis-
eases that are already diagnosed.
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If these definitions are applied to prevention of lung cancer, the stage of disease plays an 
import role in the form of prevention applied, which is depicted in Figure 1.
Hence, morbidity and mortality from lung cancer may be reduced by: 
I) Primary prevention through reducing the occurrence of lung cancer;
II) Secondary prevention through early detection by screening asymptomatic high-risk 
subjects;
III) Tertiary prevention through earlier treatment by increasing awareness of the signs 
and symptoms of lung cancer in the general population.
Primary prevention
Primary prevention may improve public health by reducing mortality and morbidity 
from lung cancer in two different ways. On the one hand, the occurrence of lung cancer 
can be reduced by protection from the carcinogenic agents that specifically cause lung 
cancer. On the other hand, the occurrence of lung cancer can be counteracted by the use 
of specific agents to reverse, suppress, or prevent the process of carcinogenesis.
The latter is called chemoprevention, and many substances, such as aspirin,40-42 
β-carotene,43-45 retinyl palmitate,45-47 13-cis-retinoic acid,46,47 vitamin E,43 N-acetylcyste-
ine47 and selenium,48,49 have been tested in clinical trials.50 None of these trials demon-
strated any beneficial effect, while some did show harmful effects.50 Therefore, to date not 
one agent is recommended for use in the chemoprevention of lung cancer.50
Hence, the reduction of exposure of the general population to the causative agents of 
lung cancer may be a safer and more effective approach to improve public health. Cur-
Figure 1. Prevention and medical care according to cancer stage
pre-malignant
malignant
symptomatic
Primary
prevention
Secondary
prevention
Tertiary
prevention
at risk
Medical
care
time → 
diagnosis and
treatment
mortality due
to cancer
In time, cancer develops in an individual at risk, from pre-malignant, to malignant, to symptomatic cancer, and 
after some delay diagnosis is made and the individual receives medical care until death. Primary, secondary and 
tertiary prevention apply to different stages of disease, but could be offered to any individual receiving medical care
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rent knowledge on the aetiology of lung cancer may be used to develop such primary 
prevention interventions. Since tobacco is responsible for 80-90% of the lung cancer 
diagnoses,3,51 both through smoking1-3 and second-hand smoke exposure,5 most benefit 
can be expected from interventions directed at prevention of the initiation of smoking 
and smoking cessation. The adverse health effects of tobacco smoking became widely 
apparent in the 1950’s,52 and many interventions have been implemented since: anti-
smoking campaigns, marketing and sales restrictions, federal cigarettes taxes, smoke-free 
air laws, smoking cessation treatments.53,54 These interventions had substantial impact on 
smoking prevalence, which was reflected in lung cancer incidence and mortality twenty 
to thirty years later.23,54 Millions of premature deaths were prevented by tobacco control 
interventions; a substantial proportion through prevention of lung cancer deaths.55,56 
Despite this success of primary prevention, global smoking prevalence was still as high 
as 23.7% in 2010.57 Moreover, it has been estimated that smoking prevalence will only 
decrease to 22.0% in 2030 if no additional tobacco control policies are applied.57 
Concluding, primary prevention is inevitable in the fight against lung cancer, and 
continuous efforts should be made to force back exposure to its causative agents, tobacco 
smoking in particular. However, primary prevention solely is not expected to be able to 
reverse the lung cancer epidemic and reduce morbidity and mortality substantially in the 
next decades.
Tertiary prevention
The aim of tertiary prevention is to improve survival and reduce mortality by early 
treatment in symptomatic lung cancer patients. To be able to treat lung cancer as early 
as possible, delays between the onset of symptoms and treatment should be minimised. 
Three types of delay are recognised in the literature:58,59
I) Patient-related delay due to failure to act immediately on suspicious symptoms 
through fear or lack of knowledge.
II) Doctor-related delay due to misinterpreting symptoms or not referring for diagnos-
tic testing.
III) System-generated delay due to inefficiency or long waiting times of appointments or 
tests.
Efforts to reduce delay type II and III are embedded in clinical guidelines and per-
formance indicators of health care.35,60 Delay type I has been recognised as the most 
important source of delay between onset of symptoms and start of treatment.61
Several studies on patient-related delay in seeking a cancer diagnosis have been pub-
lished, but identified different sets of determinants. Corner et al identified comorbidity, 
misinterpretation of symptoms, lack of knowledge, and difficulties of recognising ill 
health in elderly as determinants.58 While Leydon et al. found that a person’s experiences, 
expectations from health care, family decisions and fear of cancer were important.62 In 
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the study of Ristvedt et al. predisposition to seek help and certain personality traits were 
identified as determinants of delay.63 
Further, the spontaneous awareness of the symptoms of lung cancer is limited; nearly 
a quarter of the general population cannot mention any symptoms of lung cancer, and 
those who can mention breathlessness and coughing.64 This information is essential for 
developing tertiary prevention interventions that reduce patient-related delay, which may 
address to the poorer survival associated with delay.65 Henceforth, several initiatives to 
raise awareness of symptoms of lung cancer and to de-stigmatise the disease have been 
implemented.66-68 The effectiveness of tertiary prevention has been investigated in a lim-
ited number of studies; effects on self-reported awareness,69-72 intention to seek care,70,72 
health care policy,69,73 referral rates,70 disease incidence70 have been reported. A favour-
able effect on disease stage at diagnosis was not consistently proven,70,72 moreover none of 
the studies evaluated the effect on survival or lung cancer mortality.
Despite the fact that the effectiveness of the aforementioned interventions on lung 
cancer morbidity and mortality has not been demonstrated, and the disease itself is often 
asymptomatic in early stages, tertiary prevention should not be disregarded. The observa-
tion that clinically-diagnosed lung cancer has often already progressed to an advanced 
stage at diagnosis23 might be not exclusively caused by the biology of the disease; a part 
of this problem might also result from the social context of the disease.58,74 The general 
public has low expectations from health care, because lung cancer is considered as an 
inevitably fatal condition.58,74 Earlier diagnosis in symptomatic patients is scarcely pro-
moted because there is little expected gain.58,74 In addition, patient advocacy movements 
are disabled by the blame of self-infliction of disease and the relatively small proportion 
of patients that survive the disease.58,74 The power of tertiary prevention is best demon-
strated in breast cancer: by creating awareness, the general public has become educated 
on the symptoms of the disease and on the benefits of seeking an early diagnosis, and a 
powerful social movement has arisen.75 
Concluding, tertiary prevention has not proven to be able to reduce lung cancer mor-
bidity and mortality. Nonetheless, its effects may reach further than just earlier treatment 
of symptomatic patients; it may influence the public opinion and professional agendas, 
which contributes to the development and funding of research, screening, clinical care 
and aftercare.
Secondary prevention
Lung cancer screening is a form of secondary prevention (Box 1), and aims to reduce 
mortality by cancer detection at an early and curable stage. As this early stage is often 
not accompanied by any signs or symptoms, screening is applied to apparently healthy, 
asymptomatic persons. 
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Harms and benefits
The benefit asymptomatic high-risk subjects have from an effective screening program 
is: a reduced probability of dying from lung cancer, and a reduced probability to suffer 
from advanced disease (Table 1).76 Unfortunately, the subjects who undergo screening are 
also exposed to several harms. The harms can be related to the screening test itself; as for 
example radiation-induced cancer or psychological distress awaiting the test result. But 
harms can also be related to false positive screenings (e.g. complications of subsequent 
diagnostic tests) and false negative screenings (e.g. delayed diagnosed due to false reas-
surance). Further, overdiagnosis is considered to be an important harm of screening. A 
detailed overview of potential harms and benefits of screening is provided in Table 1.
Medical ethics
The harms and benefits listed in Table 1 represent one of the contradictions in screening. 
On the one hand, screening aims to improve (public) health by reducing morbidity and 
mortality from lung cancer, on the other hand, screening unintentionally exposes the 
screened population to a variety of harms. To be able to perform and interpret research 
in the field of screening, knowledge on the ethical principles is essential.
Ethical principles
The following four ethical principles are considered most relevant for lung cancer screen-
ing:
I) Beneficence: this principle signifies that physicians must help their patients and act 
in their patients’ best interest.
Table 1. Benefits and harms of cancer screening
Benefits
Less persons dying from lung cancer
Less persons suffering from advanced lung cancer
Less persons receiving intensive or mutilating primary treatment
Possible positive effects on smoking cessation
Harms
Undergoing screening test and awaiting result - psychological distress
Radiation-induced cancers - morbidity and mortality
False positive results - psychological distress, morbidity and mortality due to subsequent diagnostic procedures
False negative results - false reassurance, delayed diagnosis once symptoms occur
Overdiagnosis - psychological distress, morbidity and mortality due to overtreatment
Persons receiving the diagnosis of lung cancer earlier
Possible negative effects on smoking cessation
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II) Non-maleficence: this principle signifies that physicians must not harm their pa-
tients.
III) Autonomy: this principle signifies that physicians must respect the right of patients 
to decide over their own medical interventions and treatments. 
IV) Justice: this principle signifies that physicians must treat equal patients equally and 
must consider fair distribution of health care resources. 
As these ethical principles are part of the medical oath, physicians involved in screening 
have a number of responsibilities. According to the principle of beneficence physicians 
should propose lung cancer screening to those individuals in whom it is beneficial for 
their health. According to the principle of non-maleficence, physicians should not offer 
lung cancer screening to those individuals in whom it is not beneficial. Moreover, this 
principle also implies that physicians have the responsibility to minimise the harms of 
screening in whom screening is considered beneficial. According to the principle of au-
tonomy, physicians should respect a person’s decision to undergo lung cancer screening 
or not. As informed decision-making is a prerequisite for participation in screening, phy-
sicians also have the responsibility to inform screening candidates on benefits and harms 
of screening. According to the principle of justice, physicians have the responsibility to 
treat individuals, who are equal with respect to aspects relevant for screening, equally. 
This, for example, refers to providing care that is accessible and appropriate for the entire 
target population, or to the fair distribution of limited health care resources.
Ethical dilemmas
The responsibilities that result from the ethical principles can be conflicting. As men-
tioned previously, the most prominent ethical dilemma in lung cancer screening is the 
conflict between beneficence and non-maleficence. The harms a screening program 
induces should be weighed against the benefits the program yields. Obviously, it is not 
ethical to implement a screening program that causes more harm than benefit. In lung 
cancer screening, harms and benefits are not the same for every individual but depends 
i.e. on age, smoking history and co-morbidity. Therefore, the ethical dilemma between 
beneficence and non-maleficence plays an important role in defining the target popula-
tion for lung cancer screening. 
The principle of autonomy can conflict with the principles of beneficence and non-
maleficence. Well-informed individuals have the right to decide for themselves whether 
or not to undergo screening. However, this right can conflict with the principles of 
beneficence and non-maleficence when the benefits of screening do not outweigh the 
harms. For example, in case of an individual with a negligible risk of lung cancer who 
demands to undergo LDCT screening. The principle of autonomy could also conflict 
with the ethical principle of justice. The right of the individual to undergo screening can 
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conflict with the responsibility to distribute limited health care resources responsibly to 
preserve the accessibility of health care. 
The significance of the considerations surrounding the ethical principles and dilem-
mas has been recognised for decades. As a result, screening criteria that encounter these 
ethical issues have been developed to guide decisions on the implementation of screening 
programs.
Criteria for screening
In 1968, the World Health Organisation (WHO) commissioned a report from Wilson and 
Jungner on the “Principles and practice of screening for disease”.77 This report contains 
the ‘Wilson and Jungner criteria’ for screening (overview provided in Box 2), which have 
been regarded as the golden standard in decision-making for a long time.77
Although the value of the Wilson and Jungner criteria is still widely recognised,78 many 
have suggested adaptions and improvements of  the criteria.79-84 In 2008, the WHO pub-
lished ‘Revisiting Wilson and Jungner in the genomic age: a review of screening criteria 
over the past years’.78 In this article, a new set of criteria was presented, based on the 
suggested improvement of the Wilson and Jungner criteria proposed over the past forty 
years (Box 3).78
Box 2. Criteria for screening by Wilson and Jungner, 1968
I) The condition sought should be an important health problem.
II) There should be an accepted treatment for patients with recognized disease.
III) Facilities for diagnosis and treatment should be available.
IV) There should be a recognisable latent or early symptomatic stage.
V) There should be a suitable test or examination.
VI) The test should be acceptable to the population.
VII) The natural history of the condition, including development from latent to 
declared disease, should be adequately understood.
VIII) There should be an agreed policy on whom to treat as patients.
IX) The cost of case-finding (including diagnosis and treatment of patients diag-
nosed) should be economically balanced in relation to possible expenditure 
on medical care as a whole.
X) Case-finding should be a continuing process and not a “once and for all” 
project.
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Screening for lung cancer
Lung cancer fulfils a number of the criteria for mass screening (Box 3).78 Criterion I: as 
the burden of lung cancer is high, an effective screening program responds to a recog-
nized need.78 Criterion II: the objective of a lung cancer screening program would be to 
reduce morbidity and mortality from lung cancer.78 Current knowledge on the aetiology 
of lung cancer provides the opportunity to define specific target populations for screen-
ing, which is a prerequisite to fulfil criterion III.78 Criteria IV to X (Box 3) do not relate to 
characteristics of the disease itself, but to the screening program’s effectiveness, balance 
between harms and benefits, and associated costs.78
Lung cancer screening: cohort studies
Until the 1990s, there has been little role for lung cancer screening because no effec-
tive screening test was available.85 Screening studies using sputum cytology,86-88 or chest 
radiography did not show a significant lung cancer mortality reduction.89 In the 1990s, 
trials using low-dose computed tomography (LDCT) as a screening test were initiated,85 
and results were encouraging. LDCT appeared to be able to detect more and smaller lung 
cancers than chest radiography;90-92 61% to 93% of lung cancers were diagnosed at stage 
I.90-95 Moreover, survival rates in patients with screen-detected lung cancer were startling: 
five-year survival in the Japanese ALCA trial95 was 64.9% to 76.2%, and ten-year survival 
in the U.S. ELCAP trial was even 80-92%.91,96 
Box 3. Modern screening criteria proposed by the World Health Organisation
I) The screening programme should respond to a recognised need.
II) The objectives of screening should be defined at the outset. 
III) There should be a defined target population. 
IV) There should be scientific evidence of screening programme effectiveness. 
V) The programme should integrate education, testing, clinical services and 
programme management. 
VI) There should be quality assurance, with mechanisms to minimise potential 
risks of screening. 
VII) The programme should ensure informed choice, confidentiality and respect 
for autonomy. 
VIII) The programme should promote equity and access to screening for the entire 
target population. 
IX) Programme evaluation should be planned from the outset.
X) The overall benefits of screening should outweigh the harm.
23
General introduction
Bias
The survival of patients with screen-detected lung cancer is not the right endpoint to 
evaluate the effectiveness of a screening program due to three forms of bias:
I) Lead-time bias: by screening asymptomatic individuals, the diagnosis of lung cancer 
is established earlier than it would have been without screening, which is usually 
after the onset of symptoms. As survival analyses take the moment of diagnosis as 
starting point, survival of patients with screen-detected lung cancer will be longer 
than the survival of patients with clinically diagnosed lung cancer, even when there 
is no benefit of screening (Figure 2). 
II) Length-time bias: as the aforementioned cohort studies analysed survival of 
patients with screen-detected lung cancer only, this form of bias also plays a role. 
Lung cancer is a very heterogenic disease, and some subtypes of lung cancer grow 
slower than other subtypes. The slow-growing cancers have a longer asymptomatic 
phase than the fast growing cancers. As a result, the likelihood of a slow-growing 
cancer to be detected by screening is higher than the likelihood of a fast-growing 
cancer. Hence, screen-detected lung cancers grow slower on average than lung 
Figure 2. Schematic depiction of lead-time bias
time → 
Symptom-detected
Lung Cancer
Screen-detected
Lung Cancer
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Screen-detected
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In panel I, calculation of survival is depicted for symptom-detected lung cancer; starting point is the moment of 
diagnosis and endpoint is the moment of death. In panel II and III, calculation of survival is depicted for screen-
detected lung cancer. In both, survival is substantially longer than for symptom-detected lung cancer, as a result 
of advancing the moment of diagnosis through detection before the onset of symptoms. However, only in panel III 
survival is truly prolonged by screening. In panel II, the moment of diagnosis is advanced but the moment of death 
is at the same moment as when lung cancer was diagnosed through symptoms.
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cancers not detected by screening. Since slow-growing cancers are associated with 
longer survival and lower case-fatality, the survival of screen-detected cancers is 
better than the survival of lung cancers not detected by screening. As the survival 
analyses of the cohort studies only included the screen-detected lung cancers, the 
result is biased. Therefore, the survival of both screen-detected lung cancers and the 
lung cancers not detected by screening should be included in the analysis. The latter 
requires the availability of high-quality cancer registries or thorough follow-up of 
study participants. 
III) Overdiagnosis: is inseparable from screening and means the detection of cancers 
which would have never had led to symptoms or death (Figure 3). At the time the 
ALCA and ELCAP study were conducted, almost all individuals who were diag-
nosed with screen-detected lung cancer also underwent surgery. As a result, it is not 
possible to determine how many individuals had a lung cancer that would not have 
been fatal if left untreated; the overdiagnosed cancers. Subsequently, it’s not possible 
to determine to what extend overall survival is biased by overdiagnosis.
Figure 3. Schematic depiction of overdiagnosis
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Figure 3 describes a population with a constant lung cancer incidence, that underwent three low-dose computed 
tomography screening rounds. In panel I, an hypothetical lung cancer screening program that did not lead to 
any overdiagnosis is depicted. Through earlier detection of lung cancer the cumulative incidence of lung cancer 
increases faster during screening compared to no screening. However, after screening has stopped and the ‘wash-
out period’ of screening has passed, the cumulative lung cancer incidence is as high as in the situation without 
screening. Hence, the is no overdiagnosis. Note: in practice, due to concurring mortality, there will always be 
overdiagnosis. In contrary to panel II, where in the cumulative lung cancer incidence remains higher than in 
the situation without screening. The difference in lung cancer cases between the two lines are the overdiagnosed 
lung cancers.
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To avoid these three forms of bias, the primary endpoint of screening studies should 
be disease-specific mortality reduction. Ideally, the effect of screening on lung cancer 
mortality is determined in a trial wherein participants are randomised between screening 
and no screening. Next, both groups should be followed up simultaneous for a sufficiently 
long period of time after screening has stopped. Just one of the aforementioned cohort 
studies assessed lung cancer mortality reduction; the Mayo Lung Project compared lung 
cancer mortality between the screened cohort and a historical cohort; analysis showed no 
significant lung cancer mortality reduction.94 
Lung cancer screening: randomised trials
The encouraging results of the LDCT cohort studies led to the initiation of several 
randomised controlled trials (Table 2).97-104 Although design of the trials varies notably, 
the primary endpoint of all these trials was lung cancer mortality. Four of the seven 
randomised trials have currently reported their results. The largest trial, the U.S. National 
Lung Screening Trial (NLST), reported a statistically significant lung cancer mortality 
reduction of 20.0% (95% CI 6.8-26.7%) after 6.5 years of follow-up.76 In the NLST, screen-
Table 2. Characteristics of randomised controlled trials on LDCT screening for lung 
cancer
Trial Participants Initiation Design Screenings Characteristics participants
N Year N Sex Age* Smoking Cessation
NLST97,138 53,439 2002 LDCT vs. CXR 3 M/F 55-74 ≥30 py <15 yrs
NELSON108,139 15,822 2004 LDCT vs. no 
screening
4 M/F 50-75 ≥15/day for 25 
yrs or ≥10/day for 
30 yrs
≤10 yrs
DLST99 4,104 2004 LDCT vs. no 
screening
5 M/F 50-70 ≥20 py <10 yrs
MILD100 4,099 2005 LDCT vs. no 
screening
5/10 M/F ≥49 ≥20 py <10 yrs
LUSI101 4,052 2007 LDCT vs. no 
screening
4 M/F 50-70 ≥15/day for 25 
yrs or ≥10/day for 
30 yrs
≤10 yrs
UKLS102,140 4,000 2011 LDCT vs. no 
screening
1 M/F 50-75 ≥5% risk of lung cancer in 
5 yrs
ITALUNG103 3,206 2004 LDCT vs. no 
screening
4 M/F 55-70 ≥20 py <10 yrs
DANTE104 2,472 2001 Initial CXR, 
followed by LDCT 
vs. no screening
4 M 60-75 ≥20 py <10 yrs
Definition of abbreviations: LDCT = low-dose computed tomography; CXR = chest x-ray; M = male; F = female; 
py = pack-years; yrs = years.
* Age range up to, but not including upper limit.
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ing using LDCT was compared to screening using chest radiography2 which does not 
affect lung cancer mortality.89 Moreover, screening using LDCT reduced significantly 
all-cause mortality with 6.7% (95% CI 1.2-13.6%).76 When lung cancer mortality was 
not included in all-cause mortality analysis, the all-cause mortality reduction dropped to 
3.2%, and was not statistically significant anymore.76  
Three smaller trials in Europe, the Danish screening trial, and the Italian DANTE 
and ITALUNG trials, reported no significant lung cancer or all-cause mortality reduc-
tion.100,105,106 An overview of the outcomes of the trials is presented in Table 3.107 Pooled 
estimates of the relative risks of death of the four trials combined were not published. 
Possibly because the estimates were partly based on interim analyses or absolute number 
life-years were not provided for the Italian studies, or differences in design of the included 
trials. Our calculation of the pooled relative risk, based on the published data, suggested 
that LDCT screening has significantly reduced the risk lung cancer mortality.53
Concluding, efficacy of LDCT screening for lung cancer has been demonstrated by the 
NLST.76 However, the high survival rates in earlier cohort studies created high expecta-
tions from LDCT screening,91,95,96 as a result, the 20% mortality reduction might not be 
as high as hoped. Nonetheless, there have been no other interventions so far, besides 
primary prevention, that have proven to be as successful as LDCT screening in reducing 
lung cancer mortality.
Currently, the Dutch-Belgian (NELSON), German and British lung cancer screening 
trial are still ongoing.101,102,108 As soon as enough follow-up time has accrued and data 
becomes available, final mortality analyses are expected from these studies. Updated 
pooled analyses also including these trials will provide a definitive conclusion on the 
effectiveness of LDCT screening.  
Table 3. Effect of LDCT screening on lung cancer and all-cause mortality
Trial* Quality Lung cancer deaths All deaths
per 100,000 py107 Relative risk107 per 100,000 py107 Relative risk107
Intervention Control RR (95%CI) Intervention Control RR (95%CI)
NLST76 Good 247 309 0.80 (0.73-0.93) 1142 1216 0.93 (0.86-0.99)
DLST105 Fair† 154 112 1.37 (0.63-2.97) 625 429 1.46 (0.99-2.15)
MILD100 Poor‡ 216 109 1.99 (0.80-4.96) 558 310 1.80 (1.03-3.13)
DANTE106 Fair¶ 527 637 0.83 (0.45-1.54) 1212 1433 0.85 (0.56-1.27)
Definition of abbreviations: py = person-years; RR = relative risk; 95%CI = 95% confidence interval.
* Trials included with results published before January 2014.
† Unclear allocation, differential follow-up.
‡ Inadequate randomization, differences in baseline demographic characteristics, differential follow-up.
¶ Unclear allocation, differences in baseline demographic characteristics, differential follow-up.
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THE NELSON TRIAL
Design
The NELSON trial is a randomised controlled trial on the efficacy of screening using 
low-dose computed tomography. The trial was conducted in the Netherlands and Bel-
gium. NELSON is the acronym for the Dutch name of the trial: NEderlands-Leuvens 
longkanker ScreeningsONderzoek.
The NELSON trial was initiated in 2003, after favourable survival of lung cancer 
patients, who underwent low-dose computed tomography screening, was demonstrated 
in cohort studies.95,96 To determine whether LDCT screening yields not only improved 
survival but also reduced mortality from lung cancer, screening was compared to no 
screening. As presented in figure 4, study participants were randomised to no screening, 
or to four rounds of screening using LDCT; at baseline (first screening round), one year 
later (second screening round), three years later (third screening round), and five and a 
half years later (fourth screening round). Both groups of participants are followed up, and 
the difference in lung cancer mortality between the two groups is determined ten years 
after randomisation.
Endpoints
Primary research objectives of the NELSON trial are:
I) To determine whether LDCT screening yields a reduction of ≥25% in lung cancer 
mortality.
II) To estimate cost-effectiveness of LDCT screening for lung cancer.
III) Secondary research objectives of the NELSON trial are:
IV) To determine whether LDCT screening yields a reduction in all-cause mortality.
V) To determine the effect of LDCT screening on quality of life.
VI) To determine lung cancer incidence and five-year survival rates.
VII) To determine detection rates and stage distribution per screening round.
Figure 4. Design of the NELSON trial
Round 1 Round 2 Round 3 Round 4
Baseline + 6 years+ 5 years+ 4 year+ 3 years+ 2 years+ 1 year
Interval 1 year Interval 2 years Interval 2.5 years
Randomisation
Screen
arm
+ 10 years
Control
arm
Lung
cancer
mortality
Lung
cancer
mortality
Eligible 
participants
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VIII) To determine the number, stage distribution and time interval since last screening 
of interval cancers, and the ratio of the screen-detected cancers and the interval 
cancers.
IX) To determine the screening algorithm’s sensitivity, specificity and positive predic-
tive value.
X) To further define best practices in lung imaging and quality assurance.
XI) To define the molecular dynamics of very early lung cancer.
XII) To further define best practice and quality assurance in nodule evaluation and 
early stage lung cancer management.
Hypothesis
Screening using low-dose computed tomography will yield a lung cancer mortality re-
duction of ≥25% at ten years of follow-up.
Recruitment
The method of recruitment in the NELSON trial was especially designed to maximise the 
validity of extrapolation of trial results to the population eligible for lung cancer screen-
ing. Recruitment strategies based on media advertisements are known to attract health-
concerned individuals, who are eager to participate in health and life style interventions. 
As the population at high risk for developing lung cancer does not typically consist of 
health-concerned individuals, such an approach should be avoided. To minimize this 
so-called ‘self-selection bias’, a population-based recruitment strategy was chosen for the 
NELSON trial.
Potential trial participants were identified via population registries and were ap-
proached by mail. From the second half of 2003 onwards, more than a half million ques-
tionnaires on general health, smoking, alcohol consumption, physical exercise, cancer 
history, family history of lung cancer, body weight and length, education and opinion 
on screening programs, were sent to all men and women born between 1928 and 1953 
in 7 districts in the Netherlands and 14 municipalities around Leuven in Belgium.98 This 
questionnaire was neither accompanied by information on the  minimal requirements for 
participation, such as smoking history, nor by any other information about the trial, to 
prevent prejudiced answers.
The information obtained with this questionnaire was used to decide whom to invite for 
the trial. First, the estimated lung cancer mortality risk of the respondents was estimated 
using data of the US Cancer Prevention Studies.109,110 Next, the required sample size and 
the corresponding number of eligible subjects was determined using the same formulas 
as in the American PLCO (Prostate, Lung, Colorectal and Ovarian) screening trial and 
the European Randomised Screening Trial on Prostate Cancer.111,112 For this calcula-
tion, a 1:1 randomisation, a power of 80%, a one-sided a significance level of 0.05, 95% 
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compliance in the screen group, 5% contamination in the control group and 10 years of 
follow-up after randomisation were assumed. Finally, the required participation rate was 
determined. The most optimal selection scenario, which required a participation rate as 
low as possible and a required sample size within the ranges of the capacity, was to invite 
the following population: 50 to 75-year old current or former smokers who had quit less 
than 10 years ago with a smoking history of at least 15 cigarettes per day for 25 years or at 
least 10 cigarettes for 30 years.98 Hence, to be able to demonstrate a lung cancer mortality 
reduction of at least 25% in this study population, the estimated required sample size was 
17,300 subjects.98 Therefore, a possible pooling with the Danish lung cancer screening 
trial was proposed.
In the second phase of recruitment another questionnaire was send, only to the eligible 
responders, which enclosed questions on smoking habits, smoking cessation, asbestosis 
exposure and chronic obstructive pulmonary disease, and the trial’s information leaflet 
and the informed consent. However, subjects with: a moderate or bad self-reported 
health, the inability to climb 2 flights of stairs, a body weight of 140 kg or more, current 
or past renal cancer, melanoma or breast cancer, or lung cancer diagnosed less than 5 
years ago, or a chest CT examination less than 1 year ago, were excluded.
Eligible subjects without any exclusion criteria, who responded to the second question-
naire and provided written informed consent for participation in the NELSON trial were 
included and randomised. An overview of inclusion and exclusion criteria is provided in 
Table 4.
Table 4. Inclusion and exclusion criteria of the NELSON trial
Inclusion criteria
Age 50 - 75 years
Smoking history ≥ 15 cigarettes per day for 25 years 
≥ 10 cigarettes per day for 30 years
Smoking cessation ≤ 10 years ago
Exclusion criteria
Self-reported health moderate or bad
Ability to climb stairs ≤ 2 flights
Body weight ≥ 140 kg
History of lung cancer still under treatment
diagnosed < 5 years ago
History of other cancer renal cancer
breast cancer
melanoma
History of imaging Computed tomography of the chest < 1 year ago
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Equipment and execution of screening examinations
The participants randomised to the screening group were invited by mail to undergo 
a LDCT examination of the chest at the nearest of the four screening sites. These were 
in the Netherlands in University Medical Center Groningen, University Medical Center 
Utrecht, and Kennemer Gasthuis in Haarlem, and in Belgium in University Hospital 
Leuven. 
The CT scans used were all 16-detector MSCT scanners (M×8000 IDT or Brilliance 
16P, Philips Medical Systems, Cleveland, OH, USA, or Sensation-16, Siemens Medical 
Solutions, Forchheim, Germany).113 All scans were realised in about 12 seconds in spiral 
mode with 16 mm × 0.75 mm collimation and 15 mm table feed per rotation (pitch = 
1.5), in a cranial-caudal scan direction, without intravenous contrast in low-dose set-
ting.113 Depending on the body weight (less than 50 kg, 50 to 80 kg and more than 80 kg) 
the kVp settings were respectively 80-90 kVp, 120 kVp and 140 kVp.113 This corresponds 
with an effective radiation dose of less than 1.6 mSv.114 To achieve a CTDIvol of respec-
tively 0.8mGy, 1.6mGy and 3.2 mGy, the mAs settings were adjusted for the machine 
used.113 Datasets of the thorax were reconstructed at 1.0 mm slice thickness, with 0.7 mm 
reconstruction increment and soft kernel (Siemens B30 filter, Siemens Medical Solutions, 
Forchheim, Germany).114,115 To minimise breathing artefacts, scans were performed in 
inspiration after appropriate instruction of the participants. Data acquisition and scan-
ning conditions were kept standard across the four screening centres for the duration of 
the trial.
Image reading and volumetric measurements
Images were read on digital workstations (Leonardo, Siemens Medical Solutions) using 
the Syngo Lungcare software package (Version Somaris/5 VB 10A-W) for multi-dimen-
sional image processing and computer viewing. Lung windows were assessed at a width 
of 1500 to −650 Hounsfield Units.113
A nodule was defined as a small approximately spherical, non-linear circumscribed 
focus of abnormal tissue.116 Nodules were classified as non-calcified when they did not 
show a benign pattern of calcification.116 Transversal, 6 mm thick maximal intensity 
projections (MIP) reconstructions were used to identify pulmonary nodules. Software to 
aid radiologist in the detection of pulmonary nodules (Lung-CAD VB10A, Siemens AG 
Healthcare) was used (Figure 5).117
For all non-calcified nodules, the maximum dimensions in x, y and z direction, mini-
mal, maximal and mean diameter, volume, density, location (central versus peripheral, 
lung segment, slice number) were recorded, as well as nodule surface characteristics 
(smooth, spiculated or other).113 The nodule characteristics were uploaded in the NEL-
SON Management System (NMS) immediately after completion of the reading for an 
unlimited number of evaluated nodules per scan.113 In case of consecutive CT scans, 
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nodules were matched with the same nodules documented on previous scans in order to 
determine changes in volume and to estimate the volume doubling time (VDT).113 This 
could be done either automatically, using a matching algorithm in NMS that provides 
the most probable match of nodules based on the combination of consistency, size and 
location, or manually.113
For solid nodules and for the solid component of part solid nodules, volume was calcu-
lated by three-dimensional volumetric computer assessment (Figure 6).117
In case of inappropriate segmentation, the radiologist was able to enter manual mea-
surements that overrule the automatically generated volume calculations. For solid pleu-
ral based nodules, the diameter perpendicular to the costal pleura was taken to determine 
nodule size as the volumetric software used was not accurate enough for pleural-based le-
sions, due to inappropriate segmentation.113 For non-solid lesions, nodule size was based 
on two-dimensional manual measurements, namely the average of length and width.113 
Length was measured in the X-Y-axis on a single CT image that showed the maximum 
Figure 5. Computer-aided detection of pulmonary nodules in the NELSON trial
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length.113 Width was defined as the longest diameter perpendicular to length on the same 
CT image.113 For part solid lesions, both the volume of the solid part and overall size of 
the nodule were recorded.113
Throughout the study, the definition of growth was kept constant, and was defined as 
a percentage volume change (PVC) of 25% or more according to the following formula: 
PVC = 100 × ((V2 − V1) / V2)
Wherein PVC represents the percentage of the change in volume; V1 represents the 
volume of the nodule at the first screening examination, and V2 represents the volume 
of the nodule at the second screening examination.113 For nodules with a PVC of 25% or 
more, the volume doubling time (VDT) was estimated using in following formula:
VDT = (ln 2 x ∆t) / (ln (V2 / V1))
Wherein VDT represents the volume doubling time in days, ∆t represents the time 
interval between the two screening examinations in days, V1 the volume of the nodule at 
the first screening examination, and V2 represents the volume of the nodule at the second 
screening examination.113 For non-calcified nodules in which only two-dimensional size 
parameters (dmin or dmean) were available, PVC was not used but volume doubling time 
was estimated using the following formula:
VDT = (ln 2 x ∆t) / (3 ln (D2 / D1))
Figure 6. Volumetric nodule size assessment in the NELSON trial
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Wherein VDT represents the volume doubling time in days, ∆t represents the time 
interval between the two screening examinations in days, D1 the two-dimensional 
measurement of the nodule at the first screening examination, and D2 represents the 
two-dimensional measurement of the nodule at the second screening examination.113
After the initial reading of the screening examination, the images were made available 
for a second reading. The second radiologist was unaware of the conclusion of the first 
radiologist and read the images within 3 weeks.113 After the second reading, discrepan-
cies were identified by the NELSON Management System when no auto-matching was 
achieved or when the second reader disagreed on nodule number, location or volume.113 
In case of disagreement, an experienced expert radiologist performed a third reading and 
made the final decision. Finally, the nodule size category and nodule growth category 
were determined (Table 5).
Nodule management protocol
After the nodule size category and growth category are assessed, the screening test result and 
associated actions to be taken are determined according to the NELSON nodule manage-
ment protocol. A screening test in the NELSON trial could have three different outcomes:
Table 5. Nodule size and growth categories in the NELSON trial
Nodule size category Definition
NODCAT I Nodule with benign characteristics such as benign calcification patterns or fat 
deposition
NODCAT II Solid nodules with volume < 50 mm³
Pleural-based solid nodules with minimum diameter < 5 mm
Non solid component part solid nodule with average diameter < 8 mm
Solid component part solid nodule with volume < 50 mm³
Non solid nodules with average diameter < 8 mm
NODCAT III Solid nodules with volume 50 - 500 mm³
Pleural-based solid nodules with minimum diameter 5 - 10 mm
Non solid component part solid nodule with average diameter ≥ 8 mm
Solid component part solid nodule with volume 50 - 500 mm³
Non solid nodules with average diameter ≥ 8 mm
NODCAT IV Solid nodules with volume > 500 mm³
Pleural-based solid nodules with minimum diameter > 10 mm
Solid component part solid nodule with volume > 500 mm³
Nodule growth category Definition
GROWCAT A Percentage volume change ≥ 25% and VDT > 600 days
GROWCAT B Percentage volume change ≥ 25% and VDT 400 - 600 days
GROWCAT C Percentage volume change ≥ 25% and VDT < 400 days
New solid component in previously non solid nodule
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I) Negative: not suspicious of lung cancer, no additional diagnostic tests warranted. 
The participant only receives an invitation for the next screening round.
II) Indeterminate: abnormalities are identified at the screening examination; it is un-
clear whether these represent lung cancer. The participant receives an invitation for 
a follow-up CT examination to determine nodule growth. 
III) Positive: abnormalities suspicious of lung cancer are identified at the screening ex-
amination. The participant receives a recommendation to consult a pulmonologist 
for diagnostic work-up.
An overview of the NELSON nodule management protocol is presented in figure 7. At 
baseline screening, only the size category of detected nodules can be determined, as only 
one CT examination is available. All nodules in size category NODCAT I and NODCAT 
II are classified as a negative screening test result (Table 5). Nodules with size category 
NODCAT III are classified as an indeterminate screening test result, and nodules with 
size category NODCAT IV are classified as a positive screening test result (Table 5). At 
the follow-up CT examination in the participants with indeterminate baseline screening 
test results, the growth category determines the final screening test result. Hence, nodules 
with growth category GROWCAT A or GROWCAT B are classified as a negative screen-
ing result, and nodules with growth category GROWCAT C are classified as a positive 
screening result.
From the second screening round onwards, a different classification is used. Nodules 
with size category NODCAT I or growth category GROWCAT A are classified as a nega-
tive screening test result (Table 5). All nodules with size category NODCAT II or NOD-
CAT III or growth category GROWCAT B are classified as an indeterminate screening 
test result, and nodules with size category NODCAT IV or growth category GROWCAT 
C as a positive screening test result (Table 5).
Figure 7. Nodule management protocol of the NELSON trial
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Diagnostic work-up after positive screening tests
All participants who receive a positive screening result are referred to a pulmonologist via 
their general practitioner. Most often, participants are referred to one of the pulmonolo-
gists involved in the NELSON trial at one of the four screening hospitals (University 
Medical Center Groningen, University Medical Center Utrecht, and the Kennemer Gas-
thuis Haarlem in the Netherlands, and University Hospital Gasthuisberg Leuven in Bel-
gium). The nodule detected by screening, which was classified as positive, is considered 
suspicious for lung cancer, and a diagnostic work-up needs to be performed to diagnose 
or exclude lung cancer. The NELSON trial provides directives for the diagnostic work-up 
after a positive screening test result, but did not orchestrate its effectuation. As a result, 
the work-up was usually performed according to the national guideline.60
The diagnostic work-up usually consisted of: personal history, physical examination, 
regular dose contrast-enhanced CT scan from the supra-clavicular region down to the 
adrenals, whole-body fluordesoxyglucose (FDG) -positron emission tomography (PET) 
examination, and conventional white light bronchoscopy (with endobronchial washing 
and brushing, and biopsy of the nodule or lymph nodes if possible). CT-guided trans-
thoracic biopsy of the suspicious nodule was performed only in a small minority of the 
diagnostic work-ups. Next, the results of this series of initial diagnostic procedures are 
discussed in the local multidisciplinary lung oncology team, which usually has members 
from the following departments: pulmonary medicine, thoracic surgery, radiation oncol-
ogy, radiology, nuclear medicine and pathology.
In case the initial series of diagnostic procedures did not yield any result that sup-
ported the suspicion of lung cancer, or a benign cause of the nodule was identified, the 
multidisciplinary team would usually decide to end the clinical evaluation and to refer 
the participant back to the screening programme of the NELSON trial.
In case the initial series of diagnostic procedures did not yield conclusive results, the 
multidisciplinary team would usually recommend to perform another diagnostic CT 
examination after three to six months, in accordance with international guidelines.118,119
In case the initial series of diagnostic procedures confirmed the suspicion of lung can-
cer, or yielded a cytological diagnosis of lung cancer, the decision of the multidisciplinary 
team will depend on the clinical TNM disease stage and the participant’s operability.36,120
Lung cancer staging
The participants of the NELSON trial who were diagnosed with lung cancer were staged 
according to the IASLC (International Association for the Study of Lung Cancer) TNM 
lung cancer staging system. This system uses criteria for the extensiveness of the primary 
tumour, metastasis in regional lymph nodes and metastasis at distant sites, to classify 
patients in subgroups with comparable prognoses. As the NELSON trial was initiated 
in 2003, the sixth edition of the TNM staging system121 was used. However from 2009 
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onwards, the seventh edition of the staging system was used.122 For all studies in this 
thesis, the lung cancers that have initially been staged according to the sixth edition, were 
re-staged according to the seventh edition.
To determine the clinical tumour stage (cT), the contrast enhanced CT scan and bron-
choscopy are the most important diagnostic procedures. Hence, they are used to measure 
the size of the primary tumour, to determine the distance of the primary tumour to the 
lobar bronchus and carina, and to assess the presence of tumour invasion of the pleura or 
extra-pulmonary structures, separate tumour nodules in the ipsilateral lung, obstructive 
pneumonitis or atelectasis. Using this information, the T stage can be determined with 
the criteria presented in table 6a.
To determine the clinical node stage (cN), the contrast enhanced CT scan and the 
FDG-PET scan are used initially. They are used to determine whether the tumour is 
adjacent to the mediastinum, whether there are any hilar, mediastinal, infra-clavicular, 
supra-clavicular or scalene lymph nodes with a short axis diameter of 10 mm or more, 
or with relevant FDG uptake. If any of the previous is observed, the Dutch guideline 
recommends to obtain a mediastinal tissue diagnosis using endosonography or surgi-
cal mediastinoscopy.123 Using this information, the N stage can be determined with the 
criteria presented in table 6b.
To determine the clinical distant metastasis stage (cM), the contrast enhanced CT 
scan and the FDG-PET scan are used. They are used to determine whether there are any 
tumour nodules in the contralateral lung, pleural nodules, pleural or pericardial effusions 
or distant metastasis. Additionally, the Dutch guideline recommends obtaining magnetic 
resonance imaging (MRI) of the skull to rule out brain metastases in patients with clinical 
stage III.123,124 Using this information, the M stage can be determined with the criteria 
presented in table 6c.
Once the clinical T, N and M stage of the (suspected) lung cancer are known, the disease 
stage can be determined using the classification presented in table 7. The TNM disease 
stage is closely correlated with prognosis, and determines which treatment options are 
feasible.60,122-125
Treatment of screen-detected lung cancer
Participants who are diagnosed with lung cancer through the screening program are 
treated in accordance with the national guidelines for the treatment of non-small cell and 
small cell lung carcinoma.60,123,124  The NELSON trial did not provide any directives for 
the treatment of screen-detected lung cancer.
Small cell lung cancer
The treatment of small cell lung cancer according the national Dutch guideline124 is divid-
ed in two different paths; one for small cell lung cancer diagnosed at limited disease stage, 
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Table 6a. Criteria for tumour stage 7th edition IASLC staging protocol
T stage (primary tumour)
Tx Primary tumour cannot be assessed, or tumour proven by the presence of malignant cells in sputum 
or bronchial washings but not visualized by imaging or bronchoscopy
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1 Tumour ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without 
bronchoscopic evidence of invasion more proximal than the lobar bronchusa
T1a Tumour less ≤ 2 cm in greatest dimension
T1b Tumour > 2 cm but ≤ 3 cm in greatest dimension
T2 Tumour > 3 cm but ≤ 7 cm or tumour with any of the following features (T2 tumours with these 
features are classified T2a if ≤ 5 cm):involves main bronchus, ≥ 2 cm distal to the carina, invades 
visceral pleura, associated with atelectasis or obstructive pneumonitis that extends to the hilar 
region but does not involve the entire lung
T2a Tumour > 3 cm but ≤ 5 cm in greatest dimension
T2b Tumour > 5 cm but ≤ 7 cm in greatest dimension
T3 Tumour > 7 cm or directly invading any of the following: chest wall (including superior sulcus 
tumours), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumour in the main 
bronchus (< 2 cm distal to the carinaa, but without involvement of the carina; or associated atelectasis 
or obstructive pneumonitis of the entire lung or separate tumour nodule(s) in the same lobe
T4 Tumour of any size that invades any of the following: mediastinum, heart, great vessels, trachea, 
recurrent laryngeal nerve, oesophagus, vertebral body, carina, separate tumour nodule(s) in a 
different ipsilateral lobe
a The uncommon superficial spreading tumour of any size with its invasive component limited to the bronchial wall, 
which may extend proximally to the main bronchus, is also classified as T1a.
Table 6b. Criteria for node stage 7th edition IASLC staging protocol
N stage (regional lymph nodes)
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary 
nodes, including involvement by direct extension
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3 Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or 
supraclavicular lymph node(s)
Table 6c. Criteria for node stage 7th edition IASLC staging protocol
M stage (distant metastasis)
Mx Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Separate tumour nodule(s) in a contralateral lobe; tumour with pleural nodules or malignant 
pleural (or pericardial) effusionb
M1b Distant metastasis
b Most pleural (and pericardial) effusions with lung cancer are due to tumour. In a few patients, however, multiple 
cytopathologic examinations of pleural (pericardial) fluid are negative for tumour, and the fluid is non-bloody 
and is not an exudate. Where these elements and clinical judgement dictate that the effusion is not related to the 
tumour, the effusion should be excluded as a staging element and the patient should be classified as M0.
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and another for small cell lung cancer diagnosed at extensive disease stage. Whether lung 
cancer is diagnosed at limited or advanced disease stage is determined by the possibility 
to capture all tumour in a single radiation field. In case this is possible, the disease stage 
is limited, which are usually unilateral tumours with no, hilar or ipsilateral mediastinal 
lymph node involvement, otherwise the disease stage is extensive.
Patients with small cell lung carcinomas diagnosed at limited disease stage, are recom-
mended to be treated with multimodality therapy. This is usually concomitant chemo-
therapy, consisting of four cycles of Cisplatin - Etoposide, and radiotherapy, consisting of 
chest irradiation of 30 fractions of 1.5 Gy. For very early stage small cell lung carcinomas 
(T1-2N0-1M0) surgical resection may be added to the multimodality treatment. After 
the initial treatment, prophylactic cranial irradiation (10 fractions of 2.5 Gy) is recom-
mended in patients without disease progression.
Patients with small cell lung carcinomas diagnosed at extensive disease stage, who have 
a WHO performance score of 0 to 3, are recommended to be treated with chemotherapy, 
for example 4 to 6 cycles of Cisplatin or Carboplatin - Etoposide. Radiotherapy is only 
recommended for palliative purposes, such as haemoptysis, superior vena cava syndrome 
or painful bone metastases. After the initial treatment, prophylactic cranial irradiation 
(10 fractions of 2.5 Gy) is recommended in patients without disease progression.
As the majority of the patients with limited disease and about all patients with exten-
sive disease will be confronted with recurrence of the cancer after the initial therapy, the 
recommended treatment for recurrent small cell lung cancer is described as well. Hence, 
chemotherapy is the only therapeutic option and should be offered to all patients that are 
not compromised as a result of advanced age, marginal performance status, co-morbidity 
and complications from the first series of chemotherapy. In case the cancer was sensitive 
Table 7. Stage groupings 7th edition of the staging protocol
Stage groups T stage N stage M stage
Ia T1a,b N0 M0
Ib T2a N0 M0
IIa T1a,b
T2a
T2b
N1
N1
N0
M0
M0
M0
IIb T2b
T3
N1
N0
M0
M0
IIIa T1-3
T3
T4
N2
N1
N0,1
M0
M0
M0
IIIb T4
T1-4
N2
N3
M0
M0
IV T1-4 N0-3 M1a,b
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for the first chemotherapeutic, re-induction therapy or Topotecan may be given. In case 
the cancer was not sensitive for the first chemotherapeutic, other chemotherapeutics 
should be chosen as monotherapy or combination therapy.
Non-small cell lung cancer
The treatment of non-small cell lung cancer according the national Dutch guideline123 
depends on the TNM disease stage at diagnosis.36 Patients diagnosed with resectable or 
locally advanced non-small cell lung cancer are recommended to undergo surgical resec-
tion of the tumour and dissection of the mediastinal lymph nodes. In case it was not pos-
sible to establish an histological or cytological diagnosis of lung cancer pre-operatively, 
an initial  limited resection of the tumour should be performed to confirm the diagnosis 
by frozen section examination.
For confirmed non-small cell lung cancers limited to one lobe, lobectomy with system-
atic mediastinal lymph node resection is the treatment of choice. If this is not possible 
due to poor pulmonary function, a more limited resection, such as a segmentectomy or 
wedge resection can be performed. In such patients without lymph node involvement 
stereotactic radiotherapy should also be considered. For lung cancers that are not lim-
ited to one lobe, complete resection can be achieved by performing a lobectomy of the 
one lobe and a limited resection of the other lobe, or by performing a bilobectomy or a 
pneumonectomy. For lung tumours that cannot be resected completely with a lobectomy 
due to tumour extension up to the ostium of the main bronchus of a lobe or the carina, 
a sleeve-lobectomy or sleeve-pneumonectomy can be performed. For lung tumours that 
extended up to or in the parietal pleura or thorax, an ‘en bloc’ resection of the affected 
section of the thorax should be performed. For tumours that per-operatively appear 
to have invaded the intra-pericardial part of the pulmonary artery, a pneumonectomy 
should be considered. Surgical resection of lung tumours that per-operatively appear to 
have invaded the superior vena cava, the adventitia of the aortic wall, the pericardium 
or diaphragm is not excluded. However, lung tumours that have substantially invaded 
the left atrium or the vertebral column are rarely resectable. Lung tumours that invade 
the pulmonary trunk, the oesophagus, or through the aortic wall or tumours that have 
caused pleuritis carcinomatosis are irresectable.
The aforementioned procedures are usually performed via thoracotomy, however 
video-assisted thoracoscopic procedures are also acceptable in selected patients by expe-
rienced surgeons.
Adjuvant radiotherapy is recommended in case of irradical resection and unexpected 
N2-3 disease. Adjuvant chemotherapy, such as four cycles of Cisplatin combination 
therapy, is recommended in case of stage II-IIIA disease in patients with a good perfor-
mance status (WHO 0-1).
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Patients with unresectable, locally advanced non-small cell lung cancer (stage III), and 
a good performance status are recommended to be treated with concomitant chemora-
diation therapy. After this initial treatment, the tumour should be re-staged to determine 
whether complete resection has become an option.
Patients with advanced stage non-small cell lung cancer (stage IV) and performance 
stage 0-3 are recommended to be treated with combination chemotherapy. For non-
squamous cell cancers, a combination therapy of Cisplatin and a third-generation cyto-
static (except Gemcitabin) is recommended. However treatment with Carboplatin, Pacli-
taxel or Bevacizumab can also be considered. For squamous cell carcinomas, Carboplatin 
combination therapy is recommended (not with Pemetrexed). Only in patients a known 
activating EGFR-mutation, EGFR-TKIs should be used as initial treatment. EGFR-TKIs 
can be used second and later treatment lines in patients with known and unknown EGFR 
status. Pemetrexed can be used as maintenance therapy in progression-free patients after 
first line chemotherapy, as well as EGFR-Tyrosine-kinase-inhibitors in in patients with an 
activating EGFR mutation.
Follow-up
After the initial treatment of lung cancer, the Dutch guidelines123,124 recommend to 
perform regular follow-up consisting of anamnesis, physical examination and possibly 
a chest radiograph. Follow-up using imaging, which enables the assessment of disease 
progression, is only recommended in case an active second or third treatment line can be 
offered, and in case screening for late side-effects is useful. Follow-up is recommended 
every three months during the first year, every six months during the second year, and 
every year for at least five years. The NELSON trial is not actively involved in the follow-
up process of the participants who have been treated for lung cancer. 
Data collection
To determine the main outcome of the NELSON trial and to be able to perform side-
studies, data needs to be collected on the diagnosis, treatment and follow-up of lung 
cancer. This information is required for both the participants diagnosed with lung cancer 
through screening and the participants who were diagnosed with lung cancer outside the 
screening program; e.g. before screening has started, between screenings, after screening 
has stopped and in the participants randomised to the control group.
The first step of data collection is to identify all participants who were diagnosed with 
lung cancer. The information on all lung cancer diagnoses is obtained via linkages with 
the national cancer registries of the Netherlands126 and Belgium,127  which have national 
coverage. The second step is to collect copies of the medical files of all participants diag-
nosed with lung cancer from the date of the first consultation for (suspected) lung cancer, 
until the date death or the end of the study. Finally, to obtain medical information on the 
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last phase of the participants’ life, the general practitioner was approached and requested 
to answer a number of questions concerning the cause of death. 
End point verification
Lung cancer-specific mortality is the main outcome measure of the NELSON trial. There-
fore, verification of the cause of death of the study participants who were ever diagnosed 
with lung cancer is crucial. The cause of death could be obtained by using the direct 
and underlying causes of death reported on the official death certificates of the deceased 
participants. However, the use of the official certificates for this purpose is debated for 
several reasons. Firstly, two forms of bias especially affect death certification in screening 
trials:
I) Sticky-diagnosis bias: CT screening leads to an increased incidence of lung cancer 
through advanced diagnoses and overdiagnosis. As a result, the prevalence of lung 
cancer is higher in the screening group than in the control group. Since lung cancer 
is commonly recognised as a lethal disease, the deaths in the screening group are 
more likely to be attributed to lung cancer than deaths in the control group.128 
II) Slippery-linkage bias: deaths as a result of interventions of treatments for lung can-
cer may be difficult to trace back to screening and could easily be certified as death 
due to other causes.128
Secondly, the merit of death certificates depends on the accuracy of the certifying clini-
cian and nosologist, and the establishment of a correct ante mortem diagnosis.129,130 Com-
mon reasons for misclassification are coinciding malignancies, considerable comorbidity 
and death after a surgical procedure.131,132 Finally, the sensitivity and specificity of the 
death certificate has been reported to range from 84.5 to 99.7% and 91.3 to 99.7%; causing 
an error that tends to reduce the effect of screening.132-135
To overcome these problems, clinical expert committees that review the medical files 
of the deceased participants to determine the cause of death, are frequently employed in 
cancer screening trials.132-137 Assessing the cause of death by such a committee should 
yield an uniform, objective ad unbiased determination of the trials’ main end point. The 
development of a cause of death review process protocol for the NELSON trial was part 
of this thesis (Chapter 9).
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RESEARCH QUESTIONS
The purpose of this thesis was to evaluate lung cancer screening using low-dose computed 
tomography in the Dutch-Belgian NELSON trial. Implications for future lung cancer 
screening programs were identified by assessing the screening strategy’s performance 
and outcomes. The research questions and hypotheses of the studies described in the 
subsequent chapters of this thesis are described next.
Research question I
Chapter 2. Predictive value of screening test results
Volumetric computer tomography screening for lung cancer: three rounds of the NEL-
SON trial.
European Respiratory Journal
Main research question
What was the screening performance of the nodule management protocol of the NEL-
SON trial?
Sub research questions
a) What were the detection rates, test characteristics and numbers needed to screen of 
the nodule management protocol of the NELSON trial?
b) What was the incidence of invasive diagnostic procedures for false-positive screen-
ing test results?
c) What were participant’s probabilities of false-positive screening results and lung 
cancer after baseline and subsequent screening test results?
Research question II
Chapter 3. Characteristics of screen-detected lung cancer
Characteristics of lung cancers detected by computer tomography screening in the ran-
domized NELSON trial.
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American Journal of Respiratory and Critical Care Medicine
Main research question
What was the effect of screening using low-dose computed tomography on the character-
istics of screen-detected lung cancer?
Sub research questions
a) What were the tumour characteristics of lung cancers detected by low-dose CT 
screening?
b) What was the effect of screening round and gender on the characteristics of screen-
detected lung cancer?
c) To what extent was screening able to detect lung cancer before the onset of symp-
toms?
Research question III
Chapter 4. Epidemiological evaluation
Detection of lung cancer through low-dose CT screening: analysis of screening test 
performance and interval cancers. 
Lancet Oncology
Main research question
How can knowledge on the lung cancers not detected by low-dose computed tomography 
screening be used to improve the performance of the screening strategy?
Sub research questions
a) What were the detection rates and test characteristics of the nodule management 
protocol of the NELSON trial?
b) Were there any differences in the characteristics between the participants diagnosed 
with screen-detected lung cancer and the participants diagnosed with an interval 
cancer?
c) What were the tumour characteristics of the lung cancers not detected by low-dose 
computed tomography screening?
d) What were the causes of the failure to detect the interval cancers?
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Research question IV
Chapter 5. Radiological evaluation
Computed tomographic characteristics of interval and post-screen carcinomas in lung 
cancer screening.
European Radiology
Main research question
How can knowledge on the radiological characteristics of lung cancers not detected by 
low-dose CT screening be used to improve the performance of the screening strategy?
Sub research questions
a) What proportion of the lung cancers not diagnosed through screening were, in 
retrospect, present at the last LDCT screening examination?
b) What were the causes of the failure to detect the missed lung cancers?
c) What were the characteristics of the carcinomas missed on the LDCT screening 
examination due to radiological detection or interpretation errors?
Research question V
Chapter 6. Optimisation of screening protocols
Lung cancer probability in subjects with CT-detected pulmonary nodules: an analysis of 
data from the NELSON trial of low-dose CT screening. 
Lancet Oncology
Main research question
How should a participant’s predicted lung cancer probability, based on size and growth 
of CT-detected nodules, be used to optimise the nodule management protocol of the 
NELSON trial?
Sub research questions
a) Was it valid to predict  the two-year lung cancer probability of an individual who 
underwent screening using low-dose computed tomography, using a model based 
on nodule size and growth rate?
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b) What was the probability of lung cancer in an individual who underwent screening 
using low-dose computed tomography, based on nodule size and growth rate?
c) How should the current thresholds for nodule size and growth rate be adjusted to 
improve risk stratification, test characteristics and reduce harms?
Research question VI
Chapter 7. Evaluation of bronchoscopy
The role of conventional bronchoscopy in the work-up of suspicious CT screen-detected 
pulmonary nodules. 
Chest
Main research question
What was the value of bronchoscopy for diagnosing lung cancer in screen-detected 
nodules?
Sub research questions
a) What were the test characteristics of bronchoscopy and its ancillary procedures?
b) What were predictors for a true-positive bronchoscopic procedure?
c) Which diagnoses were made in false-negative bronchoscopic procedures?
Research question VII
Chapter 8. Evaluation of surgical procedures
Complications following lung surgery in the Dutch-Belgian randomized lung cancer 
screening trial. 
European Journal of Cardio-Thoracic Surgery
Main research question
To what extent did adverse events related to thoracic surgery, occur in participants after 
a positive screening test results?
Sub research questions
a) How often occurred re-thoracotomy, complications, and post-operative mortality 
in participants who underwent thoracic surgery for a positive screening test result?
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b) What was the length of hospital stay for lung resection performed by thoracotomy 
and video-assisted thoracoscopic surgery?
c) To what extent were surgical procedures performed for benign nodules?
Research question VIII
Chapter 9. Endpoint determination
Uniform and blinded cause of death verification in a lung cancer CT screening trial. 
Lung Cancer
Main research question
How should the endpoint verification process of the NELSON trial be designed to ensure 
uniform, objective and unbiased endpoint determination?
Sub research questions
a) How to develop a cause of death review protocol that ensures uniform, objective 
and unbiased endpoint determination?
b) How was the performance of the developed cause of death protocol compared to the 
official death certificates?
c) What were sources of disagreement between users of the developed cause of death 
protocol?
d) What were the best sources of information for a review of the cause of death of a 
participant?
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OUTLINE OF THIS THESIS
Part I of this thesis “Introduction” consists of the General introduction (Chapter 1). 
Part II of this thesis “Evaluation of findings” consists of four chapters, covering several 
aspects of the performance screening algorithms. In the first study (Chapter 2) , data on 
screening test results and screen-detected lung cancer were used to determine positive 
predictive value and 5.5-year lung cancer probability. In the second study (Chapter 3) 
the tumour characteristics of the lung cancers detected by screening are presented. In 
the third study (Chapter 4), the performance of the screening algorithm of the NELSON 
trial was estimated, and opportunities to improve the performance were identified. In the 
fourth study of part II of this thesis (Chapter 5), radiological causes of the failure to detect 
the lung cancers not diagnosed through screening were assessed, and opportunities to 
improve the performance of the screening algorithm were identified. Part III of this thesis 
“Optimisation of screening” presents three studies. In the first study, (Chapter 6), lung 
cancer probability of participants was estimated and used to design improved nodule 
management protocols. In the second study (Chapter 7), the value of bronchoscopy in 
the diagnostic work-up of suspicious CT-detected nodules was determined. In the third 
study (Chapter 8), adverse events related to thoracic surgery, performed in the diagnostic 
work-up of suspicious CT-detected nodules were assessed. Part IV of this thesis “Evalu-
ation of effectiveness” consists of one study (Chapter 9), which presents the design and 
evaluation of the endpoint verification process of the NELSON trial. Part V of this thesis 
“Implications for implementation”, presents an overview of lung cancer screening and 
the studies presented in the parts II to IV of this thesis. Firstly, a review of the currently 
published literature (Chapter 10) is performed to determine the state of the art in lung 
cancer screening. Secondly, a review of the studies of this thesis (Chapter 11) is performed 
to interpret important results, answer the research questions of this thesis, and formulate 
general conclusions and recommendations. Furthermore, a summary of this thesis in 
English (Chapter 12) and in Dutch (Chapter 13) is provided. Finally, part VI of this thesis 
“Miscellaneous” consists of acknowledgements (Chapter 14), curriculum vitae (Chapter 
15), PhD portfolio of the Erasmus University (Chapter 16), and the list of publications 
(Chapter 17).
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ABSTRACT
Several medical associations recommended lung cancer screening by low-dose computed 
tomography scanning for high-risk groups. Counselling of the candidates on the potential 
harms and benefits and their lung cancer risk is a prerequisite for screening.
In the NELSON trial, screenings are considered positive for (part) solid lung nodules 
with a volume >500 mm3 and for (part) solid or nonsolid nodules with a volume-
doubling time <400 days. For this study, the performance of the NELSON strategy in 
three screening rounds was evaluated and risk calculations were made for a follow-up 
period of 5.5 years.
458 (6%) of the 7582 participants screened had a positive screen result and 200 (2.6%) 
were diagnosed with lung cancer. The positive screenings had a predictive value of 40.6% 
and only 1.2% of all scan results were false-positive. In a period of 5.5 years, the risk of 
screen-detected lung cancer strongly depends on the result of the first scan: 1.0% after a 
negative baseline result, 5.7% after an indeterminate baseline and 48.3% after a positive 
baseline. 
The screening strategy yielded few positive and false-positive scans with a reasonable 
positive predictive value. The 5.5-year lung cancer risk calculations aid clinicians in 
counselling candidates for lung cancer screening with low-dose computed tomography.
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INTRODUCTION
A number of prominent medical associations recently recommended screening for lung 
cancer in high-risk groups by low-dose computed tomography (LDCT) scanning.1–4 The 
recommendation resulted from the efforts that have been made by many researchers over 
the past decade, especially by the National Lung Screening Trial (NLST) research team.5 
The latest systematic review on computed tomography (CT) screening for lung cancer 
concluded that there are still substantial uncertainties regarding how to translate the 
positive recommendation into clinical practice.6
Most individuals eligible for screening will not develop lung cancer but are exposed to 
several potential harms: radiation exposure, psychological distress while awaiting results, 
and distress, morbidity and mortality in case of false-positive results.7,8 However, for indi-
viduals who actually will develop lung cancer, LDCT screening is often able to detect lung 
cancer at an early stage.5,9,10 The NLST has demonstrated that LDCT screening reduces 
the risk of dying from lung cancer significantly.5 Nevertheless, the early detection of lung 
cancer also leads to a prolonged disease course and will not be beneficial in persons who 
would otherwise never be diagnosed with lung cancer.
Therefore, to be able to counsel individuals adequately on the benefits and harms of 
LDCT-screening, clinicians should inform the candidates of their risk of true-positive 
and false-positive screen results.6 In the NLST, for example, 24.2% of the subjects had a 
positive screening, but only 3.6% was diagnosed with lung cancer.5 Furthermore, to be 
able to make an informed choice on future screenings, high-risk subjects should know 
how their probability of screen-detected lung cancer changes after their first screening.
In our trial, the Dutch–Belgian lung cancer screening trial (NELSON) solid lung 
nodules are assessed with three-dimensional measurements (volume). Screening results 
are considered positive for volumes >500 mm3 (diameter ~9.8 mm) or volume-doubling 
times (VDT) <400 days.9,11 This is considerably more stringent than the NLST policy to 
refer any nodule with a maximum diameter ≥4 mm.11,12 The volumetry-based screening 
strategy of the Danish lung cancer screening trial (DLCST) was adopted from our trial 
and led to a positive screen result in 2.0% of the participants with 34.8% of these results 
being true-positive.10,13
In this study, we will evaluate the performance of the NELSON screening strategy in 
the first three screening rounds. We will calculate lung cancer detection rates and positive 
predictive values and compare our results with other LDCT screening trials. Furthermore, 
we will calculate the 5.5-year risk of false-positive screen results and screen-detected lung 
cancer stratified by the result of the first screening scan. This will provide valuable infor-
mation for clinicians who are confronted with individuals who consider or have already 
undergone LDCT screening for lung cancer.
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METHODS
Details of the design and conduct of the NELSON trial have been reported elsewhere.11,14 
Briefly, subjects aged 50–75 years, who had smoked either 15 cigarettes or more per day 
for 25 years or 10 cigarettes or more for 30 years and were still smoking or had quit less 
than 10 years ago met the inclusion criteria. Before inviting the eligible subjects, persons 
with a moderate or bad self-reported health, the inability to climb two flights of stairs, a 
body weight of 140 kg or more, current or past renal cancer, melanoma or breast cancer 
and lung cancer diagnosed less than 5 years ago or still under treatment were excluded.14
Ultimately, 15,822 individuals were randomised (1:1) to screening (n=7915) with low-
dose CT at baseline (first round), 1 year later (second round) and 3 years later (third 
round) or no screening (n=7909). The main purpose of the trial is to determine whether 
CT screening will have reduced mortality from lung cancer by at least 25% at 10 years of 
follow-up.14,15
For this study, all 7915 participants randomised to the screening arm were included. 
Complete data on interval cancers were not yet available and, consequently, no analyses 
of screening sensitivity were performed.
Equipment and execution of screening examinations
A detailed description of the equipment and the execution of the screening examinations 
have previously been published.11 In short, in each of the four screening sites, 16-detector 
CT scanners were used in a low-dose setting, without the administration of intravenous 
contrast media.11 Datasets were derived from images of the thorax with a slice thickness of 
1 mm and a slice interval of 0.7-mm.11 CT images were analysed using software for semi-
automated volume measurements (LungCARE; Siemens AG, Erlangen, Germany).16–18 In 
cases where the software was not able to measure nodule volume (e.g. in pleural based or 
nonsolid nodules), the diameter of the nodule was measured manually by the radiologist.
Nodule management protocol
The management protocol of the NELSON trial has been published previously.9,11,19 
Briefly, screening could lead to three different outcomes: I) a negative screen result (no 
other action than an invitation for the next screening round); II) an indeterminate result 
(invitation for a follow-up scan); III) a positive result (referral to a pulmonologist for 
diagnostic work-up).
For newly detected solid nodules and the solid component of part-solid nodules, the 
volume determined the screening result as follows: <50 mm3 was negative, 50–500 mm3 
was indeterminate and >500 mm3 was positive.
For previously detected and nonsolid nodules, the percentage volume change was 
calculated: <25% was a negative result and ≥25% led to the assessment of the VDT. The 
VDT in days was calculated using the following formula:
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VDT=(ln2 x ∆t)/(ln(V2/V1))
where V1 represents nodule volume on the first examination and V2 the volume the 
second examination and ∆t the time between the examinations in days.11 In case the 
software was not able to measure nodule volume, manually measured diameters were 
used to calculate VDT in days using the following formula:
VDT=(ln 2 x ∆t)/(ln((MaxDiamXY2 x PerpDiamXY2 x MaxDiamZ2)/MaxDiamXY1 
x PerpDiamXY1 x MaxDiamZ1))
where MaxDiamXY is the maximum diameter in the x/y-axis, PerpDiamXY the maxi-
mum diameter perpendicular to MaxDiamXY and MaxDiamZ is the maximum diameter 
in z-axis.11
For nodules with VDTs of 400–600 days, the result was indeterminate; for VDTs of 
<400 days the result was positive. From the second round onwards, participants with 
a nodule with a VDT of 400–600 days were invited for a 12-month repeat scan.19 Fur-
thermore, the screening was also positive if a new solid component had emerged in a 
previously nonsolid nodule. The screening result was negative for all nodules with fat, 
benign calcification patterns or other benign abnormalities.11,19
Referral, diagnostic work-up and diagnoses 
After a positive screening, participants were referred for diagnostic work-up via their 
general practitioner and received usual care according to national and international 
guidelines.4,20–23 All data were prospectively collected and histological specimens were 
reassessed by our chief pathologist (ET).
Definitions and statistics 
Screen-detected lung cancers are the lung cancers that are diagnosed by the diagnostic 
work-up initiated for a positive screening. The lung cancer detection rate is the number 
of screen-detected lung cancers divided by the number of screened participants. A true-
positive test result is a positive scan in a participant who actually has lung cancer. A 
false-positive test result is a positive scan, when lung cancer is not diagnosed.
The normality of the distribution of the continuous variables (age and pack-years) was 
evaluated by studying the Q-Q plots. As the variables were not normally distributed, 
the variables were described by the median and interquartile range. For analysing the 
difference between the continuous variables across the three screening rounds, the Krus-
kal–Wallis H test was used. For analysing the difference between the nominal variables 
(sex and smoking status) across the three screening rounds, the likelihood ratio-based 
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Chi-squared test was used. To calculate 95% confidence intervals of proportions, boot-
strapping was performed based on 1000 samples. For all analysis, α<0.05 was considered 
significant and PASW Statistics, SPSS version 20 (SPSS Inc., Chicago, IL, USA) was used.
Ethics and legal approval
The NELSON trial was approved by the Dutch Minister of Health and the ethics board at 
each participating centre. The NELSON trial is registered at www.trialregister.nl (number 
ISRCTN63545820). All participants gave written informed consent for participation and 
the evaluation of personal data from hospital charts and national registries.
RESULTS
7,582 (95.8%) of the 7,915 participants randomised to the screen-arm of the trial were 
actually screened. The participation rates remained high across the three screening 
rounds: 7,557 (95.5%) in round one, 7,295 (92.2%) in round two and 6,922 (87.5%) in 
round three.
In three screening rounds, 24,354 CT scans were made. 21,773 (89.4%) of the scans 
were a regular ‘‘round scans’’ and 2,581 (10.6%) were follow-up scans, performed to 
assess the VDT of indeterminately sized nodules. The scans detected a total of 31 683 
nodules: 266 (0.8%) were part-solid and 298 (0.9%) nonsolid.
The screening result was negative in 87.2% of all scans (21,232 out of 24,354). The result 
was indeterminate in 10.8% (2,629 out of 24,354) and positive in 2.0% (493/24,354) of 
the scans. In the first round, the proportion of indeterminate and positive scan results 
was relatively higher than in later rounds. A detailed overview of the scan results per 
screening round is presented in figures 1-3.
The 493 positive screen results led to the diagnosis of lung cancer in 200 participants. 
14 (7.0%) of these 200 participants were referred for a part-solid nodule and eight par-
ticipants (4.0%) for a nonsolid nodule. 40.6% (200 out of 493) of all positive screenings 
were ‘‘true-positive’’ (95% CI 36.1-45.2%). The positive predictive value slightly increased 
across the three rounds, from 35.5% (95% CI 28.4-42.1%) in round one to 42.0% in round 
two (95% CI 34.4-49.6%) to 45.5% (95% CI 37.6-53.3%) in round three.
The cumulative lung cancer detection rate of the three rounds was 200 (2.6%) out of 
7582 (95% CI 2.3-3.0%). This detection rate was relatively stable across the three screen-
ing rounds: 0.9% (75 of 6,922, 95% CI 0.7-1.2%) in round one, 0.8% (55 of 7,295, 95% CI 
0.6-1.0%) in round two and 1.1% (75 of 6,922, 95% CI 0.8-1.3%) in round three.
The 493 positive screen results did not lead to a lung cancer diagnosis in the remaining 
293 cases. Hence, 59.4% (293 of 493, 95% CI 54.8-63.9%) of the positive screen results 
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were actually ‘‘false-positive’’. Overall, 1.2% (293 of 24,354) of the scans performed in 
three rounds of the NELSON trial had a false-positive result.
The ratio of the overall true-positive and false-positive results (the true-positive/false-
positive ratio) was 0.69. The true-positive/false-positive ratio tended to improve over 
time, from 0.69 in round one to 0.72 in round two, and to 0.83 in round three.
To detect lung cancer in 200 participants, 7,582 individuals underwent three rounds 
of screening. In the first screening round, 108 (7,557/70) participants were screened to 
detect one lung cancer. In the second round, 133 (7,295/55) and in the third round 92 
Figure 1. Results of the first round of screening
7557 participants* - January 2004 to December 2006
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*  7,915 participants were randomised to the screen-arm of the trial and invited for screening; 25 (0.3%) partici-
pants missed screening in the first round, but were screened in the second round and 333 (4,2%) participants 
did not respond to the invitation.
#  Follow-up scans were performed after 99.6 days (mean; SD 18.3). In 8.3% of the subjects with an indetermi-
nate result the nodule(s) had disappeared. 
^  Reasons: administrative error (n=15), no show (n=13), refusal (n=3), already receiving treatment from other 
specialist (n=2).
~ Reasons: decision by tumour board (n=10), administrative error (n=3), already receiving treatment from other 
specialist (n=3).
$ 67 of 70 (95.7%) lung cancer diagnoses were confirmed by cytology or histology. Details concerning the basis of 
the diagnosed the three other cases can be found in the Appendix.
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(6,922/75) subjects were screened for the detection of one lung cancer. Cumulatively, to 
detect one lung cancer 38 participants underwent three screening rounds. 
Figure 2. Results of the second round of screening
7295 participants* - January 2005 to September 2008
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*  287 participants did not undergo a second-round scan (7,557 participants of the first round plus 25 partici-
pants who missed screening in round 1, minus 7,295) because of: lung cancer (n=68: two subjects diagnosed 
with lung cancer did receive a second round scan because of an administrative error), death (n=27), partici-
pant declined (n=115), participant unattainable or repeatedly no show (n=47), still in diagnostic work-up 
round one (n=1), administrative error (n=1), no screening in second round, but screened in third round 
(n=28). 
+ Cave, 1 participant missed the second round scan (therefore only 7,294 second-round scans were performed 
and only 480 scans were indeterminate), but he received a follow-up scan instead later on, which had a posi-
tive result.
#  Follow-up scans were performed after 76.5 days (mean; SD=35.4). In 15.5% of the subjects with an indetermi-
nate result the nodule(s) had disappeared.
^  Reasons: administrative error (n=12), no show (n=6), already receiving treatment from other specialist (n=5), 
death (n=1).
~ Reasons: administrative error (n=2), already receiving treatment from other specialist (n=5).
$ 52 of 55 (94.5%) lung cancer diagnoses were confirmed by cytology or histology. Details concerning the basis 
of the diagnosed the three other cases can be found in the Appendix. 
Cave: mortality data were available only for the Dutch participants until August 14th 2011.
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False-positive screenings
6% (458 out of 7,582) of the participants had at least one positive screening result. 31 
subjects had two positive screening results and two subjects had three positive screens. 
As 200 individuals were diagnosed with lung cancer, this implies that the remaining 258 
participants had one or more false-positive screening result (244 subjects had one, 12 
subjects had two and two subjects had three false-positive results). However, even 15 
participants who were diagnosed with lung cancer had a false-positive screening in an 
Figure 3. Results of the third round of screening
6922 participants* - January 2007 to October 2010
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*  400 participants were not screened in the third round (7,294 participants of the second round plus 28 partici-
pants who missed screening in round 2 minus 6,922) because of: lung cancer (n=57), death (n=84), partici-
pant declined (n=155), participant unattainable or repeatedly no show (n=98), administrative error (n=3), 
unknown (n=3).
#  Follow-up scans were performed after 60.3 days (mean; SD=61.9). In 13.6% of the subjects with an indeter-
minate result the nodule(s) had disappeared.
^  Reasons: administrative error (n=8), no show (n=6), refusal (n=3), already receiving treatment from other 
specialist (n=5).
~ Reasons: decision tumour board (n=3), refusal (n=1) already receiving treatment from other specialist (n=4)
$ 68 of 75 (90.7%) lung cancer diagnoses were confirmed by cytology or histology. Details concerning the basis 
of the diagnosed the seven other cases can be found in the Appendix. 
Cave: mortality data were available only for the Dutch participants until August 14th 2011.
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earlier round. Thus, 3.6% of all participants (273 out of 7,582) had a false-positive screen-
ing result.
67 (24.5%) out of the 273 participants with one or more false-positive screen result 
underwent an invasive procedure in the diagnostic work-up. 61 (91.0%) of these invasive 
procedures were surgeries (three mediastinoscopies, one sternotomy, nine video-assisted 
thoracoscopies and 48 thoracotomies) and the remaining six procedures were trans-
thoracic biopsies (more details are supplied in the Appendix). Hence, 0.9% (67 out of 
7,582) of all screened participants underwent an, in retrospect, ‘‘unnecessary’’ invasive 
diagnostic procedure.
5.5-year risk calculations
In this part of the study, we present an overview of subsequent screening results and lung 
cancer diagnoses to visualise the longitudinal character of the 5.5-year risk calculations 
(Figures 1a-d in Appendix). 70.4% of the screened participants (5,340 out of 7,582) had 
exclusively negative screen results.
The individuals with a negative first screening had a probability of 86.5% to receive 
exclusively negative screening results in 5.5 years (Figure 1a in Appendix). Furthermore, 
their risk of a false-positive screen result in the following 5.5 years was 1.3% (80 out of 
5,986 participants) and their 5.5-year risk of lung cancer was only 1.0% (60 out of 5,986 
participants).
The participants with an indeterminate result from their first screening had a prob-
ability of 72.1% to have exclusively negative screening results in the 5.5 years after the 
first screening (Figure 1b in Appendix). Their risk of a false-positive follow-up scan in 
the first screen round was 4.3% (62 out of 1,451). The risk of one or more false-positive 
scans in round two or three in this subgroup was 4.8% (70 out of 1,451). To summarise, 
after an indeterminate baseline scan result, the risk of one or more false-positive scan 
results in 5.5 years was 8.8% (128 out of 1,451). The risk of screen-detected lung cancer 
after an indeterminate baseline scan was 1.0% (15 out of 1,451) in round one and 4.6% 
(67 out of 1,451) in rounds two and three. Hence, the 5.5-year lung cancer risk after an 
indeterminate baseline scan result was 5.7% (82 out of 1,451).
The participants with a positive first screen result had a probability of 30.0% (36 out 
of 120) to have only negative screening results in the following 5.5 years (Figure 1c in 
Appendix). Their risk of a false-positive screening was 54.2% (65 out of 120) in the first 
round and 4.2% (five out of 120) in the second or third round. Furthermore, their risk 
to be diagnosed with screen-detected lung cancer within 5.5 years was 48.3% (58 out of 
120). This was 45.8% (55 out of 120) directly in round one and 2.5% (three out of 120) in 
rounds two and three. The three individuals with a lung cancer diagnosis in rounds two 
or three were, in retrospection, referred twice for the same suspicious nodule.
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The risk calculations show that the result of the baseline scan divides the screened 
population in three subgroups with distinct risks of lung cancer. The characteristics of the 
screened participants and the three subgroups are presented in table 1. When comparing 
participants with a negative, indeterminate and a positive baseline scan result, a statisti-
cally significant increase in age and number of pack-years was observed. However, there 
was no significant difference in the proportion of females and current smokers (Table 1).
DISCUSSION
In this study, we evaluated the performance of the NELSON screening strategy in the first 
three screening rounds and we assessed the 5.5-year risk of false-positive screenings and 
screen-detected lung cancer.
If we compare the performance of the NELSON screening strategy with other LDCT 
screening trials we find notable differences. The percentage of positive scans in our trial 
(2.0%) was the same as in a Danish trial,10,13 but substantially lower than in the NLST 
(24.2%).5 Also, the percentage of participants with one or more positive scan was 6.0% in 
our trial, which is low compared with the 39.1% in the NLST (the percentage in DLCST 
was not published).5
Despite the lower percentage positive screenings, our strategy detected 200 lung can-
cers in the three screening rounds. As a result, the cumulative lung cancer detection rate 
(2.6%) was a little higher than in the NLST (2.4%: 649 out of 26,309), but lower than in 
the DLCST (3.4%: 69 out of 2,047).5,10 The latter is probably due to the two additional 
screening rounds that have been completed in the DLCST.
The predictive value of a positive screen result was higher in the NELSON trial (40.6%) 
than in both the DLCST (34.8%) and the NLST (3.6%).5,10,13 Hence, the percentage of 
false-positive results was 59.4% in the NELSON trial, 65.2% in the DLCST and 96.4% in 
Table 1. Participants’ characteristics and comparison stratified by baseline scan result
Characteristics All screened Baseline scan result
participants
n (%)
negative
n (%)
indeterminate
n (%)
positive
n (%)
p- value
Females 1,254 (16.5) 1,016 (17.0) 210 (14.5) 22 (18.3) 0.06
Age - median (IQR) 58.0 (8) 57.0 (8) 59.0 (8) 59.0 (8) <0.001
Current smoker 4,215 (55.6) 3315 (55.4) 809 (55.8) 809 (55.8) 0.94
Pack-years - median (IQR) 37.8 (19.8) 38.0 (19.8) 38.7 (19.8) 38.7 (19.8) <0.001
Total 7,582 (100.0) 5,986 (100.0) 1,451 (100.0) 120 (100.0) NA
Data are presented as n or n (%), unless otherwise stated.
Definition of abbreviations: IQR = interquartile range; NA = not applicable.
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the NLST. The proportion of false-positive scans out of all scans is 1.2% in the NELSON 
trial, 1.3% in the DLCST and 23.3% in the NLST.5,10,13
In the NELSON trial, we observed that the ratio between the true-positive and false-
positive results improved over the rounds (0.69, 0.72 and 0.83 respectively in rounds one, 
two and three). This is probably the result of the possibility in later rounds to compare 
current with previous images and to calculate VDTs. In the NLST, the true-positive/false-
positive ratios were respectively 0.039 in round one, 0.025 in round two and 0.055 in 
round three (figures in the DLCST were not published).5 The improvement in the third 
round probably results from the fact that only in the third round were stable nodules ≥4 
mm in diameter not classified as positive.
Finally, the number needed to screen for the detection of one lung cancer was 92-133 
per round in the NELSON trial, which is a little less than in the other trials (97-147 in the 
NLST and 116-180 in the DLCST).5,10
In the three screening rounds, 3.6% of all participants had a false-positive screening 
result and this led to invasive diagnostic procedures in 0.9% of all participants. Although 
we are convinced of the need to reduce these numbers, we realise that these ‘‘unneces-
sary’’ invasive procedures cannot be eliminated because it is sometimes the only way to 
distinguish lung cancer from other malignancies or benign conditions.
In the second part of this study, we found that participants with a negative, indeter-
minate or positive baseline scan had very distinct risks of positive screening results and 
lung cancer. Hence, the risk of a false-positive screening result in the next 5.5 years was 
respectively 1.3%, 8.8% and 54.2% for the individuals with a negative, indeterminate or 
positive baseline scan. Moreover, the 5.5-year risk of screen-detected lung cancer was 
only 1.0% for the individuals with a negative baseline scan result, 5.7% for subjects with 
an indeterminate baseline result and 48.3% for those with a positive baseline. In other 
words, after the first screening, the individual’s lung cancer risk has either decreased by 
62% or increased by 219% or 1858%.
Analyses showed a significant increase in age and number of pack-years when compar-
ing participants with a negative, indeterminate and positive baseline scan, which are all 
well known risk factors for developing lung cancer.24
The presented results could aid clinicians when counselling high-risk subjects who are 
considering or have already undergone LDCT screening for lung cancer. This study has 
created the opportunity to personalise counselling and enables the individual at risk to 
make an informed choice. Moreover, this is the first study that quantifies both the poten-
tial benefit of screening (early detection) and a potential harm of screening (false-positive 
screening results).
The main strengths of this trial are its design (a large, randomised controlled trial), 
the population-based recruitment and prospective data collection.14,25 Limitations of the 
current study are the lack of data on false-negative screenings, the control arm of the trial 
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and lung cancer mortality. These analyses were not performed because the required data 
was not yet available.14
Future research should focus on confirming the efficacy of LDCT screening for reduc-
ing lung cancer mortality. The planned lung cancer mortality analyses of the NELSON 
trial will be crucial in this part, as our trial is the only other trial (besides the NLST) that is 
sufficiently powered. Furthermore, efforts should be made to reduce false-positive screen 
results by optimising the cut-off criteria for nodule volume and VDT.
CONCLUSION
In this study, we evaluated the performance of the NELSON screening strategy in the first 
three screening rounds. We demonstrated that our strategy yields a low percentage of 
positive and false-positive scans with a reasonable positive predictive value. Furthermore, 
we used our experience with lung cancer screening to provide an overview of the 5.5-year 
risks of lung cancer and false-positive screenings, which aids clinicians in counselling 
individuals who are considering or have already undergone LDCT screening for lung 
cancer.
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APPENDIX
Lung cancer diagnoses not proven by histology
Lung cancer diagnoses in the first three rounds of the NELSON trial were based on his-
tology or cytology in 187 of 200 (93.5%). The basis for the diagnosis in the 13 participants 
without histology or cytology is:
Round one:
1) Tumour in the right upper lobe, volume 1502mm³, PET-positive, cT1aN0M0, 
patient did not undergo thoracic surgery due to cardiac impairment. 
2) Tumour in left lower lobe, volume 2687mm³, and PET positive, and cT1aN0M0, 
patient did not undergo thoracic surgery due to COPD stage IV. 
3) Tumour in left lower lobe, volume 2792mm³, PET-positive, cT1aN0M0, patient did 
not undergo thoracic surgery due to COPD and renal failure.
Round two:
1) Tumour in right upper lobe, volume 580mm³, PET-positive, cT1aN0M0, the patient 
did not undergo thoracic surgery due to metastasized prostate carcinoma.
2) Tumour in right lower lobe, volume 2793mm³, PET-positive, cT1bN0M0, the pa-
tient did not undergo thoracic surgery due to poor pulmonary function. 
3) Tumour in right upper lobe, volume 891mm³, PET indeterminate, cT1aN0M0, the 
patient died just before intended thoracic surgery due to bowel ischemia.
Round three:
1) Tumour in right lower lobe, volume 731mm³, PET-positive, cT1aN0M0, the patient 
did not undergo thoracic surgery due to poor pulmonary function. 
2) Tumour in left lower lobe, volume 108mm³, VDT 125 days, PET-positive, 
cT1aN0M0, the patient did not undergo thoracic surgery because he also partici-
pated in another study and was randomised to the radiotherapy treatment arm.
3) Tumour in right upper lobe, volume 383mm³, VDT 289 days, PET indeterminate, 
cT1aN0M0, the patient did not undergo thoracic surgery because he refused, he was 
treated with stereotactic radiotherapy instead.
4) Tumour in left lower lobe, volume 1108mm³, PET positive, cT1aN1M0, the patient 
did not undergo thoracic surgery due to poor pulmonary function. 
5) Tumour in left lower lobe, diameter 10mm, PET positive, cT1aN0M0, and the 
patient did not undergo thoracic surgery due to poor pulmonary function. 
6) Tumour in right upper lobe, diameter 13.2x11.6mm, PET positive, cT1aN0M0, 
the patient did not undergo thoracic surgery due to poor pulmonary function and 
general condition
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7) Tumour in right upper lobe, diameter 19.2x12.7mm, PET positive, cT1bN0M0, the 
patient did not undergo thoracic surgery due to poor general condition
Figure 1a. Overview of subsequent screening test results and lung cancer diagnoses: 
participants with a negative baseline scan
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Figure 1b. Overview of subsequent screening test results and lung cancer diagnoses: 
participants with an indeterminate baseline scan
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Figure 1c. Overview of subsequent screening test results and lung cancer diagnoses: 
participants with a positive baseline scan
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Figure 1d. Overview of subsequent screening test results and lung cancer diagnoses: 
participants with no baseline scan
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screening:
25
Participants with 
lung cancer round 2
N (%)
Participants with 
lung cancer round 1
N (%)
Result screening scan
round 2
N (%)
Indeterminate: 5 (20.0)
Negative: 20 (80.0)
0 (0.0)
Participants with 
lung cancer round 3
N (%)
Result screening scan 
round 3
N (%)
Negative: 988 (87.0) 0 (0.0)20
Negative: 100 (75.8) 0 (0.0)4m 0 (0.0)
25
0 (0.0)
Total first 
round scans 
N=0
Total participants 
with lung cancer 
round 2 N=0
Total participants 
with lung cancer 
round 1 N=0
Total second round  
screening scans
N=25
Total participants 
with lung cancer 
round 3 N=0
Total third round 
screening scans
N=1,088
* 25 participants had no screening scan in the first round, because there was a delay in the returning of the 
informed consent.
# 15 participants had no screening scan in the second round because: participant declined (n=1), participant 
unattainable or repeatedly no show (n=14).
¶ 12 participants had no screening scan in the second round because: still in diagnostic work-up round one 
(n=2), participant declined (n=2), participant unattainable or repeatedly no show (n=4), administrative error 
(n=4).
+ 1 participant had no screening scan in the second round because: still in diagnostic work-up round one (n=1)
a  142 participants (5,986 minus 5,829) were not screened in the second and third round. Reasons: death (n=19), 
participant declined (n=81), participant unattainable or repeatedly no show (n=41), administrative error 
(n=1).
b  52 participants (1,451 minus 1,399) were not screened in the second and third round. Reasons: lung cancer 
(n=13), death (n=7) still in diagnostic work-up round one (n=1), participant declined (n=25), participant 
unattainable or repeatedly no show (n=6). Cave: the other two subjects with screen-detected lung cancer did 
receive a second round scan because of an administrative error.
c 66 participants (120 minus 54) were not screened in the second and third round. Reasons: screen-detected lung 
cancer (n=55), death (n=1), participant declined (n=10).
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d 255 participants (5,479 minus 5,224) were not screened in the third round. Reasons: death (n=56), partici-
pant declined (n=112), participant unattainable or repeatedly no show (n=82), administrative error (n=2), 
unknown (n=3).
e 21 participants (311 minus 290) were not screened in the third round. Reasons: lung cancer (n=7), death 
(n=3), participant declined (n=9), participant unattainable or repeatedly no show (n=2).
f 19 participants (39 minus 20) were not screened in the third round. Reasons: lung cancer (n=13), death (n=2), 
participant declined (n=4).
g 49 participants (1,184 minus 1,135) were not screened in the third round. Reasons: death (n=16), participant 
declined (n=22), participant unattainable or repeatedly no show (n=10), administrative error (n=1).
h 23 participants (155 minus 132) were not screened in the third round. Reasons: lung cancer (n=10), death 
(n=6), participant unattainable or repeatedly no show (n=2), participant declined (n=5). Cave, one partici-
pant was already diagnosed with lung cancer in de first round, but received a second round scan because of an 
administrative error.
i 25 participants (48 minus 23) were not screened in the third round. Reasons: lung cancer (n=24), participant 
declined (n=1). Cave, one participant was already diagnosed with lung cancer in de first round, but received a 
second round scan because of an administrative error.
j 4 participants (41 minus 37) were not screened in third round. Reasons: death (n=1), participant declined 
(n=2), participant unattainable or repeatedly no show (n=1).
k  2 participants (9 minus 7) were not screened in the third round. Reasons: lung cancer (n=2).
l 1 participant (3 minus 2) were not screened in the third round. Reasons: lung cancer (n=1).
m 1 participant (5 minus 4) were not screened in the third round. Reasons: participant unattainable or repeatedly 
no show (n =1).
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ABSTRACT
The NELSON trial is, with 15,822 participants, the largest European lung cancer computer 
tomography screening trial. A volumetry-based screening strategy, stringent criteria for 
a positive screening, and an increasing length of screening interval are particular features 
of the NELSON trial.
To determine the effect of stringent referral criteria and increasing screening interval 
on the characteristics of screen-detected lung cancers, and to compare this across screen-
ing rounds, between sexes, and with other screening trials.
All NELSON participants with screen-detected lung cancer in the first three rounds 
were included. Lung cancer stage at diagnosis, histological subtype, and tumour localisa-
tion were compared between the screening rounds, the sexes, and with other screening 
trials. 
In the first three screening rounds, 200 participants were diagnosed with 209 lung 
cancers. Of these lung cancers, 70.8% were diagnosed at stage I and 8.1% at stage IIIB–IV, 
and 51.2% were adenocarcinomas. There was no significant difference in cancer stage, 
histology, or tumour localisation across the screening rounds. Women were diagnosed at 
a significantly more favourable cancer stage than men. Compared with other trials, the 
screen-detected lung cancers of the NELSON trial were relatively more often diagnosed 
at stage I and less often at stage IIIB–IV.
Despite stringent criteria for a positive screening, an increasing length of screening 
interval, and few female participants, the screening strategy of the NELSON trial resulted 
in a favourable cancer stage distribution at diagnosis, which is essential for the effective-
ness of our screening strategy.
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INTRODUCTION
Lung cancer is the leading cause of cancer-related death in males and the second in fe-
males globally, accounting for 1.4 million lung cancer deaths per year.1 Despite treatment 
advances, survival has not improved substantially, mainly because the majority of the 
patients have distant metastases at the time of diagnosis.2 Several randomised lung cancer 
screening trials were conducted with low-dose computer tomography (LDCT) scanning 
of high-risk groups, aiming to detect lung cancer at an earlier and curable stage.3–7
The world’s largest randomised CT screening trial, the National Lung Screening Trial 
(NLST), demonstrated in 2011 that early detection by LDCT scanning has yielded a 20% 
lung cancer mortality reduction compared with screening by chest radiograph.8 Sixty-
one percent of the LDCT-detected lung cancers were diagnosed at stage I. To accomplish 
this impressive result, considerable efforts were made. Namely, 26,722 high-risk subjects 
underwent annual LDCT screening for 3 years. Positive screening results were defined 
as any non-calcified pulmonary nodule measuring at least 4 mm in any diameter. In the 
three screening rounds, 39.1% of the individuals had at least one positive result.8
Our trial, the Dutch–Belgian Lung Cancer Screening Trial (Nederlands-Leuvens 
longkanker screeningsonderzoek; the NELSON trial), is the world’s second-largest 
randomised CT screening trial and differs from the NLST by screening interval, referral 
policy, and a control arm wherein individuals receive no screening.3 The 7,915 partici-
pants randomised to the screening arm of the NELSON trial underwent LDCT screening 
at baseline, 1 year later, 2 years later, and finally 2.5 years later. Positive screening results 
were defined as non-calcified nodules with a volume greater than 500 mm3 (about 9.8 
mm in diameter) or volume-doubling time (VDT) less than 400 days.3,9,10 In the first three 
screening rounds, 6.0% of the participants had at least one positive screening. Clearly, 
the differences between the two largest randomised CT screening trials are substantial. 
Whether the NELSON trial will be able to demonstrate a significant lung cancer mortal-
ity reduction must be awaited, because the mortality analyses are planned 10 years after 
randomisation.11 However, the characteristics of the screen-detected lung cancers, espe-
cially the stage distribution, might give an indication of the effectiveness of our screening 
strategy.
For this study, all participants with screen-detected lung cancer in the first three rounds 
of the NELSON trial were included. Lung cancer stage at diagnosis, histological subtype, 
and tumour localisation were compared between the screening rounds, the sexes, and 
several randomised CT screening trials.
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METHODS
NELSON trial
The 15,822 individuals in the NELSON trial were randomised (1:1) to screening (n = 
7,915) with LDCT at baseline (first round), 1 year later (second round), 3 years later 
(third round), and 5.5 years later (fourth round) or no screening (n = 7,907) (Figure 1). 
The main purpose of the trial is to determine whether LDCT screening will have reduced 
lung cancer mortality by at least 25% at 10 years of follow-up.11,12 A more detailed report 
of the design and conduct was published previously.9,11
Figure 1. Participant flowchart in the first three rounds of the NELSON trial
N=25
Eligible 
participants
N=15,822
Screen-arm
N=7,915
Control-arm N=7,907
Round one
N=7557
Round two
N=7295
Round three
N=6922
No screening in second 
round N=219*
Non-responders N=358
No screening in third round
N=345#
Lung cancer
N=70
Lung cancer
N=55
Lung cancer
N=75
N=2
N=27
* 219 participants were not screened in the second round because of death (n = 27), participant declined (n = 
115), participant unattainable or repeatedly no show (n = 47), administrative error (n = 1), still in diagnostic 
work-up round 1 (n = 1), no screening in second round, but screened in third round (n = 27). 
# 345 participants were not screened in the third round because of lung cancer in round 1 (n = 2), death (n = 84), 
participant declined (n = 155), participant unattainable or repeatedly no show (n = 98), administrative error 
(n = 3), unknown (n = 3). 
Note: mortality data were available only for the Dutch participants until August 14, 2011.
85
Characteristics of screen-detected lung cancer
Participants
Individuals aged 50 to 75 years, who had smoked 15 or more cigarettes per day for 25 
years or 10 or more cigarettes for 30 years and were still smoking or had quit less than 10 
years ago, met the inclusion criteria. The exclusion criteria and calculation of expected 
lung cancer mortality were published in 2006.11 For this study, all participants diagnosed 
with screen-detected lung cancer in the first three screening rounds were included (Fig-
ure 1). Hence, the interval cancers were not included in the analyses.
Equipment and Nodule Management Protocol
In short, 16-detector CT modality was used in a low-dose setting, without intravenous 
contrast medium.9 CT images were analysed with software for semi-automated volume 
measurements (LungCARE, Siemens Healthcare, Erlangen, Germany).13,14
Briefly, the screening test result could be negative (invitation for the next screen round), 
indeterminate (invitation for a repeat scan to determine the VDT), or positive (referral 
for diagnostic work-up). The nodule volume determined the screen result for newly 
detected nodules: less than 50 mm³ was negative, 50 to 500 mm³ was indeterminate, 
and more than 500 mm³ was positive. The percentage volume change was calculated for 
previously detected nodules: at least 25% led to the assessment of the VDT. The VDT was 
calculated according to the formula: VDT(days) = [ln 2 x (time between current scan and 
baseline screening)]/[ln(nodule volume on current scan/volume on baseline scan)].9 The 
screen result was positive for a VDT less than 400 days. A full description of the protocol 
was published previously.9,10
Referral and Diagnostic Work-Up
After a positive screening, the participants were referred for diagnostic work-up via their 
general practitioner and received usual care according to national and international 
guidelines.15-19 All data were prospectively collected and histological specimens were 
reassessed by our chief pathologist (E.T.).
Statistical Analyses
Continuous variables were tested for normality using the Kolmogorov-Smirnov test for 
50 or more samples, and using the Shapiro-Wilk test for fewer than 50 samples. Continu-
ous, normally distributed variables were described by means and standard deviations. 
The difference between the means of continuous variables was calculated by one-way 
analysis of variance. Non-normally distributed variables were described by medians and 
interquartile ranges. The difference between nominal variables was calculated using the 
chi2-test and differences between categorical variables were calculated using the Mann-
Whitney U test. The difference between more than two samples of a categorical variable 
was calculated using the Kruskal-Wallis H test. Predictors of cancer stage were tested 
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using ordinal logistic regression; variables entered multivariate models when the P-value 
did not exceed 0.05 univariately. P-values less than 0.05 were treated as significant. SPSS 
Statistics version 20 (IBM, Armonk, NY) was used for all analyses.
Ethics and Legal Approval
The NELSON trial was approved by the Dutch Ministry of Health and the ethics board 
at each participating centre. All participants gave written informed consent for participa-
tion and the evaluation of personal data from hospital charts.
RESULTS
Participants
Of the 7,915 (95.8%) participants randomised to the screening arm of the trial, 7,582 
received at least one screening (Figure 1). Their baseline characteristics are presented in 
Table 1. The three screening rounds yielded 493 positive screen results and 200 (40.6%) 
participants were diagnosed with lung cancer. Synchronous double tumours were detected 
in four participants in round 1, in three participants in round 2, and in two participants 
in round 3. Thus, 200 participants were diagnosed with a total of 209 lung cancers. The 
patients with lung cancer were significantly older and had smoked significantly more 
pack-years than had the subjects not diagnosed with lung cancer (Table 1).
Lung Cancer Symptoms
Eleven of the 200 participants (5.5%) had symptoms suspicious of lung cancer before 
they were diagnosed. Five of them had symptoms before the screening scan was made; 
Table 1. Characteristics of the NELSON participants
Characteristics* All participants
n (%)
Participants 
diagnosed with
lung cancer †
n (%)
Participants not 
diagnosed with lung 
cancer
n (%)
p-value ‡
Female gender, n(%) 1,254 (16.5) 34 (17,0) 1,220 (16.5) 0.86
Current smoker, n(%) 4,215 (55.6) 112 (56,0) 4,103 (55.6) 0.91
Pack-years, median (IQR) 38.0 (29.7 - 49.5) 43.7 (32.2 - 75.8) 38.0 (29.7 - 49.5) < 0.001
BMI, median (IQR) 25.8 (23.9 - 28.1) 25.4 (23.3 - 28.0) 25.8 (23.9 - 28.1) 0.09
Total 7,582 (100.0) 200 (100.0) 7,382 (100.0) NA
Definition of abbreviations: IQR= interquartile range; BMI= body mass index; NA = not applicable.
* At randomisation.
† In the first three screening rounds of the NELSON trial.
‡ Comparison participants with versus without lung cancer.
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however, none of them had symptoms at randomisation. Three subjects had symptoms 
in the period between the positive scan and the first consultation, and three subjects 
had symptoms in the period between the first consultation and the diagnosis date. Box 
plots of the time to screening result, referral, and diagnosis of the 200 participants and a 
detailed description of the symptoms can be found in the Appendix (Figure 1).
Lung Cancer Characteristics
More than half of the 209 screen-detected lung cancers were adenocarcinomas (51.2%) 
and a large majority was diagnosed at an early stage (stage I, 70.8%) (Table 2).  Adeno-
carcinomas appeared to be diagnosed at a significantly lower cancer stage (univariate 
analysis p = 0.045), but in multivariate analysis this was no longer significant (p = 0.56) 
(Table 1 in Appendix). However, all bronchoalveolar carcinomas (n = 11) and carcinoids 
(n = 6) were diagnosed at stage Ia (Table 2). Four other histological subtypes were prone 
Table 2. Histology and cancer stage of 209 screen-detected lung cancers in 200 par-
ticipants
Cancer stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n(%) n(%) n(%) n (%) n (%) n (%) n (%) n (%)
Adenocarcinoma 75 (70.1) 9 (8.4) 8 (7.5) . 9 (8.4) 4 (3.7) 2 (1.9) 107 (51.2)
Bronchoalveolar carcinoma 11 (100.0) . . . . . . 11 (5.3)
Squamous cell carcinoma 21 (61.8) . 3 (8.8) . 8 (23.5) . 2 (5.9) 34 (16.3)
Adenosquamous carcinoma . . . . . . . 4 (1.9)
Large cell carcinoma 7 (41.2) 1 (5.9) . . 6 (35.3) 2 (11.8) 1 (5.9) 17 (8.1)
Large cell neuro-endocrine 
carcinoma 2 (50.0) 1 (25.0) . . 1 (25.0) . . 4 (1.9)
Small cell carcinoma . . . . 5 (62.5) . 3 (37.5) 8 (3.8)
Small/large cell carcinoma . . . . 1 (50.0) . 1 (50.0) 2 (1.0)
Pleiomorph carcinoma . . 1 (100.0) . . . . 1 (0.5)
NSCLC-NOS . . . . . 1 (50.0) 1 (50.0) 2 (1.0)
Carcinoid 6 (100.0) . . . . . . 6 (2.9)
No histological diagnosis‡ 12 (92.3) . 1 (7.7) . . . . 13 (6.2)
Total 137 (65.6) 11 (5.3) 14 (6.7) . 30 (14.4) 7 (3.3) 10 (4.8) 209 (100)
Definition of abbreviations: NSCLC = non-small cell lung carcinoma; NOS = not otherwise specified.
* 7th edition of the IASLC TNM staging system (2009).
† According to Travis et al. Pathology and Genetics. Tumours of the Lung, Pleura and Heart. IARC Press (2004).
. = 0 (0.0).
‡ In 13 participants no histological diagnosis was established because biopsies were unsuccessful or not performed 
and the patient did not undergo thoracic surgery because of poor pulmonary function (n = 7), poor heart func-
tion (n = 1), poor general condition (n = 1), metastasised prostate carcinoma (n = 1), death due to mesenteric 
ischemia before intended surgery (n = 1), radiotherapy because of participation in other clinical trial (n = 1) and 
refusal (n = 1).
 In 10 lung resection specimens the pathologist found, besides the lung cancer, a focus of atypical adenomatous 
hyperplasia.
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to be diagnosed at a higher cancer stage; for example, small cell carcinomas (multivariate 
analysis P < 0.001) (Table 1 in Appendix).
Most lung cancers were localised in the right lung (65.6%) and a large proportion (45.0% 
of all lung cancers) was localised in the right upper lobe (Figure 2). We also observed that 
the lung cancers were localised predominantly in the periphery of lungs (Figure 3). Of the 
nodules, 62.2% were found in the outer one-third of the costal-hilar diameter (Figure 3). 
In particular, adenocarcinomas were more often detected in the periphery and attached 
to the pleura than in the middle or central one-third of the lungs (82.2% vs. 17.8%; p = 
0.001). But the reverse was not true for squamous cell carcinomas (62.9% peripheral or 
pleural-attached vs. 37.1% central or middle one-third; p = 0.16).
Effect of screen round
The lung cancers detected in round 1 had a slightly higher disease stage (stage Ia 59.5%, 
stage IV 6.8%) than in later rounds (round 2: stage Ia 74.1%, stage IV 3.4%, and round 3: 
Figure 2. Localisation across the lobes of the 209 screen-detected lung cancers.
94
(45.0%)
11
(5.3%)
40
(19.1%)
3
(1.4%)
32
(15.3%)
28
(13.4%)
1
(0.5%)
A schematic depiction of the lungs and large airways. The right lung is displayed on the left side and vice versa, as 
on a chest radiograph. The left upper lobe is divided in the pars superior and the lingula by the dotted line. The lung 
cancers are depicted as dark grey dots; their localisation corresponds with the lobe where the nodule was detected, 
not with the exact localisation.
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stage Ia 64.9%, stage IV 3.9%) (Tables 2a-2c in Appendix). But this was not statistically 
significant between rounds 1 and 2 (p = 0.09) or across the three rounds (p = 0.23).
Also, the proportion adenocarcinomas was not significantly different between rounds 
1 and 2 (47.3% vs. 60.3%; p = 0.14) or across the three rounds (round 3: 48.1% adenocar-
cinomas; p = 0.26) (Tables 2a-2c in Appendix). 
Likewise, tumour localisation was not significantly different across the screen rounds: 
neither for the division over the lobes (p = 0.88) nor for the division over the peripheral 
versus central lung fields (p = 0.09).
Effect of sex
The women diagnosed with lung cancer were significantly younger (58.0 vs. 62.0 years; p 
= 0.03), had smoked less (pack-years: 36.0 vs. 43.0; p = 0.03) and had a lower BMI (23.8 
Figure 3. Localisation of the 209 screen-detected lung cancers; central versus peripheral.
13
(6.2%)
19
(9.1%)13
(6.3%)92
(44.0%) 11(5.3%)
39
(18.7%)
1
(0.5%)
7
(3.3%)
14
(6.7%)
A schematic depiction of the lungs and main carina in the transversal plane. The right lung is displayed on the left 
side and vice versa as in computer tomography images. 
The lungs are categorised in four sections: central (inner one-third of the hilar costal diameter), middle (middle one-
third of the hilar-costal diameter), peripheral (outer one-third of the hilar-costal diameter) and pleural-attached 
nodules (nodules depicted on the bold outline of the lungs) The lung cancers are depicted as dark grey dots; their 
localisation corresponds with the section where the nodule was detected, not with the exact localisation. One lung 
cancer is not represented in the figure because the  participant was referred for a fast-growing nodule peripheral 
in the right upper lobe, but this nodule disappeared during the work-up. However, soon thereafter lung cancer 
developed in the left lower lobe (transversal localisation unknown) and the patient was treated with radiotherapy. 
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vs. 25.9; p = 0.03) than the men diagnosed with lung cancer. The percentage current 
smokers however, was not lower in females (56.7 vs. 55.9%; p = 0.93).
None of the histological subtypes were unevenly distributed between the sexes (Tables 
3a and 3b in Appendix). Also, the localisation of the lung cancers was not significantly 
different between the sexes: neither for the left lung versus right lung localisation (p = 
0.92), nor for peripheral versus central localisation (p = 0.89). However, the cancer stage 
at diagnosis was significantly lower in women than in men (p = 0.005) (Tables 3a and 3b 
in Appendix). When correcting for the sex differences in age, number of pack-years and 
BMI, women still had a statistically significant lower cancer stage than men (p = 0.028) 
(Table 4 in Appendix).
Coincidentally, we found that a higher body mass index (BMI) (before randomisation) 
was a significant multivariate predictor (p = 0.004) of a more unfavourable cancer stage 
at diagnosis in both sexes (Table 4 in Appendix).
Comparison of trials
A total of 1,078 lung cancers were detected by CT screening in 43,983 participants of ran-
domised screening trials (Table 3). On average, 64.7% of the lung cancers were diagnosed 
at stage I and 10.9% at stage IIIb–IV (Table 3). The stage distribution in the NELSON trial 
appears to be relatively favourable compared with the other trials. When we compare the 
Table 3. Overview of cancer stage at diagnosis of  screen-detected lung cancers in 
randomised CT screening trials
Trial Participants
screen arm
n
Screening
rounds
n
Length
screening
interval (yrs)
Males –
females
(% – %)
No. of 
published
CT-detected
lung cancers
Stage Ia + Ib
lung cancers
n (%)
Stage IIIb + IV
lung cancers
n (%)
NLST8 26,722 3 1 59.0 – 41.0 649 400 (61.6) 130 (20.0)
NELSON 7,915 4 1, 2 and 2.5 83.5 – 16.5 209 148 (70.8) 17 (8.1)
DLST36 2,052 5 1 54.6 – 45.4 69 47 (68.1)* 11 (15.9)†
ITALUNG7 1,613 4 1 64.2 – 35.8 22 11 (50.0)‡ 5 (22.7)
DANTE37 1,276 4 1 100.0 – 0.0 58 41 (70.7) 4 (6.9)
MILD38 1,190
1,186
10
5
1
2
68.4 – 31.6
68.5 – 31.5
29
20
18 (62.1)
14 (70.0)
4 (20.0)
5 (17.2)
LUSI39 2,029 4 1 64.8 – 35.2 22 18 (81.8) 0 (0)
Total 43,983 3 to 10 1 to 2.5 65.4 – 34.6 1078 697 (64.7)§ 118 (10.9)*
Definition of abbreviations: CT = computed tomography; DLST = Danish Lung Cancer Screening Trial; MILD = 
Multicentric Italian Lung Detection; NELSON = Nederlands-Leuvens Longkanker ScreeningsOnderzoek (Dutch–
Belgian Lung Cancer Screening Trial); NSLT = National Lung Screening Trial.
* This not include two participants diagnosed with limited stage small cell lung carcinoma.
†  This includes the participant diagnosed with extensive stage small cell lung carcinoma. 
‡  This not include the three participants diagnosed with limited stage small cell lung carcinoma.
§  This does not include the four participants with limited stage small cell lung carcinoma.
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whole range of cancers stages between the two largest trials (NLST and NELSON) we 
observe that the cancer stage was significantly lower (p = 0.001) in the NELSON trial.
DISCUSSION
In this study, we have presented the characteristics of the lung cancers detected in the 
first three rounds of the NELSON trial. We investigated whether the screening strategy of 
the NELSON trial led to detection of lung cancer at a more favourable stage and how this 
relates to other randomised lung cancer CT screening trials.
In the three screening rounds, 493 participants had a positive screening result and were 
referred for diagnostic work-up. Ultimately, 200 (40.6%) participants were diagnosed 
with a total of 209 lung cancers. Eleven (5.5%) of these participants had symptomatic 
lung cancer before diagnosis; in five subjects the symptoms emerged before the screening 
scan was made.
More than half of the 209 screen-detected lung cancers were adenocarcinomas (51.2%) 
and a large majority was diagnosed at stage I (70.8%). Moreover, only 10 lung cancers 
were diagnosed at stage IV. This favourable stage distribution has created the opportunity 
for most patients to undergo curative surgery, which hopefully will reduce lung cancer 
mortality. However, screening detected only a few small cell lung cancers and all were 
diagnosed at stage III-IV. This finding could imply that LDCT screening is not, or is less, 
capable of early detection in some fast-growing histological subtypes of lung cancer. Fur-
ther research should be conducted to investigate whether the lung cancers not detected 
by screening are predominantly of the same histological subtypes that are detected only 
in small amounts or high stages by screening.
Most screen-detected lung cancers were localised in the periphery of the lungs, which 
is probably a result of the large amount of adenocarcinomas that are significantly more 
often localised peripherally (p = 0.001). We also observed that 45.0% of all lung cancers 
were localised in the right upper lobe. This is a known phenomenon in patients with 
non-small cell lung cancer and could be explained by the fact that the airflow at the be-
ginning of the breath is the largest toward the right upper lobe bronchus.20,21 As a result, 
the deposition of particles in tobacco smoke and their carcinogenic effects are the largest 
in the right upper lobe.22,23
Further, our analyses showed no significant effect of screening round on cancer stage, 
histology, or tumour localisation. However, a decrease in advanced-stage lung cancers was 
observed at the second screening round (stage IV dropped from 6.8 to 3.4%). This was 
probably not statistically significant because of the low absolute number of advanced-stage 
lung cancers. In the third screening round, no evidential increase in stage IV lung cancers 
was observed (3.9%), despite the screening interval of 2 years.
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The differences in lung cancer characteristics between men and women have been 
studied extensively. In general, studies demonstrated that women are diagnosed at an 
earlier age,24,25 at a more favourable cancer stage,25-27 and are more often diagnosed with 
adenocarcinomas than are men.24,28,29 NELSON is the first trial to report on these differ-
ences in a screening setting. We also found that women were diagnosed at a significantly 
more favourable cancer stage than men (p = 0.028, after correction for confounding). 
However, the histological subtype and localisation of the lung cancers were not signifi-
cantly different between the sexes.
In the NELSON trial, the body mass index (BMI) was not significantly higher in the 
participants diagnosed with lung cancer than in participants who were not diagnosed 
(p = 0.09). However, a higher BMI was a significant multivariate predictor of a more 
unfavourable cancer stage at diagnosis (p = 0.004). This finding is in line with one other 
study.30 However, most studies demonstrated a negative association between BMI and 
lung cancer risk and prognosis.31-33 This discrepancy could be explained in the first place 
by reversed causation: BMI is usually measured at diagnosis, at that time weight loss 
has often occurred, especially patients with a higher cancer stage. In the NELSON trial, 
BMI was measured just before randomisation and because none of the participants had 
symptomatic lung cancer at that time, the BMI was not influenced by lung cancer itself. 
In the second place, the discrepancy could be explained by the strong confounding effect 
of smoking in many trials: smokers have a lower mean BMI than non-smokers34 and 
smoking is major risk factor for lung cancer mortality.32 This bias is probably limited in 
the NELSON trial because we included only (ex-)smokers.11
In this article, we have presented an overview of the disease stage of the LDCT-detected 
lung cancers of the randomised screening trials. The cancer stage distribution in the 
NELSON trial appeared favourable relative to the other trials and was significantly lower 
(p < 0.001) than in the NLST. This last finding should be interpreted with caution because 
the NELSON trial used the 7th edition and the NLST the 6th edition of the TNM staging 
system16,35 Classification according to the 7th edition results more often in a lower cancer 
stage than in a higher stage compared with classification according to the 6th edition.16,35 
Consequently, this might have contributed to the lower cancer stage in the NELSON 
trial. Nonetheless, the NELSON trial has a number of features that could cause a higher 
cancer stage: firstly, relatively few female participants (16.5% vs. 41% in NLST), who are 
diagnosed at a lower stage; secondly, larger nodules at referral, due to relatively stringent 
referral criteria (nodule volume > 500 mm³ or nodule VDT < 400 days vs. nodule di-
ameter > 4 mm in NLST); and thirdly, a longer screening interval (1, 2, and 2.5 years vs. 
annual screening in NLST). All things considered, it seems that the  NELSON strategy 
is at least as capable as the NLST strategy to diagnose lung cancer at a more favourable 
stage.
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Naturally, this result rises a question concerning what the difference in cancer stage be-
tween the two trials would be if all lung cancers in screened participants were compared. 
Analysis showed no significant difference (p = 0.21), despite the shorter interval between 
screen rounds in the NLST.8
Strengths of this study are the robust design (a large, randomised controlled trial) and 
prospective data collection. Limitations of this study are the lack of data for the control 
arm of the trial and lung cancer mortality. We have planned to perform analyses with 
those data 10 years after randomisation, in accordance with the main purpose of our 
trial.11
CONCLUSION
Despite stringent referral criteria, an increasing length of screening interval, and a small 
proportion of female participants, the screening strategy of the NELSON trial resulted 
in a favourable cancer stage distribution at diagnosis, which is a pre-requisite for the 
effectiveness of our screening strategy.
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APPENDIX
Figure 1. Time from positive screen to first consultation and to lung cancer diagnosis
B
C D
A
time from scan (t=0) to final scan result (days) time from final result (t=0) to first consultation pulmonologist (days)
time from final first consultation pulmonologist (t=0) 
to diagnosis (days) mediastinoscopy
time from final first consultation pulmonologist (t=0) 
to diagnosis (days) no mediastinoscopy
Time to screening result, referral and diagnosis
The dotted line represents the deadline according to the NELSON protocol in the first 
box plot and the deadline according to the national Dutch guideline in the other three 
box plots. 
Panel A: The median time to the final screening result for the 200 participants with 
screen-detected lung cancer was twelve days (interquartile range (IQR): 8 - 16) and 87.5% 
(175/200) waited ≤3 weeks. 
Panel B: Thereafter, the median time to the first consultation by a pulmonologist was 
13 days (IQR: 7 - 20.75) and 27.5% (55/200) had their first consultation in ≤5 work-days.
Panel C: In subjects who did not undergo a mediastinoscopy as part of the diagnostic 
work-up (n = 162), was the median time from the first consultation to the lung cancer 
diagnosis 42 days (IQR: 26.75 - 69), 17.9% was diagnosed in 3 weeks. 
Panel D: When mediastinoscopy was performed (n = 38) the median time to diagnosis 
was 49 days (IQR: 31.5 - 66) and 28.9% was diagnosed in 5 weeks. 
Analyses showed that neither a delayed final scan result (p = 0.39) nor a delayed first 
consultation (p = 0.19) was related to a more unfavourable cancer stage at diagnosis. 
Moreover, the participants with a delayed lung cancer diagnosis had a significantly lower 
disease stage than the persons without a delay (p < 0.001).
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Outliers
Three participants had an extremely long lead-time between the positive scan and the 
first consultation (marked with a * in panel A). One participant (134 days) refused to go 
to the pulmonologist before a planned stay abroad. The two other participants (106 and 
100 days) were delayed because of an administrative error.
Fifteen subjects had an extremely long lead-time between the first consultation and the 
diagnosis (marked with a * in panel B). Reasons were: watchful waiting approach by the 
pulmonologist (n = 9), delay caused by the participant (n = 2), comorbidity that required 
immediate treatment (n = 2), malignant nodule missed by wedge-resection; requiring 
a second procedure to perform a lobectomy (n = 1) and treatment of another benign 
nodule first (n = 1).
In total, eleven of the 200 (5.5%) participants had symptoms suspicious of lung cancer 
before they were diagnosed. 
Symptomatic participants
Five participants had already symptoms suspicious of lung cancer before the screening 
scan was made:
1) 74 days before the third round scan: dyspnoea and cough
2) 287 days after the pre-randomisation questionnaire and 15 days before the baseline 
scan: dyspnoea, cough and thoracic pain. 
3) 172 days before the second round scan: start weight loss >10%
4) 88 days before the baseline scan: start weight loss >10% and thoracic pain
5) 224 days after the pre-randomisation questionnaire and 124 days before the baseline 
scan: fatigue
Three participants got their first symptoms suspicious of lung cancer in the interval 
between the positive scan and the first consultation:
1) weight loss >10% and fatigue (interval was 15 days)
2) haemoptysis and thoracic pain (interval was 4 days)
3) cough (interval was 10 days)
Three other participants developed symptoms suspicious of lung cancer in the interval 
between the first consultation and the diagnosis date:
1) cough (interval was 278 days, delay due to cardiac valve replacement that had to be 
performed before lung surgery)
2) weight loss >10% (interval was 131 days, delay due to a false-positive N3 on the 
PET-scan, which required CT-guided punction and mediastinoscopy, that were 
both negative) haemoptysis (interval was 30 days, no delay)
3) cough (interval was 10 days)
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Table 1. Predictive value of histological subtype for cancer stage at diagnosis
Thresholds for significant 
histological subtypes Adenocarcinoma
Large cell 
carcinoma
Small cell 
carcinoma
Mixed LCSC 
carcinoma
NSCLC-
NOS
All significant 
histological 
subtypes
Stage Ia to Ib 0.35 0.74 0.75 0.67 0.67 1.08
Stage Ib to IIa 0.59 0.99 1.02 0.92 0.92 1.37
Stage IIa to IIIa 0.95 1.36 1.41 1.28 1.28 1.82
Stage IIIa to IIIb 2.16 2.58 2.75 2.51 2.55 3.40
Stage IIIb to IV 2.73 3.15 3.36 3.09 3.17 4.11
Histological Univariate log regression analyses Multivariate log regression analysis
subtypes estimate 95% CI p-value estimate 95% CI p-value
Adenocarcinoma -0.57 -1.13--0.01 0.045 0.20 -0.46-0.86 0.56
Bronchoalveolar carcinoma * * *
Squamous cell carcinoma 0.19 -0.54-0.92 0.61
Adenosquamous carcinoma -0.60 -2.94-1.74 0.61
Large cell carcinoma 1.16 0.25-2.08 0.013 1.68 0.67-2.70 0.001
Large cell NE carcinoma 0.32 -1.61-2.24 0.75
Small cell carcinoma 2.93 1.57-4.28 <0.001 3.54 2.09-5.00 <0.001
Mixed LCSC carcinoma 3.08 0.45-5.72 0.022 3.97 1.29-6.65 0.004
Pleiomorph carcinoma 1.07 -2.48-4.63 0.55
NSCLC- NOS 3.67 0.84-6.50 0.011 4.59 1.70-7.47 0.002
Carcinoid * * *
No histological diagnosis -1.95 -4.04-0.13 0.07
The thresholds in the columns “adenocarcinomas”, ”large cell carcinoma”, “small cell carcinoma”, “mixed LCSC” 
and “NSCLC-NOS” are parameters for the effect of the variable on the cancer stage (like; the distance between the 
stages) in four separate univariate logistic categorical regression analysis. There is no threshold for stage IIA to stage 
IIB because none of the participants were diagnosed with stage IIB lung carcinoma. 
The threshold column “all significant histological subtypes” represents the threshold for the multivariate (adeno, 
large cell, small cell, mixed and NSCLC-NOS) logistic categorical regression model.
Definition of abbreviations: Mixed LCSL carcinoma = mixed large cell and small cell lung carcinom; NSCLC-NOS 
= non-small cell lung carcinoma; not otherwise specified; 95% CI = 95% confidence interval of the estimate; Large 
cell NE carcinoma = large cell neuro-endocrine carcinoma.
* Both the bronchoalveolar carcinomas and the carcinoids were all diagnosed in stage IA, which caused separa-
tion, therefore no estimate or p-value could be calculated.
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Table 2a. Histology and disease stage of the 74 screen-detected lung cancers in round one
Disease stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Adenocarcinoma 21 (60.0) 2 (5.7) 4 (11.4) . 4 (11.4) 3 (8.6) 1 (2.9) 35 (47.3)
Bronchoalveolar carcinoma 2 (100.0) . . . . . . 2 (2.7)
Squamous cell carcinoma 9 (60.0) . 2 (13.3) . 3 (20.0) . 1 (6.7) 15 (20.3)
Adenosquamous carcinoma 2 (100.0) . . . . . . 2 (2.7)
Large cell carcinoma 2 (40.0) 1 (20.0) . . 2 (40.0) . . 5 (6.8)
Large cell NE carcinoma 1 (33.3) 1 (33.3) . . 1 (33.3) . . 3 (4.1)
Small cell carcinoma . . . . . . 1 (100.0) 1 (1.4)
Mixed LCSC carcinoma . . . . . . 1 (100.0) 1 (1.4)
Pleiomorph carcinoma . . 1 (100.0) . . . . 1 (1.4)
NSCLC-NOS . . . . . 1 (50.0) 1 (50.0) 2 (2.7)
Carcinoïd 4 (100.0) . . . . . . 4 (5.4)
No histological diagnosis§ 3 (100.0) . . . . . . 3 (4.1)
Total 44 (59.5) 4 (5.4) 7 (9.5) . 10 (13.5) 4 (5.4) 5 (6.8) 74 (100.0)
Definition of abbreviations: large cell NE carcinoma = large cell neuro-endocrine carcinoma; mixed LCSC car-
cinoma = mixed large cell/small cell carcinoma; NSCLC-NOS = non-small cell lung carcinoma, not otherwise 
specified; . = 0.0.
* 7th edition TNM staging system (2009).
† According to IARC Tumours of the Lung, Pleura and Heart (2004).
§ In three participants no histological diagnosis was established because biopsies were unsuccessful or not per-
formed and the patient did not undergo thoracic surgery because of poor pulmonary function (N = 2) and poor 
heart function (N = 1). 
Table 2b. Histology and disease stage of the 58 screen-detected lung cancers in round two
Disease stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n (%) n (%) n (%) n (%) n (%) n (%) n (%) n(%)
Adenocarcinoma 29 (82.9) 1 (2.9) 3 (8.6) . 2 (5.7) . . 35 (60.3)
Bronchoalveolar carcinoma 3 (100.0) . . . . . 3 (5.2)
Squamous cell carcinoma 2 (66.7) . . . 1 (33.3) . . 3 (5.2)
Adenosquamous carcinoma 1 (50.0) . 1 (50.0) . . . . 2 (3.4)
Large cell carcinoma 5 (50.0) . . . 2 (20.0) 2 (20.0) 1 (10.0) 10 (17.2)
Large cell NE carcinoma . . . . . . . .
Small cell carcinoma . . . . 1 (50.0) . 1 (50.0) 2 (3.4)
Mixed LCSC carcinoma . . . . . . . .
Pleiomorph carcinoma . . . . . . . .
NSCLC-NOS . . . . . . . .
Carcinoïd . . . . . . . .
No histological diagnosis§ 3 (100.0) . . . . . . 3 (5.2)
Total 43 (74.1) 1 (1.7) 4 (6.9) . 6 (10.3) 2 (3.4) 2 (3.4) 58 (100.0)
Definition of abbreviations: . = 0 (0.0); large cell NE carcinoma = large cell neuro-endocrine carcinoma; mixed LCSC 
carcinoma = mixed large cell/small cell carcinoma; NSCLC-NOS = non-small cell lung carcinoma, not otherwise 
specified.
* 7th edition TNM staging system (2009).
† According to IARC Tumours of the Lung, Pleura and Heart (2004).
§ In 3 participants no histological diagnosis was established because biopsies were unsuccessful or not performed 
and the patient did not undergo thoracic surgery because of poor pulmonary function (n = 1), metastasised pros-
tate carcinoma (n = 1) and death due to mesenteric ischemia before intended surgery (n= 1).
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Table 2c. Histology and disease stage of the 77 screen-detected lung cancers in round three
Disease stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Adenocarcinoma 25 (67.6) 6 (16.2) 1 (2.7) . 3 (8.1) 1 (2.7) 1 (2.7) 37 (48.1)
Bronchoalveolar carcinoma 6 (100.0) . . . . . . 6 (7.8)
Squamous cell carcinoma 10 (62.5) . 1 (6.3) . 4 (25.0) . 1 (6.3) 16 (20.8)
Adenosquamous carcinoma . . . . . . . .
Large cell carcinoma . . . . 2 (100.0) . . 2 (2.6)
Large cell NE carcinoma 1 (100.0) . . . . . . 1 (1.3)
Small cell carcinoma . . . . 4 (80.0) . 1 (20.0) 5 (6.5)
Mixed LCSC carcinoma . . . . 1 (100.0) . . 1 (1.3)
Pleiomorph carcinoma . . . . . . . .
NSCLC-NOS . . . . . . . .
Carcinoïd 2 (100.0) . . . . . . 2 (2.6)
No histological diagnosis§ 6 (85.7) . 1 (14.3) . . . . 7 (9.1)
Total 50 (64.9) 6 (7.8) 3 (3.9) . 14 (18.2) 1 (1.3) 3 (3.9) 77 (100.0)
Definition of abbreviations: . = 0 (0.0); large cell NE carcinoma = large cell neuro-endocrine carcinoma; mixed 
LCSC carcinoma = mixed large cell/small cell carcinoma; NSCLC-NOS = non-small cell lung carcinoma, not oth-
erwise specified.
* 7th edition TNM staging system (2009).
† According to IARC Tumours of the Lung, Pleura and Heart (2004).
§ In 7 participants no histological diagnosis was established because biopsies were unsuccessful or not performed 
and the patient did not undergo thoracic surgery because of poor pulmonary function (n= 4), poor general 
condition (n = 1), radiotherapy because of participation in other clinical trial (n = 1) and refusal (n = 1).
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Table 3b. Histology and disease stage of the 34 screen-detected lung cancers in 34 women
Disease stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Adenocarcinoma 17 (85.0) 1 (5.0) . . 2 (10.0) . . 20 (58.8)
Bronchoalveolar carcinoma 3 (100.0) . . . . . . 3 (8.8)
Squamous cell carcinoma 4 (100.0) . . . . . . 4 (11.8)
Adenosquamous carcinoma 2 (100.0) . . . . . . 2 (5.9)
Large cell carcinoma 1 (50.0) . . . 1 (50.0) . . 2 (5.9)
Large cell NE carcinoma . . . . 1 (100.0) . . 1 (2.9)
Small cell carcinoma . . . . . . . .
Mixed LCSC carcinoma . . . . . . . .
Pleiomorph carcinoma . . . . . . . .
NSCLC-NOS . . . . . . . .
Carcinoïd 2 (100.0) . . . . . . 2 (5.9)
No histological diagnosis . . . . . . . .
Total 29 (85.3) 1 (2.9) . . 4 (11.8) . . 34 (100.0)
Definition of abbreviations: . = 0 (0.0); large cell NE carcinoma = large cell neuro-endocrine carcinoma; mixed 
LCSC carcinoma = mixed large cell/small cell carcinoma; NSCLC-NOS = non-small cell lung carcinoma, not oth-
erwise specified.
* 7th edition TNM staging system (2009).
† According to IARC Tumours of the Lung, Pleura and Heart (2004).
Table 3a. Histology and disease stage of the 175 screen-detected lung cancers in 166 men
Disease stage* Ia Ib IIa IIb IIIa IIIb IV Overall
Histology† n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Adenocarcinoma 58 (66.7) 8 (9.2) 8 (9.2) . 7 (8.0) 4 (4.6) 2 (2.3) 87 (49.7)
Bronchoalveolar carcinoma 8 (100.0) . . . . . . 8 (4.6)
Squamous cell carcinoma 17 (56.7) . 3 (10.0) . 8 (26.7) . 2 (6.7) 30 (17.1)
Adenosquamous carcinoma 1 (50.0) . 1 (50.0) . . . . 2 (1.1)
Large cell carcinoma 6 (40.0) 1 (6.7) . . 5 (33.3) 2 (13.3) 1 (6.7) 15 (8.6)
Large cell NE carcinoma 2 (66.7) 1 (33.3) . . . . . 3 (1.7)
Small cell carcinoma . . . . 5 (62.5) . 3 (37.5) 8 (4.6)
Mixed LCSC carcinoma . . . 1 (50.0) . 1 (50.0) 2 (1.1)
Pleiomorph carcinoma . . 1 (100.0) . . . . 1 (0.6)
NSCLC-NOS . . . . . 1 (50.0) 1 (50.0) 2 (1.1)
Carcinoïd 4 (100.0) . . . . . . 4 (2.3)
No histological diagnosis§ 12 (92.3) . 1 (7.7) . . . . 13 (7.4)
Total 108 (61.7) 10 (5.7) 14 (8.0) . 26 (14.9) 7 (4.0) 10 (5.7) 175 (100.0)
Definition of abbreviations: . = 0 (0.0); large cell NE carcinoma = large cell neuro-endocrine carcinoma; mixed 
LCSC carcinoma = mixed large cell/small cell carcinoma; NSCLC-NOS = non-small cell lung carcinoma, not oth-
erwise specified.
* 7th edition TNM staging system (2009).
† According to IARC Tumours of the Lung, Pleura and Heart (2004).
§ In 13 participants no histological diagnosis was established because biopsies were unsuccessful or not per-
formed and the patient did not undergo thoracic surgery because of poor pulmonary function (n = 7), poor 
heart function (n= 1), poor general condition (n = 1), metastasized prostate carcinoma (n = 1), death due to 
mesenteric ischemia before intended surgery (n = 1), radiotherapy because of participation in other clinical 
trial (n = 1) and refusal (n = 1).
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Table 4. Predictive value of histological subtype for cancer stage at diagnosis
Thresholds Gender Age BMI Pack-years All
Stage Ia to Ib 0.39 -0.28 4.11 1.20 3.90
Stage Ib to IIa 0.65 -0.03 4.38 1.45 4.18
Stage IIa to IIIa 1.01 0.33 4.77 1.82 4.58
Stage IIIa to IIIb 2.23 1.53 6.01 3.04 5.85
Stage IIIb to IV 2.80 2.09 6.64 3.61 6.48
Univariate log regression analyses Multivariate log regression analysis
Parameter estimates Estimate 95% CI p-value Estimate 95% CI p-value
Gender -1.36 -2,35--0.37 0.007 -1.13 -2.13--0.12 0.028
Age -0.01 -0.06-0.03 0.54
BMI 0.14 0.06-0.21 0.001 0.12 0.038-0.20 0.004
Pack-years 0.01 -0.000-0.03 0.047 0.008 -0.005-0.021 0.22
Definitions of abbreviations: BMI = body-mass index; 95% CI = 95% confidence interval of the estimate
The thresholds in the columns “gender” (male as reference), ”age”, “BMI” and “pack-years” are parameters for the 
effect of the variable on the cancer stage (like; the distance between the stages) in four separate univariate logistic 
categorical regression analysis. There is no threshold for stage IIa to stage IIb because none of the participants were 
diagnosed with stage IIb lung carcinoma. The threshold column “all” represents the threshold for the multivariate 
(gender and BMI) logistic categorical regression model.
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Detection of lung cancer through low-dose CT screening (NELSON): 
a prespecified analysis of screening test performance and interval 
cancers
Lancet Oncol. 2014 Nov;15(11).
ABSTRACT
Low-dose CT screening is recommended for individuals at high risk of developing lung 
cancer. However, CT screening does not detect all lung cancers: some might be missed 
at screening, and others can develop in the interval between screens. The NELSON trial 
is a randomised trial to assess the effect of screening with increasing screening intervals 
on lung cancer mortality. In this study, we aimed to assess screening test performance, 
and the epidemiological, radiological, and clinical characteristics of interval cancers in 
NELSON trial participants assigned to the screening group.
Eligible participants in the NELSON trial were those aged 50–75 years, who had 
smoked 15 or more cigarettes per day for more than 25 years or ten or more cigarettes 
for more than 30 years, and were still smoking or had quit less than 10 years ago. We 
included all participants assigned to the screening group who had attended at least one 
round of screening. Screening test results were based on volumetry using a two-step 
approach. Initially, screening test results were classified as negative, indeterminate, or 
positive based on nodule presence and volume. Subsequently, participants with an initial 
indeterminate result underwent follow-up screening at short notice to classify their final 
screening test result as negative or positive, based on nodule volume doubling time. We 
obtained information about all lung cancer diagnoses made during the first three rounds 
of screening, plus an additional 2 years of follow-up from the national cancer registry. 
We determined epidemiological, radiological, participant, and tumour characteristics by 
reassessing medical files, screening CTs, and clinical CTs. The NELSON trial is registered 
at www.trialregister.nl, number ISRCTN63545820.
15,822 participants were enrolled in the NELSON trial, of whom 7,915 were assigned 
to low-dose CT screening with increasing interval between screens, and 7,909 to no 
screening. We included 7,155 participants in our study, with median follow-up of 8.16 
years (IQR 7.56-8.56). 187 (3%) of 7,155 screened participants were diagnosed with 
196 screen-detected lung cancers, and another 34 (<1%, 19 [56%] in the first year of the 
interval, and 15 [44%] in the second year) were diagnosed with 35 interval cancers. The 
overall (three rounds of screening, and 2 years’ follow-up) sensitivity was 84.6% (95% CI 
79.6-89.2), specificity was 98.6% (98.5-98.8), positive predictive value was 40.4% (35.9-
44.7), and negative predictive value was 99.8% (99.8-99.9). Retrospective assessment of 
107
Epidemiological evaluation
CT examinations showed that 12 (35%) of the 35 interval cancers were not visible at 
the last screening CT. The remaining cancers were visible when retrospectively assessed, 
but were not diagnosed because of radiological detection and interpretation errors (17 
[50%]), misclassification by the protocol (two [6%]), participant noncompliance (two 
[6%]), and non-adherence to protocol (one [3%]). Compared with screen-detected can-
cers, interval cancers were diagnosed at more advanced stages (29 [83%] of 35 interval 
cancers vs 44 [22%] of 196 screen-detected cancers diagnosed in stage III or IV; p <0.001, 
were more often small cell carcinomas (seven [20%] vs. eight [4%], p = 0.003) and less 
often adenocarcinomas (nine [26%] vs. 102 [52%], p = 0.005).
Lung cancer screening in the NELSON trial yielded high specificity and sensitivity, 
with only a small number of interval cancers. The results of this study could be used to 
improve screening algorithms, and reduce the number of missed cancers.
INTRODUCTION
Until the 1990s, no effective screening test for lung cancer was available. Screening 
studies using sputum cytology or chest radiography did not show a significant reduc-
tion in lung cancer mortality. In the 1990s, cohort studies using low-dose CT as a lung 
cancer screening test were initiated.1,2,3 Low-dose CT seemed to be able to detect more 
and smaller lung cancers than chest radiography, with most being diagnosed at stage 
I.4-6 Moreover, survival in patients with screen-detected lung cancer was impressive. In 
2011, the National Lung Screening Trial (NLST) showed a 20% reduction in lung cancer 
mortality using low-dose CT compared with screening using chest radiography.7 
The CISNET lung cancer working group modelled and assessed hundreds of screening 
scenarios using data from NLST; 26 selected efficient screening scenarios led to reduc-
tions in lung cancer mortality of between 4.6% to 21.2%.8 As a result, the US Preventative 
Services Task Force and several medical societies recommended annual low-dose CT 
screening in the USA for subjects at high risk of developing lung cancer.8-10 However, no 
reduction in lung cancer mortality with an annual low-dose CT screening strategy has 
been reported in three smaller European trials,11-13 and results of several other European 
trials are still awaited. In many European countries, the outcome of the NELSON trial or 
pooled analyses is awaited before a decision about implementation of a national service 
lung cancer screening programme is made. 
Efficacy and acceptance of low-dose CT screening for lung cancer depends on the sen-
sitivity of the screening test (i.e., the risk of not detecting a lung cancer through screen-
ing). Lung cancers not detected by screening but diagnosed during the screening interval, 
known as interval cancers, might have been missed at screening or might have developed 
between screening and detection. Few studies about the incidence and characteristics of 
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interval cancers in lung cancer screening have been reported.14-16 None of these studies 
assessed causes of interval cancers, or whether improvements to the screening algorithm 
were possible. 
The NELSON trial is a randomised trial to assess whether low-dose CT screening with 
an increasing length of screening interval (1, 2, and 2.5 years) compared with no screen-
ing reduces lung cancer mortality.20 In this retrospective analysis, we aimed to assess the 
performance of the screening test to detect interval cancers, and provide insights into the 
incidence, histopathology, and causes for failed detection of these cancers.
METHODS
Study design and participants
Individuals from four centres in the Netherlands and Belgium were enrolled and ran-
domly assigned to receive low-dose CT screening or no screening. Eligible participants 
were adults aged 50–75 years, who had smoked 15 or more cigarettes per day for more 
than 25 years or ten or more cigarettes per day for more than 30 years, and were still 
smoking or had stopped smoking less than 10 years previously. People with self-reported 
moderate or bad health, inability to climb two flights of stairs, bodyweight of 140 kg or 
more, current or past renal cancer, melanoma, or breast cancer, lung cancer diagnosed 
less than five years ago, or a chest CT examination less than one year ago, were excluded. 
Design of the NELSON trial is presented in Figure 1.
In this study to assess the performance of the screening and the causes of the failure 
to detect the interval cancers, we included all Dutch participants who were randomly 
assigned to the screening group and received at least one screening in the first three 
Figure 1. Design NELSON trial 
Baseline 5.5 years3 years1 year
interval
1 year
interval
2 years
interval
2.5 years
Randomisation
Screen
group
10 years
Control
group
LC 
mortality
LC 
mortality
Eligible 
participants
Round 1
CT scan
Round 2
CT scan
Round 3
CT scan
Round 4
CT scan
Analyses of this study include data from the first screening round up to two years of follow-up after the third 
round scan. Median length of follow-up, from randomisation to end of follow-up at 31-12-2011 was 8.16 years 
(interquartile range: 7.56 to 8.56 years). Note, 32 of 7155 (0.4%) participants had their third round scan after 
2009; as a result, their two-year follow-up period is not completely covered by the data of the national cancer 
registry.
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screening rounds at baseline, one year later, and three years later. We did not include 
Belgian participants from the NELSON trial in this study because no data were available 
from the Belgian Cancer Registry.
The NELSON trial was approved by the Dutch Minister of Health and ethics boards at 
each participating centre. All participants gave written informed consent for participa-
tion and evaluation of personal data from hospital charts.
Procedures
Screening was done using 16-detector CT scanners in a low-dose setting22 (effective 
radiation dose <0.4 mSv to <1.6 mSv depending on bodyweight).18 Datasets were derived 
from images of the thorax (slice thickness 1 mm, interval 0.7 mm) and volumes of nod-
ules were measured using semi-automatic volumetric software (LungCARE, Siemens, 
Somaris/5 VB 10A-W). Volume doubling time was calculated for all nodules (no selec-
tion was made based on any characteristics suspicious for malignancy) with at least two 
measurement of its size using the formula: 
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  in which Δt 
represents time in days between scans, V1 the volume of the nodule at baseline, and V2 
the volume of the nodule at the current CT examination.18 
The screening test results were determined by the presence, size and growth rate of 
pulmonary nodules. Screening test results were defined to be negative: in the absence of 
nodules, for all nodules with fat, benign calcification patterns or other benign 
abnormalities,18,23 and for non-calcified nodules with a volume <50mm³,  
a percentage volume-change (PVC) <25%, or a percentage volume change ≥25% 
combined with a volume doubling-time ≥600days.18 Screening test results were defined 
to be positive for non-calcified nodules with a volume >500mm³, or with a PVC of  ≥25% 
combined with a VDT <400days, Moreover, screening test results were also positive if a 
new solid component had emerged in a previously non-solid nodule.18,23 Screening test 
results were defined to be indeterminate for nodules with a volume 50-500mm³, or a 
PVC ≥25% combined with a VDT of 400-600days.18 Subjects with an indeterminate 
screening test result were invited for one additional LDCT examination at the screening 
center at short notice to determine whether their final screening test result was positive 
or negative using the aforementioned criteria. 
   After a negative final screening test result, participants did not undergo any additional 
diagnostic procedures, but only received an invitation for the next screening round. 
After a positive final screening result, participants were referred to a pulmonologist via 
their general practitioner for diagnostic work-up to exclude or diagnose lung cancer.24-26  
   To assess interval cancers, we obtained data for all lung cancers diagnosed since the 
first screening in round one to the last screening in round three, plus an additional two 
years of follow-up from the Dutch Cancer Registry.27 For every patient diagnosed with 
lung cancer outside of screening (i.e., diagnosed with interval cancer), we collected 
medical and radiological files. Two radiologists (with 10 [PAdJ] and >30 years [EThS] of 
experience with chest CT) reviewed the last screening CT from the study and the clinical 
CT used for diagnosis of lung cancer, and reached a consensus on whether or not the 
lung cancer could retrospectively be identified on the screening CT. We determined 
epidemiological, radiological, participant, and tumour characteristics by reassessing 
medical files, screening CTs, and clinical CTs. 
in which Δt represents time in days between scans, V1 the volume of the nodule at base-
line, and V2 the volume of the nodule at the current CT examination.18
The screening test results were determined by the presence, size and growth rate of 
pulmonary nodules. Screening test results were defined to be negative: in the absence 
of odul s, for all nodules with fat, be i n calcification patterns or other benign 
abnormalities,18,23 and for non-calcified nodules with a volume <50mm³, a percentage 
volume-change (PVC) <25%, or a percentage volume change ≥25% combined with 
a volume doubling-time ≥600days.18 Screening test results were defined to be positive 
for non-calcified nodules with a volume >500mm³, or with a PVC of  ≥25% combined 
with a VDT <400days, Moreover, screening test res l re also positive if a new solid 
component had emerged in a previously non-solid nodule.18,23 Screening test results were 
defined to be indeterminate for nodules with a volume 50-500mm³, or a PVC ≥25% 
combined with a VDT of 400-600days.18 Subjects with an indeterminate screening test 
result were invited for one additional LDCT examination at the screening center at short 
notice to determin whether their final screening test result was positive or negative using 
the aforementioned criteria.
After a negative final screening test result, participants did not undergo any additional 
diagnostic procedures, but only received an invitation for the next screening round. After 
a positive final screening result, participants were referred to a pulmonologist via their 
general practitioner for diagnostic work-up to exclude or diagnose lung cancer.24-26 
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To assess interval cancers, we obtained data for all lung cancers diagnosed since the 
first screening in round one to the last screening in round three, plus an additional two 
years of follow-up from the Dutch Cancer Registry.27 For every patient diagnosed with 
lung cancer outside of screening (i.e., diagnosed with interval cancer), we collected 
medical and radiological files. Two radiologists (with 10 [PAdJ] and >30 years [EThS] of 
experience with chest CT) reviewed the last screening CT from the study and the clinical 
CT used for diagnosis of lung cancer, and reached a consensus on whether or not the lung 
cancer could retrospectively be identified on the screening CT. We determined epidemio-
logical, radiological, participant, and tumour characteristics by reassessing medical files, 
screening CTs, and clinical CTs.
Outcomes
The primary endpoint of the NELSON trial is reduction of lung cancer mortality by 25% 
or more at ten years after randomisation.20,21 The primary aim of this analysis was to assess 
the frequency of interval lung cancers, and to determine the sensitivity, specificity, positive 
predictive value, and negative predictive value of the screening protocol. The secondary 
aim was to assess, and compare, the histopathological type and stage of screen-detected and 
interval lung cancers, and to assess the causes of the failure to detect the interval cancers.
Screen-detected cancers were defined as lung cancers diagnosed by diagnostic work-up 
initiated for a positive screening test result. We defined interval cancers as: lung cancers 
diagnosed after a negative screening test; lung cancers diagnosed after an indeterminate 
screening test, but without any follow-up low-dose CT examination or diagnostic work-
up being done in the screening programme; or lung cancers diagnosed after a positive 
screening result if the diagnostic work-up initiated for the positive screening result did 
not yield a diagnosis of lung cancer, and the diagnosis was made later because symptoms 
had triggered diagnostic assessment that eventually yielded diagnosis of lung cancer. 
Diagnostic work-up was defined not to have yielded diagnosis of lung cancer if a pulmo-
nologist had concluded that the suspicious nodule was not lung cancer and dismissed the 
participant from any further diagnostic procedures or follow-up, or if diagnostic workup 
did not yield diagnosis of lung cancer and was still ongoing after two years of follow-up.
A true-positive test result was a positive result in a participant who actually was diag-
nosed with lung cancer by diagnostic work-up. A false-positive test result was a positive 
result in the absence of lung cancer. A true-negative test result was a negative scan in the 
absence of lung cancer, and a false-negative test result was a negative scan followed by 
diagnosis of interval cancer.
Statistical analysis
All screening test characteristics were estimated with the detection method, as done in the 
NLST.14 We estimated sensitivity by dividing the number of true-positive screens by the 
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numbers of true-positive and false-positive screens. We estimated specificity by dividing 
the number of true-negative screens by the numbers of true-negative and false-negative 
screens. We estimated positive predictive value by dividing all participants with a true-
positive screening by all participants with positive screening. We estimated negative predic-
tive value by dividing all participants with a true-negative screening by all participants with 
negative screening. To calculate 95% CIs, we did bootstrapping based on 5,000 samples. 
Continuous variables were tested for normality; the significance of the differences was as-
sessed using one-way analysis of variance. For nominal variables we used Fisher’s exact test 
or likelihood-based χ² test. For categorical variables we used the Mann-Whitney U test. All 
analyses were done with PASW Statistics, IBM SPSS (version 20).
RESULTS
Epidemiological characteristics
Between Dec 23, 2003, and July 6, 2006, 15,822 individuals from four centres in the Nether-
lands and Belgium were enrolled and randomly assigned to receive low-dose CT screening 
(n =7,915) or no screening (n = 7,907). For this analysis, we excluded the 7,909 participants 
randomly assigned to the no screening group, the 477 participants from Belgium (because 
no data were yet available from the Belgian Cancer Registry), and 283 participants who did 
not attend their screening examinations (because no screening test characteristics could be 
calculated in the absence of screening). Thus, we included 7,155 participants in our analysis 
(Figure 2). Median length of follow-up was 8.16 years (IQR 7.56–8.56). 
There was no significant difference between included and excluded participants’ base-
line characteristics (Table 1). 7,135 (96%) of 7,438 participants in the screening group 
attended the first round of screening, 6,890 (93%) attended the second round, and 6,538 
(88%) attended the third round. The final positive screening test results led to the diag-
nosis of lung cancer in 187 participants (3%, Table 2). Additionally, 34 (<1%) participants 
were diagnosed with lung cancer between screening rounds (19 in the first year since 
screening and 15 in the second year, Table 2).
Test characteristics for each separate screening round are provided in table 2. For the 
three screening rounds combined, sensitivity was 84.6% (95% CI 79.6–89.2%), specific-
ity was 98.6% (95% CI 98.5–98.8%), positive predictive value was 40.4% (95% CI 35.9-
44.7%), and negative predictive value was 99.8% (95% CI 99.8–99.9%). When only the 
first year of the screening interval was considered, five (26%) of the 19 participants with 
interval cancers were identified during the interval. This finding implies that maximum 
sensitivity (assuming not a single lung cancer was missed) of an annual screening pro-
gramme would be 97.4% (95% CI 94.8-99.5%), and of a two-yearly screening programme 
(with an initial annual screening round) would be 94.0% (95% CI 90.5-97.0%).
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Figure 2. Flowchart of included participants
Belgian NELSON
participants
n = 477
Randomised to 
control group
n = 7,909
All NELSON 
participants
n = 15,822
Randomised to
screen group
n = 7,915
Dutch NELSON
participants
n = 7,438
Screened
n = 7,155
Not screened
n = 283*
Screened
at round 2
n = 6,890
Screened
at round 1
n = 7,135
Excluded
Included
Screened
at round 3
n = 6,538
Drop-out after
round 2‡
n = 378
Drop-out after
round 1†
n = 239
N = 26
N = 20
* No response despite repeated invitations for first screening round.
† Reasons: screen-detected lung cancer (n = 61), death (n = 25), participant declined (n = 110), participant 
unattainable or repeatedly no show (n = 42), and still in diagnostic work-up round one (n = 1).
‡ Reasons: screen-detected lung cancer (n = 54), death (n = 79), participant declined (n = 145), participant 
unattainable or repeatedly no show (n = 94), administrative error (n = 3), and unknown (n = 3).
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Radiological characteristics
Reassessment of CT examinations of the 34 participants with an interval cancer suggested 
that no lung cancer was present at the last screening examination in 12 cases (35%, Table 
3). In the remaining 22 (65%) cases, we retrospectively identified a suspicious abnormality 
on the screening CT examination. In most cases, the suspicious abnormality was missed. 
Causes of the failure to detect these lung cancers were human error (two [6%]), interpre-
tation error (two [6%]), and detection error due to various causes (13 [38%]). The 13 lung 
Table 1. Characteristics of included and excluded participants
Characteristics All participantsn (%)
Included
n (%)
Excluded
n (%)
p-value*
Female gender 2,597 (16.5) 1,156 (16,2) 1,441 (16.7) 0.34
Current smoker 8,768 (55.4) 3,959 (55,3) 4,809 (55.5) 0.82
Age, median (IQR) 58.0 (54.0 - 62.0) 58.0 (54.0 - 62.0) 58.0 (54.0 - 62.0) 0.39
Pack-years, median (IQR) 38.0 (29.7 - 49.5) 38.0 (29.7 - 49.5) 38.0 (29.7 - 49.5) 0.53
Total 15,822 (100.0) 7,155 (45.2) 8,667 (54.8) NA
Definition of abbreviations: IQR= interquartile range; NA = not applicable.
* Difference between included and excluded participants.
Table 2. Epidemiological characteristics round one to three
Epidemiological 
characteristics
Round 1 Round 2 Round 3 Total round 1-3
year 1 year 2 year 3 year 4 year 5 1-year follow-up 2-year follow-up
Screened participants 7,135 6,890 6,538 7,155 7,155
Negative test result 6,951 6,769 6,380 20,100 20,100
- true negative 6,946 6,762 6,750 6,373 6,370 20,081 20,066
- false negative 5 7 7 + 12 7 7 + 3 19 34
Positive test result 184 121 158 463 463
- true positive 62 53 53 72 72 187 187
- false positive 122 68 68 86 86 276 276
Total no. of detected cancers 62 53 72 187 187
- per 1000 screened 8.69 7.69 11.0 26.1 26.1
Total no. of interval cancers 5 7 19 7 10 19 34
- per 1000 screened 0.70 1.02 2.76 1.07 1.53 2.7 4.8
Ratio detected : interval 12.4:1 7.6:1 2.8:1 10.3:1 7.2:1 9.8:1 5.5:1
Sensitivity 92.5 88.3 73.6 91.1 87.8 90.8 84.6
Specificity 98.3 99.0 99.0 98.7 98.7 98.7 98.6
Positive predictive value 33.7 43.8 43.8 45.6 45.6 40.4 40.4
Negative predictive value 99.9 99.9 99.7 99.9 99.8 99.9 99.8
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cancers missed because of these detection errors were: intra-bronchial localised lesions 
(five [15%]); pleural-attached lesions (two [6%]); lesion adjoining bullous structure (one 
[3%]); lesion surrounded by extensive honeycombing (one [3%]); and four cases where 
an intrapulmonary lesion was not visible but signs of lung cancer metastasis were missed 
(three [9%] cases of mediastinal lymphadenopathy, and one [3%] case of pleural effu-
sion). In the remaining five cases, the abnormality was detected, but lung cancer was not 
diagnosed because of participant non-compliance (two [6%]), or the abnormality was 
not classified as suspicious by the protocol (one [3%]), or the abnormality was manually 
classified as not suspicious by the radiologist because of a negative diagnostic work-up in 
a previous screening round (two [6%]).
We calculated test sensitivity using the results of this retrospective radiological assessment, 
using only those interval cancers that were due to test failures. Assuming a 1-year screening 
interval, test sensitivity would have been 93.9% (95% CI 87.9-98.5%) in round one, 93.0% 
(95% CI 86.0-98.2%) in round two, and 92.3% (95% CI 85.9-97.4%) in round three.
Clinical characteristics
Participants diagnosed with lung cancer (both detected and interval cancers) were sig-
nificantly older than were participants without lung cancer (Table 4). Only participants 
with an interval cancer (but not those with detected cancer) were significantly more likely 
to be current smokers than were participants with no cancer (Table 4).
The 187 participants with screen-detected lung cancer had a total of 196 tumours, and 
the 34 participants with interval cancer had a total of 35 tumours; nine participants with 
screen-detected cancers and one participant with interval cancer were diagnosed with 
synchronous double tumours. Interval cancers were diagnosed at a significantly higher 
disease stage (p <0.001) than were screen-detected lung cancers (Table 5a).
Table 3. Radiological characteristics interval lung cancers
Radiological characteristics Round 1 Round 2 Round 3 Total round 1-3
year 1 year 2 year 3 year 4 year 5 1-year follow-up
2-year 
follow-up
Causes n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Normal screening CT 1 (20.0) 3 (42.9) 7 (58.3) 1 (14.3) . 5 (26.3) 12 (35.3)
Non-compliance participant . . . . 2 (66.7) . 2 (5.9)
Non-adherence to protocol . . . 1 (14.3) . 1 (5.3) 1 (2.9)
Inadequacy protocol 1 (20.0) . . 1 (14.3) . 2 (10.5) 2 (5.9)
Detection error* 3 (60.0) 2 (28.6) 4 (33.3) 3 (42.9) 1 (33.3) 8 (42.1) 13 (38.2)
Interpretation error . 1 (14.3) 1 (8.3) . . 1 (5.3) 2 (5.9)
Human error . 1 (14.3) . 1 (14.3) . 2 (10.5) 2 (5.9)
Total no. of interval cancers 5 7 12 7 3 19 34
Definition of abbreviation: . = 0 (0.0)
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Diagnosis at stage T1N0M0 occurred only in three (9%) of 35 interval cancers, whereas 
130 (66%) of 196 screen-detected lung cancers were diagnosed at that stage. The disease 
stage of interval cancers diagnosed in the first year since screening was significantly 
higher than the stage of those diagnosed in the second year (p = 0.02). Interval cancers 
Table 4. Characteristics of 7,155 included participants
Characteristic No lung cancern (%)
Detected cancer
n (%)
P-value* Interval cancer
n (%)
P-value*
Male 5,817 (83.9) 154 (82.4) 0.57 28 (82.4) 0.81
Age - median (IQR) 58.0 (54.0 - 62.0) 61.0 (57.0 - 66.0) <0.001 61.0 (58.0-66.3) 0.03
Current smoker 3,827 (55.3) 104 (55.6) 0.93 28 (82.4) 0.002
Pack-years - median (IQR) 38.0 (30.0 - 49.0) 44.0 (32.0 - 55.0) 0.19 39.0 (34.0-59.3) 0.51
Total 6,934 187 NA 34 NA
Definition of abbreviations: IQR = interquartile range; NA = not applicable.
* Compared to included participants without lung cancer.
Table 5a. Clinical characteristics detected and interval cancers - disease stage
Disease stage
Lung cancer Ia Ib IIa IIb IIIa IIIb IV Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Round 1
   Detected cancer 41 (62.1) 3 (4.5) 5 (7.6) . 10 (15.2) 3 (4.5) 4 (6.1) 66 (100.0)
   Interval cancer . . . . . 1 (20.0) 4 (80.0) 5 (100.0)
Round 2
   Detected cancer 41 (73.2) 1 (1.8) 4 (7.1) . 6 (10.7) 2 (3.6) 2 (3.6) 56 (100.0)
   Interval cancer first year . . . . . . 7 (100.0) 7 (100.0)
   Interval cancer second year 1 (8.3) . . 1 (8.3) 3 (25.0) . 7 (58.3) 12 (100.0)
Round 3
   Detected cancer 48 (64.9) 6 (8.1) 3 (4.1) . 13 (17.6) 1 (1.4) 3 (4.1) 74 (100.0)
   Interval cancer first year . . . 1 (14.3) . 1 (14.3) 5 (71.4) 7 (100.0)
   Interval cancer second year 2 (50.0) . . 1 (25.0) . . 1 (25.0) 4 (100.0)
Total
   All detected cancers 130 (66.3) 10 (5.1) 12 (6.1) . 29 (14.8) 6 (3.1) 9 (4.6) 196 (100.0)
   Interval cancers first year . . . 1 (5.3) . 2 (10.5) 16 (84.2) 19 (100.0)
   Interval cancers second year 3 (18.8) . . 2 (12.5) 3 (18.8) . 8 (50.0) 16 (100.0)
   All interval cancers 3 (8.6) . . 3 (8.6) 3 (8.6) 2 (5.7) 24 (68.6) 35 (100.0)
   All lung cancers 133 (57.6) 10 (4.3) 12 (5.2) 3 (1.3) 32 (13.9) 8 (3.5) 33 (14.3) 231 (100.0)
Definition of abbreviation: . = 0 (0.0)
* According to the 7th edition of the TNM staging system for lung cancer.
The numbers of lung cancers presented are not equal to the number of participants as nine participants with screen-
detected lung cancer (round 1 n = 4; round 2 n = 3; round 3 n = 2), and 1 participants with an interval cancer 
(second year round 3) were diagnosed with synchronous double tumours.
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were significantly more often small-cell carcinomas (p = 0.003) and less often adenocarci-
nomas (p = 0.005) than were screen-detected cancers (Table 5b). There was no significant 
difference between other histological subtypes between screen-detected and interval 
cancers. The localisation of tumours across the lungs did not significantly differ between 
interval and screen-detected lung cancers (data not shown).
Table 5b. Clinical characteristics detected and interval cancers - histological subtype
Histological subtype*
Lung cancer Adeno BAC Squamous Large cell Small cell Other† Unknown‡ Total
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Round 1
   Detected cancer 32 (48.5) 2 (3.0) 11 (16.7) 5 (7.6) 1 (1.5) 12 (18.2) 3 (4.5) 66 (100.0)
   Interval cancer 1 (20.0) . . 3 (60.0) . 1 (20.0) . 5 (100.0)
Round 2
   Detected cancer 34 (60.7) 3 (5.4) 3 (5.4) 10 (17.9) 2 (3.6) 1 (1.8) 3 (5.4) 56 (100.0)
   Interval cancer first year 2 (28.6) . . 1 (14.3) 4 (57.1) . . 7 (100.0)
   Interval cancer second year 2 (16.7) . 5 (41.7) . 3 (25.0) 1 (8.3) 1 (8.3) 12 (100.0)
Round 3
   Detected cancer 36 (48.6) 5 (6.8) 15 (20.3) 2 (2.7) 5 (6.8) 4 (5.4) 7 (9.5) 74 (100.0)
   Interval cancer first year 1 (14.3) . 1 (14.3) 2 (28.6) . 2 (28.6) 1 (14.3) 7 (100.0)
   Interval cancer second year 3 (75.0) . . . . 1 (25.0) . 4 (100.0)
Total
   All detected cancers 102 (52.0) 10 (5.1) 29 (14.8) 17 (8.7) 8 (4.1) 17 (8.7) 13 (6.6) 196 (100.0)
   Interval cancers first year 4 (21.1) . 1 (5.3) 6 (31.6) 4 (21.1) 3 (15.8) 1 (5.3) 19 (100.0)
   Interval cancers second year 5 (31.3) . 5 (31.3) . 3 (18.8) 2 (12.5) 1 (6.3) 16 (100.0)
   All interval cancers 9 (25.7) . 6 (17.1) 6 (17.1) 7 (20.0) 5 (14.3) 2 (5.7) 35 (100.0)
   All lung cancers 107 (46.3) 10 (4.3) 35 (15.2) 23 (10.0) 15 (6.5) 22 (9.5) 15 (6.5) 231 (100.0)
Definition of abbreviations: . = 0 (0.0); Adeno = adenocarcinoma; BAC = bronchoalveolar carcinoma.
* According to the 7th edition of the TNM staging system for lung cancer.
† Other histological  sybtypes of lung cancer were: adenosquamous carcinoma; mixed large cell small cell car-
cinoma; large cell neuroendocrine carcinoma; carcinoid; mucinous carcinoma; pleiomorph carcinoma; non-
small cell lung carcinoma, not otherwise specified.
‡ In 15 participants no histological diagnosis was established because biopsies were unsuccessful or not per-
formed and the patient did not undergo thoracic surgery because of poor pulmonary function (n=7), poor 
heart function (n=1), poor general condition (n=3), metastasized prostate carcinoma (n=1), death due to 
mesenteric ischemia before intended surgery (n=1), radiotherapy because of participation in other clinical trial 
(n=1), and refusal (n=1).
The numbers of lung cancers presented are not equal to the number of participants as nine participants with 
screen-detected lung cancer (round 1 n = 4; round 2 n = 3; round 3 n = 2), and 1 participants with an interval 
cancer (second year round 3) were diagnosed with synchronous double tumours. 
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DISCUSSION
In this study, we assessed the epidemiological, radiological, and clinical characteristics 
of screen-detected and interval lung cancers in the NELSON trial. 187 (3%) of the 7,155 
participants studied were diagnosed with lung cancer detected by screening, and another 
34 (<1%) participants were diagnosed with interval lung cancer. Overall, sensitivity was 
about 85%, specificity about 99%, positive predictive value about 40%, and negative 
predictive value greater than 99%. Retrospectively, about a third of the interval cancers 
were not visible on the last screening CT; the remaining cancers were retrospectively 
visible, but were not diagnosed. Interval cancers were diagnosed at more advanced stages, 
and were more often small cell carcinomas and less often adenocarcinomas than were 
screen-detected cancers.
Screening test results were based on nodule volume and growth rate, measured by 
volumetry. Because indeterminate screening test results were not communicated to study 
participants as being suspicious for lung cancer, and follow-up low-dose CT examina-
tions were done in the context of the screening trial, indeterminate screening results 
should not be regarded as positive screening test results for the purposes of comparison 
with other screening trials.
Because all participants received a final screening result that was either positive or 
negative, calculated test characteristics can be compared with those from other screening 
trials. 
Almost all participants received negative final results from the screening test; only 2.6% 
had positive final results, and needed diagnostic procedures to exclude or diagnose lung 
cancer. In other trials of low-dose CT lung cancer screening, the proportion of positive 
screening tests was higher: 15% (annual screening group) and 14% (biennial screening 
group) in the Italian MILD trial,13 24% in the US NLST,7 26% in the ITALUNG trial,28 
27% in the German LUSI trial,16 and 27% in the Italian DANTE trial.12 These differences 
were probably caused by differences in the criteria for screening test results and the ap-
plied screening technique. In the NELSON trial, relatively stringent criteria for a positive 
screening result (nodule volume >500 mm³ or volume doubling time <400 days)18 and 
volumetry were used, which might have increased measurement accuracy, and reduced 
false-positive screening results.17,29
The predictive value of the positive screening test results was 40.4% (95% CI 35.9-44.7) 
in the NELSON trial. Although this figure implies that more than half of the participants 
were referred for false-positive results, this positive predictive value was high compared 
with positive predictive values of other trials: 3.8% (95% CI 3.4-4.3%) in the NLST,7 4.1% 
in the LUSI trial,16 and 12.7% (biennial screening group) and 16.4% (annual screening 
group) in the MILD trial.13
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Sensitivity in the first (annual) screening round was 92.5% (95% CI 85.5-98.4%), which 
is similar to that in other screening trials using annual screening: 93.8% (90.6-96.3%) 
in the NLST,14,30 and 85.3% in the annual screening group of the MILD trial.13 However, 
specificity was higher in the NELSON trial (98.3% [95% CI 98.8-99.2%]) than in either 
the NLST (73.4% [95% CI 72.8-73.9%]) or the MILD trial (86.8%). Sensitivity in the 
second screening round (biennial screening) was 73.6% (95% CI 62.5-83.6%) and in the 
third screening round (the first 2 years of the screening interval) was 87.8% (79.5-92.8%), 
which is probably similar to the overall sensitivity of 80.0% in the biennial screening 
group of the MILD trial.13
No appropriate comparison of screening test characteristics between annual and bien-
nial screening trials can be made, because differences in performance between screening 
trials are not only caused by differences in the length of screening interval, but also by dif-
ferences in the length of follow-up, criteria for a positive screening result, and lung cancer 
risk of the study population. Some comparisons of annual versus biennial screening were 
made in two modelling studies.8,31 These findings suggested that biennial screening is less 
effective in absolute terms,8,31 but induces substantially fewer harms ( i.e. radiation-related 
lung cancer deaths, false-positive screening test results, number of screening examina-
tions required per subject, overdiagnosis) than does annual screening8, and might be 
similarly cost effective.31 However, because only data from annual screening trials was 
used for these two modelling studies,8,31 estimates of effectiveness and harms of biennial 
screening were based on extrapolations and thus these data may not be accurate.8,31 
Whether the NELSON trial will show effectiveness with its increasing length of screen-
ing intervals can only be established by mortality analyses, which are planned at 10 years 
after randomisation. Nonetheless, both sensitivity and specificity noted in the current 
study are promising for cost-effectiveness. However, ratios between detected and missed 
lung cancers might be affected by overdiagnosis. The amount of overdiagnosis in the 
NELSON trial is still unknown because required data are not yet available, although 
overdiagnosis in lung cancer screening was estimated to be small in a modelling study 
using data from the NLST.8
Reassessment of clinical CT and last screening CT examination showed the causes of the 
failure to detect interval cancers. Two-thirds of the interval cancers were, retrospectively, 
visible at the last screening CT examination. Detection errors, interpretation errors, and 
human errors were identified as the main causes of failure in half of the interval cancers. 
Increased attention of screening radiologists for lung cancer presenting as endobronchial 
lesions, pleural-attached lesions, and bulla wall thickenings, and increased attention for 
extra-pulmonary signs of lung cancer, could help to reduce detection failures. Addition-
ally, one of the interval cancers was not diagnosed through screening due to manual ad-
justment of the screening test result by the radiologist from positive to negative, because 
a diagnostic work-up done in an earlier round did not yield the diagnosis of lung cancer. 
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In view of the magnitude and importance of radiological causes, a second study on this 
topic was done.32 For this study, CT examinations of interval cancers and post-screening 
cancers (diagnosed ≥2 years since last attended screening) were reviewed to determine 
causes of these errors, and to provide recommendations specifically for radiologists.32
Failure of the screening protocol to classify cancerous nodules as suspicious was rare. 
Only two of 34 participants with interval cancers were not diagnosed because the cancer-
ous nodule shrunk or had a volume doubling time greater than 400 days, suggesting 
that the relatively stringent criteria for a positive result in the NELSON trial did not lead 
to notable numbers of missed cancers. This finding is encouraging for future screening 
programmes that aim to limit harms and costs.33 Moreover, two of 34 participants with 
interval cancers were actually identified, but diagnosis was not made through screening 
because participants did not comply with the screening protocol. Instead of undergo-
ing receiving follow-up low-dose CT screening three months after their indeterminate 
screening test result, they directly underwent diagnostic resection of the nodule, which 
yielded the diagnosis of lung cancer. Arguably, these interval cancers might have been 
detected by screening if the participants had complied with the protocol. However, we de-
cided not to classify these cancers as detected by screening because of uncertainty about 
whether the nodules would have shown malignant growth at follow-up CT screening, 
and whether diagnostic work-up would have yielded a diagnosis of lung cancer. Finally, a 
third of interval cancers were, also in retrospect, not visible at the last screening examina-
tion, and thus were not missed, but arose during the interval.
All participants of this study were at substantial risk of developing lung cancer because 
of the enrolment requirements. Even within this population, older age and being a cur-
rent smoker were still significant risk factors for development of lung cancer. Notably, 
only interval cancers were significantly associated with being a current smoker, which 
might be because continued smoking promotes the development of lung cancer subtypes 
that grow faster and are less perceptible by low-dose CT screening (e.g., small-cell carci-
nomas).34 This finding reinforces urgency of smoking cessation in individuals receiving 
lung cancer screening.
Our findings showed that screening-detected lung cancers differed significantly to 
interval cancers with regards to stage of diagnosis, and histopathology. Differences in 
tumour characteristics are probably caused by both earlier diagnosis of screen-detected 
lung cancer as a result of screening asymptomatic individuals, and by the aggressive 
nature of interval lung cancers compared with detected cancers. In this study, all cancers 
that developed during the interval (i.e., were not missed at screening) were diagnosed at 
stage III or IV. Hence, these cancers grew from undetectable to incurable cancers in less 
than 1 year (five [36%] of 19) or 2 years (seven [47%] of 15), suggesting an enormous 
growth and metastatic potential. This observation is consistent with the finding that these 
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cancers were significantly more often small cell carcinomas than were interval cancers 
that did not arise during the screening interval.
In this study, 62% of all lung cancers were diagnosed at stage I, and only 18% were 
diagnosed at stage IIIB or IV. In the NLST, 59% of lung cancers were diagnosed at stage 
I, and 23% at stage IIIB or IV, which did not significantly differ from the NELSON trial 
(p = 0.20). Thus, despite longer screening intervals, slightly lower sensitivity, and fewer 
female participants (in whom CT screening appeared to detect lung cancer earlier than 
in males35) in the NELSON trial, lung cancer was diagnosed as early as in the NLST.7 This 
finding is encouraging for effectiveness of lung cancer screening regimens using 2-yearly 
screening after an initial annual screening round.
CONCLUSION
In conclusion, our findings show that using low-dose CT screening with increasing 
intervals and stringent diagnostic criteria for a positive result to detect lung cancer gives 
high specificity and a high sensitivity. The results of this study could be used to improve 
screening algorithms and reduce the number of missed cancers.
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RESEARCH IN CONTEXT
Systematic Review
As part of planning for this trial a systematic review was conducted in PubMed data-
base. To identify all relevant articles on the performance of lung cancer screening 
test performance and interval cancers, the following search terms were used: “Lung 
Neoplasms”[Mesh], “Tomography, X-Ray Computed”[Mesh], “Mass screening”[Mesh]”, 
“Epidemiologic Study Characteristics as Topic”[Mesh]. In addition, Pubmed was searched 
for articles on all randomised controlled trials on lung cancer screening by searching for 
the trial’s acronyms. Limits used for all searches: humans, adults; published in English, 
in core clinical journals or MEDLINE. Titles and abstracts of articles that were identified 
using these search terms were scanned to select articles relevant for this study. Reference 
lists of relevant articles were checked to identify more relevant articles.
Interpretation
Compared to the literature, the screening strategy of the NELSON trial performed well. 
Hence, screening test sensitivity was comparable other studies or slightly lower, the 
specificity was very high, negative predictive value was as high as in other studies and 
the positive predictive value was substantially higher. Moreover, lung cancer was as early 
diagnosed in the NELSON trial as in the NLST, which is a prerequisite for effectiveness.
Only a limited number of studies report on interval cancers in lung cancer CT screen-
ing, probably due to low incidence for interval cancers combined with limited sample 
size of most studies. Our study is the only that reports on radiological characteristics of 
interval cancers and the causes of the failure to detect interval cancers. In both our study 
and the literature, observations were made which suggests that interval cancers have 
different histopathology and are more aggressive than screening-detected lung cancers.
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Computed tomographic characteristics of interval and post-screen cancers 
in lung cancer screening
Eur Radiol. 2014 Sep 4 [Epub ahead of print].
ABSTRACT
Objective of this study was to analyse computed tomography (CT) findings of interval 
and post-screen cancers in lung cancer screening.
Consecutive interval and post-screen cancers from the Dutch-Belgium lung cancer 
screening trial were included. The prior screening and the diagnostic chest CT were 
reviewed by two experienced radiologists in consensus with knowledge of the tumour 
location on the diagnostic CT.
Sixty-one participants (53 men) were diagnosed with an interval or post-screen cancer. 
Twenty-two (36%) were in retrospect visible on the prior screening CT. Detection er-
ror occurred in 20 and interpretation error in 2 cancers. Errors involved intrabronchial 
tumour (n=5), bulla with wall thickening (n=5), lymphadenopathy (n=3), pleural ef-
fusion (n=1), and intra parenchymal solid nodules (n=8). These were missed due to a 
broad pleural attachment (n=4), extensive reticulation surrounding a nodule (n=1) and 
extensive scarring (n=1). No definite explanation other than human error was found in 
two cases (n=2). None of the interval or post-screen cancers involved a sub-solid nodule.
Interval or post-screen cancers that were visible in retrospect were mostly due to detec-
tion errors of solid nodules, bulla wall thickening or endobronchial lesions Interval or 
post-screen cancers without explanation other than human errors are rare.
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INTRODUCTION
Early detection of lung cancer by low dose computed tomography (CT) scanning in 
asymptomatic smokers at high risk for developing lung cancer is a promising strategy 
to reduce lung cancer mortality. Several randomised lung cancer screening trials were 
conducted using low-dose CT scanning of high-risk groups, with the aim to detect lung 
cancer at an early and curable stage.1-6 The National Lung Screening Trial (NLST) re-
ported in 2011 a 20.0% decrease in lung cancer mortality when comparing CT screening 
with chest radiography screening.7 
Fast growing tumours, protocol inadequacies and protocol violations and missed 
cancers on CT may result in an interval cancer. Interval cancers are cancers diagnosed be-
tween screening rounds after a negative or indeterminate screening result (defined as no 
recommendation for referral) or after a positive screen in which diagnostic work-up did 
not yield the diagnosis of cancer. Interval cancers may be missed or may arise during the 
screening interval. Missed cancers may be caused by detection and interpretation errors. 
In detection errors, the lesion is not mentioned in the report but can be seen in retrospect 
on the last CT. While in interpretation errors, the lesion was noted but considered a benign 
lesion. Post-screen cancers are lung cancers diagnosed after the last scheduled screening 
CT of the participant. In this study, interval cancers were distinguished from post-screen 
cancers; both are subdivided in radiological detection errors, interpretation errors and 
other causes (e.g. normal screening examination, or non-compliance participant).
Missed cancers in CT-based lung cancer screening trials have received limited attention 
in radiological literature.8 In 1999, Kakinuma et al9 concluded on a study of seven interval 
cancers, that minute nodules may be missed at spiral CT exams with a slice thickness 
of 10 mm. Further, Li et al10 reported in 2002 a study of 32 missed lung cancers in a 
CT screening setting (using 10-mm slice thickness) that the missed cancers were very 
subtle, appeared as small faint nodules, and 92% of their 20 detection errors involved 
sub-solid nodules. Henceforth, many studies were published on Computer Aided Diag-
nosis (CAD) systems for detection of pulmonary nodules and CT equipment improved 
substantially.11-18
Purpose of the present study was to analyse CT findings in post-screen and interval 
cancers of the NELSON trial, focussing on CT findings in cases with radiological detec-
tion and interpretation errors. This is the first study reporting on missed lung cancers 
in a lung cancer screening program using multi-detector CT equipment and thin-slice 
reconstruction. 
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METHODS
This is an ancillary study of NELSON trial1, which was approved by the Dutch Ministry 
of Health and ethical boards of participating hospitals. Written informed consent was 
obtained from each participant. Screening was initiated in 2004. Study population com-
prised of current and former smokers aged 50 to 75 years, with a smoking history of 15 
or more cigarettes per day during more than 25 years, or 10 or more cigarettes per day 
during more than 30 years. Former smokers were included only if they quit smoking less 
than 10 years before start of the study. Exclusion criteria were: self-reported moderate or 
poor health status, inability to climb two flights of stairs, a chest CT within the last twelve 
months, body weight 140 kg or more, history of lung cancer in the last five years, history 
of melanoma, breast cancer or hypernephroma, and a previous pneumonectomy.
CT scanning and reading protocol
In participants randomised to the screening group, CT screening was performed at base-
line, 1 year and 3 years and 5.5 years after baseline, plus additional follow-up CT exams in 
case indeterminate nodules were detected.19 Multi-detector scanners (Somatom Sensation 
16, Siemens Medical Solutions, Mx8000 IDT or Brilliance-16, Philips Medical Systems, 
Cleveland, OH) were used with 16x0.75mm collimation and 1.3 pitch. Unenhanced full 
inspiration CTs were acquired using 30mAs at 120kVp for subjects weighing 80kg or less, 
and 30mAs at 140kVp for those weighing more than 80kg. Axial 1.0mm images were 
reconstructed at 0.7mm increment using a 512x512 matrix, with a moderately soft kernel 
and the smallest field of view that included both lungs.
All CTs were analysed for non-calcified nodules. Detected nodules were characterised 
as solid nodule or sub-solid nodule, the latter being either pure or part-solid. At each 
site, CT data were analysed by the local radiologist with 1 year to more than 20 years of 
experience with thoracic CT. Subsequently, CT data were independently analyses by a 
second central reader with more than 6 years of experience. One type of digital work-
station (Leonardo, Siemens Medical Solutions) with software for nodule identification 
and semi-automated volume measurements (LungCare, version Somaris/5 VA70C-W, 
Siemens Medical Solutions) was used; its use for nodule detection was not obligatory. 
After the radiologist marked a potential nodule with a mouse click, the program defines a 
volume of interest around the nodule which can further be analysed by volume rendering 
displays or multi-planar reformations. Once a potential nodule was approved, a second 
mouse-click initiated the automatic volume measurement program. In case of discrep-
ancy, the radiologists tried to reach a consensus about the reading. If no consensus was 
reached, a third reading was performed by an expert radiologist with over twenty years of 
experience, who made the final decision.
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Participants who were referred to a pulmonologist underwent diagnostic work-up 
which included a standard dose CT with intravenous contrast, bronchoscopy and/or 
biopsy. Based on results of these exams, the pulmonologist decided whether resection of 
the suspicious nodule was appropriate. 
Study population 
For the present study, all 7,155 participants (1254 females, 16.5%) randomised to the CT 
screening group of the participating Dutch screening centres (University Medical Center 
Groningen, University Medical Center Utrecht and Kennemer Gasthuis, Haarlem, The 
Netherlands) were included. Belgian participants (n=935) had to be excluded as no data 
on interval cancers were available yet. Median age at baseline of included subjects was 
58.0 years (interquartile range (IQR) 54.0-62.0), median number of pack-years was 38.0 
(IQR 29.7-49.5), and 4215 participants (55.6%) were current smokers.
Interval and post-screen cancers
Some participants developed lung cancer a considerable time, up to six years, after their 
last attended screening examination. Since conclusions may be drawn from these cases, 
they were included in this study. Interval and post-screen cancers were identified through 
linkages with the Dutch Cancer Registry, which has complete national coverage.
In the first three screening rounds, 187 of the 7,155 (2.6%) included subjects were 
diagnosed with screen-detected lung cancer. Between or after screening examinations 
in the NELSON trial, 61 of 7,155 participants (0.85%) were diagnosed with interval or 
post-screen cancer; 53 men and eight women. Hence, a total of 248 screen-detected-, 
interval, - and post-screen cancers were diagnosed. Median age of these participants at 
the time of the diagnosis was 64 years (IQR 6 years). 
Of the 61 participants with interval or post-screen cancer, clinical and radiological files 
were retrieved from the various hospitals where diagnosis of lung cancer was established. 
Also, their last available screening CT examination was reviewed and compared to the 
clinical CT at the time of the diagnosis. Two radiologists, one chest radiologist with 10 
years of experience, and one general radiologist with over 30 years of experience with 
chest CT decided in consensus whether or not lung cancer or CT evidence of metastatic 
disease (such as mediastinal or bone metastases) could in retrospect be identified on the 
screening CT, and whether it was not mentioned or misinterpreted in the original report 
in the trial database. Furthermore, significant other pathology that might has influenced 
the original reading was noted as well. Depending on the findings noted in the trial data-
base, missed cancers were classified as either a detection error or an interpretation error. 
An error was considered a detection error if no mention of the lesion was found in the 
trial database and an interpretation error if the lesion was mentioned but the potentially 
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malignant character not recognized.  An attempt was made to formulate reasons why the 
abnormality was not detected or misinterpreted by the screening radiologists.
Data analysis
Descriptive statistics were used to analyse and present the data.
RESULTS
Based on consensus reading, 26 of 61 cases (42.6%) had a normal last screening CT 
examination and the screening protocol was not violated. In 11 of these 26 cases (42.3%) 
the lung cancer was considered an interval cancer as it was diagnosed before the next 
scheduled screening CT examination, the remaining 15 cases (57.7%) were considered 
a post-screen cancer as they were diagnosed after the screening program was finished 
(Table 1).
Table 1. CT findings of interval and post screen cancers: causes and length of delay
Findings Interval 
cancer
n (%)
Days since last 
CT at diagnosis
median (range)
Post-screen 
cancer
n (%)
Days since last 
CT at diagnosis
median (range)
Screening CT examination normal:
   Protocol followed 11 (18.0) 425 (169-676) 15 (24.6) 817 (202-2037)
Cancer not treated due to:
   Protocol inadequate 1 257 1 349
   False-negative work-up 0 NA 3 815 (68-1140)
   Non-compliance participant 2 (373-461) 6 1805 (1319-2179)
Cancer not detected due to detection error:
   Intrabronchial localisation 5 367 (232-646) 0 NA
   Adjoining bullous structure 1 358 3 890 (735-1290)
   Lymphadenopathy 3 310 (217-436) 0 NA
   Pleural effusion 1 177 0 NA
   Extensive fibrotic changes 0 NA 1 311
   Small pleural attachment 1 581 1 1515
   Large pleural attachment 1 234 1 1089
   Probably human error 0 NA 1 323
Cancer not detected due to interpretation error:
   Large nodule classified as scarring 1 192 0 NA
   Adjoining bullous structure 1 562 0 NA
Total 29 (47.5) 32 (52.5)
Definition of abbreviations: CT = computed tomography; NA = not applicable.
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In 13 of 61 cases (21.3%), lung cancer was not diagnosed through screening due to a 
variety of reasons: participant drop-out (n=8, 61.5%); two (15.4%) were interval cancers 
and six (46.2%) post-screen cancers. Lung cancer was not diagnosed through screening 
after a previous false-negative work-up by the pulmonologist (n=3, 23.1%); both were 
post-screen cancers. In the remaining two of 13 cases (15.4%), the protocol was con-
sidered inadequate as it was adhered to but the malignant nodules were not classified as 
positive. Hence, one 13mm nodule failed to show growth on at follow-up scanning after 
3 months (later diagnosed as interval cancer), and another 12 mm nodule was considered 
stable over a period of three years, but was later on diagnosed as a post-screen cancer.
The remaining 22 of 61 cases (36.1%) were 15 interval cancers and 7 post-screen can-
cers; the radiological abnormality was either not detected (in 20 cases) or misinterpreted 
(in 2 cases). These 22 cases were 0.31% of the total study population of 7,155 participants, 
and 8.9% of 248 lung cancers.
Table 2. Characteristics of participants with 22 missed lung cancers
Participant characteristics n (%)
Age at diagnosis - median (range) 64.0 yrs (56-76 yrs)
Male gender 21 (95.5)
Current smoker 15 (68.1)
Pack-years - median (range) 49.5 (28.0-123.5)
Computed tomography characteristics n (%)
Tumour size at diagnosis
   >5 cm 11 (50.0)
   <5 cm 10 (45.5)
   Not measurable 1 (4.5)
Tumour localisation
   Left upper lobe 6 (27.3)
   Left lower lobe 4 (18.2)
   Right upper lobe 8 (36.4)
   Middle lobe 1 (4.5)
   Right lower lobe 3 (13.6)
Tumour type
   Solid 17 (77.3)
   Non-solid 0 (0.0)
   Bulla wall thickening 5 (22.7)
Underlying lung disease
   Fibrosis 1 (4.5)
Definition of abbreviations: yrs = years.
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Missed endobronchial abnormalities
In 5 of the 22 (22.7%) cases wherein the abnormality was not detected or misinterpreted, 
a central intra-bronchial tumour was overlooked on the screening examination. All were 
small, although difficult to measure, estimated to be about 5 mm (Figure 1). Four of the 
endobronchial tumours were right-sided: two localised in the pectoral segmental bron-
chus, one in the lateral segmental bronchus, and one in the right upper lobe bronchus. 
One endobronchial tumour was localised left at the lingular bronchus. In one of the cases, 
a note was made that lymphadenopathy was present, but no further action was taken. 
All five cancers were classified as interval cancers. Median number of days since the last 
screening CT at the time of diagnosis was 367 days (range 232-646). 
Missed focal bulla wall thickenings
In 5 of 22 cases (22.7%), a bulla with a thickening of the wall was noted during the consen-
sus meeting that was not reported in the database. In four of these cases, the thickening of 
the wall was already visible at the first screening CT examination. In one case, the bulla 
with wall thickening developed in a previously normal lung. The five lesions were evenly 
distributed over the lungs: two in the right upper lobe, and one in the left upper lobe, 
right lower lobe and left lower lobe. In two cases the wall thickening was focal; in one 
of these cases a 7 mm nodule was noted in the trial database, so this was considered an 
Figure 1. Example of missed endobronchial lung cancer
Narrowing of right upper lobe segmental bronchus (arrows).
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interpretation error as no mention was made about the adjoining bulla (Figure 2). Of the 
five lung cancers, two were classified as interval cancers and three as post-screen cancers; 
the latter were all detected more than two years after the last screening CT. 
Missed lymphadenopathy
In 3 of 22 cases (13.6%), lymphadenopathy was missed: two were localised in a slightly 
enlarged right hilum, in which it was without intra venous contrast inseparable from 
the right pulmonary artery. One was mainly localised in the aortopulmonary window, 
maximal diameter was 22 mm. All three cases were classified as interval cancers. Time 
since the last screening CT at the time of diagnosis was 217, 310 and 436 days.
Missed pleural effusions
In one of 22 cases (4.5%), right-sided pleural fluid remained unnoticed on the screening 
CT examination. An interval cancer was diagnosed 177 days after the last CT, presenting 
as a large carcinoma with massive pleural effusions.
Figure 2. Example of missed lung cancer in bulla wall
Small (7 mm) elliptical nodule in bulla wall (arrow).
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Missed cancers due to other reasons
The remaining 8 of 22 cases (36.4%) were not detected due to various causes. Small nodule 
size might have played a role in three cases, as small nodules of 7, 7 and 5 mm were not 
detected. However, two of these nodules were also attached to the pleura, which may also 
have played a role (delay of diagnosis were 581 days for the interval cancer, and 1515 days 
for the post-screen cancer). One nodule was surrounded by extensive reticulation (Figure 
3), which probably caused the detection error (delays of diagnosis of this post-screen 
cancer was 311 days).
Further, five larger (>1 cm) nodules were also not detected: two in the left lower lobe, 
and one in the left upper lobe, right upper lobe and right lower lobe. Three of these large 
nodules were classified as an interval cancer, two as a post-screen cancer. One of these five 
nodules was a 22 mm-large pleural-attached nodule that was interpreted by the screening 
radiologists as scarring (Figure 4); consequently this lung cancer was considered missed 
due to interpretation error. Two of five lesions were broadly pleural-based (Figure 5). Two 
other of the five larger nodules were not attached to the pleura. As no obvious reason for 
not detecting these lesions was found, these detection failures were attributed to human 
error. Median number of days since the last CT at the time of diagnosis was 234 days 
(range 96-1089) for the five larger nodules.
Figure 3. Example of missed lung cancer due to distractive other pathology
Small nodule in left under lobe hidden in reticulation (arrow).
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Figure 4. Example of missed lung cancer due to interpretation error
Image suggestive of lung cancer, but interpreted as fibrotic scarring.
Figure 5. Example of missed lung cancer attached to the pleura
Prevertebral broad-based tumour on the right (arrows).
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DISCUSSION
In this study, the radiological characteristics and causes of the failure to detect interval 
cancers and post-screen cancers in the NELSON trial were investigated.  The majority of 
the 61 (n=39, 64%) interval and post-screen cancers were not due to radiological detec-
tion or interpretation errors. A minority of 22 (36%) cancers was visible in retrospect at 
the last screening examination and missed. Most missed cancers were due to detection 
errors of a nodule either localised in a bronchus, attached to a bulla or sub-pleural in 
the lung parenchyma. According to the protocol, these nodules (with possibly exception 
of the bulla wall thickening) should have been followed up by either a repeat CT scan 
after three months or by referral to a pulmonologist for further evaluation. Interpretation 
errors seemed to have played a minor role in missed lung cancers. Findings of this study 
may aid improving lung cancer detection in lung cancer screening, although the predic-
tive value of some findings, especially bulla wall thickenings, need to be determined yet.
Limited number of studies have been published on interval, - and post-screen cancers 
in a CT-based lung cancer screening setting. In contrast to the findings of Li et al.10, who 
reported in 2002 that 92% of their missed cancers were non-solid, none of the missed 
nodules were part or pure non-solid. This can at least partly be explained by the consider-
able difference in spatial resolution of the 1 mm slice thickness used in the NELSON 
study, compared to the 10 mm slice thickness in the study by Li et al.10 However, since 
sub-solid nodules may grow very slowly, it cannot be excluded that an interval cancer 
arising from a sub-solid nodule will manifest in a longer follow-up period.
In this study, the most common detection error was missing endobronchial lesions. This 
is probably because endobronchial nodules are far less common in a screening popula-
tion than intraparenchymal nodules. As a result, attention of screening radiologists was 
probably primarily focused on the lungs and not the bronchi. This is not compensated 
by the CAD-system its search for nodules does not include the bronchi. In 1996, White 
et al.20 reported on 14 primary lung cancers overlooked on CT in a clinical setting; 67% 
were at a central endobronchial location.20 White et al. gave a similar explanation, not 
focusing on central airways, for detection error in their series. Another important factor 
at the time of their study was the use of 5 mm or even thicker sections. Computer Aided 
Diagnosis of lung cancer in the bronchi has had considerable attention in the literature21 
and as a training tool.22 Extension of lung cancer detection CAD systems to the bronchi 
may prove helpful in reducing these detection errors. However, until this extension is 
realised extra focus on the bronchial tree is warranted.
Another common characteristic of missed lung cancers was a thickened bulla wall. This 
entity was not recognised as an important abnormality at the start of the NELSON screen-
ing trial in 2004. Therefore, bulla wall thickenings were not a pre-defined abnormality in 
the nodule management system. In 2010, Keneda et al.23 described clinical features of 
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primary lung cancer adjoining bullae. In their retrospective study of 545 clinical cases 
who underwent surgery for lung cancer, they identified an adjoining bulla in 19 cases 
(3.5%)23, which suggests that this finding is not uncommon. Keneda et al. also state that 
the association of bullae and lung cancer is not well recognised. This was confirmed in 
this study, as it was identified as one of the main causes for detection errors. Hence, in 
one of five cases with nodular thickening in the wall of a bulla the abnormality was noted 
and its nodule features were described in the database, but no mention was made of the 
adjoining bulla. In 2012, Farooqi et al. reported on lung cancers associated with cystic 
airspaces in the Early Lung Cancer Action Program.24 They found that in their baseline 
and annual screening series respectively 25% and 12% of lung cancers were associated 
with cystic airspaces. They concluded that the finding of an isolated cystic air space with 
increased wall thickness at annual repeat CT screening is suspicious for lung cancer. 
Since no data on the prevalence of bulla wall thickening in the NELSON population was 
collected, no positive predictive value of this finding can be estimated. However, findings 
of this study justify increased attention to focal and diffuse bulla wall thickenings in lung 
cancer screening.
Intraparenchymal nodules were, with 8 cases (36%), the most common cause for a 
missed cancer. Two smaller and two larger lesions were probably missed by the screen-
ing radiologist due to pleural-attachment or a broad shape. One case of these cases was 
interpreted as fibrotic scarring, which was classified as an interpretation error. White 
et al.20 reported in a clinical series of 14 primary lung cancers overlooked on CT that 6 
of 14 cases (43%) were due to major distractive findings elsewhere in the chest, such as 
aortic aneurysm or large oesophageal tumour. In the current study, similar cases were 
not common. Only one lesion was missed due to extensive reticulation in its immediate 
surroundings. In two cases of a missed large intrapulmonary nodule no plausible reason 
other than human error could be found.
Lymphadenopathy is more difficult to detect on low-dose screening CTs without 
intravenous contrast than on clinical contrast enhanced CT’s. Moreover, the screening 
radiologist’s focus is primarily on the lungs, and significant lymphadenopathy uncom-
mon compared to in a clinical setting. Concluding, missed lymphadenopathy, which was 
responsible for 13.6% of missed lung cancers, is probably difficult to prevent.
The most important limitation of this study was the lack of data on the prevalence of 
abnormalities such as bulla wall thickening. As a result, it is not possible to determine 
the positive predictive value of the characteristics of missed lung cancers. This problem 
may be resolved as screening programs check the CT for abnormalities such as bulla wall 
thickenings, and report them as a separate item. Another limitation was that the total 
number of cancers found in the NELSON study is not known at present, so this number 
cannot be related to the number of interval cancers. However, this study suggests that in-
terval-, or post-screen cancers due to human errors were rare, as it only concerned 0.31% 
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of the total screen population. A third limitation is the inherent focus on cancers not 
detected by screening. Performing the same analysis of cancers found in during screening 
may learn whether and how screen-detected cancers can be detected in earlier screening 
rounds. Finally, limited experience of some screening radiologists with thoracic CT could 
have been a limitation of the study. However, this is not supported by a previous study on 
the benefit of consensus double reading in screening for lung cancer.25
In conclusion, interval-, and post-screen cancers in the NELSON trial that were visible 
in retrospect, were mostly due to detection errors of solid nodules. Thickening of a bulla 
wall should be looked at with suspicion, at least until more of the natural course of such 
lesions is known. Detection of endobronchial lesions might improve with extension of 
CAD systems to the bronchi. 
141
Radiological evaluation
SUPPORT STATEMENT
The NELSON study has received funding by: “Zorg onderzoek Nederland - Medische 
wetenschappen” (Zon-Mw), “KWF Kankerbestrijding”, “Stichting Centraal Fonds van 
Reserves voor Voormalig Vrijwillige Ziekenfondsverzekeringen”(RvvZ), “G. Ph. Verha-
gen Foundation”, “Rotterdam Oncologic Thoracic Study Group” (ROTS) and “Erasmus 
Trust Fund”, “Stichting tegen Kanker”, “Vlaamse Liga tegen Kanker”, and LOGO Leuven 
en Hageland”.
CONFLICTS OF INTEREST
The authors of this manuscript declare no relationships with any companies, whose 
products or services may be related to the subject matter of the article.
Chapter 5
142
REFERENCES
 1. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in 
a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung 
cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120(4):868-74.
 2. National Lung Screening Trial Research Team, Aberle DR, Berg CD, et al. The National Lung Screening 
Trial: overview and study design. Radiology 2011; 258(1):243-53.
 3. Pedersen JH, Ashraf H, Dirksen A et al. The Danish randomized lung cancer CT screening trial--overall 
design and results of the prevalence round. J Thorac Oncol 2009; 4(5):608-14.
 4. Infante M, Lutman FR, Cavuto S, et al. Lung cancer screening with spiral CT: baseline results of the 
randomized DANTE trial. Lung Cancer 2008; 59(3):355-63.
 5. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG 
trial for lung cancer screening with low-dose CT. Lung  Cancer 2009; 64(1):34-40.
 6. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: 
prevalence in 817 asymptomatic smokers. Radiology 2002; 222(3):773-81.
 7. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer 
mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5):395-409.
 8. Fardanesh M, White C. Missed lung cancer on chest radiography and computed tomography. Semin 
Ultrasound CT MR 2012; 33(4):280-7.
 9. Kakinuma R, Ohmatsu H, Kaneko M, et al. Detection failures in spiral CT screening for lung cancer: 
analysis of CT findings. Radiology 1999; 212(1):61-6.
 10. Li F, Sone S, Abe H, MacMahon H, et al. Lung cancers missed at low-dose helical CT screening in 
a general population: comparison of clinical, histopathologic, and imaging findings. Radiology 2002; 
225(3):673-83.
 11. Awai K, Murao K, Ozawa A, et al. Pulmonary nodules: Estimation of malignancy at thin-section helical 
CT - Effect of computer-aided diagnosis on performance of radiologists. Radiology 2006; 239:276-284.
 12. Lee Y, Hara T, Fujita H, et al. Automated detection of pulmonary nodules in helical CT images based on 
an improved template-matching technique. IEEE Trans Med Imaging 2001; 20:595-604.
 13. Armato SG 3rd, Roy AS, Macmahon H, et al. Evaluation of automated lung nodule detection on low-
dose computed tomography scans from a lung cancer screening program. Acad Radiol 2005; 12:337-
346.
 14. Giger ML, Bae KT, MacMahon H. Computerized detection of pulmonary nodules in computed tomog-
raphy images. Invest Radiol 1994; 29:459-465.
 15. Li Q, Li F, Doi K. Computerized detection of lung nodules in thinsection CT images by use of selective 
enhancement filters and an automated rule-based classifier. Acad Radiol 2008; 15:165-175. 
 16. Godoy MC, Cooperberg PL, Maizlin ZV, et al. Detection sensitivity of a commercial lung nodule CAD 
system in a series of pathologically proven lung cancers. J Thorac Imaging 2008; 23:1-6.
 17. Yuan R, Vos PM, Cooperberg PL. Computer-aided detection in screening CT for pulmonary nodules. 
Am J Roentgenol 2006; 186:1280-1287.
 18. Goldin JG, Brown MS, Petkovska I. Computer-aided diagnosis in lung nodule assessment. J Thorac 
Imaging 2008; 23:97-104.
 19. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computer tomography screening for 
lung cancer: three rounds of the NELSON trial. Eur Respir J 2013; 42(6):1659-67.
 20. White CS, Romney BM, Mason AC, et al. Primary carcinoma of the lung overlooked at CT: analysis of 
findings in 14 patients. Radiology 1996; 199(1):109-15.
143
Radiological evaluation
 21. Hoppe H, Dinkel HP, Thoeny H, et al. Virtuelle Endoskopie der oberen, zentralen und peripheren 
Atemwege mit Mehrzeilen-Spiral-CT. Radiologe 2002; 42(9):703-11.
 22. Colt HG, Crawford SW, Galbraith O 3rd. Virtual reality bronchoscopy simulation: a revolution in 
procedural training. Chest 2001; 120(4):1333-9.
 23. Kaneda M, Tarukawa T, Watanabe F, et al. Clinical features of primary lung cancer adjoining pulmonary 
bulla. Interact Cardiovasc Thorac Surg 2010; 10(6):940-4.
 24. Farooqi , Cham M, Zhang L, et al. Lung cancer associated with cystic airspaces. Am J Roentgenol 2012; 
199(4):781-6.
 25. Wang Y, van Klaveren RJ, de Bock GH, et al. No benefit for consensus double reading at baseline screen-
ing for lung cancer with the use of semiautomated volumetry software. Radiology 2012; 262(1):320-6.

Part III
Optimisation of screening

Chapter 6
Optimisation of screening protocols
Lung cancer probability in subjects with CT-detected pulmonary nodules: an 
analysis of data from the NELSON trial of low-dose CT screening
Horeweg N*, 
van Rosmalen J*, 
Heuvelmans MA, 
van der Aalst CM, 
Vliegenthart R, 
Scholten ET, 
ten Haaf K, 
Nackaerts K, 
Lammers JWJ, 
Weenink C, 
Groen HJM, 
van Ooijen P, 
de Jong PA, 
de Bock GH, 
Mali W, 
de Koning HJ*, 
Oudkerk M*
Lancet Oncology 
November 2014
* equal contribution
Chapter 6
148
Lung cancer probability in subjects with CT-detected pulmonary 
nodules: an analysis of data from the NELSON trial of low-dose CT 
screening
Lancet Oncol. 2014 Nov;15(11).
ABSTRACT
The main challenge in CT screening for lung cancer is the high prevalence of pulmonary 
nodules and the relatively low incidence of lung cancer. Management protocols use 
thresholds for nodule size and growth rate to determine which nodules require additional 
diagnostic procedures, but these should be based on individuals’ probabilities of develop-
ing lung cancer. In this retrospective analysis, using data from the NELSON CT screening 
trial, we aimed to quantify how nodule diameter, volume, and volume doubling time 
affect the probability of developing lung cancer within two years of a CT scan, and to 
propose and evaluate thresholds for management protocols.
Eligible participants in the NELSON trial were those aged 50–75 years, who have 
smoked 15 cigarettes or more per day for more than 25 years, or 10 cigarettes or more 
for more than 30 years and were still smoking, or had stopped smoking less than 10 
years ago. Participants were randomly assigned to low-dose CT screening at increasing 
intervals, or no screening. We included all participants assigned to the screening group 
who had attended at least one round of screening, and obtained data on lung cancer diag-
noses from the national cancer registry database. We calculated lung cancer probabilities, 
stratified by nodule characteristics, by nodule diameter, volume and volume doubling 
time and did logistic regression analysis using diameter, volume, volume doubling time, 
and multinodularity as potential predictor variables. We assessed management strategies 
based on nodule threshold characteristics for specificity and sensitivity, and compared 
them to the American College of Chest Physicians (ACCP) guidelines.
Volume, volume doubling time and volumetry-based diameter of 9,681 non-calcified 
nodules detected by CT screening in 7,155 of 7,915 participants in the screening group of 
NELSON were used to quantify lung cancer probability. Lung cancer probability was low 
in participants with a nodule volume of 100 mm³ or smaller (0.6% [95% CI 0.4-0.8%] or 
maximum transverse diameter smaller than 5 mm (0.4% [CI 0.2-0.7%]), and not signifi-
cantly different from participants without nodules (0∙4% [0∙3–0∙6], p = 0.17 and p = 1.00, 
respectively. Lung cancer probability was intermediate if nodules had a volume of 100-
300 mm³ (2.4% [1.7-3.5%]), or a diameter 5-10 mm (1.3% [1.0-1.8%]). Volume doubling 
time further stratified the probabilities: 0.8% (95% CI 0.4-1.7%) for volume doubling 
times of 600 days or more, 4.0 (1.8–8.3%) for volume doubling times 400-600 days, and 
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9.9% (95% CI 6.9-14.1%) for volume doubling times of 400 days or fewer. Lung cancer 
probability was high for participants with nodule volumes 300 mm³ or bigger (16.9% 
[95% CI 14.1-20.0%]) or diameters 10 mm or bigger (15.2% [12.7-18.1%]), even if these 
nodules had long volume doubling times. The simulated ACCP management protocol 
yielded a sensitivity and specificity of 90.9% (95% CI 89.3-90.7), and 87.2% (86.4-87.9) 
respectively. A diameter-based protocol with slightly adjusted thresholds (based on lung 
cancer probability) yielded a higher sensitivity (92.4% [95% CI 83.1-97.1]), and a higher 
specificity (90.0% [81.2–96.1). A volume-based protocol (with thresholds based on lung 
cancer probability) yielded the same sensitivity as the ACCP protocol (90.9% [95% CI 
81.2-96.1]), and a very high specificity (94.9% [94.4-95.4]). 
Small nodules (those with a volume <100 mm³ or diameter <5 mm) are not predictive 
for lung cancer. Immediate diagnostic evaluation is necessary for large nodules (≥300 
mm³ or ≥10 mm). Volume doubling time assessment is advocated only for intermediate-
sized nodules (with a volume ranging between 100–300 mm³ or diameter of 5–10 mm). 
Nodule management protocols based on these thresholds performed better than the 
simulated ACCP nodule protocol.
INTRODUCTION
Several prominent medical associations have recommended regular low-dose CT screen-
ing for subjects at high risk of developing lung cancer.1,2 The main challenge faced by 
clinicians doing CT screening for lung cancer is that about half of people screened have 
one or more pulmonary nodules, but only a small percent of these people either have 
lung cancer.3,4 Validated guidelines to determine optimum patient management strategies 
based on characteristics of detected nodules are urgently needed.
At first, the accepted standard of practice was to regard all non-calcified pulmonary 
nodules detected at CT as potentially malignant lesions requiring follow-up screening 
until proven stable for a period of 2 years.5-7 Later, the Fleischner Society recommended 
that nodules of 4 mm or smaller in diameter in high-risk people required no further 
follow-up if the nodule was unchanged at a 12-month follow-up examination, because 
the risk of the nodule being malignant was less than 1%.8 However, people with nodules 
4-8 mm in size were still recommended to undergo two to three follow-up examinations 
over a period of 2 years. Individuals with nodules larger than 8 mm were recommended 
to undergo diagnostic work-up, which consisted of more invasive diagnostic procedures.8 
Recently, the results of the Early Lung Cancer Action Project (ELCAP)9 - which suggested 
raising of the threshold for initiation of follow-up CT examinations to nodules of 8 mm 
or larger - were reproduced with data from the National Lung Screening Trial (NLST).10 
However, the ELCAP analyses were limited to screen detected lung cancers, and only 
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false-positive values and time to diagnosis were taken into account when assessing new 
thresholds for nodule diameter. 
Increasing the protocol-screening thresholds for nodule diameter to determine which 
patients should undergo diagnostic follow-up reduces the potential harms of diagnostic 
procedures, exposure to ionising radiation, and costs.11,12 However, it might also  decrease 
the sensitivity for cancerous nodules, thus, in turn, increasing lung cancer mortality, and 
so it is important to balance these potential benefits and harms.4  Therefore, thresholds 
for negative, indeterminate, and positive screening results should be based on probability 
of individual participants’ developing lung cancer, and should be assessed in terms of 
sensitivity, specificity, number of required CT examinations, and number of required 
invasive diagnostic procedures.
Recommendations of the latest American College of Chest Physicians (ACCP) guide-
lines for management of individuals with pulmonary nodules with a volume of 8 mm³ or 
larger were based on the consensus statement of the Fleischner Society.8 This statement 
has not been formally validated, and alternative management strategies might yield an 
improved performance in terms of sensitivity, specificity, and the number of required 
follow-up scans. 
The NELSON trial is a randomised trial to assess whether low-dose CT screening with 
an increasing length of screening interval (1, 2, and 2.5 years) compared with no screening 
reduces lung cancer mortality.15 We used data from NELSON to quantify the probability 
of developing lung cancer within two years of CT screening, based on measurements 
of lung nodule diameters, volumes, and volume doubling times. We used lung cancer 
probabilities to assess the nodule management protocol recommended by the ACCP, and 
to propose improved management protocols.8,13
METHODS
Study design and participants
Details about the design and conduct of the NELSON trial have been reported  previ-
ously.15,16 Briefly, participants from four centres in the Netherlands and Belgium were 
enrolled and randomly assigned to receive low-dose CT screening or no screening. 
Eligible participants were adults aged 50–75 years, who had smoked 15 or more cigarettes 
per day for more than 25 years or ten or more cigarettes per day for more than 30 years, 
and were still smoking or had stopped smoking less than 10 years previously. People with 
self-reported moderate or bad health, inability to climb two flights of stairs, bodyweight 
of 140 kg or more, current or past renal cancer, melanoma, breast cancer, or lung cancer 
diagnosed less than 5 years ago, or a chest CT examination less than 1 year ago, were 
excluded. 
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All participants who were diagnosed with lung cancer were identified from the national 
cancer registries of the Netherlands. We included all Dutch participants who were ran-
domly assigned to the screening group, who had attended at least one round of screening 
in the first two screening rounds at baseline and one year later. We excluded Belgian 
participants because data about interval cancers were not yet available from the Belgian 
cancer registry; interval cancers from Dutch participants were identified with use of the 
Dutch Cancer Registry.
Procedures
The protocol describing how CT screening was done in the NELSON trial has been previ-
ously published,16 and is summarised in the appendix. Briefly, CT screening was done 
with 16-detector CT scanners in a low-dose setting (effective radiation dose <0.4 mSv, 
<0.8 mSv and <1.6 mSv, dependent on bodyweight).16 Datasets were derived from images 
of the thorax (slice thickness 1 mm, interval 0.7 mm) and analysed with software for 
semi-automated volume measurements (LungCARE, Somaris/5 VB 10A-W, Siemens).16
For any CT screen-detected non-calcified nodules, semi-automatic volumetric software 
independently then measured volume and maximum transverse diameter [A: please con-
firm edits correct?]. Hence, the diameters used in this study were not measured manually. 
In cases in which no volume (V) could be assessed (e.g., in non-solid nodules), volume 
was estimated with use of a manually measured diameter (D), assuming a spherical shape 
of the nodule with the formula:  
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analyses were done at the participant level; for participants with more than one nodule, 
we used the size of the largest nodule and volume doubling time of the fastest growing 
nodule (of 50-500 mm³). 
Using these findings we calculated probabilities of developing lung cancer, stratified by 
nodule characteristics. Two-year probability was chosen because it is the recommended 
follow-up time for indeterminate nodules.8,13 We predicted lung cancer risk in the two 
years following each screening round using regression analysis with nodule character-
istics as potentially predictive variables. Based on these outcomes, we designed nodule 
management protocols for both nodule volume and diameter. Participants without 
nodules or with a lung cancer probability not significantly different from those without 
nodules were classified as negative, and were not recommended undergoing intensified 
CT surveillance8 besides screening.  Participants with a significantly increased lung can-
cer probability (but less than about 5%; adopted from ACCP guideline13) were classified 
as indeterminate, and were recommended to undergo CT surveillance to assess nodule 
growth; if lung cancer probability based on volume doubling time was significantly higher 
than in participants without nodules, the final result was classified as positive, otherwise, 
it was classified as negative. Participants with a lung cancer probability of more than 5% 
were directly classified as positive, and recommended to undergo additional diagnostic 
procedures immediately (adopted from ACCP guideline for nodules with a 5% to 65% risk 
of malignancy).13 Furthermore, the ACCP management protocol8,13 (originally designed 
for manually measured nodules) was simulated as follows: follow-up CT at 12 months 
for nodules 4 mm or smaller (classified as negative); follow-up CT at 6-12 months and 
18-24 months for nodules 4-8 mm in size (classified as indeterminate; final result positive 
for volume doubling times <400 days,12 otherwise negative); and additional diagnostic 
procedures for nodules larger than 8 mm (classified as positive).
Outcomes
The primary endpoint of the NELSON trial is reduction of lung cancer mortality by 25% 
or more at 10 years after randomisation.15,17 The primary aim of this study was to quantify 
the probability of developing lung cancer within two years after the screening round, 
stratified by measured nodule diameters, volumes, and volume doubling times. The 
secondary aims were to model lung cancer risk using predictive variables, and to propose 
and assess thresholds for nodule management protocols.
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Statistical analysis
Probabilities of developing lung cancer stratified by different nodule variables were 
calculated by the number of cases with cancer by the total number of cases per stratum. 
Differences between lung cancer probabilities were tested using with Fisher’s exact test; 
95% CIs were calculated using the Agresti-Coull method.
To predict lung cancer risk in the two years after each screening round, we did logistic 
regression analysis using diameter, volume, volume doubling time, and multinodular-
ity as potential predictor variables. The model only included participants whose largest 
nodule measured 50–500 mm³ and who had one nodule or more growing in this volume 
range, because volume doubling time was available only for this subgroup. We accounted 
for non-linear effects of the predictor variables using fractional polynomials. For each 
predictor variable, we included two terms of the form XK, with the value of K chosen 
from the set (–2, –1, –0∙5, 0, 0∙5, 1, 2, 3); X⁰ denoted a logarithmic transformation. The 
predictor variables in the final model and the non-linear transformations were chosen 
with backward elimination with a significance level of 5%, on the basis of the multivari-
able fractional polynomials algorithm.18 We used a closed-test procedure to control the 
family-wise type I error rate in a situation with multiple testing.19 The calibration of the 
model was assessed with the Hosmer-Lemeshow test.
We estimated test characteristics of all three nodule management protocols using the 
detection method with a 1-year interval plus all lung cancers detected in the same screen-
ing round (details provided in the Appendix). Hence, we estimated sensitivity by dividing 
the number of true-positive screens by the numbers of true-positive and false-positive 
screens. We estimated specificity by dividing the number of true-negative screens by the 
numbers of true-negative and false-negative screens. We estimated positive predictive 
value by dividing all individuals with a true-positive screening by all individuals with 
positive screening. We estimated negative predictive value by dividing all participants 
with a true negative screening by all participants with negative screening (more details 
provided in the Appendix). 
All statistical tests were two-sided, used a significance level of 5%, and were done with 
Stata (version 12), R (version 2.15), and Microsoft Excel (2010).
RESULTS
Participants
A total of 15,822 participants were enrolled in the NELSON trial between Dec 23, 2003, 
and July 6, 2006. Screening round one was conducted from Jan, 2004 to Dec, 2006, and 
screening round two from Jan, 2005 to Sept, 2008. For this study, we excluded 7,907 
participants randomly assigned to the no screening group, 477 participants from Belgium 
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(no data were yet available from the Belgian Cancer Registry), and 283 participants who 
did not attend their screening examinations (no screening test characteristics could be 
calculated in the absence of screening). Thus, we included 7,155 participants in our 
study; 7,135 of whom received screening at the first screening round, and 6,889 of whom 
received screening at the second screening round (Figure 1).
Median length of available follow-up of the participants was 8.16 years (IQR 7.56-8.56). 
Median age was 58 years (IQR 50-66). 1,206 (16%) of 7,438 participants were women, 
6,232 (84%) were men, 4165 (56%) were current smokers, and their median number of 
pack-years at randomisation was 38 (IQR 19-57).
Figure 1. Participant flowchart 
All NELSON participants
N = 15,822
Randomized to
screen arm
N = 7,438
Randomized to 
control arm
N = 7,449
Dutch participants
N = 14,887 
Belgian 
participants
N = 935
Screening round two
Screened participants
N = 6,889
Never screened
N = 283†
No screening in 
2nd round
N = 266‡
Missed screening 
round one
N = 20*
Screening round one
Screened participants
N = 7,135
Screening round one was conducted from January 2004 to December 2006 and screening round two from January 
2005 to September 2008. 
* 20 Dutch participants missed the baseline CT due to late returning of their informed consent.
† 283 Dutch participants were randomised but did not respond to the invitation for the baseline CT.
‡ 27 Dutch participants missed the second round CT, but were screened in the third round due to: participant 
declined (n = 3), participant unattainable or repeated no show (n = 16), still in diagnostic work-up round one 
(n = 3), administrative error (n = 5). The remaining 239 Dutch participants underwent no screening in the 
second round due to lung cancer (n = 61), death (n = 25), participant declined (n = 110), participant unattain-
able or repeated no show (n = 42), still in diagnostic work-up round one (n = 1).
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Quantifying lung cancer probability 
Two-year lung cancer probability for all included participants was 1.3% (95% CI 1.2-1.5, 
Table 1). Participants without any pulmonary nodule (7,630 [54%] of 14,024 screenings 
in rounds one and two combined) had a lung cancer probability of 0.4% (95% CI 0.3-0.6). 
In all participants with CT-detected nodules, lung cancer probability was 2.5% (95% CI 
2.1-2.9%), but individuals’ probabilities depended strongly on nodule volume, diameter 
and volume doubling time (Table 1).
We used volume, volume doubling time, and volumetry-based diameter of 9,681 non-
calcified nodules detected by CT screening in 7,155 participants in the screening group 
of NELSON to quantify lung cancer probability (Table 1). Lung cancer probability did not 
significantly differ between participants who had nodules of less than 100 mm³ in volume 
and participants who had no detected nodules (0.6% [95% CI 0.4-0.8%] vs. 0.4% (95% CI 
0.3-0.6), p=0.17. Participants who had nodules between 100-300 mm³ had a significantly 
greater probability of developing lung cancer compared to participants with no screening-
detected nodules (2.4% [95% CI 1.7-3.5%], p <0.0001) and so these participants could be 
regarded as being at intermediate risk for developing lung cancer. Participants who had 
nodules of 300 mm³ or more also had a significantly greater probability of developing 
lung cancer compared to participants with no nodules (16.9% [95% CI 14.1-20.0%],  p 
<0.0001 and so can be regarded as at a high risk of developing lung cancer. 
We noted slightly different thresholds for volumetry-based nodule diameter (Table 1). 
Lung cancer probability was not significantly increased in participants whose nodules 
measured less than 5 mm compared with those with no nodules (0.4% [95% CI 0.2-
0.7%] vs. 0.4% [0.3-0.6], p = 1.00, but was significantly increased for participants whose 
nodules measured 5-10 mm (1.3% [95% CI 1.0-1.8%], p <0.0001, and participants whose 
nodules measured 10 mm or more (15.2% [95% CI 12.7-18.1%], p <0.0001, who could be 
regarded at being at intermediate and high risk of developing lung cancer, respectively.
The probability of being diagnosed with lung cancer within two years after CT scan 
according to nodule volume doubling time for the participants whose largest nodule 
measured 50-500 mm³ is presented in Table 1. Participants with slowly-growing (volume 
doubling time ≥600 days), stable, shrunken, or resolved nodules had a low probability 
of lung cancer (0.0% to 1.0%). Lung cancer probability was not significantly increased 
for participants with nodule volume doubling times of 600 days or more (0.8% [95% CI 
0.4-1.7], p = 0.06. Lung cancer probability was significantly increased for participants 
with nodule volume doubling times of times 400-600 days (4.0% [95% CI 1.8-8.3%], p 
<0.0001, who could be regarded at low risk of developing lung cancer, and for participants 
with a nodule volume doubling time of 400 days or, fewer (9.9% [95% CI 6.9-14.1%], p 
<0.0001, who could be regarded at high risk of developing lung cancer. 
Probabilities of developing lung cancer according to other categories of nodule volume 
and volume doubling time (such as stable, shrinking, and resolving nodules) were done, 
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Table 1a. Probability of lung cancer diagnosis within two years after a screening test, 
by volume of largest nodule 
Volume of largest 
nodule in mm³†
Round 1 Round 2 Rounds 1 and 2 Lung cancer probability+
Cases
n
All
n
Cases
n
All
n
Cases
n
All
n percentage (95%CI)
p value
≥1000 36 137 26 104 62 241 25.7 (20.6-31.6) <0.0001
750 - 1000 8 33 4 30 12 63 19.0 (11.1-30.6) <0.0001
500 - 750 8 63 4 47 12 110 10.9 (6.2-18.2) <0.0001
300 - 500 12 101 6 102 18 203 8.9 (5.6-13.7) <0.0001
200 - 300 9 127 5 116 14 243 5.8 (3.4-9.5) <0.0001
100 - 200 6 428 7 440 13 868 1.5 (0.9-2.6) 0.0002
50 - 100 6 800 6 843 12 1,643 0.7 (0.4-1.3) 0.07
25 - 50 6 961 4 1,008 10 1,969 0.5 (0.3-0.9) 0.44
<25 3 539 2 515 5 1,054 0.5 (0.2-1.1) 0.61
No nodule detected 15 3,946 15 3,684 30 7,630 0.4 (0.3-0.6) ref
All participants 109 7,135 79 6,889 188 14,024 1.3 (1.2-1.5) <0.0001
Definition of abbreviation: 95%CI = 95% confidence interval; ref = reference value.
† Volume of the largest non-calcified nodule in a participant in mm³, the interval includes the lower limit, not 
the upper limit.
+ Probability of malignancy within two years after a CT scan. The difference in lung cancer risk with subjects 
without nodules was evaluated using Fisher’s exact test.
Table 1b. Probability of lung cancer diagnosis within two years after a screening test, 
by volumetry-based diameter of largest non-calcified nodule
Max. diameter of 
largest nodule†
Round 1 Round 2 Rounds 1 and 2 Lung cancer probability+
Cases
n
All
n
Cases
n
All
n
Cases
n
All
n percentage (95%CI) p value
≥30 3 10 3 9 6 19 31.6 (15.2-54.2) <0.0001
20 - 30 13 52 9 36 22 88 25.0 (17.1-35.0) <0.0001
15 - 20 22 84 7 64 29 148 19.6 (14.0-26.8) <0.0001
10 - 15 28 229 21 213 49 442 11.1 (8.5-14.4) <0.0001
8 - 10 7 260 9 296 16 556 2.9 (1.7-4.7) <0.0001
7 - 8 8 327 4 328 12 655 1.8 (1.0-3.2) <0.0001
6 - 7 1 371 2 331 3 702 0.4 (0.1-1.3) 0.75
5 - 6 7 628 5 721 12 1,349 0.9 (0.5-1.6) 0.03
4 - 5 3 799 1 776 4 1,575 0.3 (0.1-0.7) 0.50
<4 2 429 3 431 5 860 0.6 (0.2-1.4) 0.40
No nodule detected 15 3,946 15 3,684 30 7,630 0.4 (0.3-0.6) ref
All participants 109 7,135 79 6,889 188 14,024 1.3 (1.2-1.5) <0.0001
Definition of abbreviation: 95%CI = 95% confidence interval; ref = reference value.
† Maximum diameter of the largest nodule in a participant in mm, the interval includes the lower limit, not 
the upper limit. Estimates based on diameters assessed using semi-automated volumetry. Manually measured 
diameters are less accurate and will overestimate nodule size, which corresponds with lower lung cancer prob-
abilities than presented in this table. 
+ Probability of lung cancer within two years after a CT scan. The difference in lung cancer risk with subjects 
without nodules was evaluated using Fisher’s exact test.
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but did not significantly differ from the findings above. Lung cancer probability accord-
ing to few categories of nodule volume and VDT is provided in Table 1 of the Appendix.
Predicting lung cancer probability
We did logistic regression analyses to predict lung cancer probability: nodule diameter, 
volume, volume doubling time and multinodularity were used as potential predictors. 
All four candidate predictors were significant univariate predictors (data not shown). 
Nodule volume, nodule volume doubling time (Table 2 in Appendix), and multinodu-
larity (Table 3a-b in Appendix) were also significant multivariate predictors. However, 
the relationship between multinodularity and lung cancer risk was ambiguous: for 
those participants whose nodules were growing and measured 50-500 mm³, the relative 
proportion of participants with lung cancer decreased as the numbers of nodules per 
participant increased (Figure 1a in Appendix). However, in the total study population, 
the proportion of lung cancers varied as the amount of nodules per participant increased 
(Figure 1b in Appendix). Therefore, we thought it appropriate to do further studies to 
Table 1c. Probability of lung cancer within two years by VDT of fastest growing nod-
ule 
VDT of fastest growing nodule
 in days†
Round 1 Round 2 Rounds 1 and 2 Lung cancer probability+ 
Cases
n
All
n
Cases
n
All
n
Cases
n
All
n percentage (95%CI)
p value
<100 7 24 2 10 9 34 26.5 (14.4-43.3) <0.0001
100 - 200 3 40 3 16 6 56 10.7 (4.7-21.8) <0.0001
200 - 400 5 130 7 52 12 182 6.6 (3.7-11.3) <0.0001
400 - 600 3 92 4 81 7 173 4.0 (1.8-8.3) <0.0001
600 - 800 0 56 0 74 0 130 0.0 (0.0-3.4) 1.00
800 - 1000 0 45 1 63 1 108 0.9 (0.0-5.6) 0.35
≥1000 5 171 2 542 7 713 1.0 (0.4-2.1) 0.03
Smaller or equal volume on 2nd CT 3 476 3 430 6 906 0.7 (0.3-1.5) 0.27
Resolved on 2nd CT 0 135 0 70 0 205 0.0 (0.0-2.2) 1.00
No follow-up CT, not referred 4 281 0 155 4 436 0.9 (0.3-2.4) 0.11
No follow-up CT, directly referred 3 5 2 6 5 11 45.5 (21.3-72.0) <0.0001
All participants with largest 
nodule 50-500mm³ 33 1,455 24 1,499 57 2,954 1.9 (1.5-2.5) <0.0001
Definition of abbreviations: VDT = volume doubling time; 95%CI = 95% confidence interval; ref = reference value
† Maximum VDT in subjects whose largest nodule measured 50-500 mm³, the interval for VDT includes the 
lower limit, not the upper limit.
+ Probability of lung cancer within two years after a CT scan. The difference in lung cancer risk with subjects 
without nodules was evaluated using Fisher’s exact test.
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unravel the association between multinodularity and lung cancer risk before inclusion of 
multinodularity in the prediction model and nodule management protocols, and so did 
not analyse multinodularity further in this study.
Figure 2 shows the combined effect of nodule volume and volume doubling time (with 
the final prediction model) on lung cancer probability; the interaction between volume 
and volume doubling time was not statistically significant (p = 0.95). Figure 2 shows 
Table 2. Performance evaluation of simulated nodule management protocols for CT-
detected nodules at the first screening round
Screening result+ Management protocolusing volume
Management protocol
using diameter*
Management protocol
of the ACCP*
Positive volume ≥300 mm³ diameter ≥10 mm diameter ≥8 mm
Indeterminate volume ≥100 to ≤300 mm³‡ diameter ≥5 to <10 mm‡ diameter >4 to <8 mm‖
Negative volume <100 mm³ diameter <5 mm diameter ≤4 mm
Screening test results Percentage (n/n) Percentage (n/n) Percentage (n/n)
Direct referral due to positive result 4.7 (334/7,135) 5.3 (375/7,135) 8.9 (635/7,135)
Follow-up examination due to
indeterminate result 7.8 (555/7,135) 22.2 (1586/7,135) 29.8 (2125/7,135)
- positive result after follow-up 
examination 1.2 (84/7,135) 5.5 (394/7,135) 4.7 (333/7,135)
- negative result after follow-up 
examination 6.6 (471/7,135) 16.7 (1192/7,135) 25.1 (1792/7,135)
Detected lung cancers 90.9 (60/66) 92.4 (61/66) 90.9 (60/66)
Screen test parameters Percentage (95%CI) Percentage (95%CI) Percentage (95%CI)
Sensitivity 90.9 (81.2 - 96.1) 92.4 (83.1 - 97.1) 90.9 (81.2 - 96.1)
Specificity 94.9 (94.4 - 95.4) 90.0 (89.3 - 90.7) 87.2 (86.4 - 87.9)
Positive predictive value 14.4 (11.3 - 18.1) 7.9 (6.2 - 10.1) 6.2 (4.8 - 7.9)
Negative predictive value 99.9 (99.8 - 100.0) 99.9 (99.8 - 100.0) 99.9 (99.8 - 99.9)
Definition of abbreviation: 95%CI = 95% confidence interval (calculated using the Agresti-Coull method).
+ In case of multiple nodules, the size of the largest nodule determines the screening result.
* Estimates based on diameters assessed using semi-automated volumetry. Manually measured diameters are 
less accurate and will overestimate nodule size. As a result, the performance of the presented nodule protocol 
using diameter will be worse when manually measured diameters are used to calculate nodule size and nodule 
VDT.
‡ Subjects with an indeterminate screening result should undergo a follow-up scan after three months to assess 
the VDT; a VDT<600 days is a positive screening result and leads to referral for diagnostic work-up. 
‖ Subjects with an indeterminate screening result should undergo a follow-up scan after three months to assess 
the VDT; a VDT<400 days is a positive screening result and leads to referral for diagnostic work-up, according 
to the ACCP guideline (2013).
The test characteristics were estimated using the detection method; using a one-year interval plus all lung cancers 
detected in the same screening round (details are provided in the Appendix).
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that in participants with nodules of 300 mm³ in size or larger, the lung cancer prob-
ability remained substantial (from 5.9% to >50%), even in case of slow nodule growth. In 
participants with nodules sized 100-300 mm³, lung cancer probability ranged from less 
than 3% to 20%, dependent on the volume doubling time.
Evaluating management protocols for CT-detected nodules
Two nodule volume or diameter thresholds based on lung cancer probability, or using the 
simulated ACCP management protocol, are presented in Table 2. After the first screening 
round (for a one year interval), the protocol that used nodule volume had a sensitivity 
of 90.9% (95% CI 81.2-96.1), and a specificity of 94.9% (95% CI 94.4-95.4). Due to its 
high specificity, relatively few patients would have had follow-up CT examinations (555 
Figure 2. Contour plot of the effect of the combined effect of nodule volume and VDT 
on the two-year lung cancer probability
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[8%] of 7,135) and additional diagnostic procedures (418 [6%] of 7,135) compared to 
the other protocols. The protocol that used (volumetry-based) nodule diameter had a 
lower specificity than the volume protocol (90.0% [95% CI 89.3-90.7]), which would have 
led to more follow-up examinations (1,586 [22%] of 7,135), and additional diagnostic 
procedures (769 [11%] of 7,135), but had a slightly higher sensitivity for lung cancer 
(92.4% [95% CI 83.1-97.1]). The simulated ACCP protocol had a sensitivity of 90.9% 
(95% CI 81.2-96.1), and the lowest specificity of the three evaluated protocols (87.2% 
[95% CI 86.4-87.9], and would have led to the and additional diagnostic procedures (968 
[14%] of 7,135). Performance of the lung cancer probability-based volume and diameter 
protocols in the second screening round with the same thresholds is provided in Table 4 
of the Appendix.
DISCUSSION
In this analysis, we used NELSON trial data to calculate the probability developing lung 
cancer within two years after a low-dose CT scan, and stratified this risk by nodule vol-
ume, diameter, and volume doubling time. We used lung cancer probability to design 
and assess nodule management protocols. Our findings show that screened participants 
with nodules with volumes of 100 mm³ or smaller, or diameters of 5 mm or smaller, 
have a lung cancer risk that is not significantly different from that in participants without 
nodules and should not undergo additional CT examinations. Individuals with nodules 
of 100-300 mm³ in volume or 5-10 mm in diameter represent an indeterminate subgroup 
for whom assessment of volume doubling time is appropriate (<600 days warrants follow-
up evaluation). Those participants whose largest nodules’ volume measured 300 mm³ or 
more, or had a diameter of 10 mm or more, should have immediate diagnostic evaluation.
In more than half of the included participants, no pulmonary nodules were detected. 
Their 2-year probability developing lung cancer was 0.4%, which suggests that a screen-
ing interval of at least 2 years might be safe to apply in these individuals.
Our findings support previous evidence that the probability of small nodules (volume 
<50 mm³ or diameter <4 mm) being, or developing into, lung cancer is low: 0.6% or lower, 
similar to the previously reported values of less than 1%.7,13,21-25 Moreover, the two-year 
probability of developing lung cancer in participants whose nodules measured 50-100 
mm³ or 4-5 mm was also low, and did not significantly differ from that in participants 
without nodules. At present, guidelines recommend two to four follow-up scans for such 
nodules.8,13,26 Omission of these CT surveillance schedules for this patient population 
should be considered, because the risk of malignancy does not justify harms of ionising 
radiation (effective dose estimated at 10 mSv per full-dose CT),11  psychological distress 
(clinically relevant increase in lung-cancer-specific distress as shown by van den Bergh 
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and colleagues,14 and confusion, distress and frustration as reported by Wiener and col-
leagues27), and associated pressure on financial resources.28,29 
Participants whose nodules measured 100-300 mm³ (or 5-10 mm in diameter) had 
a significantly higher two-year lung cancer risk than did participants without nodules, 
which, according to current guidelines,8,14,26 justifies additional CT examinations. Because 
lung cancer risk of participants with nodules between 5 mm and 8 mm is similar (0.9% 
to 1.8%),23 a uniform CT surveillance schedule could be applied, with volume doubling 
time assessed at CT surveillance used to reassess lung cancer probability. Participants 
with slowly growing (volume doubling time of ≥600 days), stable, shrunken or resolved 
nodules were at low risk of developing lung cancer, and could withdraw from intensi-
fied CT surveillance8 and return to regular screening.1,2 By contrast, participants whose 
nodules had a volume doubling time of less than 600 days had a significantly increased 
risk of lung cancer which justifies intensified CT surveillance8 and additional diagnostic 
procedures.1 Participants whose nodules had a volume doubling time of 400-600 days 
could be regarded as at intermediate risk, because their lung cancer probability was 4.0% 
(95% CI 1.8-8.3) over two years. Hence, a follow-up CT scan at short notice to reassess 
nodule size and growth might be a better initial option instead of more invasive diagnos-
tic procedures.
These findings lend support to the notion that people with large nodules have a high 
probability of developing lung cancer, reported to be more than 10% in previous stud-
ies8,21,24,30 and 8.9% (95% CI 5.6-13.7) or higher for volumes 300 mm³ or greater, or to 
11.1% (8.5-14.4) diameters 10 mm or greater in this study. Risk for these large nodules 
remained high even when they grew slowly (Figure 2). However, risk of developing lung 
cancer for participants with large nodules that had shrunken or resolved within 2 years 
was very low.Although classification of large slow-growing nodules as possibly malignant 
might add to overdiagnosis, the risk of large nodules (defined as those measuring ≥300 
mm³ or ≥10 mm) being or developing into lung cancer is thought to be too high to delay 
diagnosis. Therefore, follow-up CT examinations to assess growth for large nodules pro-
vide little additional information, but may delay lung cancer diagnosis. Hence, immediate 
diagnostic work-up is suggested instead.
We did logistic regression analyses to predict lung cancer probability, and found that 
nodule diameter, volume, volume doubling time and multinodularity were significant 
univariate predictors. Nodule volume, nodule volume doubling time, and multinodularity 
were also significant multivariate predictors. The interaction between nodule volume and 
volume doubling time was not statistically significant; these two variables were included 
in the final lung cancer prediction model. The relationship between multinodularity and 
lung cancer risk was ambiguous; lung cancer probability varied as the number of nodules 
per subject increased. These findings contradict those of McWilliams and colleagues,25 
who demonstrated an increased lung cancer risk for one, two, and three nodules per 
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participant, and a decreased risk for more than four nodules per participant. Therefore, 
we thought it appropriate to do further studies to unravel the association between mul-
tinodularity and lung cancer risk before inclusion of multinodularity in the prediction 
model and nodule management protocols. 
Based on these findings, we proposed and evaluated nodule management protocols, 
based on a two-step management approach as described above. Participants without 
nodules, or nodules smaller than the lower thresholds were to be classified as negative, 
and receive no additional diagnostic procedures. Participants whose nodules measured 
between the lower and upper thresholds were to be classified as indeterminate. Partici-
pants whose nodules are larger than the upper size threshold were to be classified as posi-
tive, and were directly referred for diagnostic work-up to diagnose or rule lung cancer. 
Participants who were classified as indeterminate were to undergo another low-dose CT 
examination to determine their final screening test result based on nodule growth using a 
single volume doubling time threshold. The advantage of nodule management protocols 
using a two-step approach compared to protocols that use just one nodule evaluation 
(e.g., as used in the ELCAP7 and the NLST4 trials) is a single low-dose CT examination is 
given at short notice (for example after three months) for indeterminate nodules, instead 
of 2-3 CT scans in two years.8 Further, this approach allows for a better risk stratification 
by nodule volume doubling time which is a strong lung cancer predictor.3,5,13
The protocol that used lung cancer probability-based diameter thresholds was more 
sensitive than the simulated ACCP protocol8,15 and would have led to fewer CT exami-
nations and additional diagnostic procedures. Nonetheless, these results imply that the 
simulated ACCP nodule management protocol performs well, but improvements are 
possible. 
The protocol that used lung cancer probability-based thresholds for nodule volume had 
high specificity, and would have led to substantially fewer follow-up CT examinations 
and additional diagnostic procedures than would the simulated ACCP protocol. More-
over, this protocol was as sensitive as the simulated ACCP protocol. However, if manual 
diameter measurements had been used instead of volumetry-based measurements, as 
recommended in the ACCP protocol, it is unlikely that such high sensitivity values would 
have been reached due to the intrinsic unreliability of manual measurements.20 We believe 
that the advantages of an increase in specificity of the volume protocol indicate that lung 
cancer screening should be performed using volumetric software, despite the fact that 
volumetry demands more advanced CT equipment and takes more time than manual 
nodule measurements. Moreover, the use of volumetry enables reliable nodule growth 
assessment at short notice, which is not possible when manual nodule measurements are 
used, due to the lower sensitivity for actual nodule growth as a result of measurement 
error. 
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Analyses in this study were done at the participant level by using the largest and fastest 
growing nodule in participants with multiple nodules. This approach is recommended by 
the ACCP,13 and accounts for the fact that some interval cancers could not be matched 
to a nodule previously detected by screening. Lung cancer probability of the largest or 
fastest growing nodule in a participant could be a slight overestimate, as lung cancer was 
not always diagnosed in this nodule. Also, the presented lung cancer probabilities may be 
slightly overestimated due to advancing lung cancer diagnoses by screening in the 2-year 
follow-up. However, the probabilities may also be slightly underestimated because some 
lung cancers diagnosed as the two-year follow-up period may not have been present at 
the time of screening. 
A limitation of this study is the inability of the LungCARE software to calculate vol-
ume of sub-solid nodules, and so we had to estimate some volumes based on manually 
measured diameters, which may have introduced some inaccuracies. Another limitation 
may be the length of follow-up, which was limited to two years. As a result, we cannot 
provide results to aid decision making for nodule management for periods longer than 2 
years. Moreover, presented lung cancer probabilities may only be extrapolated to popula-
tions with a comparable prevalence of lung nodules (about 50%)3 and a comparable lung 
cancer risk (about 1.3% in 2 years).15 
Lastly, presented lung cancer probabilities, volume doubling times, and nodule proto-
cols were all estimated and evaluated using a data set of nodule measurements that were 
mainly assessed using volumetry. Evaluation of two nodule management protocols using 
diameter was done under the assumption that nodule diameters measured using semi-
automatic volumetry software were comparable to manually measured nodule diameters. 
However, measurement error of manual measurement of nodule diameter is larger than 
measurement error of the volumetry-based diameters we used in this study.20,31-34 Further, 
calculations of volume doubling time based on manually measured nodule diameters 
are less accurate than calculations of volume doubling time based on semi-automated 
volumetry. As a result, the relationship between nodule diameter and lung cancer prob-
ability may be weaker for manually measured nodule diameters. In addition, when results 
of this study are applied to manually measured diameters, presented sensitivities and 
specificities of protocols using diameter are likely to be too high, and the false-positive 
rate, number of follow-up CTs and diagnostic work-ups are likely to be too low. These 
discrepancies could be reduced by using the mean transverse nodule diameter instead 
of maximal nodule diameter. Nonetheless, the aforementioned theoretical discrepan-
cies in lung cancer probability and performance characteristics are probably limited in 
practice, as our estimates of lung cancer probability are comparable to the probabilities 
published by the ELCAP, NLST, and the Pan-Canadian Early Detection of Lung Cancer 
Study, which used manual measurements of nodule diameters for analyses.9,10,24,25 Since 
our conclusions are restricted to volumetry-based diameter analysis, it remains unclear 
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whether the protocol using manually-measured diameters with the thresholds of 5 mm 
and 10 mm, can be applied to situations in which it is not possible to use semiautomatic 
volumetric software.
In the current study, nodule size and volume doubling time were used to determine an 
individual’s lung cancer probability. Other nodule characteristics, such as nodule attenu-
ation and multiplicity, and background characteristics, such as age and smoking history, 
may also affect lung cancer probability.25 Future studies need to determine whether we 
could include such characteristics in our prediction model to estimate an individual’s 
lung cancer probability more accurately. Further, validation of presented lung cancer 
probabilities on a large, reliable data set would be valuable.
CONCLUSION
We designed improved management protocols for CT detected nodules, using thresholds 
for nodule size and VDT that are based on lung cancer probability. Subjects with nodules 
≤100 mm³ or ≤5 mm have a lung cancer risk that is not significantly different from that 
in subjects without nodules and should not undergo additional CT examinations. Indi-
viduals with nodules 100-300 mm³ or 5-10 mm represent an indeterminate subgroup 
for whom assessment of VDT is appropriate (<600 days warrants follow-up evaluation). 
Lung cancer risk of subjects whose nodules measure >300 mm³ or >10 mm demands 
immediate diagnostic evaluation. 
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RESEARCH IN CONTEXT 
Systematic Review
A systematic review was done as part of planning for this trial. To identify all relevant 
articles on management of solitary pulmonary nodules, we searched PubMed with the 
terms “lung neoplasms” [MeSH] AND “solitary pulmonary nodule” [MeSH] AND “to-
mography, x-ray computed” [MeSH] and “probability” [MeSH]; limits: humans, adults; 
published in the past 10 years, in English, in core clinical journals, or MEDLINE. To 
identify all articles of lung cancer CT screening trials that described pulmonary nodules, 
we used the terms “lung neoplasms” [MeSH] AND “early detection of cancer” [MeSH] 
AND “tomography, x-ray computed” [MeSH] AND “epidemiologic study characteristics 
as topic” [MeSH]. The search was limited to studies done in adults, and published from 
Jan 1, 2000, in English. Titles and abstracts of articles that were identified with these 
search terms were scanned to select articles relevant for this study. Reference lists of 
relevant articles were checked to identify more relevant articles. Current clinical practice 
guidelines on management of pulmonary nodules use thresholds for nodule diameter to 
determine appropriate follow-up strategy. In addition, use of prediction models to assess 
individual lung cancer risk is recommended by some guidelines. Data used to design cur-
rent clinical practice guidelines is mainly obtained from published results of lung cancer 
screening cohort studies conducted in the 1990s.
Interpretation
Published probabilities of lung cancer stratified by nodule size were comparable to the 
probabilities estimated in our study. However, none of the published studies provided 
estimates for such small ranges of diameters, as in our study. Moreover, no estimates 
of lung cancer probability were published for nodule volume and nodule VDT. This 
retrospective analysis showed that the simulated ACCP guidelines performed well when 
volumetry-based diameter measurements were used, but also that improvements were 
possible. By small adjustments of thresholds for nodule size and growth rate, which were 
determined based on the associated lung cancer probability, sensitivity and specificity of 
the simulated ACCP protocol may be increased. Further, this study evaluated a nodule 
management protocol with lung cancer probability-based thresholds for nodule volume 
and volume doubling time, which yielded the same sensitivity as the simulated ACCP 
guideline and a substantially higher specificity. These results imply that use of lung cancer 
probability-based thresholds for nodule size and growth and volumetry in nodule man-
agement protocols can improve lung cancer detection, and reduce unnecessary follow-up 
CTs, invasive diagnostic procedures and costs.
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APPENDIX
NELSON nodule management protocol
Below is a more detailed description of the NELSON nodule management protocol. At 
the first detection of a pulmonary nodule, it is classified according to its size:
NODCAT 1: 
•	 Only	nodules	with	benign	features	(e.g.	benign	calcification	patterns,	fat	com-
ponent)
NODCAT 2: 
•	 Solid	nodules	<50mm³
•	 Solid	pleural	based	nodules	<5mm	in	minimal	diameter
•	 Part-solid	nodules,	non-solid	component	<8mm	in	mean	diameter
•	 Part-solid	nodules,	solid	component	<50mm³
•	 Non-solid	nodules	<8mm	in	mean	diameter
NODCAT 3:
•	 Solid	nodules	50-500mm³
•	 Solid	pleural	based	nodules	5-10mm	in	minimal	diameter
•	 Part-solid	nodules,	non-solid	component	≥8mm	in	mean	diameter
•	 Part-solid	nodules,	solid	component	50-500mm³
•	 Non-solid	nodules	≥8mm	in	mean	diameter
NODCAT 4:
•	 Solid	nodules	>500mm³
•	 Solid,	pleural	based	nodules	>10mm	in	minimal	diameter
•	 Part-solid	nodules,	solid	component	>500mm³
If a nodule is detected at the second and later screenings, it is classified according to its 
growth rate. First the percentage volume change is calculated. If this percentage change is 
>25%, VDT is calculated, which categorizes the nodules as follows:
GROWCAT A
•	 VDT	>600	days
GROWCAT B
•	 VDT	400-600	days
GROWCAT C
•	 VDT	<400	days
Referral algorithm of the first screening round:
NEGATIVE:
•	 NODCAT	1
•	 NODCAT	2
Chapter 6
170
•	 NODCAT	3	with	GROWCATs	A	or	B	at	follow-up	examination
POSITIVE:
•	 NODCAT	3	with	GROWCAT	C	at	follow-up	examination
•	 NODCAT	4
Referral algorithm of the second screening round:
NEGATIVE:
•	 NODCAT	1
•	 NODCAT	2	with	GROWCATs	A	or	B	at	follow-up	examination
•	 NODCAT	3	with	GROWCATs	A	or	B	at	follow-up	examination
POSITIVE:
•	 NODCAT	2	with	GROWCAT	C
•	 NODCAT	3	with	GROWCAT	C
•	 NODCAT	4
The screening result could be negative (invitation for the next screen round), indeter-
minate (invitation for a repeat scan to determine the VDT), or positive (referral for 
diagnostic work-up). Nodule volume determined the screen result for newly detected 
nodules: <50mm³ was negative, 50-500mm³ was indeterminate, and >500mm³ was posi-
tive. For previously detected nodules, VDT was calculated and determined the screening 
result: >600days was negative, 400-600days was indeterminate and <400days was posi-
tive. The protocol allowed radiologists to adjust the screening result in case of inaccurate 
measurements by LungCARE, high suspicion of malignancy (e.g. new solid component 
in non-solid nodule), or high suspicion of benignancy (e.g. benign calcification patterns).
Framework for evaluating alternative nodule management protocols
The referral decisions made in the NELSON trial were based on the aforementioned 
formal NELSON protocol. Using the results of the NELSON trial, we can also assess how 
alternative nodule management protocols would have performed, if they had they been 
implemented in the NELSON trial. A complication in the analysis is that if an alternative 
protocol advised follow-up scanning to assess VDT, this VDT could only be calculated 
for subjects who received a follow-up scan in the NELSON trial. Below we describe the 
framework we used to estimate the lung cancer probabilities and the test characteristics 
of the evaluated nodule management protocols. 
The evaluated protocols differ in several important ways from the original NELSON 
protocol. First, a single set of nodule size thresholds based on volume or diameter was 
used for all nodule types. Also, for nodules for which the volume could not be calculated 
using the volumetric software, the volume (V) was imputed using the maximal diameter 
D (formula:).
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formal NELSON protocol. Using the results of the NELSON trial, we can also assess how 
alternative nodule management protocols would have performed, if they had they been 
implemented in the NELSON trial. A complication in the analysis is that if an alternative 
protocol advised follow-up scanning to assess VDT, this VDT could only be calculated for 
subjects who received a follow-up scan in the NELSON trial. Below we describe the 
framework we used to estimate the lung cancer probabilities and the test characteristics 
of the evaluated nodule management protocols.  
   The evaluated protocols differ in several important ways from the original NELSON 
protocol. First, a single set of nodule size thresholds based on volume or diameter was 
used for all nodule types. Also, for nodules for which the volume could not be calculated 
using the volumetric software, the volume (V) was imputed using the maximal diameter 
D (formula: V= 16 πD
3 ). For part-solid nodules, only the solid component was used to 
determine the nodule size category. Finally, the criterion that the percentage volume 
change should be >25% before calculating the VDT was ignored.  
   Each evaluated protocol uses a nodule size threshold for a negative screening and a 
nodule size threshold for a positive screening. These two thresholds are based on either 
the volume or the diameter of a nodule. In each protocol, each detected nodule was 
classified as negative, indeterminate, or positive according to the following rules. 
   Negative: Nodules with benign features (e.g. benign calcification patterns, fat 
component; NODCAT 1 in the NELSON protocol) and nodules with volume/diameter 
below the nodule size threshold for a negative screening. The VDT is not relevant for 
these nodules since the participant is not referred even when the nodule is growing fast. 
Hence, when VDT was missing, it was not imputed. 
   Indeterminate: Nodules with volume/diameter above the threshold for a negative 
screening and below the threshold for a positive screening. For the participants with at 
least one indeterminate nodule and no positive nodules, the VDT determines whether 
the participant should be referred. For newly detected nodules, the VDT was calculated 
using a comparison of the volume on the initial scan and the first available follow-up 
For part-solid nodules, only the solid component was used to determine the nodule 
size category. Finally, the criterion that the percentage v lume change should be >25% 
before calculating the VDT was ignored. 
Each evaluated protocol uses a nodule size threshold for a negative screening and a 
nodule size threshold for a positive screening. These two thresholds are based on either 
the volume or the diameter of a nodule. In each protocol, each detected nodule was clas-
sified as negative, indeterminate, or positive according to the following rules.
Negative: Nodules with benign features (e.g. benign calcification patterns, fat compo-
nent; NODCAT 1 in the NELSON protocol) and nodul s with vol m /diameter below 
the nodule size threshold for a negative screening. The VDT is not relevant for these 
nodules since the participant is not referred even when the nodule is growing fast. Hence, 
when VDT was missing, it was not imputed.
Indeterminate: Nodules with volume/diameter above the threshold for a negative 
screening and below the threshold for a positive screening. For the participants with at 
least one indeterminate nodule and no positive nodules, the VDT determines whether 
the participant should be referr d. For ewly detected nodules, the VDT was calculated 
using a comparison of the volume on the initial scan and the first available follow-up 
scan in the same round; if no follow-up scan was available or if no growth was observed, 
the VDT could not be calculated. For nodules observed on the second round scan that 
had previously been seen on the baseline scan, we calculat d the VDT by comparing the
volumes on the baseline scan and the second round scan. 
Positive: Nodules with volume/diameter above the threshold for a positive screening. 
The VDT is not relevant for these nodules since the participant should be referred, even 
in case of slow nodule growth. Hence, when VDT was missing, it was not imputed.
Participants with at least one positive nodule should be referred and participants with 
no nodules or only negative nodules should not be referred. For the remaining partici-
pants (i.e. participants with at least one indeterminate nodule and no positive nodules), 
the referral decision was based on the following rules:
I) For the evaluation of the simulated ACCP algorithm: participants with at least one 
indeterminate nodule with a VDT ≤400 days are referred; participants in whom all 
indeterminate nodules have VDT>400 days are not referred. For the evaluation of 
the two new algorithms: participants with at least one indeterminate nodule with 
a VDT ≤600 days are referred; participants in whom all indeterminate nodules 
have VDT>600 days are not referred.
II) If the VDT of a nodule could not be calculated because the nodule had not grown 
or was not visible on the follow-up scan, this did not lead to a decision to refer 
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the participant. If the VDT could not be calculated because no follow-up scan had 
been made in the NELSON trial, the decision to refer the patient was imputed 
using the referral decision made by the radiologists in the NELSON trial. This ap-
proach was necessary in approximately 15% of the subjects with the largest nodule 
in the 50-500 mm³ range, e.g. due to manual adjustments of the screening result 
by the radiologists.
Methods for estimating screening test characteristics
The nodule management algorithms that were evaluated in this study classified each scan 
result as positive, indeterminate, or negative. In all evaluated algorithms, subjects with 
an indeterminate screening result receive a second CT examination and the result of this 
scan was either positive (VDT <400 days) or negative (VDT ≥400 days). Summarizing, all 
scans have a ‘final’ screening result that was either positive or negative.
Next, whether a lung cancer was present at the time of the CT examination was deter-
mined as follows. A screening was classified as being done in the presence of lung cancer 
if:
I) The diagnostic work-up, which was initiated for a positive ‘final’ screening result, 
led to the diagnosis of lung cancer (true positive screening results).
II) A lung cancer diagnosis was made during the period from the first CT examina-
tion of the screening round to either the next screening round or one year later, 
whichever came first (false negative screening results).
Via linkages with the national cancer registry, which has complete national coverage, 
all lung cancer diagnoses made outside the screening trial were obtained. If the screening 
was not classified as being done in the presence of lung cancer, it was defined as being 
done in the absence of lung cancer.
Finally, definitions of the screening test parameters were defined as follows:
I) Sensitivity was estimated by dividing the number of true positive screens by the 
numbers of true positive and false positive screens (positive screens in the absence 
of lung cancer).
II) Specificity was estimated by dividing the number of true negative screens (nega-
tive screens in the absence of lung cancer) by the numbers of true negative and 
false negative screens.
III) The positive predictive value was estimated by dividing all subjects with a true 
positive screening by all subjects with positive screening. 
IV) The negative predictive value was estimated by dividing all subjects with a true 
negative screening by all subjects with negative screening.
All screening test parameters were presented with 95% binomial confidence intervals 
(95%CI), which were calculated using the Agresti-Coull method.
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Lung cancer diagnoses not confirmed by histological specimens
Lung cancer diagnoses in the first three rounds of the NELSON trial were based on 
histology or cytology in 174 out of 187 cases (93.0%). The basis for the diagnosis in the 13 
participants without histology or cytology was:
I) Tumour in the right upper lobe, volume 1,502 mm³, PET-positive, cT1aN0M0, 
patient did not undergo thoracic surgery due to cardiac impairment. 
II) Tumour in left lower lobe, volume 2,687 mm³, PET positive, cT1aN0M0, patient 
did not undergo thoracic surgery due to COPD stage IV. 
III) Tumour in left lower lobe, volume 2,792 mm³, PET-positive, cT1aN0M0, patient 
did not undergo thoracic surgery due to COPD and renal failure.
IV) Tumour in right upper lobe, volume 580 mm³, PET-positive, cT1aN0M0, patient 
did not undergo thoracic surgery due to metastasized prostate carcinoma.
V) Tumour in right lower lobe, volume 2,793 mm³, PET-positive, cT1bN0M0, patient 
did not undergo thoracic surgery due to poor pulmonary function. 
VI) Tumour in right upper lobe, volume 891 mm³, PET indeterminate, cT1aN0M0, 
and patient died due to bowel ischemia just before intended thoracic surgery.
VII) Tumour in right lower lobe, volume 731 mm³, PET-positive, cT1aN0M0, patient 
did not undergo thoracic surgery due to poor pulmonary function. 
VIII) Tumour in left lower lobe, volume 108 mm³, VDT 125 days, PET-positive, 
cT1aN0M0, patient did not undergo thoracic surgery because he also participated 
in another study and was randomised to the radiotherapy treatment arm.
IX) Tumour in right upper lobe, volume 383 mm³, VDT 289 days, PET indeterminate, 
cT1aN0M0, patient did not undergo thoracic surgery because he refused; he was 
treated with stereotactic radiotherapy instead.
X) Tumour in left lower lobe, volume 1,108 mm³, PET positive, cT1aN1M0, patient 
did not undergo thoracic surgery due to poor pulmonary function. 
XI) Tumour in left lower lobe, diameter 10 mm, PET positive, cT1aN0M0, and patient 
did not undergo thoracic surgery due to poor pulmonary function. 
XII) Tumour in right upper lobe, diameter 13.2 x 11.6 mm, PET positive, cT1aN0M0, 
patient did not undergo thoracic surgery due to poor pulmonary function and 
general condition
XIII) Tumour in right upper lobe, diameter 19.2 x 12.7 mm, PET positive, cT1bN0M0, 
patient did not undergo thoracic surgery due to poor general condition
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Figure 1a. Relationship multi-nodularity and lung cancer probability in all 
subjects with nodules 
Figure 1b. Relationship multi-nodularity and lung cancer probability in subjects 
whose largest measure 50-500mm³ and have a VDT>0
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Table 1. Two-year lung cancer probability by nodule volume and volume doubling-time
Nodule volume doubling-time
Nodule volume <600 days ≥600 days shrunken or resolved
< 100 mm³ 7/199 (3.5%) 2/521 (0.4%) 0/4,803 (0.0%)
≥100 to <300 mm³ 19/207 (9.2%) 3/379 (0.8%) 0/525 (0.0%)
≥300 mm³ 99/464 (21.3%) 3/51 (5.9%) 0/102 (0.0%)
Table 2. Multivariable logistic regression model for the probability to be diagnosed 
with lung cancer
Variable Odds ratio (95% CI)
Nodule volume^ 2.12 (1.64-2.75)*
Nodule VDT+ 0.45 (0.35-0.60)*
Constant 1.35 (0.24-7.79)
In this model, only the participants in whom the largest detected nodule had a volume of  ≥50 mm³ and <500 mm³ 
and who had at least two screenings were included. The dependent variable indicates whether a diagnosis of lung 
cancer has occurred during the follow-up period; the independent variables are volume, VDT, and a constant term. 
Hosmer-Lemeshow goodness-of-fit test: p = 0.7.
Abbreviations: VDT = volume-doubling time, 95% CI = 95% confidence interval using the Agresti-Coull method.
^ Linear effect: nodule volume was defined as the volume in mm³ divided by 100.
+   Logarithmic effect: nodule VDT was defined as the natural logarithm of VDT in days.
* p-value < 0.001.
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Table 3a. Multivariable logistic regression model for the probability to be diagnosed 
with lung cancer
Variable Odds ratio (95% CI) p-value
Nodule volume^ 2.19 (1.69-2.84) <0.001
Nodule VDT+ 0.43 (0.32-0.57) <0.001
Multi-nodularity* 0.68 (0.55-0.85) 0.001
Constant 5.00 (0.74-33.79) 0.099
In this model, only the participants in whom the largest detected nodule had a volume of  ≥50 mm³ and <500 mm³ 
and who had at least two screenings were included. The dependent variable indicates whether a diagnosis of lung 
cancer has occurred during the follow-up period; the independent variables are volume, VDT, multi-nodularity, 
and a constant term. Hosmer-Lemeshow goodness-of-fit test: p = 0.8.
Abbreviations: VDT = volume-doubling time, 95% CI = 95% confidence interval using the Agresti-Coull method.
^ Linear effect: nodule volume was defined as the volume in mm³ divided by 100.
+ Logarithmic effect: nodule VDT was defined as the natural logarithm of VDT in days.
* Linear effect: multi-nodularity was defined as the number of nodule present at the scan.
Table 3b. Multivariable logistic regression model for the probability to be diagnosed 
with lung cancer
Variable Odds ratio (95% CI) P value
Nodule volume^ 2.20 (1.69-2.88) <0.001
Nodule VDT+ 0.44 (0.33-0.59) <0.001
Multi-nodularity* 0.20 (0.10-0.41) <0.001
Constant 3.60 (0.55-33.41) 0.18
In this model, only the participants in whom the largest detected nodule had a volume of  ≥50 mm³ and <500 mm³ 
and who had at least two screenings were included. The dependent variable indicates whether a diagnosis of lung 
cancer has occurred during the follow-up period; the independent variables are volume, VDT, multinodularity, and 
a constant term. Hosmer-Lemeshow goodness-of-fit test: p = 0.8.
Abbreviations: VDT = volume-doubling time, 95% CI = 95% confidence interval using the Agresti-Coull method.
^ Linear effect: nodule volume was defined as the volume in mm³ divided by 100.
+ Logarithmic effect: nodule VDT was defined as the natural logarithm of VDT in days.
* Linear effect: multinodularity as binary variable (0 = 1 nodule, 1 = ≥ 2 nodules).
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The role of conventional bronchoscopy in the work-up of suspicious 
CT screen-detected pulmonary nodules
Chest. 2012 Aug;142(2):377-84.
ABSTRACT
Up to 50% of the participants in CT scan lung cancer screening trials have at least one 
pulmonary nodule. To date, the role of conventional bronchoscopy in the workup of sus-
picious screen-detected pulmonary nodules is unknown. If a bronchoscopic evaluation 
could be eliminated, the cost-effectiveness of a screening program could be enhanced and 
the potential harms of bronchoscopy avoided.
All consecutive participants with a positive result on a CT scan lung cancer screening 
between April 2004 and December 2008 were enrolled. The diagnostic sensitivity and 
negative predictive value were calculated at the level of the suspicious nodules. In 95% 
of the nodules, the gold standard for the outcome of the bronchoscopy was based on 
surgical resection specimens.
A total of 318 suspicious lesions were evaluated by bronchoscopy in 308 participants. 
The mean SD diameter of the nodules was 14.6 8.7 mm, whereas only 2.8% of nodules 
were <30 mm in diameter. The sensitivity of bronchoscopy was 13.5% (95% CI, 9.0%-
19.6%); the specificity, 100%; the positive predictive value, 100%; and the negative predic-
tive value, 47.6% (95% CI, 41.8%-53.5%). Of all cancers detected, 1% were detected by 
bronchoscopy only and were retrospectively invisible on both low-dose CT scan and CT 
scan with IV contrast.
Conventional white-light bronchoscopy should not be routinely recommended for 
patients with positive test results in a lung cancer screening program.
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INTRODUCTION
Depending on the geographic region, 26% to 51% of participants in multi-detector com-
puted tomography (CT) lung cancer screening trials showed at least one non-calcified 
pulmonary nodule on their CT scan.1-4 The likelihood of these nodules being malignant 
depends on their size.1,5 The Fleischner Society guideline recommends a recall CT scan, 
PET scan, or biopsy for nodules >8 mm detected on a CT scan 5 but not by bronchoscopy. 
The American College of Chest Physicians (ACCP) guideline recommends only evalu-
ation by bronchoscopy under the condition that an air bronchogram is present on CT 
scan or in centres with expertise in newer techniques.6,7 Literature on the role of newer 
techniques, such as ultrathin bronchoscopy, autofluorescence bronchoscopy, and CT 
scan-guided bronchoscopy in lung cancer screening settings is sparse. To our knowledge, 
a study by McWilliams et al8 is the only one to report on the role of autofluorescence 
bronchoscopy in a lung cancer screening trial. The diagnostic yield of bronchoscopy to 
evaluate solitary pulmonary nodules outside a CT scan screening program varies from 
51% to 76%9-14 and highly depends on the size and location of the nodule.9,10,13-15
The nodule management strategy of the Dutch-Belgian Randomised Lung Cancer 
Screening Trial (NELSON) is based on the size and the volume-doubling time (VDT) 
of nodules detected by CT scan, without the use of fine-needle aspiration, PET scan, or 
evaluation after antibiotics.1 Subjects with positive test results were referred for work-up 
of suspicious nodules, which included a physical examination, a standard CT scan with 
contrast, and bronchoscopy.5,6,16,17
Recently, a the U.S. National Lung Screening Trial (NLST) demonstrated a 20% mortal-
ity reduction with low-dose CT screening.20 In the low-dose CT group, 320 subjects (1.8% 
of all subjects with a positive test result) underwent bronchoscopy without biopsy or 
cytological testing, whereas 391 subjects (2.2% of all subjects with a positive test result) 
underwent bronchoscopy with biopsy or cytological testing. The investigators did not 
report on the diagnostic performance of bronchoscopy in their study. In Pan-Canadian 
Lung Cancer Screening Trial, all participants were offered an auto-fluorescence bron-
choscopy to detect central airway lesions; 67% (378 of 561) actually underwent this pro-
cedure.21 Ideally, all subjects should have undergone bronchoscopy for this purpose. Four 
of 22 subjects (18%) bronchoscopy yielded a diagnosis of radiological occult lung cancer. 
In the Canadian trial, the purpose of bronchoscopy appears to have been inspection of 
the central airways.21 In about 45% (320 of 711) of cases, cytology or histology specimens 
were obtained. It is unclear to what extent the ACCP guidelines were followed. In both 
the Canadian trial and the NLST, no nodule criteria were specified before the decision to 
perform bronchoscopy.
So far, lung cancer screening trials have not provided specific recommendations on 
the use of bronchoscopy to evaluate suspicious CT-detected nodules,2,18,19,22  nonetheless 
Chapter 7
182
a significant number of bronchoscopies have been performed.20 Screening detects more 
early-stage lung cancers, whereas advanced-stage lung cancers that are present as interval 
cancers amenable to bronchoscopy are excluded from analyses.1 Our hypothesis was that 
the diagnostic value of bronchoscopy in this workup process might be low as suspicious 
nodules are usually small and peripherally located.1,18,19 If this is true, bronchoscopic 
evaluation may be eliminated from the standard work-up of suspicious CT-detected 
nodules; which would enhance the cost-effectiveness of a lung cancer screening program 
and avoid the harms of bronchoscopy. Therefore, our objective was to prospectively 
investigate the diagnostic value of bronchoscopy in the NELSON trial and to evaluate the 
diagnostic yield of the various diagnostic techniques used during bronchoscopy.
METHODS
Study Population
The nodule management strategy of the NELSON trial has been published previously.16,23 
Briefly, 15,822 individuals with at high risk for developing lung cancer were randomised 
to either four low-dose CT examinations (n=7,915) at baseline (first round), one year 
later (second round), three years later (third round), and five and a half years later, or no 
screening (n=7,907). All consecutive participants with a positive test result at the first, 
second, and third screening round from April 2004 to December 2008 were included in 
this study.
A test result was considered positive for pulmonary nodules with a volume of >500 
mm3(about 9.8 mm in diameter) and nodule with a volume doubling-time (VDT) of 
<400 days.1,16,21 For nodules with a solid component  measuring ≥50 to ≤500 mm3 the 
test result was indeterminate, and a repeat scan was performed to assess the VDT of 
the nodule. When the VDT was <400 days at repeat scanning, the final test result was 
considered positive, otherwise, it was considered negative.1,16
The NELSON trial was approved by the ethics committees of all participating centres, 
and all participants provided written informed consent (approval number IRB00001838).
Bronchoscopy
Conventional white-light bronchoscopies were performed by experienced pulmonolo-
gists working at the four screening sites in The Netherlands (Utrecht, Groningen, and 
Haarlem) and Belgium (Leuven).16 During bronchoscopy, bronchial washings were 
performed for cytology and culture; bronchial brushings and biopsy specimens were 
taken (52C-1 forceps) in the case of central lesions. In less than 1% of the cases, biopsy 
was performed under fluoroscopic guidance. The bronchoscopists did not use CT scan 
fluoroscopic guidance or ultrathin bronchoscopes. A flexible Pentax video bronchoscope 
183
Evaluation of bronchoscopy
(Pentax Medical Company) was used in Utrecht, whereas Groningen and Haarlem used 
the Olympus flexible video bronchoscope (Olympus America Inc), and in Leuven both 
types were used. 
Endobronchial abnormalities were classified as visible tumour, constriction, or com-
pression of the airways. Nodules within the inner third, middle, and outer third of the 
hilar-costal diameter on CT scan were classified as respectively central, intermediate, or 
peripheral.
If the bronchoscopy revealed cancer, the outcome of the procedure was considered 
positive; otherwise, it was considered negative. The gold standard for the outcome of the 
bronchoscopy was the pathology result of the surgical resection specimen of the suspi-
cious lesion. If no surgical resection was performed, the presence or absence of cancer 
during a follow-up of at least two years after the first and second screening rounds and at 
least one year after the third round was used as the gold standard. Nodules with a VDT of 
>400 days at follow-up CT examinations were considered benign.1
Data Analysis
Statistical analyses were performed using SPSS, version 17.0 (SPSS, Inc.) software. The 
sensitivity was defined as the ratio between the number of positive bronchoscopy results 
and the number of positive results according to the gold standard. The diagnostic sen-
sitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
were calculated at the level of the suspicious nodules. Suspicious nodules that were not 
approached during bronchoscopy were excluded from the analysis. 
Mann-Whitney U test was used for continuous variables, and chi2-test was used for 
binomial and categorical data. Binary logistic regression was used to determine the ef-
fect of the individual nodule characteristics on the diagnostic yield of bronchoscopy. In 
the multivariate analysis, the characteristics with a p-value ≤0.10 were included for a 
stepwise-forward procedure. P-values <0.05 were considered statistically significant.
RESULTS
Of the 415 participants with positive test results, 74.2% (308 of 415) underwent bronchos-
copy to evaluate 318 suspicious pulmonary lesions; 25.8% (107 of 415) did not undergo 
bronchoscopy for several reasons (Fig 1). In 2.4% (10 of 415) of the cases, referral was 
based on non-nodular lesions on CT. Six bronchoscopies were performed (Fig 1) on these 
participants. No significant differences were found in participant characteristics and nod-
ule characteristics between those who did and those who did not undergo bronchoscopy 
(Table 1); except for a sex difference and a difference in cancer detection rate of 22.4% 
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(24 of 107) in the group without bronchoscopy compared with 57.8% (178 of 308) in the 
bronchoscopy group (p<0.001) ( Fig 1 ).
The average maximum diameter of the suspicious nodules was 14.6 mm; the maximum 
diameter varied from 5 to 68 mm (SD 8.7 mm), only 2.8% of the lesions measured >30 
mm. Cancer was diagnosed by bronchoscopy in only 24 of 318 suspicious lesions. Suspi-
cious nodules identified as cancer by bronchoscopy were significantly larger (odds ratio 
(OR) 1.07, 95% CI 1.02-1.13), and were more often visible during bronchoscopy (OR 
87.6, 95% CI 4.9-564.9) compared to the cancer cases missed by bronchoscopy (Table 2).
Based on the gold standard used in this study, a total of 178 cancer cases were detected 
among the 318 lesions, including 167 lung cancer cases. In 77% (137 of 178) of cases the 
gold standard was based on surgical resection specimens, in 18.5% (33 of 178) of cases 
it was based on surgical biopsy specimens (mediastinoscopy, true-cut biopsy performed 
during surgery), and in 4.5% (eight of 178) of the cases it was based on the combination 
of a new and growing PET-positive lesion on CT scan. 
In 24 of the 178 subjects with cancer, bronchoscopy yielded the diagnosis of cancer. 
Hence, the sensitivity of bronchoscopy to detect cancer was 13.5% (95% CI 9.0-19.6%), 
Table 1. Participant and nodule characteristics of participants who underwent and 
who did not underwent bronchoscopy
Characteristics Bronchoscopy
n (%)
No bronchoscopy
n (%)
p-value
Female gender 60 (19.5) 8 (7.5) <0.001
Age - mean(range) 62 (50-75) 62 (51-74) 0.44
Pack-years - mean(range) 47 (21-160) 43 (22-108) 0.12
Nodule
   Diameter - mean(SD) 14.6 (8.7) 14.6 (9.1) 0.78
   VDT <400 days 132 (90.4) 39 (84.8) 0.29
   Localisation, central* 38 (12.8) 9 (9.2) 0.33
   Lobe, upper 152 (51.0) 48(48.0) 0.60
Screen round
   First 144 (46.8) 44 (41.4) 0.31
   Second 91 (24.5) 29 (27.1) 0.63
   Third 73 (23.7) 34 (31.8) 0.10
Scan type
   Regular scan 202 (65.6) 67 (62.6) 0.58
   Repeat scan 106 (34.4) 40 (37.4) 0.58
Total 308 (100.0) 107 (100.0) NA
Definition of abbreviations: NA = not applicable, VDT = volume doubling-time, n=number, SD= standard deviation.
* Central indicates a localisation within in the inner one-third of the costal-hilar diameter on computed tomo-
graphy.
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and the NPV was 47.6% (140 of 294; 95% CI 41.8-53.5%). Accordingly, 48.4% (154 of 
318) of the bronchoscopic findings were false-negative (Table 3). As no false-positive 
diagnoses were made by bronchoscopy specificity and PPV were both 100%. 
In 7.5% (23 of 308) of all bronchoscopies, an endobronchial abnormality was found, 
and in 47.8% (11 of 23) of the cases, the tumour was endobronchially visible. When an 
endobronchial tumour was visible, the sensitivity of bronchoscopy to detect cancer was 
81.8% (95% CI 47.8-96.8%). In 2.6% of the 308 bronchoscopies, an endobronchial tumour 
was detected, which was not visible on CT scan, also in retrospect. This accounts for 4.5% 
(eight of 178) of all cancer cases detected by CT scan screening in this period. Of these 
eight additional cancer cases, only three were stage I, the remaining five were stage III 
or IV. When the diagnostic performance of bronchoscopy was limited to the suspicious 
nodules visible on CT scan, the sensitivity to detect cancer was 8.3% (14 of 168, 95% CI 
4.8-13.9%), and the NPV was 47.6% (140 of 294, 95% CI 41.8-53.5%).
Figure 1. Bronchoscopies performed for the evaluation of positive screening test re-
sults in the NELSON trial
Partcipants with a 
bronchoscopy 
N = 308
Participants without a 
bronchoscopy
N = 107
Reasons: 
---------------------------------------------
- Not referred to pulmonologist
N = 21
- Bronchoscopy refused 
N = 6
- Nodule disappeared on CT 
N = 14
- Tumour board decision
N = 15
- Advanced disease
N = 1
- Bronchoscopy not applicable†
N = 7
- Reason unclear 
N = 43malignant
24/107
(22.4%)
benign
83/107
(77.6%)
No cytology or histology 
obtained from suspicious 
nodule
N = 39
No. of suspicious nodules 
analysed by bronchoscopy
N = 318
Cytology or histology obtained 
from suspicious nodule
N = 279
Final diagnosis
Reasons:
---------------------------------------------
- Non-nodular lesion 
N = 6
- Other visible endobronchial 
abnormality 
N = 9
- Approached lobe not mentioned 
in report 
N = 10
- Wrong lobe approached
N = 8
- No cytology obtained during 
bronchoscopy 
N = 6
Final diagnosis Final diagnosis
malignant
158/279
(56.6%)
malignant
20/39
(51.3%)
benign
121/279
(43.4%)
benign
19/39
(48.7%)
Screen positive participants
N = 415*
Outcome of the bronchoscopies performed for the evaluation of 308 participants with positive screening results of 
the Dutch-Belgian randomised lung cancer screening trial. 
* Includes 10 participants referred for non-nodular lesions detected on screening CT scan (interstitial lung dis-
ease, pneumonia, lobar atelectasis, pleural effusion, pleural thickening, or mediastinal mass).
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The sensitivities of the various diagnostic techniques used during bronchoscopy ranged 
from 7.9% for brush to 45.8% for endobronchial biopsy (Table 4).
During the bronchoscopies, minor complications (nose bleeding and mild bleeding 
after the biopsy) occurred in only 0.6% (2 of 308) of participants. There were no major 
complications. 
Table 2. Univariate and multivariate analyses of bronchoscopies in participants with 
cancer
Cancer 
diagnosed by 
bronchoscopy 
(n=24)
Final diagnosis 
of cancer 
(n=178)
Univariate Multivariate
Characteristic n (%) n (%) OR (95% CI) p-value OR (95% CI) p-value
Nodule*
   Diameter in mm - mean 
(SD) 26.0 (3.6) 17.7 (0.7) 1.08 (1.04-1.13) <0.001
   VDT >400 days 0/5 (0.0) 8/86 (9.3) ref
   VDT <400 days 5/5 (100.0) 78/86 (90.7)
Localisationa
   Peripheral 11/22 (50.0) 146/176 (83.0) ref
   Centralb 11/22 (50.0) 30/176 (17.0) 7.11 (2.71-18.63) <0.001 0.44 (0.04-5.16) 0.52
   Middle and lower lobe 5/21 (23.8) 64/175 (36.6) ref
   Upper lobe 16/21 (76.2) 111/175 (63.4) 1.99 (0.69-5.71) 0.20
Screen round
   First 12/24 (50.0) 74/178 (41.6) ref
   Second 6/24 (25.0) 51/178 (28.7) 0.69 (0.24-1.97) 0.49
   Third 6/24 (25.0) 53/178 (29.8) 0.66 (0.23-1.89) 0.44
Scan type
   Regular scan 17/24 (70.8) 12/178 (69.1) ref
   Repeat scan 7/24 (29.2) 55/178 (30.9) 0.91 (0.35-2.34) 0.84
Bronchoscopy
   Normal 11/24 (45.8) 155/178 (87.1) ref
   Bronchial compression 4/24 (16.7) 12/178 (6.7) 6.54 (1.70-25.19) <0.001 4.06 (0.56-29.21) 0.16
   Visible tumour 9/24 (37.5) 11/178 (6.2) 58.91 (11.31-306.8) <0.001 87.61 (4.90-564.9) <0.001
Definition of abbreviations: OR = odds ratio; 95% CI = 95% confidence interval; SD = standard deviation; VDT 
= volume doubling-time.
a The denominator is not always equal to 24 or 178 because it was not possible to classify all nodules.
b Central indicates the inner one-third of the costal-hilar diameter on CT scan.
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DISCUSSION
In this study, the diagnostic value of conventional white-light bronchoscopy in the NEL-
SON trial was prospectively evaluated. 
The overall sensitivity was 13.5%, and the NPV was 47.6%. The sensitivity was only 
8.3% when limited to CT-detected suspicious nodules. Of all cancers detected within the 
time frame of this study, 4.5% were identified by bronchoscopy only and were not visible 
on CT. 
In non-screening studies, the sensitivity of conventional bronchoscopy varied from 
51% to 76%,9-14 which  is much higher than the 13.5% in the NELSON trial. This can be 
Table 3. Overview of false-negative diagnoses by bronchoscopy
Cytological or histological diagnosis No. (%)
No abnormality 101 (65.6)
Infectious
   Aspergillus fuminatus 1 (0.6)
   Aspecific inflammation 42 (27.3)
Preinvasive lesion
   Atypia 1 (0.6)
Benign, other
   Fibrosis 2 (1.3)
   Resolving haemorrhage 1 (0.6)
   Metaplasia 6 (3.9)
Total false-negative diagnoses 154 (100.0)
Table 4. Diagnostic value of ancillary procedures during bronchoscopy
Malignancy Diagnostic performance
Diagnostic technique Bronchoscopy Final diagnosis Sensitivity 95% CI NPV 95% CI
Wash 17/322 (5.3) 182/322 (56.5) 9.3 5.7-14.8 45.9 40.2-51.7
Brush 6/125 (4.8) 76/125 (60.8) 7.9 3.3-17.0 41.2 32.4-50.6
TBNA 2/6 (33.3) 6/6 (100.0) 33.3 6.0-75.9 0.0 0.0-6.0
TBB 1/12 (8.3) 8/12 (66.7) 16.7 0.9-63.5 44.4 15.3-77.3
EBB 11/40 (27.5) 24/40 (60.0) 45.8 26.2-66.8 55.2 36.0-73.0
Overall 37/505 (7.3) 296/505 (58.6) 12.5 9.1-16.4 44.7 40.1-49.3
Definition of abbreviations: 95% CI = 95% confidence interval; NPV = negative predictive value; TBNA = trans-
bronchial needle aspiration; TBB = transbronchial biopsy; EBB = endobronchial biopsy.
No false-positive diagnoses were made by any of the ancillary procedures during bronchoscopy, therefore all speci-
ficities and positive predictive values were 100%.
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explained by the fact that in the present study, only 2.8% of the nodules were >30 mm, 
whereas in non-screening studies, lesion size ranged from 48 to 72 mm.9,10,13,14  Further, 
fewer lesions were endobronchially visible in the current study compared to the literature 
(7.3% vs. 8-64%).10-12 Both nodule size and endobronchial visibility were independent 
predictors for high diagnostic yield in the present study.
As far as we know, only Kanemoto et al24 retrospectively evaluated the diagnostic value 
of bronchoscopy in a selected study population in which 108 suspicious pulmonary nod-
ules had been detected by mass screening (chest radiography or CT scan). All nodules 
were ≤20 mm and 42% of the nodules were malignant; based on fluoroscopy-guided 
bronchoscopy or lung biopsy specimens. The drawback of that study is the selection 
bias of the study population and the absence of a gold standard for the outcome of the 
bronchoscopy. As a result, the investigators were unable to provide data on the diagnostic 
performance of bronchoscopy in this screening program.
According to current guidelines, bronchoscopy is recommended only for the evalua-
tion of nodules with an air bronchogram6,25,26 without a standard position in the routine 
workup of suspicious pulmonary nodules. Although we did not evaluate whether the 
presence of an air bronchogram increased the diagnostic yield of bronchoscopy, the 
results clearly demonstrate that bronchoscopy is not justified for the evaluation of CT-
detected pulmonary nodules, because of its very low sensitivity and NPV.
The use of more advanced bronchoscopic techniques is not yet recommended by the 
ACCP.6 Nevertheless, we believe that electromagnetic-navigated or peripheral endo-
bronchial ultrasound-guided bronchoscopy may play a role in the evaluation of small, 
peripheral CT-detected nodules, since their sensitivity is respectively 59-74%27-30 and 49-
80%27,31-34. In addition, ultrathin bronchoscopy may play a role in the future for diagnostic 
evaluation of peripheral pulmonary nodules.35,36
Because of the poor diagnostic performance, we do not recommend the routine use 
of conventional bronchoscopy for patients with suspicious CT-detected nodules, even 
though bronchoscopy yielded the detection of eight cancers that were not visible on CT. 
Only one-third of these cancers was early stage and may be treated with curative intent. 
It is arguable what percentage missed lung cancers is acceptable. We believe that this 
depends on the setting, lung cancer screening, or daily practice. In lung cancer screening 
trials, vast numbers of subjects are exposed to invasive procedures, which are accompa-
nied by morbidity, anxiety and costs. Therefore, we consider the benefit of bronchoscopy 
too small. Moreover, only 38% of these radiologically occult cancers were stage I. The 
reason that the eight cancers detected by bronchoscopy were not visible on CT may be 
the use of low-dose CT examinations, without the use of intravenous contrast. The lesions 
were, in retrospect, visible on the standard-dose CT with intravenous contrast performed 
in the workup of these participants. Other investigators reported that 1%37 to 5%6 of CT 
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occult tumours was detected by white-light bronchoscopy, whereas 18% was detected 
with autofluorescence bronchoscopy.21
Additional diagnostic techniques, such as brush and biopsy, should only be used to 
evaluate visible endobronchial tumours. In the present study, we found sensitivity of 
>80% for brush and biopsy.
The strength of the present study lies in the fact that it was prospectively conducted and 
that for the majority of the suspicious nodules, histologic conformation was obtained by 
either surgical resection or biopsy specimen. So far, the diagnostic value of a conventional 
bronchoscopy has not previously been evaluated properly in a CT screening trial which 
included asymptomatic, high-risk participants from the general population. In addition, 
we were able to evaluate the diagnostic value of bronchoscopy based on individual nodule 
level. Despite this, our study also has its limitations. The proportion of women and the 
cancer detection rate in the group that did not undergo bronchoscopy was lower than 
in those who underwent bronchoscopy. Because sex was not associated with a higher 
diagnostic yield in the study, this did not introduce selection bias. The cancer detection 
rate in the group without bronchoscopy was lower because 20% (21 of 107) of cases were 
referred for non-nodular lesions or because the suspicious nodule had disappeared on the 
diagnostic CT scan with contrast. If all participants with positive test results had under-
gone bronchoscopy, the sensitivity may have been even lower, which further strengthens 
the present conclusions. In the workup protocol, bronchoscopy only was performed on 
participants with positive test results. To date, it is not known what the performance of 
conventional bronchoscopy is, when it is used as a screening tool, instead of as diagnostic 
tool. This is currently under investigation in the Pan-Canadian lung cancer screening 
trial.38
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CONCLUSION
In conclusion, routine use of conventional bronchoscopy in patients with suspicious CT-
detected pulmonary nodules in a lung cancer screening program is not recommended.
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ABSTRACT
To assess the complication rate in participants of the screen group of the NELSON lung 
cancer screening trial who underwent surgical resection and to investigate, based on a lit-
erature review, whether the complication rate, length of hospital stay, re-thoracotomy and 
mortality rates after a surgical procedure were different from those of the non-screening 
series, taking co-morbidity into account.
Between April 2004 and December 2008, 198 subjects underwent thoracic surgery. Co-
morbid conditions were retrieved from the medical records. Postoperative complications 
were classified as minor and major.
In total, 182 thoracotomies, 5 thoracotomies after video-assisted thoracoscopic surgery 
(VATS), and 11 VATS procedures were performed. 36% of the participants had chronic 
obstructive lung disease, 16% coronary artery disease, 14% diabetes mellitus and 11% 
peripheral vascular disease. Following thoracotomy, 47% (88/187) had ≥1 minor (7-57% 
in literature) and 10% (18/187) ≥1 major complication (2-26% in literature); following 
VATS, 38% (6/16) had ≥1 minor complication, but no major complications. Seventeen 
percent (3/18) of major complications and 21% (20/96) of minor complications were 
observed in subjects operated for benign disease. The re-thoracotomy rate was 3%, there 
was no 30-day mortality after thoracotomy or VATS (0-8.3% in literature). The mortality 
rate of 0% after surgical procedures is low compared to non-screening series (0-8.3%); 
the rate of complications (53%) was within the range of published non-screening series 
(8.5-58%).
In conclusion, mortality rates after surgical procedures were lower in the NELSON 
lung cancer screening trial than in non-screening series. The rate of complications was 
within the same range as in non-screening series.
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INTRODUCTION
It has been shown that lung cancer screening by low-dose multi-detector computer to-
mography (CT) can detect lung cancer at an early stage.1 Before considering implementa-
tion of CT screening, a reduction in lung cancer mortality has to be demonstrated by 
randomised clinical trials, and the balance between the benefits and harms of screening 
has to be evaluated thoroughly. Important aspects to be taken into account are the effects 
of CT screening on health-related quality of life, and the occurrence of complications 
associated with the work-up and treatment of participants with a positive test result.
Patient-related factors, such as a poor general health status, age and co-morbidity, 
contribute to the risk of postoperative pulmonary complications.2 Screening populations 
usually consist of heavy current and former smokers at an advanced age and at high risk 
for co-morbid disease. In several studies, it has been demonstrated that co-morbidity is 
predictive of morbidity and mortality related to surgical procedures.3 Hence, to be able to 
make a fair comparison with the mortality and complication rates reported in non-lung 
cancer screening series, the co-morbidity of the screened population should be assessed. 
Our objective was to assess the complication rate in participants in the screen group 
of the Dutch-Belgian lung cancer screening trial (NELSON) who underwent a surgical 
resection, and to investigate, based on a literature review, whether the complication rate, 
length of stay and re-thoracotomy and mortality rates after a surgical procedure were 
different from those in non-screening series.
METHODS
Inclusion criteria and work-up
NELSON trial participants were current and former smokers at high risk for develop-
ing lung cancer. Detailed information on the inclusion and exclusion criteria have been 
reported previously.4 Briefly, current and former smokers aged 50–75 with a smoking 
history of >15 cigarettes per day during >25 years or >10 cigarettes per day during >30 
years (quit ≤10 years ago) were invited. Subjects with a moderate or bad self-reported 
health, subjects who were unable to climb two flights of stairs and persons with a body 
weight ≥140 kg were excluded, as were those with a history of cancer.
The prospective screening study was approved by the Ministry of Health and by the 
Medical Ethical Boards of each of the four participating hospitals. Written informed 
consent was obtained from all participants. 
In the NELSON trial, 7,557 subjects underwent a CT scan at baseline, the second 
screening round (1 year after baseline) and the third screening round (2 years after the 
second round).1 Subjects with a positive test result were referred for work-up to a pul-
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monologist and, depending on the outcome of this work-up, a resection of the suspicious 
lesion was performed. The standard non-invasive work-up included a physical exam, 
pulmonary function test, bronchoscopy, FDG-PET-scan and a standard-dose CT scan 
with intravenous contrast of the chest and upper abdomen.
CT data acquisition and image reading
Data acquisition and image reading were as described previously.5 In brief, all four par-
ticipating screening sites used 16-detector CT scanners (Sensation-16, Siemens Medical 
Solutions, Forchheim, Germany Mx8000 IDT or Brilliance 16P, Philips Medical Systems, 
Cleveland, OH, USA). Scan data were obtained in a spiral mode, with 16 × 0.75 mm 
collimation and 1.5 pitch. No contrast was administered. Data acquisition and scan-
ning conditions were standardized and equal for baseline and repeat screening. Digital 
workstations (Leonardo®, Siemens Medical Solutions, Erlangen, Germany) were used 
in all screening sites with commercially available software for semi-automated volume 
measurements (LungCare®, Siemens Medical Solutions, version Somaris/5:
VA70C-W).
Nodule management and diagnostic work-up
At baseline, a scan was considered positive if any non-calcified nodule had a solid com-
ponent >500 mm3 (about >9.8 mm in diameter) and indeterminate if the volume of the 
largest solid nodule or the solid component of a partially solid nodule was 50-500 mm3 
(about 4.6-9.8 mm in diameter), or >8 mm in diameter for non-solid nodules.5 Subjects 
with an indeterminate result underwent a follow-up scan after three months to assess 
nodule growth. Significant growth was defined as a change in volume between the first 
and second scan of ≥25%. Subjects with positive screening tests were referred to a chest 
physician for work-up and diagnosis.1 If lung cancer was diagnosed, the participant was 
treated for the disease and no longer underwent screening; if no lung cancer was found 
the regular second-round CT scan was scheduled twelve months after baseline scan. For 
participants with one or more new nodules on the second-round scan, the result (positive 
or negative) was based on the size of the nodule, as for round one; in the case of an 
indeterminate result, a follow-up scan was performed 6 weeks later.5 For participants 
with previously existing nodules, the second-round result was based on the volume 
doubling-time (VDT). If there was no growth, or if the VDT was >600 days, the scan 
was classified negative.1 If the VDT was <400 days, or if a new solid component had 
emerged in a previously non-solid nodule, the scan was considered positive. When the 
VDT was 400-600 days, the test was classified indeterminate and follow-up scanning was 
performed one year after the second round. For nodules with a VDT of <400 days, the 
final result was considered to be positive. If both new and existing nodules were present, 
the nodule with the largest volume or fastest growth determined the screening test result. 
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All participants with a negative second-round result were invited to undergo the third 
screening two years after the second round. 
Work-up and staging were standardized for all screening sites according to national 
and international guidelines and included a physical exam, a standard CT scan with 
contrast of the chest and upper abdomen, FDG-PET scan and a bronchoscopy.5 Subjects 
with a negative non-surgical work-up were referred for surgery to obtain histology of the 
suspicious nodule. Bronchoscopies were done in accordance with Dutch national guide-
lines in order to evaluate the central airways and (if possible) to diagnose lung cancer or 
benign disease. Pulmonologists and thoracic surgeons were not blinded for the result of 
the positron emission tomography (PET) examination. All subjects with suspected lung 
cancer were discussed in multidisciplinary tumour boards, which included a thoracic 
surgeon, before progressing to surgery; all imaging studies were available during these 
meetings. National and international pathology review panels evaluated all cytological 
and histological specimens.
Operative details
All resections were performed at one of the four screening centres, of which three were 
academic institutions and one a peripheral hospital. In Groningen, three experienced 
thoracic surgeons were involved, in Haarlem two, in Louvain three and in Utrecht eleven. 
Participants with a benign diagnosis after non-surgical work-up were scheduled for the 
next screening round. In the remaining test-positive subjects, the suspicious nodules 
were removed either by VATS or thoracotomy with wedge resection and frozen sec-
tion. A preoperative tissue biopsy was not routine. Lobectomies were performed only 
for central nodules that could not be approached by wedge resection, meaning limited 
resections were performed for benign lesions. If lung cancer was diagnosed by VATS, 
the procedure was converted to an open thoracotomy with sampling of lobar, interlobar, 
hilar and mediastinal lymph nodes. This is because VATS resection for lung cancer was 
not yet fully implemented in daily practice in the Netherlands at the time of the present 
study. A mediastinoscopy was performed before proceeding to VATS or thoracotomy 
in subjects with mediastinal lymph nodes larger than 10 mm in the short-axis and/or 
FDG-PET positive mediastinal lymph nodes. No specific strategies were employed to 
prevent prolonged air leak, such as reinforced staple lines. The chest tube was removed if 
there was no air leak and the fluid production was 200 ml or less per 24 hours.
Data collection and co-morbidity scoring
The date, nature, number and outcome of all adverse events related to all diagnostic 
and treatment procedures between April 2004 and 31 December 2008 were entered into 
an web-based database ‘the NELSON Management System’ by investigators at the four 
screening sites after completion of the diagnostic work-up and therapeutic procedures. 
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In addition, a hard copy of the medical records of all subjects referred for work-up and 
treatment was centrally stored at the data centre of Erasmus MC Rotterdam in order to 
review for complications. 
Co-morbid conditions were retrieved from the medical records based on the medical 
history at the time of referral because of a positive screening test result. Subjects were 
defined as having chronic obstructive pulmonary disease (COPD) when the forced expi-
ratory volume in one second (FEV1) and forced vital capacity (FVC) ratio was <0.70 and/
or the medical history mentioned COPD and the participant used inhaled steroids and/
or bronchodilators. Coronary artery disease included a history of myocardial infarction, 
coronary artery bypass graft, percutaneous transluminal coronary angioplasty or angina 
pectoris. Peripheral vascular disease included a history of intermittent claudication, 
abdominal aneurysm, percutaneous transluminal angioplasty or bypass grafting of the 
peripheral arteries.
Literature search
A review of the literature was performed using a Pubmed search up to February 2011. 
The search string consisted of a combination of medical subject headings [MeSH] and 
keywords including ‘Lung Neoplasms’, ‘Postoperative Complications’, ‘Co-morbidity’,
‘Mortality’, ‘Thoracotomy’, ‘Thoracic Surgery, Video-Assisted’ and related synonyms. 
We summarised the main results of the literature study and the current study with regard 
to co-morbidity and adverse events following thoracotomy in forest plots. This was not 
done for VATS procedures in view of the low number of VATS procedures in the cur-
rent study. Lack or incomplete reporting of comorbidity was not used as an exclusion 
criterion. Studies in which all participants had previously received chemotherapy and/
or radiotherapy were excluded. For studies without classification of complications, com-
plications were scored according to our definitions of minor and major complications, 
provided that a complete overview of all complications was reported. In addition, in the 
case of studies that graded complications based on the Common Terminology Criteria 
for Adverse Events, grade 4–5 events were considered major complications.
Definitions of complications
Postoperative mortality was defined as death within 30 days after the operation or 
within the same hospital admission. According to EuroSCORE6 and Birim et al.7 major 
complications included bleeding requiring re-operation, empyema, pneumonia (Center 
for Disease Control and Prevention definition of nosocomial pneumonia)2, myocardial 
infarction, renal failure requiring temporary or permanent dialysis, postoperative  stroke, 
critical arrhythmia (ventricular fibrillation, ventricular tachycardia) and pulmonary em-
bolism. Additional major complications included respiratory failure requiring ventilator 
support for >48 hours8 and postoperative heart failure with pulmonary oedema.9 We 
201
Evaluation of surgical procedures
classified a chylothorax, haemothorax and gastro-intestinal complications requiring op-
erative re-intervention (re-thoracotomy) or laparotomy as major complications. Non-life 
threatening complications were classified as minor complications. All minor and major 
complications were scored for each VATS and thoracotomy procedure.
Statistical analysis
Data were analysed using SPSS (version 17.0, SPSS, Inc., Chicago, IL, USA). A two-tailed 
Mann–Whitney U-test was used to analyse continuous data in the absence of normal 
distribution. Chi²-test was used for binomial or categorical data and Fisher’s exact test 
for small groups. Statistical significance was defined as a p-value <0.05. Asymmetric 
confidence intervals (CI) were calculated for the literature study data presented in Figures 
1 and 2 using log-linear regression, where we estimated the observation as the log of a 
β; a weighted standard error (SE) was calculated for this β and subsequently the CI was 
obtained.
RESULTS
Background and treatment characteristics
A total of 415 subjects had a positive test result following CT screening between April 
2004 and December 2008. The role of FDG-PET in the work-up of these test-positive 
participants has been described elsewhere. In seventeen of the participants surgical 
procedures consisted of a mediastinoscopy only; fifteen were subsequently diagnosed 
with lung cancer, which was at an early stage in two, who were inoperable because of 
co-morbidity (Figure 3). In 178 participants, the final benign diagnosis was based on 
FDG-PET, CT with intravenous contrast or biopsies. Transthoracic biopsies were only 
performed in 5% (22/415) of test-positive participants.
In twenty-two participants cancer was diagnosed but the subjects did not undergo 
resection because of: advanced stage disease (n=13) or co-morbidity (n=9), the latter 
group was treated with stereotactic radiotherapy. In the twenty-two subjects, diagnosis 
was based on biopsy (n=15) cases, or imaging studies (n=7). In 198 participants, non-
surgical work-up showed lung cancer or was inconclusive. These subjects underwent a 
resection either via thoracotomy (n=182), VATS converted to thoracotomy (n=5), or 
wedge resection by VATS (n=11) (Figure 3). 
The characteristics of the subjects who underwent a resection are presented in Tables 
1 and 2. The most frequent comorbid conditions were COPD (36%), coronary artery 
disease (16%), diabetes mellitus (14%) and peripheral vascular disease (11%) (Table 
2). Table 1 shows the clinical and pathological lung cancer stages. Three subjects with 
clinical stage III (T4N0M0) were operated and a microscopic complete resection could 
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be achieved. Five subjects had pathological stage IV lung cancer after surgery. Two of 
them had an indeterminate preoperative FDG-PET result, which in retrospect appeared 
to be metastatic lesions. In two patients the preoperative FDG-PET was false-negative 
for distant metastasis. In one subject, no preoperative FDG-PET was made due to an 
Figure 1. Prevalence of comorbidity in subjects undergoing thoracotomy
Prevalence of chronic obstructive pulmonary disease, coronary artery disease, diabetes mellitus and peripheral 
vascular disease in NELSON lung cancer screening participants who underwent a thoracotomy in comparison with 
non-screening series from the literature.
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administrative error; the postoperative FDG-PET scan showed distant metastasis. Of 
eight patients with pathological stage III disease, this was due to unforeseen N2 disease 
in seven patients and due to a bronchoalveolar carcinoma in the middle lobe, which was 
resected in one patient; a second suspicious upper lobe nodule could not be found during 
surgery. The clinical stage at that time was cT1N0M1. One month later the upper lobe 
Figure 2. Prevalence of complications and mortality in subjects undergoing thora-
cotomy
Complication and mortality rates after thoracotomy in the NELSON lung cancer screening trial in comparison with 
non-screening series from the literature.
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nodule showed rapid growth and mediastinal lymphadenopathy was noted (clinical stage 
T1N2M0); mediastinoscopy showed metastasis of a large cell carcinoma.
Table 1. Characteristics of participants who underwent surgery after a positive screen-
ing test
Characteristics Lung surgery
n (%)
Female gender 35 (18)
Age - mean(range) 61 (50-74)
Pack-years - mean(range) 46 (21-133)
COPD 71 (36)
   GOLD I 38 (19)
   GOLD II 20 (10)
   GOLD III 6 (3)
   GOLD stage unknown 7 (4)
Type of surgery
   Pneumonectomy 4 (2)
  (Bi)lobectomy 137 (70)
   True cut biopsy, segment/wedge resection 56 (26)
   Sternotomy 1 (0.5)
Diagnosis
   Lung cancer 139 (70)
   Other cancer 12 (6)
   Benign abnormalities 47 (24)
Clinical lung cancer stagea
   I 117 (84)
   II 18 (13)
   III 3 (2)
   IV 1 (1)
Pathological lung cancer stage
   I 112 (81)
   II 11 (8)
   III 11 (8)
   IV 5 (4)
Total 198 (100)
Definition of abbreviations: COPD = Chronic Obstructive Pulmonary Disease, GOLD = Global initiative for 
chronic Obstructive Lung Disease.
a Sixth edition of TNM classification for lung cancer.
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Complications after surgery
Tables 3 and 4 present all complications observed. Following thoracotomy, 47% (88/187) 
had at least one minor and 10% (18/187) at least one major complication. Thirty-eight 
percent (6/16) of the VATS procedures was complicated by at least one minor complica-
tion, but no major complications have been observed. As 5% had both minor and major 
complications, the proportion of participants with any complication was 53%. Seventeen 
percent (3/18) of major complications and 21% (20/96) of minor complications were seen 
in subjects operated for benign disease. 
The overall median length of hospital stay was 13 days (2-51 days) after thoracotomy 
and 8 days (4-12 days) after VATS. In subjects with minor complications, this was 15 
days (6-51 days) and 9 days (7-12 days), respectively. In the case of major complications 
following thoracotomy, the median length of stay was 21 days (range 8-51 days). The re-
thoracotomy rate was 3% after thoracotomy and 0% after VATS. Re-admissions occurred 
in 5% of those who underwent a thoracotomy (eight after minor complications and one 
after a major complication), but were absent after VATS. There was no 30-day mortality 
after thoracotomy or VATS in the NELSON trial.
Table 5 shows that a higher rate of minor complications was seen in the case of more 
extensive resections. Limited resections (true-cut biopsies, and wedge and segment resec-
tions) had lower rates of minor complications (OR 0.51, 95% CI 0.26-1.03, p-value 0.06) 
compared to bilobectomy, lobectomy and pneumonectomy. No significant correlation 
could be established between type of resection and risk of major complications. 
Five subjects were re-admitted because of minor complications: three subjects with 
chest pain and one with dyspnoea a pulmonary embolism could be excluded; in one 
Table 2. Comorbidity of participants who underwent surgery after a positive screen-
ing test
Comorbidity Lung surgery
n (%)
Any primary tumour 16 (8)
Chronic obstructive pulmonary disease 71 (36)
Congestive heart failure 5 (3)
Coronary artery disease 31 (16)
Cerebrovascular disease 5 (3)
Peripheral vascular disease 22 (11)
Diabetes mellitus 28 (14)
Chronic kidney disease 2 (1)
Connective tissue disease 4 (2)
Peptic ulcer disease 7 (4)
Total 198 (100)
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Table 3. Minor complications following thoracotomy and VATS procedures
Minor complication Thoracotomy
n (%)
VATS
n (%)
Air-leakage >5 days 42 (23) 5 (31)
Supraventricular tachycardia 17 (9) 0
Infection 16 (9) 1 (6)
Diaphragm paralysis 10 (5) 0
Chest tube >5 days 8 (4) 0
Atelectasis 8 (4) 1 (6)
Drop hand 3 (2) 0
Wound infection 3 (2) 0
Delirium 3 (2) 0
Chest pain 3 (2) 0
COPD exacerbation 2 (2) 2 (13)
Blood transfusion 2 (2) 0
Urinary retention 2 (2) 0
Haemoptysis 2 (2) 0
Persistant ptosis 1 (1) 0
Paralysis serratus anterior muscle 1 (1) 0
Deep venous thrombosis 1 (1) 0
Ileus 1 (1) 0
Pleuritic effusion 1 (1) 0
Dyspnoea 1 (1) 0
Definition of abbreviations: VATS = video-assisted thoracoscopic surgery; COPD = Chronic Obstructive Pulmo-
nary Disease.
Table 4. Major complications following thoracotomy
Major complication n (%)
Pneumonia 10 (5)
Empyema 2 (1)
Bleeding, re-operation 1 (0.5)
Chylothorax, re-operation 1 (0.5)
Pulmonary embolism 1 (0.5)
Respiratory failure 1 (0.5)
Myocardial infarction 1 (0.5)
Congestive heart failure 1 (0.5)
Ventricular tachycardia 1 (0.5)
Bowel perforation 1 (0.5)
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subject with pleural effusion an empyema was excluded; no repeat chest tube placement 
or thoracocentesis was necessary (Table 3). Atelectasis was diagnosed by chest radiograph 
in nine subjects; in five subjects bronchoscopy was performed.
Data from the literature review
Literature search revealed sixteen studies on thoracotomy and twelve studies on both tho-
racotomy and VATS which met the selection criteria (Appendix Table 1). The prevalence 
of comorbidity in the literature on thoracotomy ranged from 43% to 80%3,7 (Appendix 
Table 1). Figure 1 shows the prevalence of co-morbidities in subjects who underwent 
a thoracotomy in non-lung cancer screening studies. The most frequently reported co-
morbid conditions were COPD (10–52%), coronary artery disease (10-52%), diabetes 
mellitus (7-19%) and peripheral vascular disease (6-26%). The number of lobectomies 
performed during thoracotomy procedures varied from 40% to 100%.22 (Suemitsu et 
al. 2009), while pneumonectomies were performed in 0-27%10,14 (Pagni et al. 1998). 
The percentage of stage I disease in the thoracotomy group was 69.0% (median, range 
31-100%).10,11 Mortality rates reported after thoracotomy varied from 0% to 8% (Figure 
2). The National Emphysema Treatment Trial (NETT) found a 90-day mortality of 5% 
following lung volume reduction surgery in subjects with severe emphysema (mean 
FEV1 0.7 l; 26% of predicted).12 Figure 2 shows major and minor complications after 
thoracotomy, ranges varied respectively from 4-26% and 7-57%. The median length of 
hospital stay after thoracotomy reported in the literature was 5-22 days13 (Boffa et al, 
2008). The reported re-thoracotomy rates after a thoracotomy varied from 0% to 9%.7,13
In the majority of the studies on VATS, lobectomies were performed. Complications 
after VATS were reported in 9-51% (Kim et al. 2010, Petersen et al. 2010) and major 
Table 5. Complications according to type of surgery
Thoracotomy Minor complications Major complications VATS Minor complications
Type of surgery n (%) 1 2 Any Total 1 2 Any Total n (%) 1 2 3 Any Total
True cut biopsy 6 (3) 2 0 2 (33) 2 0 0 0 (0) 0 0 (0) 0 0 0 0 (0) 0
Wedge resection 35 (19) 8 3 11 (31) 14 3 0 3 (9) 3 16 (100) 4 1 1 6 (38) 9
Segmentectomy 4 (2) 1 0 1 (25) 1 1 0 1 (25) 1 0 (0) 0 0 0 0 (0) 0
Lobectomy 131 (70) 40 26 69 (53) 101 11 2 13 (10) 15 0 (0) 0 0 0 0 (0) 0
Bilobectomy 5 (3) 1 2 4 (80) 8 1 0 1 (20) 1 0 (0) 0 0 0 0 (0) 0
Sleeve resection 1 (1) 0 0 0 (0) 0 0 0 0 (0) 0 0 (0) 0 0 0 0 (0) 0
Pneumonectomy 4 (3) 1 0 1 (25) 1 0 0 0 (0) 0 0 (0) 0 0 0 0 (0) 0
Sternotomy 1 (1) 0 0 0 (0) 0 0 0 0 (0) 0 0 (0) 0 0 0 0 (0) 0
Total 187 (100) 53 31 88 (47) 127 16 2 18 (10) 20 16 (100) 4 1 1 6 (38) 9
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complications in only 0-12%17 (Jaklitsch et al. 1996, Petersen et al. 2010). The median 
length of stay after a VATS reported in the literature was 4-23 days13 (Villamizar et al. 
2009). The reported re-operation rate after a VATS varied from 1% to 5%13 (Paul et al. 
2010), with a mortality rate of 0-4%21 (Handy et al. 2009).
Figure 3. Flowchart of surgical procedures and outcomes
S urgic al work-up
N = 215
Non-s urgic al work-up
N = 200
malignant
N = 22
benign
N = 178
Medias tinos c opy only
N = 17
Medias tinos c opy
N = 44
F inal diagnos is
L ung s urgery
N = 198
---------------------------------------------
T horacotomy 
N = 182
V AT S
N = 11
V AT S  converted to thoracotomy
N = 5
F inal diagnos is
malignant
N = 15
benign
N = 2
S c reen pos itive partic ipants
N = 415
Surgical procedures and outcomes in 415 screen positives of the NELSON randomised lung cancer screening trial.
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DISCUSSION
Our study compared the complications rates, length of hospital stay, rethoracotomy and 
mortality rates of participants of the NELSON trial who underwent thoracic surgery 
with data from non-screening series. The comparison with non-screening series could 
be made because we demonstrated that the age range and co-morbidity level of the NEL-
SON trial participants who underwent a surgical resection was the same as those in the 
non-screening series.
Literature review and complications
The studies included in our literature review displayed a large heterogeneity with respect 
to the definition, classification and way in which data on complications have been col-
lected so far. For example, prolonged air leak has been defined as >5 days7 and >7 days.13 
In addition, chest-tube management with regard to output differs in studies or is not 
defined. Few authors make a distinction between minor and major complications, and 
complication data are collected by reviewing individual patient charts, based on ICD-9 
codes14 or on claims in Medicare files.3 The latter methods may lead to underreporting 
of complications, especially for minor complications. Probably because we screened all 
individual patient files, our minor complication rates are in the higher range of what has 
been reported before. The most important observation was the relatively low rate of ma-
jor complications and the absence of postoperative mortality after the thoracotomy and 
VATS procedures performed in the screen group of the NELSON trial. This could prob-
ably be explained by the fact that screening participants were asymptomatic individuals, 
screen-detected tumours are usually smaller15,16 and that pneumonectomies were less 
often required in the NELSON compared to published studies, wherein more complex 
resections with a higher expected complication rate were performed. Nevertheless, the 
proportion of stage I disease was in the same range of what has been reported in our 
literature review of the non-screening series. 
Lung cancer-screening studies and complications
In a recent study, Infante et al.17 report on the outcome of surgical procedures in the 
DANTE trial. A total of 59 subjects underwent a thoracotomy procedure. Three died 
following the thoracotomy and a total of twenty complications were noted, which were 
major complications in nine subjects. No major complications or postoperative deaths 
were seen in subjects diagnosed with benign disease. Fifteen subjects underwent a VATS 
procedure; no postoperative deaths or major complications were noted in this subset of 
patients. The postoperative mortality rate in the DANTE study was higher than expected. 
All subjects had central tumours of stage IIA or higher, two had co-morbid conditions 
and two had undergone a pneumonectomy. Veronesi et al.18 reported that 25% of subjects 
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developed complications following thoracotomy and VATS procedures, which were seri-
ous in 6% and required re-operation in 2%. No postoperative complications or mortality 
was noted in the subjects with benign disease. While only two subjects underwent a 
pneumonectomy in this study,18 pneumonectomies were performed on four subjects in 
our study. Infante et al.17 performed a relatively high number of pneumonectomies, in 
seven subjects in total, which may explain the higher mortality rate. The rate of major 
complications in lung cancer screening studies is at the lower limit of the range published 
in the literature. Mortality rates are also at the lower limit18, however with more extensive 
resections the rate may be the same as in the literature.17 An important observation to 
make is that no major complications and no deaths were seen in subjects operated for 
benign disease.17,18 However, in our study 17% (3/18) of major complications and 21% 
(20/96) of minor complications were observed in subjects operated for benign disease.
Length of stay after VATS and thoracotomy 
Despite these observations, the length of stay (LOS) after thoracotomy and VATS proce-
dures was not shorter for NELSON participants than the average. This can be explained 
by the fact that patients in the Netherlands and Belgium usually stay in the surgery or 
pulmonary medicine department and do not routinely go to a short-stay facility after 
surgery. It has been shown that LOS decreases when the use of skilled nursing facilities 
increases.19 Another possible explanation may be that in the Netherlands and Belgium it 
is socially much less accepted to discharge patients home after three or four days. None 
of the participants in the NELSON study went to a long-term nursing facility. Prolonged 
air leak has been described as the most important factor for prolonged hospital stay20, 
this was not the case in the current study, presumably because of less severe emphysema.
Type of resection
In the NELSON trial, VATS procedures were only performed for wedge resections, 
whereas in the majority of studies VATS was used to perform lobectomies, which is a 
major difference. This is due to the fact that VATS lobectomy had only recently been 
introduced in the Netherlands at the time of the study.21 The proportion of lobectomies in 
the thoracotomy group was comparable with the literature. Therefore, and because of the 
low number of VATS procedures in the current study, the comparison we made between 
the VATS results in the NELSON screening trial and the non-screening series from the 
literature should be interpreted with caution. There is general consensus in the literature 
that morbidity and mortality rates after VATS are lower than after  thoracotomy, and 
that patients have a better postoperative physical functioning and a shorter postoperative 
length of stay.22 In addition, the oncological validity of VATS resections for lung cancer 
has been proved as 5-year survival rates are similar to those after thoracotomy.23 We 
therefore believe that lung cancer screening sites should be equipped to perform VATS 
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procedures, especially in view of the substantial risk of false-positive test results and 
resections for benign disease.1
SUMMARY
In the NELSON lung cancer screening trial, the rate of minor complications after thora-
cotomy and VATS was in the upper range of what has been reported for the non-screening 
series, while the rate of major complications was in the lower range. The postoperative 
length of stay was not shorter than in the literature. The re-thoracotomy rate for compli-
cations such as a haemothorax requiring re-intervention in the NELSON trial was in the 
range reported in the literature, but no re-thoracotomies were performed after VATS. No 
postoperative deaths were observed after the thoracotomy and VATS procedures.
To our knowledge, this is the first report on the prevalence of co-morbidity and of 
complications in a lung cancer screening population. Veronesi et al. presented data 
on complications as an abstract without information on co-morbidity.18 Their results 
support our encouraging data, which demonstrate that participants are at low risk of 
major complications or postoperative death following thoracotomy or VATS lung cancer 
screening. Nonetheless, the high rate of resection for benign disease and associated mor-
bidity continues to be a concern. Seventeen percent of the major complications and 21% 
of the minor complications were seen in subjects operated for benign disease. The use of 
FDG-PET24 and combination of FDG-PET and VDT25 may help to reduce the number of 
resections for benign disease. 
In conclusion, mortality rates after surgical procedures were lower in the NELSON 
lung cancer screening trial than in non-screening series. The rate of minor and major 
complications is within the range of non-screening series.
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APPENDIX
Table 1. Outline studies on thoracotomy and studies on thoracotomy and VATS  
Study Period Participants Age*
Pagni 1971-1996 385 75 (70-96)
Thomas 1975-1996 500 74 ± 3
Moro 1979-2003 588 63 (33-86)
Igai† 1982-2008 37 82 ± 2.3
Bach 1985-1996 2,118 ≥ 65
Sirbu 1986-2001 273 73 (70-88)
Memtsoudis 1988-2002 512,758 62 (1-91)
Birim 1989-2001 125 74 (70-82)
Harpole 1991-1995 3,516 64 (22-91)
Birim 1996-2001 205 64 (29-82)
Suemitsu 1996-2006 756 20-90
Yang† 1996-2003 508 52 (23-79)
Matsuoka 1997-2004 40 82 (80-88)
Sugiura† 1997-1998 22 61 ± 9
Meguid 1998-2003 26,310 66
Handy† 1998-2007 64 64
Whitson† 1998-2005 88 65
Allen 1999-2004 1,023 68 (23-89)
Berry† 1999-2007 119 76 ± 0.2
Boffa 1999-2006 9,033 67 (20-94)
Scott† 1999-2004 686 68 ± 9
Villamizar† 1999-2008 382 64 ± 11
Little 2001 11,668 67
Mishra 2001-2005 597 69 (63-74)
Flores† 2002-2007 343 67 (35-89)
Cattaneo† 2002-2005 82 76 (70-89)
Paul† 2002-2007 1,281 65 ± 12
NELSON 2004-2008 187 62 (50-74)
Infante† 2001-2009 59 64 (64.0-64.7)
Definition  of abbreviations: VATS = video-assisted thoracoscopic surgery.
* Median (range) or, mean ± standard deviation.
† Thoracotomy arm.	
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Table 2. Outline of studies on VATS and studies VATS and thoracotomy
Study Period Participants
n 
Age*
Igai† 1982-2008 58 83 ± 2.4
Jaklitsch 1991-1994 307 65-90
McKenna 1992-2004 1,100 71 (16-94)
Walker 1992-2001 178 66 (43-85)
Congregado 1993-2006 237 61 (12-79)
Yang† 1996- 2003 113 54 (9-77)
Sugiura† 1997-1998 22 62 ± 12
Handy† 1998-2007 49 63
Whitson† 1998-2005 59 67
Berry† 1999-2007 219 76 ± 0.2
Scott† 1999-2004 66 71 ± 9.7
Villamizar† 1999-2008 697 67± 10
Nakanishi 2000-2006 58 70 (52-90)
Cattaneo† 2002-2005 82 76 (70-88)
Flores 2002-2007 328 67 (36-90)
Paul† 2002-2007 1,281 65 ± 12.1
Kim 2003-2008 704 57 (12-86)
Petersen 2005-2008 197 65 (44-85)
Belgers 2006-2008 70 66 (41-85)
Infante† 2001-2009 15 64 (64.0-64.7)
NELSON 2004-2008 16 61(52-72)
Definition  of abbreviations: VATS = video-assisted thoracoscopic surgery.
* Median (range) or, mean ± standard deviation.
† VATS arm.
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Uniform and blinded cause of death verification in a lung cancer CT 
screening trial
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ABSTRACT
Disease-specific mortality is the final outcome of a lung cancer screening trial, therefore 
cause of death verification is crucial. The use of death certificates for this purpose is 
debated because of bias, inaccurate completion and incorrect ante mortem diagnoses. 
A cause of death evaluation process was designed to ensure a uniform and unbiased 
determination of the graduation of certainty that lung cancer was the underlying cause 
of death. An independent clinical expert committee will review the medical files of all 
deceased participants once diagnosed with lung cancer and will make use of a flow chart 
and predetermined criteria. A pilot study of fifty cases was conducted to determine the 
performance of this process and to compare the outcome with the official death cer-
tificates. The independent review has shown an agreement of 90% (kappa 0.65), which 
demonstrates a uniform classification. The sensitivity and specificity of the death certifi-
cates for lung cancer specific mortality were 95.2 and 62.5%. This demonstrates a limited 
distinctive character of the death certification process in lung cancer patients. Our results 
imply that the final outcome of a lung cancer screening trial cannot reliably be established 
without predetermined criteria and an independent review of blinded cases.
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INTRODUCTION
Lung cancer is the first cause of cancer-related death in males and the second in females 
globally, accounting for 1.4 million deaths per year.1 Despite treatment advances, survival 
has not improved substantially over the past 30 years, mainly because the majority of 
the patients have distant metastasis at the time of diagnosis.2 The early detection of lung 
cancer by screening asymptomatic smokers with low dose computer tomography (CT) 
scanning is a promising strategy to reduce lung cancer mortality, since the results of the 
National Lung Screening Trial (NLST) were published.3,4 
Disease-specific mortality is the outcome of lung cancer screening; therefore, cause of 
death (CoD) verification is crucial. The use of death certificates for this purpose is de-
bated for several reasons. Firstly, two forms of bias especially affect death certification in 
screening trials. Sticky-diagnosis bias; because lung cancer is more likely to be diagnosed 
in the screen arm, deaths are more likely to be attributed to lung cancer compared to the 
usual care arm.5 Slippery-linkage bias; deaths as a result of interventions for lung cancer 
may be difficult to trace back to screening and could easily be certified as death due to 
other causes.5 Secondly, the merit of death certificates depends on the accuracy of the 
certifying clinician and nosologist and the establishment of a correct ante mortem diag-
nosis.6,7 Common reasons for misclassification are coinciding malignancies, considerable 
comorbidity and death after a surgical procedure.8,9 Finally, the sensitivity and specificity 
of the death certificate has been reported to range from 84.5 to 99.7% of screening9–12 and 
91.3 to 99.7%; causing an error that tends to reduce the effect of screening.9–12
To overcome these problems clinical expert committees (CEC), reviewing the medical 
files of the deceased participants to determine the cause of death, are frequently em-
ployed in cancer screening trials.9–14 The additional value of a CEC depends on the use of 
predetermined criteria and a thorough and independent evaluation of all cases with lung 
cancer blind towards each arm, to prevent an unbalanced outcome between the study 
arms. 
We hypothesized that a clinical expert committee cannot reliably establish the outcome 
of a lung cancer screening trial, unless they are independent and review the medical files 
blinded and with predetermined criteria and flowcharts. The aim of this study is to de-
velop a CoD review process protocol that will be used in the Dutch-Belgian lung cancer 
CT screening trial (NELSON). The performance of the protocol has been tested in a pilot 
and the outcomes will be compared with the official death certificates.
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METHODS
Study design and subjects for the NELSON trial
Details of the design and conduct of the Dutch-Belgian lung cancer screening trial have 
been reported elsewhere.15,16 Briefly, randomly assigned eligible participants underwent 
CT screening at baseline (first round), 1 year later (second round), 3 years later (third 
round) and 5.5-year later (fourth round) or no screening. The purpose of the trial is to 
determine whether at 10 years after randomisation, CT screening will have reduced mor-
tality from lung cancer by at least 25%.16 The trial was approved by the Dutch Minister 
of Health and the ethics board at each participating centre.4 All participants provided 
written informed consent for the evaluation of personal data from hospital charts and 
national registers. The CoD evaluation process of the NELSON trial was designed to en-
sure a uniform and unbiased determination of the primary cause of death in participants 
with lung cancer.
Identification of subjects for the CoD review and data collection
The causes of death of all participants of the NELSON trial that are diagnosed with lung 
cancer (during their lifetime or at autopsy) are subject of the ‘review process’ to ensure 
a valid determination of the primary outcome measure of the screening trial. The lung 
cancer cases are identified by linkages with the national cancer registries of the Nether-
lands and Belgium and by checking all official death certificates for the diagnosis lung 
cancer, which are obtained from Statistics Netherlands and the Flemish Agency for Care 
and Health. For all identified cases, the diagnosis of lung cancer is verified by a pathol-
ogy panel17 or clinical experts for cases without cytology or histology. This verification 
process of the lung cancer diagnosis was performed separately from the CoD-verification 
process in the NELSON-trial and will not be addressed in this manuscript.
After the identification of the subjects, all relevant medical information will be col-
lected and blinded for the participant’s identity and study arm by an individual who is 
not otherwise involved in the trial. The medical files include: information provided by 
the general practitioner, discharge, outpatient visit letters, reports of radiology, nuclear 
medicine, pathology and microbiology, laboratory results, and autopsy reports.
Formation of the clinical expert committee
All cases will be reviewed and classified separately by the three members of the CEC, 
who are no employees of the screening trial. The committee is formed by a pulmonolo-
gist–oncologist and pathologist specialised in lung oncology and a clinical epidemiologist 
specialised in screening. For a random sample of 10%, cases with disagreement and all 
intervention related deaths the committee will meet. An international committee will be 
consulted in case no consensus is reached.
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The cause of death evaluation process protocol 
The evaluation process performed by the experts will be guided by the use a flowchart 
(Figure 1a-d in Appendix) and a detailed list of criteria (Table 1 in Appendix). The prod-
uct of the evaluation is the classification of the cause of death of the participant in one of 
the six categories which define graduation of certainty that lung cancer was the primary 
cause of death (Table 1).
Design and subjects of the CoD pilot
Before the implementation of the protocol we decided to perform a pilot study by our-
selves with a limited number of cases to test its user-friendliness and performance com-
pared with the official death certificates. Therefore, we included the first fifty consecutive 
deceased participants diagnosed with lung cancer. In contrary to the CEC of externals 
to be formed for the review of all lung cancer deaths, a medical doctor (N.H.) and a 
clinical epidemiologist (H.J.d.K), internals of the NELSON-trial formed the committee 
for the pilot study. The collection and blinding of the medical files and the review process 
itself was performed as described. After the completion of the evaluation of the cases by 
Table 1. Classification of the cause of death
Cause of death Definition
Definitely lung cancer death Death certainly as a direct result of (second primary) lung cancer, a 
paraneoplastic syndrome or a diagnostic or therapeutic intervention, 
including euthanasia and palliative sedation. No clear other cause of 
death is present.
Probable lung cancer death Participants with (second primary) lung cancer with evidence of loco-
regional or distant disease progression or a paraneoplastic syndrome. 
It is uncertain whether this is the final direct cause of death. No clear 
other cause of death is present.
Possible lung cancer death Participants with (second primary) lung cancer with evidence of loco-
regional or distant disease progression or a paraneoplastic syndrome 
and one or more coinciding malignancies. It is not possible to 
determine which malignancy was the primary cause of death.
Unlikely lung cancer death Participants with (second primary) lung cancer, but without evidence of 
loco-regional or distant disease progression, a paraneoplastic syndrome 
or death as a result of an intervention for lung cancer. No clear other
cause of death is present.
Definitely no lung cancer death The cause of death is definitely not a direct or indirect result from 
(second primary) lung cancer, a paraneoplastic syndrome or an 
intervention for lung cancer. Another cause of death is present.
Intercurrent death with lung cancer as 
contributing factor
Only use this option when the cause of death cannot be classified as 
listed above. The cause of death is definitely not a direct result from 
(second primary) lung cancer. Another cause of death is present and 
lung cancer contributed to the death of the patient.
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both reviewers separately, the reviewers met and discussed the cases with disagreement. 
Two of the pulmonologist–oncologists of the NELSON trial (H.J.M.G. and J.-W.J.L.) were 
consulted in case of persistent disagreement. After that, the final outcome of the pilot 
study was compared with the primary cause of death on the official death certificate.
Analysis
The primary cause of death is defined as ‘the disease that initiated the chain of morbid 
events directly leading to death’. Lung cancer mortality, the primary endpoint of the study, 
is defined as “definitely” or “probable lung cancer death” (Table 1). “Possible”, “unlikely” 
and “definitely no lung cancer death” and “intercurrent death with lung cancer as a con-
tributing factor” are considered as death due to other causes (Table 1).
The agreement between the two reviewers of the CoD pilot is assessed by means of 
kappa statistics. A kappa of 1 and 0, respectively indicates a perfect agreement and no 
agreement. 
The cause of death, as assigned by the review committee of the pilot after consensus 
meeting, is considered as the gold standard. The sensitivity and specificity of the official 
death certificates were defined as the proportion of lung cancer deaths assigned by both 
sources and as death due to other causes.
Because it is not yet allowed to analyse the data by study arm, no absolute numbers of 
lung cancer deaths per arm are disclosed. Therefore, it is not possible to determine if the 
CoD review process enhances or attenuates the effect of screening.
RESULTS
The baseline characteristics, base for the diagnosis of lung cancer and the disease stage 
of the fifty subjects that were included in the pilot are displayed in Table 2. The separate 
classification of the cause of death by the reviewers is shown in Table 3. In thirty-eight 
of the fifty participants (76%) the reviewers reached a concordant conclusion. The 
twelve remaining cases with disagreement had; significant comorbidity (n=3), multiple 
malignancies (n=2), death after an intervention (n=3) and death indirectly caused by 
lung cancer (n=4), such as death due to post-obstruction pneumonia or paraneoplastic 
pulmonary embolism. However, when clustering all “definitely” and “probable” lung 
cancer deaths into one group and “possible”, “unlikely” and “definitely not” lung cancer 
death and “intercurrent death” into another, the differences were minimal; agreement in 
45 cases (90%) resulting in a kappa of 0.65. 
The comparison between the results of the CoD review, after consensus meeting, 
and the primary cause of death on the official certificates is displayed in Table 4. The 
sensitivity and specificity of the death certificates are 95.2% (95% confidence interval: 
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84.2-98.7%) and 62.5% (95% confidence interval: 30.6–86.3%), respectively. Disagree-
ment was observed in 10% (5 of 50 individuals) with the following causes of death: adult 
respiratory distress syndrome after lobectomy, rupture of an abdominal aneurysm during 
chemotherapy, another malignancy besides lung cancer in two cases (breast carcinoma 
and acute myeloid leukaemia) and small cell lung carcinoma diagnosed after the person’s 
death by autopsy. 
Autopsy was performed in 3 (6%) of the cases. Five of the 41 (12%) lung cancer deaths 
involved euthanasia or palliative sedation. The place of death was in the hospital in 48%, 
in a hospice or nursing home in 10% and at home in 42% of the subjects. In 65% of the 
Table 2. Characteristics of the fifty subjects of the pilot study
Agea Mean: 62.6 years
Range: 51-73 years
Gender Male: 42/50 (84%)
Female: 8/50 (16%)
Base for the diagnosis 
lung cancer
Surgical resection of primary tumour: 16/50 (32%)
Histology or cytology of primary tumour: 15/50 (30%)
Histology or cytology of lymph node metastasis: 6/50 (12%)
Histology or cytology of distant metastasis: 8/50 (16%)
Autopsy: 1/50 (2%)
Clinical picture and imaging techniques: 4/50 (8%)
Disease stage at 
diagnosisb
Ia: 12/50 (24%)
IIa: 2/50 (4%)
IIb: 1/50 (2%)
IIIa: 6/50 (12%)
IIIb: 3/50 (6%)
IV: 26/50 (52%)
a Age at the inclusion in the NELSON trial.
b TNM staging system for lung cancer 7th edition.
Table 3. Outcome of the separate review of the cause of death
Lung cancer death Review 1 Review 2 Level of agreement
n of 50 (%) n of 50 (%) kappa
Definitely or probable 41 (82) 42 (84) 0.65
- definitely 33 (66) 41 (82) 0.60
- probable 8 (16) 1 (2) 0.19
Possible 1 (2) 0 (0) -
Unlikely 1 (2) 0 (0) -
Definitely not 3 (6) 7 (14) 0.56
Contributory to other CoD 4 (8) 1 (2) 0.38
Definition of abbreviation: CoD = cause of death.
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cases, the reviewers indicated the letters of the pulmonologist as the most valuable source 
of information.
DISCUSSION
In this pilot study, we have presented the principles of the CoD review process that will be 
used in the NELSON trial. The pilot study of fifty cases has shown an agreement of 90% 
(kappa 0.65) between the two reviewers, which demonstrates a reasonable classification. 
We expect an increase of the level of agreement for the actual review process, performed 
by clinical experts, with the number of cases they evaluate; the so-called ‘learning-effect’. 
When comparing to the CoD process, the sensitivity and specificity of the official death 
certificates for lung cancer specific mortality were 95.2 and 62.5%, respectively. Despite 
the lack of a ‘gold standard’ for the cause of death of lung cancer participants, this still 
demonstrates, in our opinion, a limited distinctive character of the official cause of death 
certification in lung cancer patients for scientific purposes.
Potential limitations of the present study relate to the sample size and the selection of 
subjects of the pilot study. We have taken the first fifty consecutive deceased participants 
that were diagnosed with lung cancer. This has introduced a selection bias of individuals 
with a high lung cancer disease stage at diagnosis (Table 2) compared with the screen-
arm of the trial.4 In the pilot study, most deaths were due to lung cancer. It is plausible 
that death due to other causes than lung cancer plays a bigger part when the files of 
all NELSON participants will be reviewed. Hence, the figures demonstrated in the pilot 
could differ from those of the entire study.
No other lung cancer CT screening trial has published results of their methodology 
of CoD evaluation yet, to our knowledge. In the chest X-ray screening trials, such as the 
Mayo Lung Project, Hopkins and Sloan-Kettering Lung Trials and the Prostate, Lung, 
Colorectal and Ovarian (PLCO) cancer screening trial, an expert review panel deter-
mined the CoD.11,18–20 Lung cancer mortality was 5–6% overestimated in the intervention 
Table 4. The causes of death by the reviewers and the official certificates
CoD reviewa Death certificates
LC death
n (%)
Other CoD
n (%)
Total
n (%)
LC death 40 (80) 2 (4) 42 (84)
Other CoD 3 (6) 5 (10) 8 (16)
Total 43 (86) 7 (14) 50 (100)
Definition of abbreviations: CoD = cause of death; LC = lung cancer.
a Cause of death after consensus meeting of the reviewers.
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arm and 2% underestimated in the usual-care arm by the death certificates in these tri-
als.11,18 In this initial pilot, the misestimate is 10%.
CONCLUSION
Our and other studies’ results imply that the outcome of a lung cancer screening trial 
cannot reliably be established without a concordance analysis between vital statistics and 
a CoD review of blinded cases. Moreover, the principles and flowcharts presented here 
aim to provide one of the essential tools to make data pooling with other CT screening 
trials in the future possible.
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APPENDIX
Figure 1a. Cause of death evaluation flowchart part I
Yes
No
1.
Death as a result of
an intervention?
5.
Clear cause of death
present, other than
lung cancer?
2.
Evidence for
progressive,
recurrent or new
metastasis present?
3.
Evidence for
progressive,
recurrent or second
primary tumour
present?
4.
Evidence for
paraneoplastic
syndrome present?
DefinitelyLC
death
No
Lung cancer
contributing
factor?
Not enough
information
available
Yes
Doubt
Definitely no
LC death
Yes
No
other CoD direct
result of lung
cancer?
No
Not enough
information
available
Yes
Doubt
DefinitelyLC
death
Unlikely LC
death
IntercurrentCoD,
LC contributory
Flowchart part I
Doubt
Possible LC
death
Not enough
information
available
Intervention for
lung cancer?
No
Not enough
information
available
Yes
Doubt
Definitely noLC
death
Lung cancer
contributing
factor?
IntercurrentCoD,
LC contributory
Yes
No
Yes
See
 flowchart part II
No
See
 flowchart part III
See
 flowchart part IV
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Definition of abbreviations: LC = lung cancer; CoD = cause of death.
233
Endpoint determination
Fi
gu
re
 1
b.
 C
au
se
 o
f d
ea
th
 ev
al
ua
tio
n 
flo
wc
ha
rt
 p
ar
t I
I
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
D
ef
in
it
el
y
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
Y
es N
o
D
o
u
b
t
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
ro
b
ab
le
L
C
d
ea
th
P
ro
b
ab
le
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
M
et
as
ta
si
s 
lu
n
g
ca
n
ce
r?
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
U
n
lik
el
y
L
C
d
ea
th
U
n
lik
el
y
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
P
o
ss
ib
le
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
o
ss
ib
le
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
1.
D
ea
th
 a
s 
a 
re
su
lt
 o
f
an
 in
te
rv
en
ti
o
n
 f
o
r
lu
n
g
 c
an
ce
r?
5.
C
le
ar
 c
au
se
 o
f 
d
ea
th
p
re
se
n
t,
 o
th
er
 t
h
an
lu
n
g
 c
an
ce
r?
2.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
n
ew
m
et
as
ta
si
s 
p
re
se
n
t?
3.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
se
co
n
d
p
ri
m
ar
y 
tu
m
o
u
r
p
re
se
n
t?
4.
E
vi
d
en
ce
 f
o
r
p
ar
an
eo
p
la
st
ic
sy
n
d
ro
m
e 
p
re
se
n
t?
Y
es
N
o
Fl
ow
ch
ar
t p
ar
t I
I
N
o
Y
es
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
N
o
Y
es
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
III
N
o
Y
es
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
IV
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
D
efi
ni
tio
n 
of
 a
bb
re
vi
at
io
ns
: L
C 
= 
lu
ng
 ca
nc
er
; C
oD
 =
 ca
us
e o
f d
ea
th
.
Chapter 9
234
Fi
gu
re
 1
c. 
Ca
us
e o
f d
ea
th
 ev
al
ua
tio
n 
flo
wc
ha
rt
 p
ar
t I
II
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
D
ef
in
it
el
y
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
Y
es N
o
D
o
u
b
t
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
ro
b
ab
le
L
C
d
ea
th
P
ro
b
ab
le
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
T
u
m
o
u
r  
lu
n
g
ca
n
ce
r?
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
U
n
lik
el
y
L
C
d
ea
th
U
n
lik
el
y
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
P
o
ss
ib
le
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
o
ss
ib
le
L
C
d
ea
th
Lu
ng
 c
an
ce
r
co
nt
rib
ut
in
g
fa
ct
or
?
ot
he
r
C
oD
 d
ire
ct
re
su
lt 
of
 lu
ng
ca
nc
er
?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
1.
D
ea
th
 a
s 
a 
re
su
lt
 o
f
an
 in
te
rv
en
ti
o
n
 f
o
r
lu
n
g
 c
an
ce
r?
5.
C
le
ar
 c
au
se
 o
f 
d
ea
th
p
re
se
n
t,
 o
th
er
 t
h
an
lu
n
g
 c
an
ce
r?
2.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
n
ew
m
et
as
ta
si
s 
p
re
se
n
t?
3.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
se
co
n
d
p
ri
m
ar
y 
tu
m
o
u
r
p
re
se
n
t?
4.
E
vi
d
en
ce
 f
o
r
p
ar
an
eo
p
la
st
ic
sy
n
d
ro
m
e 
p
re
se
n
t?
Y
es
N
o
Fl
ow
ch
ar
t p
ar
t I
II
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
Y
es
N
o
N
o
Y
es
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
II
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
IV
Y
es
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
N
o
D
efi
ni
tio
n 
of
 a
bb
re
vi
at
io
ns
: L
C 
= 
lu
ng
 ca
nc
er
; C
oD
 =
 ca
us
e o
f d
ea
th
.
235
Endpoint determination
Fi
gu
re
 1
d.
 C
au
se
 o
f d
ea
th
 ev
al
ua
tio
n 
flo
wc
ha
rt
 p
ar
t I
V
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
D
ef
in
it
el
y
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
Y
es N
o
D
o
u
b
t
N
o
In
te
rc
u
rr
en
tC
o
D
,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
ro
b
ab
le
L
C
d
ea
th
P
ro
b
ab
le
L
C
d
ea
th
L
u
n
g
 c
a
n
ce
r
co
n
tr
ib
u
tin
g
fa
ct
o
r?
o
th
e
r
C
o
D
 d
ir
e
ct
re
su
lt 
o
f 
lu
n
g
ca
n
ce
r?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
P
ar
an
eo
p
la
st
ic
sy
n
d
ro
m
e 
re
su
lt
o
f  
lu
n
g
 c
an
ce
r?
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D
,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
U
n
lik
el
y
L
C
d
ea
th
U
n
lik
el
y
L
C
d
ea
th
L
u
n
g
 c
a
n
ce
r
co
n
tr
ib
u
tin
g
fa
ct
o
r?
o
th
e
r
C
o
D
 d
ir
e
ct
re
su
lt 
o
f 
lu
n
g
ca
n
ce
r?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
L
u
n
g
 c
a
n
ce
r
co
n
tr
ib
u
tin
g
fa
ct
o
r?
In
te
rc
u
rr
en
tC
o
D
,
L
C
 c
o
n
tr
ib
u
to
ry
W
as
 t
h
is
 t
h
e
C
o
D
?
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
Y
es N
o
P
o
ss
ib
le
L
C
d
ea
th
O
th
er
 c
le
ar
C
o
D
p
re
se
n
t?
N
o
In
te
rc
u
rr
en
tC
o
D
,
L
C
 c
o
n
tr
ib
u
to
ry
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y 
n
o
L
C
d
ea
th
N
o
Y
es
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
P
o
ss
ib
le
L
C
d
ea
th
L
u
n
g
 c
a
n
ce
r
co
n
tr
ib
u
tin
g
fa
ct
o
r?
o
th
e
r
C
o
D
 d
ir
e
ct
re
su
lt 
o
f 
lu
n
g
ca
n
ce
r?
N
o
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
Y
es
D
o
u
b
t
D
ef
in
it
el
y
L
C
d
ea
th
N
o
t 
en
o
u
g
h
in
fo
rm
at
io
n
av
ai
la
b
le
D
o
u
b
t
1.
D
ea
th
 a
s 
a 
re
su
lt
 o
f
an
 in
te
rv
en
ti
o
n
 f
o
r
lu
n
g
 c
an
ce
r?
5.
C
le
ar
 c
au
se
 o
f 
d
ea
th
p
re
se
n
t,
 o
th
er
 t
h
an
lu
n
g
 c
an
ce
r?
2.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
n
ew
m
et
as
ta
si
s 
p
re
se
n
t?
3.
E
vi
d
en
ce
 f
o
r
p
ro
g
re
ss
iv
e,
re
cu
rr
en
t 
o
r 
se
co
n
d
p
ri
m
ar
y 
tu
m
o
u
r
p
re
se
n
t?
4.
E
vi
d
en
ce
 f
o
r
p
ar
an
eo
p
la
st
ic
sy
n
d
ro
m
e 
p
re
se
n
t?
Y
es
N
o
Fl
ow
ch
ar
t p
ar
t I
V
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
Y
es
N
o
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
II
Y
es
Y
es
N
o
N
o
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
III
S
ee
 f
lo
w
ch
ar
t 
p
ar
t 
I
D
efi
ni
tio
n 
of
 a
bb
re
vi
at
io
ns
: L
C 
= 
lu
ng
 ca
nc
er
; C
oD
 =
 ca
us
e o
f d
ea
th
.
Chapter 9
236
Table 1. The cause of death evaluation process protocol
1. Death as a result of an intervention of lung cancer? (Figure1a in appendix)
Death certainly as a direct result of a diagnostic intervention (for example: intravenous contrast or radiopharmacon 
(CT, Magnetic Resonance Imaging (MRI) or Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET)), 
endoscopic interventions (transbronchial biopsy, endoscopic ultrasound (EUS) or endobronchial ultrasound 
(EBUS)), transthoracic punction or biopsy, pleural punction or drainage, punction of distant metastases or 
mediastinoscopy) or a therapeutic intervention (such as: surgery (in-hospital mortality and 30-day mortality), 
chemotherapy, radiotherapy, combined modality treatment, pleural drainage, endobronchial and endoesophageal 
interventions and brachytherapy, medication, euthanasia, palliative sedation) performed for (second primary) lung 
cancer or a paraneoplastic syndrome.
2. Evidence for progressive, recurrent or new metastasis present? (Figure 1b in appendix)
3. Evidence for progressive, recurrent or second primary tumour present? (Figure 1c in appendix)
To answer these two questions the following criteria are used:
I. Pathology
Proof of relapse, progression or a second primary lung cancer:
· Histological/cytological proof of lung cancer relapse, progression or 2nd primary
II. Radiology (X-ray, CT scan, MRI)[17]
Proof of relapse, progression or a second primary lung cancer:
· Growth of primary tumour (≥20% increase in largest diameter or unequivocal progression if not 
measurable)
· Recurrence (short axis >10mm) or progressive pathologically enlarged lymph nodes (≥20% increase in short 
axis or unequivocal progression if not measurable)
· Recurrence or progressive growth of previously existing intrapulmonary tumours (≥20% increase in largest 
diameter or unequivocal progression if not measurable)
· Recurrence or progressive growth of previously existing distant metastases (≥20% increase in diameter or 
unequivocal progression if not measurable)
· The appearance of any new malignant lesion (intrapulmonary or at distant sites) or pathologically enlarged 
lymph nodes (short axis >10mm)
· Increase of pleural or pericardial effusions from ‘trace’ to ‘large’
· Increase of  lymfangitis carcinomatosa  from ‘localised’ to ‘widespread’
III. Nuclear scans (FDG-PET scan, bone scintigraphy)
Proof of relapse, progression or a second primary lung cancer:
· New positive lesion(s) in case of a previously negative scan
IV. Bronchoscopy
Proof of relapse, progression or a second primary lung cancer:
· New, recurrent or progressive visible endobronchial tumour 
· New, recurrent or progressive compression of the airways by tumour mass
V. Laboratory
Findings suggestive of relapse, progression or a second primary lung tumour, which must be confirmed by 
additional testing:
· Hypercalcaemia
· Progressive liver chemistry abnormalities
· Increase in alkaline phosphatase
· Increase in tumour markers (carcinoembryonic antigen, neuron-specific enolase, cytokeratin 19 fragments 
(CYFRA))
VI. Clinical picture
Proof of relapse, progression or a second primary lung tumour:
· Physical exam: vena cava superior syndrome, pathologically enlarged lymph nodes ≥10mm.[17]
Findings suggestive of relapse, progression or a second primary lung tumour, which must be confirmed by 
additional testing:
· Physical exam: brain metastases, abdominal masses or organomegaly, pleura or pericardial effusions, ascites, 
skin metastases.
· Anamnesis: decline in WHO-performance status, weight loss >10% in past 3 months, progressive dyspnoea, 
bone pain
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4. Evidence for paraneoplastic syndrome present? (Figure1d in appendix)
To answer this questions the following criteria are used:
I. Angiography
Proof of a paraneoplastic syndrome:
· Deep venous thrombosis (DVT): contrast venography (intraluminal filling defect in two or an abrupt cut-off 
of a deep vein)[18]
· Pulmonary embolism (PE): pulmonary angiography (intraluminal filling defect in two views and or an 
occluded pulmonary artery with or without a trailing edge)[18-19]
II. Radiology
Proof of a paraneoplastic syndrome:
· DVT: ultrasound (compression technique, duplex or colour flow imaging)[18-19]
· DVT: MRI (intravascular filling defect or occlusion of a vessel)[18]
· PE: spiral CT scanning (intravascular filling defect or occlusion of a vessel)[18-19]
· PE: MRI (intravascular filling defect or occlusion of a vessel with a ‘trailing embolus’ sign)[18]
· Nonbacterial thrombotic endocarditis: thoracic or transoesophageal echocardiography (evident valve 
vegetation)
Findings suggestive of a paraneoplastic syndrome, which must be confirmed by additional testing:
· PE: chest X-ray (no abnormalities, atelectasis, pleural effusion, pulmonary infiltrates, elevation of a 
hemidiaphragm, Hampton’s hump, Westermark’s sign)[18]
· PE: thoracic or transoesophageal echocardiography (emboli in the main, right or left pulmonary artery, right 
ventricular dysfunction)[18-19]
· PE using transthoracic ultrasound (peripheral wedge-shaped opacities)[19]
III. Nuclear scans
Proof of a paraneoplastic syndrome:
· PE: (ventilation-)perfusion scanning ((sub)segmental perfusion defect)[18-19]
IV. Electrocardiography (ECG)
Findings suggestive of a paraneoplastic syndrome, which must be confirmed by additional testing:
· PE: P-wave pulmonale, axis deviation, right bundle branch block, S1 Q3 T3 pattern, ST segment 
abnormalities, T-wave changes.[18]
V. Laboratory
Proof of a paraneoplastic syndrome:
· Hypercalcaemia of malignancy (elevated total serum calcium corrected for albumin and low intact 
parathyroid hormone(PTH) and elevated PTH-related protein)
· Syndrome of inappropriate Antidiurectic Hormone (ADH) secretion (low serum sodium and 
 elevated ADH and elevated urine osmolality)
· Ectopic Adrenocorticotropic Hormone (ACTH) secretion causing Cushing’s syndrome (elevated ACTH 
(>20pg/ml) and a negative corticotrophin-releasing hormone simulation or dexamethasone suppression test 
and no central step-up at inferior petral sinus sampling)
· Neurologic paraneoplastic syndrome; always in combination with corresponding clinical picture (antibodies: 
anti-Hu, anti-Ri, anti-Tr, anti-Crossveinless-2/anti-Collapsin response mediator protein-5, anti-Ma1, anti-
Ma2, anti-amphiphysin, anti-Zic 4, anti-neuronal nuclear antibody-3, purkinje cell antibody-2, anti-Voltage-
gated calcium channel, anti-Nicotinic acetylcholine receptors)
· Disseminated intravascular coagulation: microangiopathic changes on the peripheral blood smear and 
increased fibrinolysis (e.g. elevated fibrinogen-fibrin degradation products and D-dimer)
· Thrombotic microangiopathy: haemolytic anaemia, thrombocytopenia, increased turnover of platelets, 
normal level of  coagulation components and little or no prolongation of prothrombine time or activated 
partial thromboplastin time.
Findings suggestive of a paraneoplastic syndrome, which must be confirmed by additional testing:
· PE (hypoxemia in arterial blood gas analysis and positive D-dimer)[18-19]
VI. Clinical picture
Findings suggestive of paraneoplastic syndrome, which must be confirmed by additional testing:
· DVT: limb pain, tenderness or swelling, Homans’ sign.[18]
· PE: unexplained dyspnoea, pleuritic chest pain, haemoptysis, tachypnea, tachycardia, syncope, hypoxemia.
[18]
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· Hypercalcaemia: constipation, fatigue, polyuria, polydipsia, dehydration, anorexia, nausea, muscle weakness.
· Syndrome of inappropriate ADH secretion: fatigue, headache, oedema, nausea, vomiting, altered mental 
status, coma.
· Cushing’s syndrome: muscle weakness, weight loss, hypertension, hirsutism.
· Severe paraneoplastic syndrome of the central nervous system (e.g. Lambert-Eaton myasthenic syndrome, 
cerebellar degeneration, pandysautonomia): focal neurological signs, autonomic dysfunction.
· Disseminated intravascular coagulation: signs of bleeding, acute organ failure (renal, liver, lungs), shock, 
thromboembolism, central nervous system dysfunction.
· Thrombotic microangiopathy: signs of anaemia, bleeding, acute renal failure, central neurologic 
abnormalities.
· Nonbacterial thrombotic endocarditis: acute ischemic cerebrovascular accident or acute peripheral arterial 
thromboembolism.
5. Clear cause of death present, other than lung cancer? (Figure 1a in appendix)
In the last step of the flowchart (Fig. 1a), no evidence for death related to interventions, (second) primary or 
metastatic lung cancer or a paraneoplastic syndrome is present. In case no other clear cause of death is known, the 
case is categorised as “unlikely lung cancer death”.
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THE IMPORTANCE OF SCREENING FOR LUNG CANCER
Expert Rev Respir Med. 2014 Aug 27; 1-18.
ABSTRACT
Lung cancer is a major public health problem since it causes most cancer-related deaths 
worldwide. As the disease often causes no symptoms at early stages, diagnosis at advanced 
stages, wherein cure is no longer possible, is common. 
Improvements in lung cancer treatment have been made, but yielded only modest 
improvement in survival over the last decades. Continuous efforts should be made to 
force back exposure to causative agents of lung cancer, tobacco smoking in particular. 
However, this is not expected to reverse the lung cancer epidemic in the next decades. 
The U.S. National Lung Cancer Screening Trial has demonstrated that lung cancer 
screening using low-dose computed tomography can reduce morbidity and mortality by 
detecting lung cancer at an early and curable stage. Effectiveness of a screening program 
is a prerequisite for implementation. In addition, the benefits of a screening program 
should outweigh the harms the program induces. 
The currently available literature on all relevant aspects of LDCT screening for lung 
cancer was reviewed to determine whether the benefits of LDCT screening outweigh 
the harms. Next, it was determined whether LDCT screening meets the World Health 
Organisation criteria for screening. 
Initial estimates of many harms and benefits of screening have been made, suggesting 
that the benefits of LDCT screening outweigh the harms. Nonetheless, the success of an 
implemented screening program will be determined by the benefit it yields for public 
health. 
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LUNG CANCER SCREENING: STATE OF THE ART
On November 4th 2010, the U.S. National Cancer Institute announced that lung cancer 
screening using low-dose computed tomography (LDCT) reduced mortality from lung 
cancer by 20%, compared to screening using chest radiography.1 This impressive result 
was achieved in the U.S.  National Lung Screening Trial (NLST), which is the world’s 
largest randomised lung cancer screening trial.2 As lung cancer is the leading cause of 
cancer-related death in the U.S. and beyond,3,4 the impact of a significant lung cancer 
mortality reduction was directly recognised. 
In this review, the World Health Organisation (WHO) criteria for screening (Box 1) 
were used as a guide for the literature search through all relevant aspects of LDCT screen-
ing for lung cancer. Hence, the ten WHO criteria for screening will be discussed, followed 
by a series of general conclusions on LDCT screening for lung cancer. Ultimately, the 
author’s current and five year view on lung cancer screening will be presented.
I) The screening programme should respond to a recognised need
A lung cancer screening programme responds to a recognised need, since lung cancer 
is a major public health problem. Lung cancer is currently the most prevalent cause of 
cancer-related death.3,4 Considering the ongoing global tobacco epidemic, lung cancer is 
expected to stay an important cause of death over the next decades.5 Screening could be 
Box 1. Modern screening criteria proposed by the World Health Organisation
I) The screening programme should respond to a recognized need.
II) The objectives of screening should be defined at the outset. 
III) There should be a defined target population. 
IV) There should be scientific evidence of screening programme effectiveness. 
V) The programme should integrate education, testing, clinical services and 
programme management. 
VI) There should be quality assurance, with mechanisms to minimize potential 
risks of screening. 
VII) The programme should ensure informed choice, confidentiality and respect 
for autonomy. 
VIII) The programme should promote equity and access to screening for the entire 
target population. 
IX) Programme evaluation should be planned from the outset.
X) The overall benefits of screening should outweigh the harm.
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a valuable addition to clinical care, primary and tertiary prevention in the fight against 
lung cancer.
II) The objectives of screening should be identified at the outset
The objective of screening should be reducing morbidity and mortality from lung cancer. 
Earlier detection of cancer should not be the objective of screening, since a prolonged 
disease course without a reduced burden of disease or a lower risk of lung cancer death is 
not beneficial (Table 1). Increasing survival should also not be the objective of screening, 
since estimates of survival in a screening setting are distorted by lead-time bias, length-
time bias and overdiagnosis.
III) There should be a defined target population
The significant mortality reduction in the NLST made many medical societies recom-
mend the NLST inclusion criteria as the definition of the optimal target population for 
screening (Table 2).6-9 The National Cancer Comprehensive Network (NCCN) and the 
American Association of Thoracic Surgery (AATS) recommended an extended or modi-
fied versions of the NLST inclusion criteria.10,11 Remarkably, two New England Journal 
of Medicine publications by the NLST pointed out that the trial’s inclusion criteria were 
suboptimal.12,13 
The first article demonstrated that the use of a lung cancer prediction model, (including 
age, race, education, body-mass index, chronic obstructive pulmonary disease, personal 
and family history of cancer, smoking status, intensity duration and quit time) yielded a 
higher sensitivity and an equal specificity for lung cancer compared to the NLST inclu-
Table 1. Benefits and harms of cancer screening
Benefits
Less persons dying from lung cancer
Less persons suffering from advanced lung cancer
Less persons receiving intensive or mutilating primary treatment
Possible positive effects on smoking cessation
Harms
Undergoing screening test and awaiting result - psychological distress
Radiation-induced cancers - morbidity and mortality
False positive results - psychological distress, morbidity and mortality due to subsequent diagnostic procedures
False negative results - false reassurance, delayed diagnosis once symptoms occur
Overdiagnosis - psychological distress, morbidity and mortality due to overtreatment
Persons receiving the diagnosis of lung cancer earlier
Possible negative effects on smoking cessation
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sion criteria.12 The second article demonstrated that screening was most effective and 
least harmful in the NLST participants at the highest risk of lung cancer mortality.13 In 
the participants at a relatively low 5-year risk of lung cancer death (lowest risk quintile 
0.15-0.55%), the benefit of screening (1% of prevented lung cancer deaths) was small 
compared to the numbers needed to screen (5276:1) and the false-positive screenings 
(97.0%).13 
The CISNET lung cancer working group assessed benefits and harms of LDCT screen-
ing for lung cancer for the U.S. Preventive Services Task Force (USPSTF).14 Five model-
ling groups independently evaluated 576 screening scenarios to determine the optimal 
target population.14 Eligibility criteria were: age at begin and end of screening, minimum 
number of pack-years, and maximum number of years since smoking cessation. Their 
analyses identified a range of possible ‘optimal’ target populations, including the set of 
eligibility criteria for screening which were adopted by the USPSTF (Table 3).14 
The latter study provided solid evidence for optimal target populations for lung cancer 
screening. Future studies will provide more insight in the value of prediction models 
Table 2. Inclusion criteria of randomised controlled trials on LDCT screening for 
lung cancer
Trial Inclusion criteria
Sex Age* Cigarette smoking Cessation
NLST2,21 male or female 55-74 ≥30 pack-years <15 yrs
NELSON29,33 male or female 50-75 ≥15 per day for 25 years or ≥10 per day for 30 years ≤10 yrs
DLST34 male or female 50-70 ≥20 pack-years <10 yrs
MILD40 male or female ≥49 ≥20 pack-years <10 yrs
LUSI38 male or female 50-70 ≥15 per day for 25 years or ≥10 per day for 30 years ≤10 yrs
UKLS44,55 male or female 50-75 ≥5% risk of lung cancer in 5 years
ITALUNG56 male or female 55-70 ≥20 pack-years <10 yrs
DANTE57 male 60-75 ≥20 pack-years <10 yrs
* Age range up to, but not including upper limit.
Table 3. Eligibility criteria for lung cancer screening adopted by the USPSTF
Eligibility criteria Estimated optimum
Age of start screening 55
Age of end screening 80
Pack-years of smoking ≥ 30
Years since cessation <15
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for selecting eligible subjects for screening, and optimal inclusion criteria for Asian and 
other specific populations. Since all prominent medical associations have published their 
guidelines on lung cancer screening in the past two years, none of them incorporates all 
currently available evidence on this subject. Possibly, the next generation of guidelines 
will recommend definitive criteria for the optimal target population for lung cancer 
screening.
IV) There should be scientific evidence of screening programme effectiveness
The NLST has demonstrated 20% lung cancer mortality reduction by screening using 
LDCT compared to screening using chest radiograph (Table 4).1 When the CISNET lung 
cancer working group evaluated hundreds of screening scenarios, mortality reductions 
were also estimated.14 Estimates for twenty-six selected efficient screening scenarios 
ranged from 4.6-21.2%, which demonstrates the strong correlation between the benefit 
of a screening programmes and its design and target population. The USPSTF eligibil-
ity criteria (Table 3) with annual screening was estimated to yield a 14.0% lung cancer 
mortality reduction, which corresponds with 497 lung cancer deaths averted and 5250 
life-years gained per the 100,000-member cohort.14 Lung cancer mortality  reductions 
in several European trials are still awaited (Table 4). Since the outcomes of European 
trials combined have enough statistical power to affect the significant mortality reduction 
of the NLST, no definitive conclusion can be drawn on the magnitude of the mortality 
reduction to date.
V) The programme should integrate education, testing, clinical services and 
programme management
Since LDCT screening has been recommended by several U.S. medical associations,6-8 
these implementation-related aspects of screening have become relevant. So far, little has 
been published about lung cancer screening programme management, clinical services, 
Table 4. Effect LDCT screening on lung cancer and all-cause mortality
Lung cancer deaths All deaths
Trial* per 100,000 py20 Relative risk20 per 100,000 py20 Relative risk20
Intervention Control RR (95%CI) Intervention Control RR (95%CI)
NLST1 247 309 0.80 (0.73-0.93) 1142 1216 0.93 (0.86-0.99)
DLST41 154 112 1.37 (0.63-2.97) 625 429 1.46 (0.99-2.15)
MILD40 216 109 1.99 (0.80-4.96) 558 310 1.80 (1.03-3.13)
DANTE58 527 637 0.83 (0.45-1.54) 1212 1433 0.85 (0.56-1.27)
Definition of abbreviations: py = person-years; RR = relative risk; 95%CI = 95% confidence interval. 
* Trials included with results published before July 2014.
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education, and testing. Nonetheless, recommendations on these aspects have been made 
by several medical associations.
I) Multi-disciplinary approach: is recommended by all guidelines.6-11,15,16 Hence, 
radiologists, pulmonologists and thoracic surgeons should have regular meetings 
wherein screening cases are discussed. However, close cooperation with other 
specialties is also warranted: nuclear medicine experts and pathologists for the as-
sessment of respectively nuclear scans and small biopsies of CT-detected nodules, 
and medical and radiation oncologists for the treatment of screen-detected lung 
cancer.
II) Process management: all subsequent steps from the candidate’s first attendance to 
the screening clinic to the treatment of screen-detected lung cancer should be or-
chestrated before screening is implemented. Two steps of this process have been de-
scribed in lung cancer screening guidelines; a defined algorithm for scan interpreta-
tion,6-8,15-17 and a diagnostic algorithm for suspicious CT-detected nodules.6-8,10,11,15,16 
Clinical guidelines on the management of incidentally-detected pulmonary nodules 
may be complementary, since many recommendations are based on data from lung 
cancer screening studies. Furthermore, logistics of the screening programme should 
be coordinated to prevent drop-outs and limit waiting times.
III) Facilities: the availability and quality of radiological, surgical, and other facilities is 
essential for a screening programme’s effectiveness and safety. A number of screen-
ing guidelines emphasise that screening should be performed in ‘centres similar 
to those wherein the NLST was conducted’.6-8 This suggest that screening should 
be performed in large centres which comply with the NLST minimum equipment 
standards,2 and have specialised thoracic radiologists and board-certified thoracic 
surgeons on staff. 
Detailed descriptions of radiological requirements are provided in the AATS guide-
line and are expected from the International Association for the Study of Lung Cancer 
(IASLC) Radiology Working Group,15,18 and the Radiological Society of North America 
(RSNA) / American College of Radiology (ACR) collaboration.17 The use of volumetry 
to assess nodule size and growth is currently only recommended by IASLC15 and AATS 
guidelines.11 
Specific recommendations for surgical management of suspicious nodules are only 
provided by the IASLC and the AATS. Both recommend lobectomy with systematic 
lymph node sampling as preferred procedure for suspected or confirmed early stage lung 
cancer.15,16 Segmentectomies with sampling of  N1 and N2 lymph node stations are only 
recommended by the IASLC for sub-solid nodules smaller than 2cm, and in individuals 
with limited pulmonary reserve or multiple lesions.15 Wedge resections should only be 
used for diagnostic purposes according to the IASLC,15 however according to the AATS, 
wedge resections could also be used as therapeutic procedure for lung cancers appearing 
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as sub-solid nodules on CT.16 The preferred approach to perform these procedures is 
video-assisted thoracoscopic surgery (VATS), because of the lower post-operative mor-
tality compared to thoracotomy.8,11,15,16
The integration of a smoking cessation programme along with screening is recom-
mended by all guidelines.6-8,10,11,15,16 Besides the ethical necessity of this recommendation, 
smoking cessation will also increase the benefits of a screening programme. 
VI) There should be quality assurance, with mechanisms to minimise potential 
risks of screening
Screening bears the risk of several harms (Table 1), which can be minimised by adequate 
quality assurance. This aspect of lung cancer screening is still under development. Many 
useful lessons could be learned from successfully implemented screening programmes, 
such as breast cancer screening. However, the implementation of lung cancer screen-
ing will give rise to new challenges. Besides screening trials, screening demonstration 
projects7,8,15 are also useful for the development of quality metrics and minimum stan-
dards for lung cancer screening.7,8,15,16 CT quality controls are currently already recom-
mended.6-8,10,11,15,16 Moreover, a LDCT-screening quality standards act and independent 
quality assurance units that collect and collate data about the performance and outcomes 
of screening programmes and organise quality assurance visits would enforce quality 
assurance.19
VII) The programme should ensure informed choice, confidentiality and respect 
for autonomy
Persons, who consider undergoing LDCT screening, should be informed on harms and 
benefits of screening (Table 1). Currently, many harms have been identified and some risk 
estimates of these harms have been published.7,14,20 Education of screening candidates is 
recommended in almost all guidelines.6-8,10,16 However, minimum requirements for the 
harms and benefits that should be discussed, and the level of knowledge of counsellors 
have not been published. Naturally, the individual’s choice on participation after educa-
tion on the harms and benefits should be respected. By no means, fear of cancer should 
be used to convince subjects to undergo screening. Once eligible screening candidates are 
informed and voluntarily agree to undergo LDCT screening, written informed consent 
should be obtained. In case data from their screening will be used for research purposes, 
explicit permission should be requested.
VIII) The programme should promote equity and access to screening for the 
entire target population
The benefit of lung cancer screening for public health depends on the participation rate 
in the target population. The applied recruitment method influences the population that 
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will attend to screening. Recruitment through the media attracts younger individuals 
who are more often ex-smokers with better education and higher social economic status, 
compared to the entire target population.21,22 The latter is not desirable13 since subjects 
at high risk for developing lung cancer are most predominantly represented in lower 
social-economic groups.23
Henceforth, recruitment should effectively reach out to the lower educated propor-
tion of the population. The population participating in the Dutch-Belgian lung cancer 
screening trial was slightly lower educated, smoked more heavily, had a worse general 
health and a higher prevalence of malignancies, but had the same age, percentage current 
smokers, and BMI as the general population.24 Recruitment for this trial was performed 
by determining eligibility for screening first (via an initial mailing which did not contain 
any information on the trial), followed by a second mailing only to eligible subjects, with 
information and the invitation to participate in lung cancer screening. Although lower 
educated groups can be recruited with this method, it will be difficult to obtain informa-
tion on eligibility from the target population without informing them on lung cancer 
screening outside a clinical trial nowadays. Unfortunately, no other screening trial, that 
used a population-based recruitment strategy wherein anyone in the target age range 
received a mailing with an invitation for screening and a questionnaire to determine 
eligibility, also investigated participation bias especially by educational level.
Besides difficulties with recruitment of lower educated groups, reaching out to minori-
ties and ethnic groups other than Caucasians is also challenging. The NLST institutions 
were encouraged to identify regional minorities and develop plan for targeted recruit-
ment.25 Seven institutions were selected and received funding to implemented their 
proposals, which were diverse; advertising in minority-specific media, distribution of 
culturally adapted and translated brochures, outreach programs via general practitioners, 
face-to-face interaction and word-of-mouth dissemination.25 The success of the afore-
mentioned strategies varied, and no single strategy was successful among  all institu-
tions.25 Nonetheless, recruitment of local minorities increased from 9.3% to 15.2% in the 
seven institutes using any strategy.25 Knowledge on local cultural and ethnic diversity 
and cooperation with local stakeholders and minority organisations are probably vital for 
developing suitable recruitment strategies and successful implementation. 
Concluding, recruiting the higher educated, health-concerned part of the popula-
tion for lung cancer screening will probably be successful. However, making the lower 
educated and minority groups aware of the availability and advantages of lung cancer 
screening will be more difficult. It will require social responsibility of health policy mak-
ers to put effort and resources in the recruitment of these subgroups. Since the subjects at 
high risk for developing lung cancer are predominantly represented in these subgroups, 
the success of lung cancer screening for public health will partly depend on it. 
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IX) Programme evaluation should be planned from the outset
As for all health care programmes, evaluation and feedback with the objective to detect 
deficiencies and improve care should be planned from the outset. Current guidelines on 
lung cancer screening do not explicitly mention programme evaluation, but registry/data 
collection is recommended.7,8,11,15,16 Collected data could be used to monitor and improve 
performance, as well as collate with quality standards, as described at criterion VI.
X) The overall benefits should outweigh the harm
One of the most important criteria for screening. Determining whether the benefits of a 
screening programme outweigh the harms is complex. The benefits of screening can be 
expressed as the number of quality-adjusted life-years (QALYs) gained, which should 
be estimated using the number of deaths prevented and the number of advanced stage 
disease prevented by screening. The number of life-years gained can be estimated with 
data from randomised controlled trials and micro-simulation modelling. Next, the life-
years gained should be corrected for quality of life using utility estimates.26 Further, the 
same should be done for the harms of screening; estimating the number of QALYs lost 
by screening using data from trials, implemented programmes, registries and modelling 
studies. Once this has been established, it can be determined whether the benefits of lung 
cancer screening outweigh the harms. An example of such a calculation has recently been 
published for prostate cancer screening.27
Currently, only the gain in quality-adjusted life-years for NLST participants in whom 
death was prevented has been estimated: 21.7 QALYs per 1000 screened individuals.28 The 
gain QALYs for those in whom advanced stage disease was prevented by LDCT screening 
should be added to obtain an estimate for the total benefit of screening. Moreover, the es-
timate would become more reliable if data from other screening trials, such as the largest 
European trial,29 was added. The CISNET lung cancer working group estimated that per 
100,000-person cohort screened with the recommended regimen (Table 4) 497 subjects 
would not die from lung cancer and 550 no longer needed treatment for advanced lung 
cancer.
Estimates for numbers of QALYs lost due to screening have not been published yet. 
However, some estimates of the magnitude of many harms have been published to date, 
briefly:
I) Undergoing screening test: could be accompanied by psychological distress, 
however neither clinically relevant, nor statistically significant negative effects 
on physical health, mental health, self-reported health, generic anxiety, lung 
cancer-specific distress and on the impact of event scale were demonstrated.30 
Further, undergoing the screening test leads to exposure to ionising radiation.31 
The harmful effect of radiation related to both the screening examination and the 
subsequent diagnostic procedures for positive screenings have been estimated for 
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the participants of the NLST; it was estimated that cancer for every 2,500 screened 
subjects, one subject would die from radiation-induced cancer.7,8 The CISNET 
lung cancer working group estimated the number of radiation-related lung cancer 
deaths for a range of screening scenarios; per a 100,000-person cohort followed 
from ages 45 to 90, 24 deaths were expected both with the screening strategy 
most similar to the NLST eligibility criteria (Table 2), and the screening strategy 
adopted by the USPSTF (Table 3).
II) Awaiting screening test result: led to discomfort in 46.0-51.3% of the screened 
subjects of the NELSON trial.32 Awaiting the follow-up scan after an initial indeter-
minate screening result led to a clinically relevant increase in lung cancer-specific 
distress; which recovered in case of a negative follow-up scan and remained in 
case of a positive follow-up scan.30
III) False-positive screenings: a positive screening in subjects without lung cancer. The 
proportion of all screening results that is false-positive depends on the defini-
tion of a positive screening (i.e. threshold for nodule size or growth), and to a 
lesser extent to the technique that is used to review the screening examination (i.e. 
manual measurements semi-automated volumetry). In the NLST, a relatively low 
threshold of ≥4 mm for manually measured nodule diameter was applied, and a 
high percentage of false-positive screenings (23.3%) was observed.1 In compari-
son, in the NELSON trial a higher threshold of 500 mm³ for semi-automatically 
assessed nodule volume (about 9.8 mm in diameter) was applied, and a relatively 
low percentage of false-positive screenings was observed (1.2%).33  False-positive 
screenings lead to unnecessary diagnostic procedures and psychological distress 
in subjects without lung cancer. The magnitudes of the psychological distress and 
their long-term effects have not been investigated in any of the randomised lung 
cancer screening trials. Invasive diagnostic procedures for false-positive screenings 
were performed in 0.4-1.3% of the participants of lung cancer screening trials.33-38 
The CISNET lung cancer working group modelled that 67,550 persons would 
have a false-positive result and 910 would undergo invasive diagnostic procedures 
for benign nodules per 100,000-person cohort screened annually from age 55 to 
80.14 Data on the incidence of morbidity and mortality as a result of complications 
of the invasive procedures for false-positive screenings were not published.
IV) False-negatives: a negative screening result in a subject with (early) lung cancer 
could lead to delayed diagnosis through false reassurance once symptoms emerge. 
In the randomised lung cancer screening trials, 0.0-6.3% of the lung cancers was 
not detected through screening.29,35,38-41 Estimates of the delay to diagnosis caused 
by the false negative screening result were not provided.
V) Overdiagnosis: estimates of the amount of overdiagnosis for a range of hypothetical 
screening programmes were made by the CISNET lung cancer working group in a 
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comparative modelling study.14 The screening strategy as applied in the NLST was 
estimated to have led to 8.7% overdiagnosis.14 The slightly adjusted screening algo-
rithm that was recommended from this study after weighing several harms and ben-
efits of screening (Table 3) would yield 9.9% overdiagnosis.14 This corresponds with 
190 persons with an overdiagnosed lung cancer per 100,000-person cohort.14 The 
associated harms consist of the physical harms induced by diagnostic procedures 
and overtreatment, and mental harms caused by distress due to the aforementioned 
interventions and anxiety of having a cancer diagnosis; none of these have been 
quantified to date. 
VI) Prolonged disease course: effective screening programmes advance diagnosis of 
lung cancer. For some screenees, this will lead to cure from lung cancer, however 
in most screenees screening will not prevent lung cancer death.1 In these subjects 
the course of disease was longer because of the earlier diagnosis, but there was no 
health benefit; which is a harmful side-effect of screening. It was estimated by that 
1,970 persons per 100,000-person cohort would receive the diagnosis of lung cancer 
earlier when annual screening from the age of 55 to 80 is implemented.14  Estimates 
of the harms and duration of the lead time in these persons have not been published.
VII) Negative impact on life-style: another potential harm of lung cancer screening is 
that the screened population considers the LDCT examination as a substitute for 
smoking cessation; the so-called health certificate effect. In two screening trials, this 
was investigated and no differences were found in the cessation rate and the number 
of quit attempts between subjects who received screening and those who received 
no screening.42,43 However, in one study smoking abstinence was significantly higher 
for participants receiving no screening compared to participants who received 
LDCT examinations.42 The difference in smoking abstinence between the screened 
group and the control group was 4.6% (OR 1.40, 95% CI 1.01-1.92).42 Henceforth, 
it cannot be precluded that LDCT screening does not have a negative impact on 
life-style. Effective smoking cessation programmes implemented along with LDCT 
screening may compensate for any harmful effect of screening on life-style.
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CONCLUSIONS ON LDCT SCREENING FOR LUNG CANCER
I) The screening programme should respond to a recognised need
 Lung cancer screening responds to a recognised need as lung cancer is a major 
public health problem.
II) The objectives of screening should be defined at the outset
 The objectives of lung cancer screening are reducing morbidity and mortality 
from lung cancer.
III) There should be a defined target population
 Although evidence for an optimal target population for lung cancer screening has 
been published, discussions are ongoing.
IV) There should be scientific evidence of screening programme effectiveness
 Effectiveness of lung cancer screening has been demonstrated in one study, future 
results of a pooled analysis of all lung cancer screening trials will provide definite 
conclusions.
V) The programme should integrate education, testing, clinical services and 
programme management
 Current lung cancer screening guidelines provide some useful recommendations 
on the integration of education, testing, clinical services and management in lung 
cancer screening programmes, however substantial gaps remain.
VI) There should be quality assurance, with mechanisms to minimise potential 
risks of screening
 Since LDCT screening is already (recommended to be) implemented and ad-
equate quality assurance is still under development, the population undergoing 
screening is exposed to several risks.
VII) The programme should ensure informed choice, confidentiality and respect 
for autonomy
 Although any lung cancer screening guideline recommends informing screening 
candidates on the harms and benefits of screening and respecting their autonomy, 
no minimum requirements on screening information and knowledge of the 
counsellor are defined.
VIII) The programme should promote equity and access to screening for the entire 
target population
 Successful implementation of LDCT screening depends on the benefit the pro-
gramme yields for public health, therefore effective methods need to be developed 
to reach out to the lower educated and minority groups.
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IX) Programme evaluation should be planned from the outset
 Data collection from lung cancer screening programmes is recommended by sev-
eral guidelines, and should at least be used for evaluation and quality assurance, 
which is not recommended yet.
X) The overall benefits of screening should outweigh the harm
 Initial estimates of many harms and benefits of screening have been made, sug-
gesting that the benefits of LDCT screening outweigh the harms.
AUTHOR’S VIEW ON LUNG CANCER SCREENING
Screening a population at high risk of developing lung cancer using low-dose computed 
tomography examinations is a promising technique to reduce morbidity and mortality 
from lung cancer. A significant reduction in lung cancer mortality by screening using 
LDCT examination has been demonstrated in one large, high-quality randomised trial.1 
Future pooled analysis of multiple randomised lung cancer screening trials will provide 
definitive evidence for the effectiveness of LDCT screening.29 
Initial estimates of many harms and benefits of screening have been made using data 
from the U.S. lung cancer screening trials.14 It is unknown to what extent these estimates 
apply to other screening strategies, such as the volumetry-based nodule protocols of the 
European trials.29,34,38,44 Available evidence suggests that LDCT screening can be beneficial 
if applied as in the NLST.7,20 However, it is uncertain whether LDCT screening for lung 
cancer screening is beneficial when implemented in different settings without established 
safety and quality assurances.
The success of any screening programme is determined by the benefits it yields for 
public health. Ma et al. estimated that if the screening regimen adopted in the NLST was 
fully implemented among the 8.6 million screening-eligible U.S. population, 12,250 lung 
cancer deaths could be averted per year.45 If the optimal screening scenario according to 
the USPSTF (Table 4) is implemented in the U.S., 10.5 million individuals will be eligible 
for screening.14 The yield, assuming 100% adherence to screening, is estimated at 18,000 
deaths avoided per year, which corresponds with a 25% lung cancer mortality reduction 
in the eligible population and 14% overall lung cancer mortality reduction.14 Clearly, the 
projected benefits of LDCT screening for public health are significant. Implementation 
of LDCT screening programmes that reach out to the entire target population will be 
essential in realising the potential benefit for public health.
Continued efforts and advances in lung cancer treatment, primary prevention, and 
tertiary prevention are also expected to reduce the burden of lung cancer in the future. 
However, each of these methods solely will not be able to reverse the lung cancer epi-
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demic. Therefore, screening using LDCT should be regarded as a valuable new tool in the 
fight against lung cancer. 
AUTHOR’S FIVE-YEAR VIEW ON LUNG CANCER SCREENING
Implementation of LDCT screening for lung cancer has only recently become at issue. 
Hence, the next five years will be important for its success. Many remaining uncertainties 
and discussions are likely to be addressed to within five years.
Hence, final results of all randomised lung cancer screening trials have become avail-
able.29,38,44 Meta-analyses of lung cancer and all-cause mortality reduction will provide 
definitive conclusions on the efficacy of LDCT screening. Further, data from lung 
cancer screening trials and implemented screening programmes will give insight in the 
magnitude and impact of the harms associated with LDCT screening. With this data, 
more comprehensive calculations of the balance between harms and benefits of screening 
can be made. This will eventually also facilitate the performance of more integral cost-
effectiveness analyses.  
In the next five years, some lingering questions surrounding LDCT screening will prob-
ably be answered. Among these are probably: the value of lung cancer prediction models 
for the selection of eligible subjects;44 the optimal screening method, including insight 
in the added value of volumetry and the use of imaging biomarkers for the interpreta-
tion and accuracy of screening examinations;29,46 and the optimal diagnostic work-up 
from positive screening result to diagnosis for any type of screen-detected pulmonary 
nodule.47,48
Finally, a number of issues will become more relevant in the next five years than they 
have been so far, as a result of the recommended implementation of LDCT screening. 
Examples are: recruitment of elderly, lower educated and minority groups for screening,25 
shared decision-making,47,49,50 management systems for screening programmes,51 quality 
assessment and performance indicators,8,19 non-surgical treatments for screen-detected 
lung cancer,52 follow-up regimens for curatively treated screen-detected lung cancers,53 
and  patient-centred research.50,54
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In this thesis, the harms and benefits of lung cancer screening using low-dose computed 
tomography were investigated. Data of the Dutch-Belgian NELSON trial were used to 
quantify its harms and benefits and develop strategies to improve the balance between 
them. If the NELSON trial demonstrates that low-dose CT screening is an effective 
method to reduce mortality from lung cancer, balance between harms and benefits is a 
perquisite for the implementation of a lung cancer screening program.
 In the General Discussion, this thesis is evaluated to determine its implications. Firstly, 
the research objectives of this thesis are summarised. Secondly, background informa-
tion necessary for the interpretation of the results is provided. Thirdly, the main and sub 
research questions of this thesis are evaluated for each chapter consecutively.  The sub 
research questions are used to present and interpret the main results in each chapter. 
All sections on the interpretation of results conclude by answering a sub research ques-
tion. The main research question of each chapter is answered in the conclusion section. 
Fourthly, a list of general conclusions based on the conclusions of each chapter are 
presented. Finally, general recommendations for further research and clinical practice 
are presented. 
THIS THESIS
As the design of an effective and feasible screening algorithm is crucial for the implemen-
tation of screening, the evaluation of screening trials may provide valuable knowledge. 
Topic of this thesis is the evaluation of the screening algorithm of the Dutch-Belgian lung 
cancer screening trial; the NELSON trial. Hence, aims of this thesis were to estimate test 
characteristics (sensitivity, specificity and predictive values), number of required follow-
up CT examinations and additional diagnostic tests, to determine whether improvements 
to the screening algorithm were possible by identifying failures and unnecessary proce-
dures, and to estimate the performance of improved hypothetical screening algorithms. 
Ideally, the evaluation of the performance of the screening algorithm also considers 
effectiveness, which is reduction in lung cancer mortality. However, these analyses are 
planned at ten years after randomisation, which is outside the scope of this thesis. None-
theless, this thesis contributed to these mortality analyses by developing the protocol for 
endpoint verification.
BACKGROUND
A screening algorithm is the management protocol of a screening programme or trial. 
The algorithm should define each possible screening test result and recommend an ap-
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propriate management strategy. Since low-dose computed tomography examination of 
the chest (LDCT) is used as a screening test, there are numerous options to define the 
screening test result. Therefore, many different screening algorithms have been designed 
and applied in lung cancer screening trials.
Although the interpretation of the LDCT examination differs substantially between 
lung cancer screening trials, three screening test outcomes have been defined quite con-
sistently. Firstly, in case the screening LDCT examination did not show any abnormality, 
the screening test result is usually defined as ‘normal’ or ‘negative’ and the recommended 
management is not to perform any additional diagnostic tests. Secondly, in case the 
screening LDCT examination showed an abnormality that required immediate medical 
care, for example a large aortic aneurysm, screening is usually put on hold and adequate 
medical care is arranged. After this, an assessment is made to determine whether con-
tinuation of screening and consequential diagnostic testing is still appropriate. Finally, 
in case abnormalities suspicious for advanced lung cancer are detected on the screening 
LDCT examination, the screening test result is usually defined as ‘positive’,  and the rec-
ommended management is to perform a work-up for diagnosis and staging followed by 
treatment according to (inter)national guidelines. In all other cases (thus cases wherein 
abnormalities not suspicious for advanced lung cancer were visible and no acute medical 
care was indicated) lung cancer screening trials use various definitions for screening test 
results and recommend opposing management strategies.
Although a variety of different abnormalities may be detected on the LDCT screening 
examination, the screening test result is determined by those abnormalities that are sus-
picious for (pre)cancerous lesions, which are lung nodules or masses. Pulmonary nodules 
are defined by the Fleischner Society as rounded or irregular opacities, that are well or 
poorly defined and measure up to 3 cm in diameter.1 Masses are defined as pulmonary, 
pleural, or mediastinal lesions that are seen as an opacity greater than 3 cm in diameter, 
and are usually solid or partly solid.1 Traditionally, the visual characteristics and size of 
the lung nodules or masses detected on the LDCT screening examination determines the 
screening test result.
In the first lung cancer screening cohort studies, such as the U.S. Early Lung Cancer 
Action Project (ELCAP study), all detected lung nodules which did not show a benign 
calcification pattern, were classified as a suspicious for lung cancer and the screening test 
result as ‘positive’. Usually, the recommended management strategy was to perform series 
follow-up CT scans for a period of two years for small nodules (<6 mm in diameter) and 
invasive diagnostic procedures, such as transthoracic biopsy, for larger nodules and lung 
masses. From this first generation of lung cancer CT  screening algorithms we learned 
that the majority of these small non-calcified pulmonary nodules were not malignant.2 
As a result, the predictive value of a ‘positive’ screening test results was very low.2 This 
led to vast amounts of follow-up CT examinations and diagnostic procedures for benign 
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nodules. Another important lesson we learned from these studies is that the size of the 
nodule is highly correlated with the probability of malignancy.3
The next generation of lung cancer screening studies, such as the U.S. National Lung 
Screening Trial (NLST) used the knowledge from previous studies. Hence, these studies 
applied screening algorithms that did not classify all non-calcified pulmonary nodules 
as suspicious for lung cancer, but used the size of the nodule to determine whether the 
screening test result was ‘positive’ or not.4 A threshold for nodule size that was commonly 
used to define ‘suspicion of lung cancer’ was a nodule diameter of 4 mm.5 Hence, subjects 
with nodules smaller than 4 mm would not receive follow-up CT scans or diagnostic 
tests. While subjects with nodules of 4 mm or larger were considered as suspicious for 
lung cancer and were recommended to undergo series of follow-up CT examinations or 
additional diagnostic tests (often depending on clinical judgement of the referring physi-
cian).4 From these studies we learned that the sensitivity for lung cancer of such screening 
algorithms is high, which means that it is safe to perform no additional CTs for nodules 
smaller than 4mm in diameter.6,7 Nonetheless, the predictive value of a ‘positive’ screen-
ing test result was still low due to a moderate specificity of these screening algorithms.6,7 
The next generation of lung cancer screening studies, such as the NELSON trial, 
aimed to achieve both a high sensitivity for lung cancer and a high specificity. To achieve 
this, another nodule feature that is highly predictive of malignancy was included in the 
screening algorithms: nodule growth.8-11 Unfortunately, the traditional manual or visual 
assessment of nodule diameter was not accurate enough to determine the growth rate of 
small non-calcified nodules at short notice. Therefore, these studies used semi-automatic 
volumetric software to assess the differences in nodule size on subsequent screening 
examinations.8-11 Hence, the screening protocols used a two-step approach to determine 
which of the detected non-calcified nodules were suspicious of lung cancer. First, nodules 
under a certain size threshold (smaller than 50 mm³ in the NELSON trial) were classified 
as not suspicious or ‘negative’, and nodules larger than a certain size threshold (larger 
than 500 mm³ in the NELSON trial) were directly classified as suspicious for lung cancer 
or ‘positive’. Next, the nodules with a size between these thresholds were classified as 
‘indeterminate’ and were scheduled for another LDCT screening examination at short 
notice to determine nodule growth. Only the indeterminate-sized nodules that demon-
strated malignant growth were classified as suspicious for lung cancer or ‘positive’ (in the 
NELSON trial defined as a percentage volume change of ≥25% combined with a volume-
doubling time shorter than 400 days). Summarising, only nodules above a certain size 
threshold and intermediate-sized nodules growing faster than a certain threshold are 
classified as suspicious for lung cancer or ‘positive’ and additional diagnostic testing is 
recommended. Hypothetically, the use of follow-up CT scans in these screening algo-
rithms will lead to more targeted and economical use of additional diagnostic tests, which 
will improve specificity and will still yield a high sensitivity for lung cancer.
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The series of diagnostic tests performed after a positive screening test result are called 
the diagnostic work-up, and have the objective to either diagnose or rule out lung cancer. 
In general, the diagnostic work-up is not coordinated by the screening trial. Referring 
physicians use (inter)national guidelines for the management of pulmonary nodules to 
assist them with decision-making in the diagnostic work-up for suspicious screen-detect-
ed nodules. Despite the fact that this process is not incorporated in most screening trials, 
the performance evaluation of a screening protocol should also consider the diagnostic 
work-up. This is because performing and interpreting a screening test only identifies 
persons who are suspected of having lung cancer. The work-up is the next essential step 
in diagnosing lung cancer.  Medical tests, other than LDCT examinations, are used to 
distinguish persons who actually have lung cancer from those who had a false-positive 
screening test result. The sensitivity of a screening programme will be affected when the 
diagnostic work-up does not effectively pick out all subjects with lung cancer. 
Once the diagnosis of lung cancer has been made, the next essential step is the treat-
ment of lung cancer. This might seem trivial, but diagnosing lung cancer earlier by LDCT 
screening does not affect lung cancer mortality. It is only a prerequisite that enables the 
early treatment of lung cancers. Only in case the treatment of early diagnosed lung can-
cers has a higher cure rate than in lung cancers diagnosed through symptoms, mortality 
from lung cancer can be reduced by screening. Therefore, the performance evaluation 
of a screening algorithm should also consider the lung cancer mortality reduction. To 
determine the mortality reduction of a screening program, a randomised controlled trial 
is indispensable. The NELSON trial is the largest randomised trial wherein screening 
using low-dose CT is compared to no screening. 
RESEARCH QUESTIONS
Research question I
Chapter 2. Predictive value of screening test results 
Volumetric computer tomography screening for lung cancer: three rounds of the NEL-
SON trial.
European Respiratory Journal
Main research question
What was the screening performance of the nodule management protocol of the NEL-
SON trial?
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Sub research questions
a) What were the detection rates, test characteristics and numbers needed to screen of 
the nodule management protocol of the NELSON trial?
b) What was the incidence of invasive diagnostic procedures for false-positive screen-
ing test results?
c) What were participant’s probabilities of false-positive screening results and lung 
cancer after baseline and subsequent screening test results?
Main results
a) In the first three rounds of the NELSON trial a total of 24,354 CT scans were per-
formed. 89.4% of the scans were a regular scans and 10.6% performed to assess the 
VDT of indeterminately sized nodules, the so-called ‘follow-up scans’. The screen-
ing test result was negative in 87.2%, indeterminate in 10.8% and positive in 2.0% 
of the scans. The positive scans eventually led to the diagnosis of lung cancer in 200 
persons (cumulative lung cancer detection rate: 2.6%).  Hence, the predictive value 
of a positive screening test result was 40.6% and 59.4% of the positive screening test 
results was false-positive. Overall, 1.2% of all 24,354 CT scans had a false-positive 
result. Finally, the number needed to screen for the diagnosis of one lung cancer was 
92-133 per round.
b) Across the three screening rounds, 6.0% of the participants received one or more 
positive screening result. As 59.4% of the positive screening test screening results 
was false-positive, 3.6% of all participants had one or more false-positive screen-
ing result. 24.5% of the subjects with a false-positive screening result underwent 
an invasive diagnostic procedure. Hence, invasive diagnostic procedures for false-
positive screening results were performed in 0.9% of all participants. 
c) The probabilities of receiving a false-positive screening result or being diagnosed 
with lung cancer depend on the result of the baseline and subsequent screening tests. 
The estimated risk of a false-positive screening result within the next 5.5 years was 
respectively 1.3%, 8.8% and 54.2% for the individuals with a negative, indeterminate 
or positive baseline scan. Moreover, the estimated 5.5-year risk of screen-detected 
lung cancer was only 1.0% for the individuals with a negative baseline scan result, 
5.7% for subjects with an indeterminate baseline result and 48.3% for those with a 
positive baseline.
Interpretation of results
a) The majority of the LDCT screening examinations in the NELSON trial had a 
negative result. Only in about one in ten screening tests an additional follow-up 
LDCT examination had to be performed. Moreover, only 2% of the LDCT screen-
ing examinations were positive. These results are comparable to the results of the 
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Danish lung cancer screening trial (DLCST), which also has a ‘third generation’ 
volumetry-based screening algorithm.9,12 However, the number of positive screening 
tests results was substantially lower than the 24.2% positive screening test results in 
the NLST, wherein a second-generation screening algorithm using a single nodule 
size criterion of 4mm is used to define suspicion for lung cancer.13 
Despite the lower percentage of positive screenings, the cumulative lung cancer 
detection rate of 2.6% was slightly higher than in the NLST (2.4%),13 but lower than 
in the DLCST (3.4%).9,12 The latter is probably due to the two additional screening 
rounds that have been completed in the DLCST. 
The predictive value of a positive screen result was higher in the NELSON trial 
(40.6%) than in both the DLCST (34.8%) and the NLST (3.6%).9,12,13 As a result of 
this and the low percentage positive screening test result, the proportion of false-
positive scans out of all scans is slightly lower in the NELSON trial (1.2%) compared 
to the DLCST (1.3%), substantially better than in the NLST (23.3%).9,12,13 
Finally, the number needed to screen for the detection of one lung cancer was 
92-133 per round in the NELSON trial, which is a little less than in the other trials 
(97-147 in the NLST and 116-180 in the DLCST).9,12,13
Concluding, the detection rate, positive predictive value and number needed to 
screen of the screening algorithm of the NELSON trial compare favourably to other 
lung cancer screening trials. Nonetheless, before an eventual implementation of lung 
cancer screening, efforts should be made to reduce the proportion of indeterminate 
screening test results without loss of efficacy.
b) The percentage of participants with one or more positive scan (6.0%) was low in our 
trial compared to the NLST (39.1%).13 Therefore, also the percentage of participants 
that had one or more false-positive screening tests was lower in the NELSON trial 
(3.6%) compared to the NLST (25.8% in round one, 27.2% in round two and 15.9% 
in round three).6,7
Despite this, more invasive diagnostic procedures for false-positive screening 
results were performed in the NELSON trial (0.9%) than in the NLST (0.6%). Ap-
parently, a more cautious approach to positive screening test results was applied 
in the United States than in the Netherlands and Belgium. Probably, suspicious 
screen-detected nodules were more often followed up using serial CT examinations, 
instead of directly proceeding to invasive procedures.14 
Concluding, invasive procedures for false positive screening test results cannot be 
eliminated because biopsy or surgery is sometimes the only way to distinguish lung 
cancer from a benign nodule. Nonetheless, this study showed that the incidence 
of these ‘unnecessary’ procedures could be lower than observed in the NELSON 
trial, as it is lower in the NLST (corrected for the difference in percentage positive 
screening tests). Therefore, efforts should be made to investigate what the causes of 
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the slightly higher rate of invasive procedures in the NELSON trial were. Examples 
are: insufficient guidance of referring clinicians, lack of a national guideline on the 
management pulmonary nodules, unavailability of tools to estimate lung cancer 
probability of screen-detected nodules or inexperience with CT-detected nodules. 
Once the causes have been identified, targeted interventions should be developed, 
evaluated and if successful implemented before lung cancer screening is imple-
mented.
c) This study demonstrated that participants with a negative, indeterminate or positive 
first screening test had very distinct risks of false-positive screening results and lung 
cancer. Analyses showed a significant increase in age and number of pack-years 
in participants with respectively negative, indeterminate and positive screening 
test result, which are all well known risk factors for developing lung cancer.15,16 The 
presented results could aid clinicians when counselling individuals comparable to 
NELSON study participants when LDCT examinations are interpreted in the same 
fashion as in the NELSON trial.
Concluding, the result of the LDCT screening test adequately stratifies partici-
pants by their risk of lung cancer. Moreover, the predictive value of screening results 
lasts up to 5.5 years. As the screening test result is based on the size and growth 
rate of pulmonary nodules, these variables are probably very strong predictors of 
lung cancer risk. Hence, future studies should assess whether it is possible to build 
a reliable lung cancer prediction model that uses nodule size and growth rate in ad-
dition to individual characteristics such as age, gender, smoking status and smoking 
history.  Once a reliable lung cancer prediction model has been built and validated, 
it should be investigated how the model can be made useful for clinicians who are 
confronted with the management of CT-detected pulmonary nodules. Such a lung 
cancer prediction tool may help identifying the malignant nodules and may reduce 
unnecessary diagnostic procedures for benign nodules.
Conclusion 
The screening algorithm of the NELSON trial adequately stratified participants according 
to their lung cancer risk. The NELSON screening algorithm yielded a limited number 
of follow-up LDCT scans for indeterminate screening test results and a low number of 
diagnostic work-ups for positive screening test results. Although the predictive value of 
screening test results compared favourably to other studies, perhaps too many invasive 
diagnostic procedures for benign nodules were performed.
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Research question II
Chapter 3. Characteristics of screen-detected lung cancer
Characteristics of lung cancers detected by computer tomography screening in the ran-
domized NELSON trial.
American Journal of Respiratory and Critical Care Medicine
Main research question
What was the effect of screening using low-dose computed tomography on the character-
istics of screen-detected lung cancer?
Sub research questions
a) What were the tumour characteristics of lung cancers detected by low-dose CT 
screening?
b) What was the effect of screening round and gender on the characteristics of screen-
detected lung cancer?
c) To what extent was screening able to detect lung cancer before the onset of symp-
toms?
Main results
a) In the first three screening rounds of the NELSON trial, a total of 209 lung cancers 
in 200 persons were detected via screening.  The most common histological type 
was adenocarcinoma (51.2%), followed by squamous cell carcinoma (16.3%), large 
cell carcinoma (8.1%), bronchoalveolar carcinoma (5.3%) and small cell carcinoma 
(3.8%). The majority of the screen-detected lung cancers were detected at a limited 
stage (70.8% at stage I), a minority was detected at a locally advanced stage (21.1% 
at stage II and IIIA) and few at an advanced disease stage (8.1% at stage IIIB and IV). 
Most screen-detected lung cancers were localised in the right lung (65.6% whereof 
45.0% in the right upper lobe). The cancers were also predominantly localised in 
the periphery of lungs; 62.2% in the outer one-third of the costal-hilar diameter; 
adenocarcinomas in particular (82.2% vs. 17.8%, p=0.001).
b) The lung cancers detected in round 1 had a slightly higher disease stage (stage IA 
59.5%, stage IV 6.8%) than in later rounds (round 2: stage IA 74.1%, stage IV 3.4%, 
and round 3: stage IA 64.9%, stage IV 3.9%), but this was not statistically significant. 
Also, the proportion histological type and localisation of the screen-detected lung 
cancers was not significantly different across the screen rounds.
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None of the histological subtypes of lung cancer were unevenly distributed 
between the sexes. Also, the localisation of the lung cancers was not significantly 
different between the sexes: neither for the left lung versus right lung localisation 
nor for peripheral versus central localisation. However, cancer stage at diagnosis 
was significantly lower in women than in men (p=0.005). After correction for the 
sex differences in age, number of pack-years and BMI, women still had a statistically 
significant lower cancer stage than men (p=0.028).
c) 189 of the 200 (94.5%) participants who were diagnosed with lung cancer through 
screening had no symptoms suspicious of lung cancer. The remaining eleven 
participants (5.5%) had symptoms suspicious of lung cancer before they were di-
agnosed. In five of them symptoms emerged before the screening scan was made; 
however, none of them had symptoms at randomisation. Three subjects experienced 
suspicious symptoms for the first time in the period between the positive scan and 
the first consultation, and three subjects had reported the symptoms in the period 
between the first consultation and the diagnosis date. 
Interpretation of results
a) The stage distribution of the screen-detected lung cancers in the NELSON trial 
(70.8% at stage I and 8.1% at stage IIIB/IV) is considerably more favourable than 
the stage distribution of clinically diagnosed lung cancers (28% at stage I and 18% 
at stage IIIB/IV).89 Moreover, the stage distribution appears also to be relatively 
favourable compared with the other lung cancer screening trials (on average: 64.7% 
at stage I and 10.9% at IIIB–IV).11-13,51,86,87
This study demonstrated that the disease stage at diagnosis strongly correlated 
with the histological subtype of the lung cancer. On the one hand, LDCT screening 
detected many relatively slow growing, peripherally localised adenocarcinomas an 
early stage. On the other hand, LDCT screening detected only a few small cell lung 
cancers and all were diagnosed at stage III-IV. This finding could imply that LDCT 
screening is not, or is less, capable of early detection in some fast-growing histologi-
cal subtypes of lung cancer. Therefore, future studies should include all lung cancers 
in screened participants, not only the screen-detected lung cancers, to complete the 
picture of lung cancer characteristics.
This study also demonstrated that most screen-detected lung cancers were lo-
calised in the periphery of the lungs, which is probably a result of the detection 
of many adenocarcinomas and the use of low-dose, unenhanced CT scans which 
can have limited image quality in hilar regions and the mediastinum.19 The finding 
that 45.0% of all lung cancers were localised in the right upper lobe is known from 
patients with non-small cell lung cancer. This phenomenon may be explained by 
the fact that the airflow at the beginning of the breath is the largest toward the right 
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upper lobe bronchus.90,91 As a result, the deposition of particles in tobacco smoke 
and their carcinogenic effects are the largest in the right upper lobe.92,93
Concluding, the tumour characteristics of the lung cancers detected by low-dose 
CT screening in the NELSON trial are typically described as early stage adeno-
carcinomas localised in the periphery of the right upper lobe. Although the stage 
distribution of the screen-detected lung cancers suggests a stage shift as a result of 
LDCT screening, a comparison of all lung cancers diagnosed in the screening group 
with all lung cancers diagnosed in the control group is the only valid method to 
determine this. 
b) Analyses showed no significant effect of screening round on cancer stage, histol-
ogy, or tumour localisation. However, a decrease in advanced-stage lung cancers 
was observed at the second screening round (stage IV dropped from 6.8 to 3.4%). 
This was probably not statistically significant because of the low absolute number of 
advanced-stage lung cancers. In the third screening round, no evident increase in 
stage IV lung cancers was observed (3.9%), despite the screening interval of 2 years.
The differences in lung cancer characteristics between men and women have 
been studied extensively. In general, studies found that women are, in general, 
diagnosed at an earlier age,94,95 at a more favourable cancer stage,95-97 and are more 
often diagnosed with adenocarcinomas than are men.94,98,99 This study was the first 
trial to report on sex differences in lung cancer in a screening setting and also 
demonstrated that women were diagnosed at a significantly more favourable cancer 
stage compared to men. However, the histological subtype and localisation of the 
lung cancers were not significantly different between the sexes. In 2013, a post hoc 
analyses using data from the NLST was published. The investigators did not spe-
cifically analyse sex differences in lung cancer characteristics, however they showed 
that women benefitted more from LDCT screening than men.20 This is in line with 
the more favourable stage distribution in women as demonstrated in the current 
study of the NELSON trial.
Concluding, no effect of screening round on lung cancer characteristics could be 
demonstrated in the NELSON trial. The gender of the participants only affected the 
disease stage at diagnosis of the screen-detected lung cancer, but no effect on histo-
logical subtype or localisation has been observed. Because of the more favourable in 
stage distribution and higher effectiveness of LDCT screening in women, post hoc 
analyses of the effectiveness of LDCT screening in the NELSON trial stratified by 
gender should be performed in the future.
c) Almost all (94.5%) screen-detected lung cancers were diagnosed before the onset 
of symptoms. In 5.5% of the participants, lung cancer was diagnosed after the first 
symptoms emerged. In 3.0% the participants reported that the symptoms had 
started in the interval between the LDCT screening test and the date of diagnosis. 
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It cannot be excluded that these symptoms were actually present for a longer time, 
but only recognised as serious by the participant after a suspicion of lung cancer was 
raised by the screening examination and subsequent tests.
Concluding, LDCT screening in the NELSON trial was able to detect lung cancer 
before the onset of symptoms in the large majority of the participants.
Conclusion
This study suggests that screening using low-dose computed tomography leads to a stage 
shift towards earlier diagnosis, more in women than in men, and a shift in histology 
towards slower growing and more peripherally localised subtypes of lung cancer. 
Research question III
Chapter 4. Epidemiological evaluation
Detection of lung cancer through low-dose CT screening: analysis of screening test 
performance and interval cancers. 
Lancet Oncology
Main research question
How can knowledge on the lung cancers not detected by low-dose computed tomography 
screening be used to improve the performance of the screening strategy?
Sub research questions
a) What were the detection rates and test characteristics of the nodule management 
protocol of the NELSON trial?
b) Were there any differences in the characteristics between the participants diagnosed 
with screen-detected lung cancer and the participants diagnosed with an interval 
cancer?
c) What were the tumour characteristics of the lung cancers not detected by low-dose 
computed tomography screening?
d) What were causes of the failure to detect the interval cancers?
Main findings
For this study, all Dutch participants who received at least one screening in the first three 
rounds (n=7,155) were included. Data on all lung cancers diagnosed from the first screen-
ing round to the last screening in round three, plus an additional two years of follow-up 
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were obtained from the Dutch Cancer Registry. The Belgian participants (n=935) were 
excluded as a linkage with the Belgian Cancer Registry was not yet possible.
a) In the first three screening rounds, a total of 187 participants were diagnosed with 
lung cancer through screening. Another 34 subjects were diagnosed with lung can-
cer between screening rounds. Hence, per 1000 screened subjects, 26.1 lung cancers 
were detected by screening, and 4.8 lung cancers were not (ratio 5.5:1). Across the 
three screening rounds, the ratio between the detected and missed lung cancers 
decreased from the first to the second round from 12.4:1 to 2.9:1, and increased 
from round two to round three to 7.2:1.
The test characteristics for the three screening rounds combined were: sensitivity 
84.6% (95% confidence interval (CI) 79.9-89.3%), specificity 98.6% (95% CI 98.5-
98.8%), PPV 40.4% (95% CI 35.9-44.7%), and NPV 99.8% (95% CI 99.8-99.9%). 
When only the first year of the interval between the screening rounds was consid-
ered, the performance was: sensitivity 90.8% (95% CI 86.4-94.5%), specificity 98.7% 
(95% CI 98.5-98.8%), positive and negative predictive values respectively, 40.4% 
(95% CI 35.9-44.7%) and 99.9% (95% CI 99.9-99.9%). Across the three screening 
rounds, the sensitivity and specificity were respectively: 92.5% and 98.3% in the first 
round, 73.6% and 99.0% in the second round, and 87.8% and 98.7% in the third 
screening round.
b) The participants diagnosed with either screen-detected lung cancer or interval lung 
cancer were significantly older than the subjects without lung cancer, however no 
differences were observed in the gender, or number of pack-years smoked. Only 
participants diagnosed with an interval cancer were significantly more often current 
smokers than those without lung cancer. Analyses between the participants with 
interval cancer and participants with screen-detected lung cancer showed that there 
was only a significant difference in smoking status.
c) The cancer stage at diagnosis of the lung cancers not detected by screening was as 
follows: 8.6% was diagnosed at stage IA, 8.6% at stage IIB, 8.6% at stage IIIA, 5.7% 
at stage IIIB, and 68.6% at stage IV. This disease stage distribution was significantly 
less favourable than the stage distribution of the screen-detected lung cancers. The 
interval cancers diagnosed within the first year of the screening interval had a sig-
nificantly higher disease stage than in the interval cancers diagnosed in the second 
year of the interval.
The distribution over the histological subtypes of lung cancer was as follows for 
the interval cancers: 25.7% adenocarcinomas, 20.0% small cell carcinomas, 17.1% 
squamous cell carcinomas, 17.1% large cell carcinomas, the remaining 20.0% were 
other rarer subtypes and lung cancers of unknown histopathological subtype. The 
interval cancers were significantly more often small cell carcinomas, and signifi-
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cantly less often adenocarcinomas compared to screen-detected cancers. The other 
histological subtypes were equally distributed. 
Finally, the localisation of both the interval cancers and screen-detected cancer 
was equally distributed across the lungs. 
d) Re-evaluation of the CT examinations of the 34 participants with an interval can-
cer learned that no lung cancer was present at the last screening examination in 
35.3%. In the remaining 64.7% an abnormality suspicious for lung cancer could, in 
retrospect, be identified on the screening CT examination. In the majority of these 
cases, the suspicious abnormality was missed. The causes of the failure to detect 
these lung cancers were: detection errors (38.2%), interpretation errors (5.9%) and 
human error (5.9%). In the remaining cases, the abnormality was actually detected, 
but lung cancer was not diagnosed because of: participant non-compliance (5.9%), 
not classified as suspicious by the protocol (2.9%), and manually classified as not 
suspicious by the radiologist due to a negative diagnostic work-up at a previous 
screening round (5.9%). 
Interpretation of results
a) This study demonstrated that the detection rate was high at 26.1 per 1000 screened 
subjects for three screening rounds. Since the NELSON trial has screening intervals 
of more than one year from the second round onwards, only the detection rates of 
the first round and the first year of the second round may be compared to other 
screening trials with a one-year screening interval. Henceforth, the detection rate 
for the first screening round was 8.69 per 1000 screened in the NELSON trial, 
which was lower than in the U.S. National Lung Screening Trial (NLST): 10.3 per 
1000 screened.6 This difference may be explained by the lower lung cancer risk of 
the NELSON participants compared to the NLST participants,17,18 and the slightly 
lower sensitivity in the NELSON trial (92.5%) than in the NLST (93.8%).6 The 
incidence of interval cancers between the first and second round was comparable 
in the two trials (0.70 per 1000 screened in NELSON and 0.68 per 1000 in NLST).6 
This might indicate that the majority of lung cancers not detected at baseline in 
the NELSON trial, did not become symptomatic in the one-year interval and were 
diagnosed through screening in the second round. This explanation is supported by 
the observation that the lung cancer detection rate in the second screening round 
was higher in the NELSON trial (7.69 per 1000) than in the NLST (6.80 per 1000).7 
In the first year of the screening interval after the second round scan, substantially 
more interval cancers were diagnosed in the NELSON trial (1.02 per 1000) than in 
the NLST (0.40 per 1000).7 This probably results from the difference in sensitivity in 
the second round (NELSON 88.3% versus NLST 94.4%).7
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The sensitivity and specificity of NELSON screening algorithm were respectively 
92.5% and 98.3% in round one, 73.6% and 99.0% in round two, and 87.8% and 
98.7% in round three. Whether the sensitivity is sufficient to obtain a significant 
lung cancer mortality reduction can only be determined by the final mortality 
analyses of the NELSON trial, which are planned ten years after randomisation. It is 
likely that the specificity is sufficient to obtain cost-effectiveness.
Since the NELSON trial has screening intervals of more than one year from the 
second round onwards, only the detection rates of the first round and the first year 
of the second round may be compared to other screening trials with a one-year 
screening interval. Henceforth, the sensitivity of 92.5% in the first round and 88.3% 
in the second round is slightly lower than in the NLST (93.8% in the first round and 
94.4% in the second round).6,7 The specificity of 98.3% in the first round and 99.0% 
in the second round is substantially higher than in the NLST (73.4% in the first 
round and 72.6% in the second round).6,7
Concluding, the detection rate for the first three screening rounds of NELSON 
trial was 26.1 per 1000 participants. Simultaneously, 4.8 lung cancers per 100 par-
ticipants were not detected by screening. The test characteristics for the first three 
screening rounds combined were: sensitivity 84.6%, specificity 98.6%, PPV 40.4%, 
and NPV 99.8%. These detection rates and test characteristics are promising for 
the cost-effectiveness of the NELSON screening trial. Nonetheless, the results of 
the mortality analysis and subsequent cost-effectiveness analysis should be awaited.
b) All participants of this study were at substantial risk of developing lung cancer as 
they were at least 50 years old and had smoked ten or more cigarettes a day for 
over 30 years, or fifteen or more cigarettes a day for over 25 years. Even within this 
population, older age and being a current smoker were still significant risk factors 
for developing lung cancer. Remarkably, being a current smoker is only associated 
with an increased risk of being diagnosed with an interval lung cancer. This may 
be because continued smoking promotes the development of lung cancer subtypes 
that grow faster and are less perceptible by LDCT screening, such as small cell car-
cinomas.19 This finding reinforces the urgency of smoking cessation in individuals 
undergoing lung cancer screening.
Concluding, subjects diagnosed with an interval cancer were significantly more 
often current smokers than the participants with screen-detected lung cancer; no 
differences in age, gender and number of pack-years smoked were observed.
c) This study demonstrated, not surprisingly, that screen-detected lung cancers are 
diagnosed at a notable more favourable cancer stage than interval cancers. More 
noticeable was the finding that the disease stage of the interval cancers diagnosed 
in the first year since screening was significantly higher than the stage of those 
diagnosed in the second year.
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This study also demonstrated that interval cancers are different in histopathol-
ogy compared to screen-detected lung cancers. Interval cancers were significantly 
less often adenocarcinomas and not a single interval cancer was a bronchoalveolar 
carcinoma. Interval cancers were slightly more often large cell carcinomas and 
squamous cell carcinomas, and significantly more often small cell carcinomas than 
screen-detected lung cancers. 
The differences in tumour characteristics are both caused by the earlier diagnosis 
of screen-detected lung cancer as a result of screening asymptomatic individuals, 
and by the more aggressive nature of interval lung cancers compared to detected 
cancers. This study revealed that 35.3% of the interval cancers newly developed 
during the screening interval, all these interval cancers were diagnosed at stage III/
IV. Hence, these cancers grew from undetectable to incurable cancers in less than 
one or two years. This observation suggests an enormous growth and metastatic 
potential. This suits with the finding that these interval cancers were significantly 
more often small cell carcinomas than the interval cancers that did not arise during 
the screening interval (41.7% versus 8.7%, p=0.03).
This study is the first to present the cancer stage distribution of both the screen-
detected and the interval cancers of the NELSON trial. Hence, 61.9% of all lung 
cancers were diagnosed at stage I, and only 17.8% at stage IIIB/IV. In the NLST, 
59.0% of the lung cancers was diagnosed at stage I, and 22.9% at stage IIIB/IV, which 
is not significantly different (p=0.20). Thus, despite longer screening intervals, 
slightly lower sensitivity, and fewer female participants20 in the NELSON trial, lung 
cancer was diagnosed as early as in the NLST.13 This finding is encouraging for the 
effectiveness of lung cancer screening regimens using biannual screening after an 
initial annual screening round.
Concluding, the lung cancers not detected by CT screening were characterised 
by a higher cancer stage at diagnosis; more than 70% of the interval cancers were 
diagnosed at an incurable stage (IIIB/IV). Further, the interval cancers were most 
frequently of the adenocarcinoma subtype, followed by small cell, squamous cell 
carcinomas, and large cell subtype.
d) Re-evaluation of the clinical CT and last screening CT examination revealed the 
causes of the failure to detect interval cancers. Surprisingly, 64.7% of the interval 
cancers were, in retrospect, visible at the last screening CT examination. Detection, 
interpretation and human errors were identified as the main cause of failure in 50.0% 
of the interval cancers. In addition, 2.9% of the interval cancers were not diagnosed 
through screening because the screening test result was adjusted manually by the 
radiologist from positive to negative because a diagnostic work-up performed in an 
earlier round did not yield the diagnosis of lung cancer. 
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Another remarkable finding of this study was that failure of the screening proto-
col to classify cancerous nodules as suspicious was rare. Only 5.9% of the interval 
cancers were not diagnosed because the cancerous nodule shrunk or had a volume 
doubling-time of more than 400 days. This suggests that the relatively stringent 
criteria for a positive result in the NELSON trial, did not lead to notable numbers of 
missed cancers. This finding is encouraging for future screening programmes that 
pursue limited harms and costs, as more stringent criteria contribute to this.21 
Further, 5.9% of the interval cancers were actually detected, but the diagnosis 
was not made through screening because participants refused to comply with the 
screening protocol. Instead of undergoing a follow-up CT at three months after their 
indeterminate screening test result, they directly underwent a diagnostic resection 
of the nodule, which yielded the diagnosis of lung cancer. Arguably, these interval 
cancers may have been screen-detected lung cancer in case the participants had 
complied with the protocol.
Finally, 35.3% of the interval cancers were, also in retrospect, not visible at the 
last screening examination. Hence, these interval cancers were not missed but arose 
during the interval.
Concluding, radiological errors were the most important cause of the failure to 
detect the interval cancers. Failures by the protocol or non-adherence to the proto-
col were infrequent causes of detection failure. More than one third of the interval 
cancers could not be prevented as they were not present at the last screening CT 
examination, but arose during the screening interval. 
Conclusion
The detection rates and sensitivity of the NELSON screening protocol were sufficient to 
diagnose lung cancer as early as in the NLST, which demonstrated to have an effective 
screening protocol.13 Moreover, the NELSON screening protocol yielded a very high 
specificity, which is a prerequisite for cost-effectiveness. Nonetheless, the performance of 
the screening protocol may be improved by co-implementation of CT screening with an 
effective smoking cessation program, and training of the screening radiologists to reduce 
the number of detection and interpretation errors. 
Research question IV
Chapter 5. Radiological evaluation
Computed tomographic characteristics of interval and post-screen cancers in lung cancer 
screening.
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European Radiology
Main research question
How can knowledge on the radiological characteristics of lung cancers not detected by 
low-dose CT screening be used to improve the performance of the screening strategy?
Sub research questions
a) What proportion of the lung cancers not diagnosed through screening was, in 
retrospect, present at the last LDCT screening examination?
b) What were the causes of the failure to detect the missed lung cancers?
c) What were the characteristics of the carcinomas missed on the LDCT screening 
examination due to radiological detection or interpretation errors?
Main findings
For this study all 7,155 Dutch participants randomised to the CT screening arm of the 
NELSON trial were included. The participants with lung cancer diagnosed between 
screening rounds (interval cancers) and the participants with lung cancer diagnosed 
after screening (post-screen cancers) were identified via linkages with the Dutch Cancer 
Registry. The Belgian participants (n=935) were excluded as a linkage with the Belgian 
Cancer Registry was not yet possible. 
In the first three rounds of the NELSON trial, LDCT screening detected lung cancer 
in 187 of the 7,155 (2.6%) participants. In another 61 of the 7,155 (0.85%) participants, 
lung cancer was diagnosed between screening rounds or after the subject’s last attended 
LDCT screening examination. Of these 61 participants clinical and radiological files were 
retrieved from the various hospitals in which the diagnosis was established. The clinical 
CT examination made at the time of the diagnosis was compared to the last screening 
LDCT examination by two experienced radiologists to determine whether any CT 
evidence of lung cancer could be identified in retrospect on the screening CT. In case 
of any abnormalities on the LDCT screening examination, the radiologists determined 
whether abnormalities were missed or misinterpreted by comparing their reading re-
port by the original reading report in the trial database. The missed lung cancers could 
be caused by detection errors and interpretation errors. In detection errors the lesion 
was not mentioned in the report but can be seen in retrospect on the last CT, while in 
interpretation errors the lesion was noted but considered a benign lesion. Finally, the 
radiologists searched for other abnormalities on the LDCT screening examination, which 
may influence detection or interpretation. 
a) In 26 of the 61 (42.6%) participants with a lung cancer not detected through screen-
ing no abnormalities suspicious of lung cancer were visible on their last attended 
LDCT screening examination. In eleven of these 26 subjects (42.3%) the lung cancer 
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was an interval cancer as it was diagnosed before their next scheduled LDCT screen-
ing examination. In 15 of the 26 subjects (57.7%) the lung cancer was diagnosed 
after the participant ceased with the screening program; a ‘post-screening cancer’. 
In the remaining 35 of the 61 (57.4%) participants with a lung cancer not detected 
through screening, the radiological re-evaluation showed that the lung cancer was 
actually present at the last LDCT screening examination.
b) In 35 of the 61 participants with a lung cancer not diagnosed through screening a 
suspicious abnormality was visible on the last LDCT screening examination.  Twen-
ty of these 35 lung cancers were interval cancers and fifteen were post-screening 
cancers. Radiological re-evaluation of these 35 cases showed that there were various 
reasons for the failure to diagnose the lung cancers.
In twenty cases, the lesions suspicious of lung cancer were not found on the LDCT 
examination by the radiologist due to detection error or human error. In another 
two cases the lesions suspicious for lung cancer were detected, but the lung cancers 
were not diagnosed due to interpretation errors by the radiologist. In thirteen cases 
the lesions suspicious of lung cancer were detected, but the lung cancers were not 
diagnosed due to:
I) Failure of the protocol: two (5.7%) lung cancers were not diagnosed via the 
NELSON trial because the protocol did not classify the nodules as suspicious 
for lung cancer. In these cases the protocol was adhered to and no positive 
screening result was issued as the nodules did not show growth.
II) Non-compliance with the protocol by the participant: eight (22.9%) lung can-
cers were not diagnosed via the NELSON trial because the participant refused 
to comply with the study’s recommendations based on the LDCT screening 
examination. 
III) Non-compliance with the protocol by the radiologist: three (8.6%) lung can-
cers were not diagnosed via the NELSON trial because the radiologist had 
replaced the actual screening result by a negative screening result because a 
previous diagnostic work-up had not yielded the diagnosis of lung cancer.
c) In the 22 of the 61 participants a suspicious abnormality was in retrospect visible 
on the last LDCT screening examination, but lung cancer was not diagnosed due 
to interpretation detection or radiological errors. Two lung cancers were detected 
but not diagnosed due to interpretation error.  In one case, a lesion of 7 mm in 
diameter was noted, but no further action was undertaken because it was inter-
preted as benign bulla wall thickening. In the other case, a lesion attached to the 
pleura of 22 mm in diameter was detected, but not referred for diagnostic work-up 
because it was interpreted as scarring. In the remaining twenty participants, lung 
cancer was present but was not detected at the LDCT screening examination. The 
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characteristics of these twenty lung cancers may give an indication of the causes of 
the detection errors:
I) Endobronchial localisation: Five lung cancers were visible on CT as small 
central endobronchial tumours. Two were localised in the right pectoral seg-
mental bronchus, one in the right lateral segmental bronchus, one in the right 
upper lobe bronchus and one in the lingular bronchus.
II) Bulla wall thickening: Four lung cancers were visible on CT as a thickening of 
the wall of a bulla. These lung cancers were localised in the right upper lobe (n 
= 2), left upper lobe and the left lower lobe. In one case the wall thickening was 
focal. 
III) Pleural attachment: Four lung cancers were visible on CT as nodules attached 
to the pleura.  Three of these nodules were smaller than 1 cm (5, 7 and 7 mm) 
and one was larger than 1 cm. 
IV) Pleural effusion: One lung cancer was not visible as a lung nodule or lung mass 
on CT, but as a pleural effusion on the right side. 177 days after the screening 
examination, the diagnosis of lung cancer with massive malignant pleural ef-
fusion was made.
V) Lymphadenopathy: Three lung cancers were not visible as a lung nodule or 
lung mass on CT, but as lymphadenopathy. In two cases the lymphadenopathy 
was located in the right hilum, inseparable from the pulmonary artery due to 
the lack of intravenous contrast. In the third case, lymphadenopathy measured 
22 mm was mainly located in the aortopulmonary window.
VI) Fibrosis: One lung cancer was visible on CT as a nodule smaller than 1 cm in 
diameter surrounded by extensive reticulation.
VII) Human error: Two lung cancers were visible on CT as nodules larger than 1 
cm localised in the parenchyma of the lung. As radiological evaluation did not 
reveal any explanation for the failure to detect these two lung cancers, human 
error is considered to be the most plausible cause.
Interpretation of results
a) Sixty-one (0.85% of 7,155) Dutch participants randomised to the screening group 
of the NELSON trial, were diagnosed with a lung cancer that was not detected by 
screening. In 42.6% of the participants no abnormality suspicious for lung cancer 
could be identified on the last screening CT examination. Hence, these lung cancers 
arose after the last screening CT was made. In the remaining 57.4% of the partici-
pants, an abnormality suspicious of lung cancer was visible on the LDCT screening 
examination. 
Missed carcinomas in CT-based lung cancer screening trials have received only 
limited attention in the radiological literature.22 Moreover, not a single lung cancer 
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screening study re-evaluated screening CT examinations of the subjects with an in-
terval or post-screen lung cancer to determine which lung cancers were missed and 
in which subjects the lung cancers developed after the last screening CT examina-
tion. As a result, the finding in this study that 57.4% of the interval and post-screen 
lung cancers were missed cannot be compared to any other study. 
The results of this study may be extrapolated to populations with a risk of de-
veloping lung cancer that is comparable to the lung cancer risk of the NELSON 
population. As a previous study of the NELSON trial demonstrated that higher age 
and current smoking status of the participants were associated with a significantly 
increased risk of being diagnosed with an interval cancer,23 the incidence of missed 
lung cancers may depend on these variables in different populations.
Concluding, about half of the lung cancers (57.4%) not diagnosed through 
screening was, in retrospect, present at the last LDCT screening examination. 
b) In the 35 participants with an interval or post-screen lung cancer lung cancer an 
abnormality suspicious for lung cancer was visible on the last LDCT screening ex-
amination. Radiological re-evaluation showed that 57.2% of the lesions suspicious 
of lung cancer were not found on the LDCT examination by the radiologist due to 
detection error or human error. In 5.7%, the lesions suspicious for lung cancer were 
detected, but the lung cancers were not diagnosed due to interpretation errors by 
the radiologist. In 37.1%, the lesions suspicious of lung cancer were detected, but 
the lung cancers were not diagnosed due to: failure of the protocol (5.7%), non-
compliance with the protocol by the participant (5.7%), and non-compliance with 
the protocol by the radiologist (8.6%).
In the literature, detection errors or interpretation errors by the radiologist are 
reported as common causes of missed lung cancers.22,24-28 In contrary, no studies 
indicating the incidence of missed lung cancers on CT due to nodule management 
protocol failure or non-compliance to the protocol by either the radiologist or the 
patient have been published. Despite this, the incidence of missed lung cancers due 
to protocol failure might be somewhat lower in clinical practice. This is because the 
most commonly used guidelines (based on the criteria of the Fleischner Society) 
recommend serial follow-up CT examinations for any non-calcified pulmonary 
nodule of 4mm or more in diameter. Hence, more nodules are followed up and 
probably less lung cancers are missed. However, the adherence to guidelines has 
been proven to be moderate,29 which may result in more missed lung cancers in 
clinical practice than in a clinical trial.
Concluding, detection errors were the most common cause of the failure to 
detect interval and post-screen lung cancers that were, in retrospect, visible at the 
last screening CT examination. Less common causes of missed lung cancers were 
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interpretation errors, failure of the screening protocol, and non-adherence to the 
protocol by either the radiologist or the participant.
c) In the 22 of the 61 participants a suspicious abnormality was in retrospect visible 
on the last LDCT screening examination, but lung cancer was not diagnosed due to 
interpretation detection or radiological errors. There were a number of typical lung 
cancer characteristics that may have caused or contributed to the failure to detect 
them. 
The most common characteristic was endobronchial tumour localisation (22.7%, 
n=5 all detection errors), which was also the most common cause in a study by White 
et al.24 There are two possible explanations for this: firstly, endobronchial nodule 
localisation is far less common than intraparenchymal localisation. As a result, the 
attention of the radiologist is primarily focused on the lungs and not the bronchi 
which facilitates the occurrence of detection errors. Secondly, the computed-aided 
detection system that is used to find nodules the radiologist misses, cannot search 
for nodules in the bronchial tree.30 To reduce the occurrence of missed lung can-
cers, it is recommended to screening radiologists to force themselves to check the 
bronchial tree visually after the regular reading using the computed-aided detection 
system.
The other most common characteristic was bulla wall thickening (22.7%, one 
interpretation error and four detection errors). Bulla wall thickening was not classi-
fied as an important abnormality in the protocol of the NELSON trial. Hence, this 
characteristic was not reported unless the radiologist recognised it as suspicious for 
lung cancer. As a result, it is unknown what the incidence of bulla wall thickening is 
in the whole screened population and in the participants with screen-detected lung 
cancer in particular. Nonetheless, it is possible that the incidence of a localisation in 
a bulla wall is higher in missed lung cancers than in detected lung cancer as no spe-
cific attention was paid to bulla walls in the NELSON trial. There are no published 
studies that report on the incidence of this characteristic in lung cancers missed at 
CT examinations. However, bulla wall thickening was reported to be not uncommon 
in lung cancers that were detected by CT: in the Early Lung Cancer Action Project, 
2% of the lung cancers detected at the first screening round and 12% of those de-
tected in the second screening round were associated with cystic airspaces31; and in 
a clinical series of 545 lung cancer patients 3.5% of the cancers were associated with 
a bulla.25 Since no data on the prevalence of bulla wall thickening in the screened 
population is available, the positive predictive value of this characteristic for lung 
cancer is unknown. Nonetheless, the prevalence of this characteristic of 22.7% (of 
the lung cancers missed due to radiological errors) justifies the recommendation to 
pay more attention to focal or diffuse bulla wall thickening in lung cancer screening.
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The other most common characteristic of missed lung cancer due to detection 
and interpretation errors was pleural attachment of the nodule (22.7%, n=5, four 
detection errors and one interpretation error). Malignant nodules that are pleural-
attached may be more difficult to detect and interpret than intraparenchymal 
localised malignant lung cancers as the computer aided-detection system is less 
sensitive for pleural attached nodules, and the size of pleural-attached nodules can-
not be assessed by the volumetric software used in the NELSON trial.8 Moreover, 
the NELSON publication by Xu et al. wherein in a sub-selection of 891 nodules 
was determined that none of the screen-detected lung cancers were attached to the 
pleura32, may have induced a decreased alertness of the NELSON radiologists to 
pleural-attached lesions. Missed lung cancer in pleural-attached lesions (22.7%) 
was relatively more common in the NELSON trial than in to other studies: 6.3%26, 
6.7%24, 11.1%28 and 14.3%.27 This may indicate that screening radiologists should 
consider pleural-attached nodules as potentially malignant despite the fact that no 
association between this characteristic and lung cancer could be established in the 
study by Xu et al.32
A less common presentation of missed lung cancers was lymphadenopathy with-
out visible lung lesions (13.6%, n=3). This type of missed lung cancer is probably 
difficult to prevent as the radiological evaluation of the screening CTs is focussed on 
the lungs. Moreover, the low-dose scans are performed without the administration 
of intravenous contrast, which is not optimal for imaging the mediastinum.
One other missed lung cancer was also not visible as a lung lesion, but presented 
as pleural effusion at the screening CT examination (4.5%). Also in this case the 
effusion was probably overlooked because the screening radiologists focussed on 
intrapulmonary abnormalities.
Detection errors due to other pathology were uncommon in this study, only one 
lung cancer was not detected because it was surrounded by extensive reticulation 
(4.5%). Missed lung cancers due to other distractive pathology on the CT is also 
reported in several clinical series.22,26,27
No plausible explanation for the failure to detect the two remaining missed lung 
cancers of this study could be identified. As both nodules were larger than 1 cm in 
diameter and no specific characteristics or distractions were present, these nodules 
should have been detected. Nonetheless, human error will be difficult to prevent.
Some specific nodule characteristics that were reported to be associated with 
missed lung cancers were not observed in the NELSON trial; smaller nodule 
size,22,26,28 peripheral nodule localisation22, sub-solid nodule type26 and attachment 
to a vessel.27 
Concluding, this study identified several radiological characteristics that were 
related to the failure to detect or interpret interval and post-screening lung cancers. 
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Some of the causes of the detection and interpretation errors were probably not 
preventable, such as lung cancer presenting as extra-pulmonary abnormalities, 
distractive other pathology and human error. However, three different causes may 
presented opportunities to reduce the number of missed lung cancers: endobron-
chial tumours, tumours arising from thickenings in bulla walls and pleural-attached 
nodules. The design of this study does not allow for the calculation of the positive 
predictive value of these characteristics. To determine this, the incidence of these 
characteristics should be determined both in the detected lung cancers and rep-
resentative sample of the screened population without lung cancer. If such a study 
would demonstrate that endobronchial tumours, tumours arising from thickenings 
in bulla walls and pleural-attached nodules are relevant risk-factors for (interval) 
lung cancer, the recommendation to check the bronchial tree visually, pay more 
attention to bulla wall thickening and consider also pleural-attached nodules as 
potentially malignant should be included in guidelines for lung cancer screening.
Conclusion
The majority of the lung cancers not detected by low-dose CT screening were not prevent-
able. The performance of the screening strategy may be improved by reducing the number 
of detection and interpretation errors. This may achieved by increasing the radiologist’s 
attention for endobronchial lesions, bulla wall thickenings, and pleural-attached lesions.
Research question V
Chapter 6. Optimisation of screening protocols
Lung cancer probability in subjects with CT-detected pulmonary nodules: an analysis of 
data from the NELSON trial of low-dose CT screening. 
Lancet Oncology
Main research question
How should a participant’s predicted lung cancer probability, based on size and growth 
of CT-detected nodules, be used to optimise the nodule management protocol of the 
NELSON trial?
Sub research questions
a) Was it valid to predict the two-year lung cancer probability of an individual who 
underwent screening using low-dose computed tomography, using a model based 
on nodule size and growth rate?
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b) What was the probability of lung cancer in an individual who underwent screening 
using low-dose computed tomography, based on nodule size and growth rate?
c) How should the current thresholds for nodule size and growth rate be adjusted to 
improve risk stratification, test characteristics and reduce harms?
Main findings
For this study all 7,155 Dutch participants randomised to the CT screening arm of the 
NELSON trial were included. The participants with lung cancer diagnosed between 
screening rounds (interval cancers) and the participants with lung cancer diagnosed 
after screening (post-screen cancers) were identified via linkages with the Dutch Cancer 
Registry. The Belgian participants (n=935) were excluded as a linkage with the Belgian 
Cancer Registry was not yet possible. 
a) This study aimed to improve the management of CT-detected pulmonary nodules 
by designing improved management protocol based on lung cancer probability. As 
nodule size and growth rate are reported to be the most important predictors of 
lung cancer probability, these determinants were chosen as the base for the new 
protocols. The first step in the design of the new protocols was to determine whether 
nodule size (volume or diameter) and nodule growth rate (volume-doubling time) 
were valid predictors of lung cancer probability in our dataset.
For this, logistic regression analysis was performed to predict lung cancer risk in 
the two years following each screening round, using diameter, volume and VDT as 
potential predictor variables. The model only included participants whose largest 
nodule measured 50-500 mm³ and who had ≥1 growing nodule in this volume 
range, because the VDT was available only for this subgroup. 
The model estimated that nodule volume, nodule diameter and nodule VDT 
were significant lung cancer predictors (all p<0.001). However, nodule volume was 
a stronger predictor of lung cancer than nodule diameter; if nodule volume was 
included in the model, nodule diameter was not a significant predictor anymore.
b) The two-year lung cancer probability for all included participants was 1.3% (95% 
CI 1.2-1.5%). On the CT examinations of 54.4% of the participants no pulmonary 
nodules were detected. Their probability to be diagnosed with lung cancer over the 
next two years was only 0.4%. 
The probability to be diagnosed with lung cancer in the two years following the 
screening examination was low for subjects with small nodules: for nodule with 
a volume <100 mm³ 0.5-0.7%, and for nodule with a diameter <5 mm 0.3-0.6%. 
Moreover, these probabilities were not significantly different from the lung cancer 
probability of subjects without nodules.
The two-year lung cancer probability was intermediate for subjects whose nodules 
had a volume of 100-300 mm³ or a diameter of 5-10 mm, as the associated risks were 
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respectively 1.5-5.8% and 0.9-2.9%; which was significantly increased compared to 
the probability of subjects without nodules. 
Lung cancer probability in the two years following the screening examination was 
high for subjects whose nodules measured ≥300 mm³ or >10 mm; 8.9-25.7% and 
11.1-31.6% respectively. These probabilities were also significantly higher than the 
probability of subjects without any nodules. 
The lung cancer probability according to nodule volume doubling-time (VDT) 
was calculated for the subjects whose largest nodule measured 50-500mm³. Subjects 
with slowly-growing nodules (VDT ≥600 days), or nodules that were stable in size, 
or nodules that had shrunken or resolved, had a low probability of lung cancer (0.0-
1.0%). Lung cancer probability was significantly increased for subjects with nodules 
with a VDT <600 days. Hence, subjects whose nodules had a VDT of 400-600 days 
were at intermediate risk (4.1% in two years), and subjects whose nodules had a 
VDT <400 days were at high risk (6.7-25.0% in two years).
Finally, both nodule volume and nodule VDT were used to estimate the two-year 
lung cancer probability. In subjects with large nodules of ≥300 mm³, lung cancer 
probability remained substantial (from 5∙9% to >50%) even in case of slow nodule 
growth. In subjects with intermediate-sized nodules (volume 50-300 mm³), the lung 
cancer probability ranged from low (<1∙5%) to high (30%), for VDTs ranging from 
<50 days to 600 days.
c) The current guideline33 for the management of CT-detected pulmonary nodules is 
based on the criteria of the Fleischner Society.5 To be able to estimate the perfor-
mance of the current guideline, it was simulated as follows: 
I) Subjects whose nodules measured ≤4 mm were classified as negative. In these 
subjects the next screening examination was made after one year, which is 
in accordance with the guideline which recommends follow-up CT at twelve 
months.33 
II) Subjects whose nodules measured 4-8 mm were classified as indeterminate. In 
these subjects a follow-up CT is made after three months, while the guideline 
recommends performing a follow-up CT at 6-12 and 18-24 months. The final 
result is classified as positive for VDTs <400 days, and negative for VDTs ≥400 
days, in accordance with the guideline.33
III) Subjects whose nodules measured >8 mm were classified as positive. In these 
subjects additional diagnostic procedures were performed, which is in accor-
dance with the guideline.33 
The simulated ACCP protocol yielded a sensitivity of 90.9% (95% CI 81.2-96.1%), 
and a specificity of 87.2% (95% CI 86.4-87.9%). The predictive value of a positive test 
result (PPV) was 6.2% (95% CI 4.8-7.9%), which led to follow-up CT examinations 
in 29.8% of the screened subjects, and additional diagnostic procedures in 13.6%.
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Next, a nodule management protocol was designed using thresholds for nodule 
diameter that were based on the lung cancer probability:
I) Subjects whose nodules measured ≤5 mm were classified as negative. In these 
subjects the next screening examination was made after one year.
II) Subjects whose nodules measured 5-10 mm were classified as indeterminate. 
In these subjects a follow-up CT was made after three months, to assess nodule 
VDT. The final result was classified as positive for VDTs <600 days, and nega-
tive for VDTs ≥600 days.
III) Subjects whose nodules measured >10 mm were classified as positive. In these 
subjects additional diagnostic procedures were performed. 
This protocol yielded a sensitivity of 92.4% (95% CI 83.1-97.1%) and a specificity 
of 90∙0% (95% CI 89.3-90.7%). The PPV of this protocol was 7.9% (95% CI 6.2-
10.1%), which led to follow-up CT examinations in 22.2% of the screened individu-
als and to additional diagnostic procedures in 10.8%.
Finally, a nodule management protocol was designed using thresholds for nodule 
volume that were based on the lung cancer probability:
I) Subjects whose nodules measured ≤100 mm³ were classified as negative. In 
these subjects the next screening examination was made after one year.
II) Subjects whose nodules measured 100-300 mm³ were classified as indetermi-
nate. In these subjects a follow-up CT was made after three months, to assess 
nodule VDT. The final result was classified as positive for VDTs <600 days, and 
negative for VDTs ≥600 days.
III) Subjects whose nodules measured >300 mm³ were classified as positive. In 
these subjects additional diagnostic procedures were performed.
This protocol yielded a sensitivity of 90.9% (95% CI 81.2-96.1%) and a specificity 
of 94.9% (95% CI 94.4-95.4%). The PPV of this protocol was 14.4% (95% CI 11.3-
18.1%), which led to follow-up CT examinations in 7.8% of the screened individuals 
and to additional diagnostic procedures in 5.9%. 
Interpretation of results
a) A logistic regression model was used to determine whether nodule size (volume or 
diameter) and nodule growth rate (volume-doubling time) were valid predictors of 
lung cancer probability in our dataset. Analyses showed that nodule volume, nodule 
diameter and nodule VDT were significant lung cancer predictors. However, nodule 
volume was a stronger predictor of lung cancer than nodule diameter.
Concluding, nodule volume, diameter and volume-doubling time are strong pre-
dictors of the lung cancer probability of subjects with CT-detected nodules. There-
fore, it is valid to use these determinants for designing new nodule management 
protocols. The performance of protocols using nodule diameter is expected to be 
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worse than the performance of protocols using nodule volume, as the relationship 
between nodule diameter and lung cancer probability is weaker than the relation-
ship between nodule volume and lung cancer probability.
b) In more than half of the included participants (54.4%) no pulmonary nodules were 
detected. Their two-year lung cancer probability of only 0.4% suggests that it may 
be safe to apply a screening interval of at least two years in these individuals. In the 
subjects with CT-detected nodules, lung cancer probability depended strongly on 
nodule volume and VDT.
This study confirms that the lung cancer probability of small nodules (volume 
<50 mm³ or diameter <4 mm) is low; at ≤0.6% compared to <1% reported in the 
literature.2, 6, 33-36 Moreover, the lung cancer probability in subjects whose nod-
ules measure 50-100 mm³ or 4-5 mm, is also low (0.3-0.7%) and not significantly 
different from that in subjects without nodules. Currently, guidelines recommend 
two to four follow-up scans for such nodules.5,33,37 Omitting these CT surveillance 
schedules should be considered, as the risk of malignancy does not justify the harms 
of ionizing radiation, psychological distress, and the associated costs.38-40
Next, subjects with intermediate-sized nodules (volume 100-300 mm³ or di-
ameter 5-10 mm) have a significantly higher two-year lung cancer risk (0.9-5.8%) 
compared to subjects without nodules. This justifies additional CT examinations, 
which is in accordance with current guidelines.5,33,37 Since the lung cancer risk of 
subjects with nodules between 5 and 8 mm is comparable (0.9-1.8%),6 a uniform CT 
surveillance schedule may be applied. 
For intermediate-sized nodules, the VDT assessed at CT surveillance should be 
used to re-assess the lung cancer probability. Subjects with slowly-growing (VDT 
≥600 days), stable, shrunken and resolved nodules are at low risk of lung cancer 
(0.0-1.0%) and could withdraw from intensified CT surveillance and return to 
regular screening. By contrast, subjects whose nodules have a VDT <600 days have a 
significantly increased risk of lung cancer (4.1-25.0%), which justifies intensified CT 
surveillance and  additional diagnostic procedures. Subjects whose nodules have 
a VDT of 400-600 days may be regarded as at intermediate risk, since their lung 
cancer probability is 4.1% in two years. Hence, a follow-up CT examination at short 
notice to re-assess nodule size and growth may be preferred over more invasive or 
expensive diagnostic procedures.
Finally, this study confirmed the high lung cancer probability in subjects with 
large nodules (volume ≥300 mm³ or diameter ≥10 mm): >10% in the literature5,6,34,41 
and 8.9-31.6% in this study. A remarkable finding was that the risk of these large 
nodules is also high (5.9-50%) when they grow slowly. Therefore, a follow-up CT 
examination to assess growth for nodules ≥300 mm³ or ≥10 mm provides little 
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additional information, but may delay lung cancer diagnosis. Hence, immediate 
diagnostic work-up is suggested instead.
Concluding, the probability of lung cancer in subjects who underwent CT 
screening depends on the presence, size and growth rate of CT-detected pulmonary 
nodules. Subjects without nodules, subjects with small nodules (volume ≤100 mm³ 
or diameter ≤5 mm), or with slow growing (VDT ≥600 days), stable, shrinking, 
resolving nodules that are smaller than 300 mm³ or 10 mm, have a low lung cancer 
risk. Individuals with intermediate-sized nodules (volume 100-300 mm³ or diam-
eter 5-10 mm), or nodules smaller than 300 mm³ or 10 mm with a VDT of 400-600 
days, have an intermediate lung cancer risk. Subjects with large nodules (volume 
>300 mm³ or diameter >10 mm), or with fast-growing nodules (VDT <400 days) 
are at high risk of developing lung cancer within two years. 
c) In this study, three nodule management protocols were simulated and their per-
formance evaluated; the ACCP guideline for nodule management33 based on the 
Fleischner criteria,5 a new lung cancer probability-based protocol using nodule 
diameter, and a new lung cancer probability-based protocol using nodule volume.
Comparing the new lung cancer probability-based protocol using diameter to 
the simulated ACCP protocol, the new protocol yielded a higher sensitivity (92.4% 
instead of 90.9%), fewer follow-up CT examinations (-7.6%), and additional diag-
nostic procedures (-2.8%), than the ACCP protocol. These results imply that the 
ACCP nodule management protocol performed well. However, with small adjust-
ments of the thresholds for nodule diameter (raising the lower threshold from 4 mm 
to 5 mm, and raising the upper threshold from 8 mm to 10 mm) and the criterion 
for malignant nodule growth (VDT <600 days instead of VDT <400 days), the 
performance could be improved.
The new lung cancer probability-based protocol using volume classified no nod-
ules and nodules <100 mm³ as negative, nodules 100-300 mm³ as indeterminate (fi-
nal result positive if VDT <600 days, otherwise negative), and nodules >300 mm³ as 
positive. This protocol demonstrated a very high specificity (94.9%), which yielded 
substantially less follow-up CT examinations (-22.0%), and additional diagnostic 
procedures (-7.7%) compared to the ACCP protocol. Moreover, the sensitivity of this 
volume protocol is as high as the ACCP protocol’s sensitivity: 90.9%. Although this 
sensitivity is slightly lower than the sensitivity of the new protocol using diameter, 
the advantages of the very high specificity of the volume-based protocol outweighs 
the disadvantage of a slightly lower sensitivity. Therefore, the use of the new lung 
cancer probability-based protocol using nodule volume has the best performance of 
these three nodule management protocols.
Concluding, the current guideline for the management of CT-detected nodules33 
may be optimised by adjusting the thresholds for nodule size and growth. Hence, 
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the threshold that is used to classify nodules as at very low risk of lung cancer should 
be raised from 4 mm to 5 mm. The threshold that is used to classify nodule as 
at substantial risk of lung cancer, requiring more invasive diagnostic procedures, 
should be raised from 8 mm to 10 mm. Furthermore, for intermediate-sized nod-
ules, more invasive procedures should only be performed for nodule demonstrating 
growth with VDT of <600 days, instead of visual growth or VDT <400 days. A more 
efficient alternative for these diameter protocols is the new lung cancer probability-
based protocol using nodule volume. In this protocol, no nodules and nodules <100 
mm³ were classified as negative, nodules 100-300 mm³ as indeterminate (final result 
positive if VDT<600 days, otherwise negative), and nodules >300 mm³ were clas-
sified as positive. Prospective studies or micro-simulation studies using these new 
protocols are required to determine the effect on lung cancer mortality.
Conclusion
The size and growth of CT-detected nodules are valid predictors of the screened indi-
vidual’s two-year lung cancer probability. Subjects with nodules ≤100 mm³ or ≤5 mm 
have a lung cancer risk that is not significantly different from that in subjects without 
nodules and should not undergo additional CT examinations. Individuals with nodules 
100-300 mm³ or 5-10 mm represent an indeterminate subgroup for whom the assessment 
of VDT is appropriate (<600 days warrants follow-up evaluation). The risk of subjects 
with nodules >300 mm³ or >10 mm demands immediate diagnostic evaluation. New 
management protocols for CT-detected nodules using these thresholds for nodule size 
and VDT were estimated to perform better than the current guideline.
Research question VI
Chapter 7. Evaluation of bronchoscopy
The role of conventional bronchoscopy in the work-up of suspicious CT screen-detected 
pulmonary nodules. 
Chest
Main research question
What was the value of bronchoscopy for diagnosing lung cancer in screen-detected 
nodules?
Sub research questions
a) What were the test characteristics of bronchoscopy and its ancillary procedures?
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b) What were predictors for a true-positive bronchoscopic procedure?
c) Which diagnoses were made in false-negative bronchoscopic procedures?
Main results
In a series of 415 participants with a positive screening result in the NELSON trial, 308 
(74.2%) underwent a conventional white-light bronchoscopy as part of the diagnostic 
work-up. In these 308 persons, a total of 318 suspicious pulmonary nodules or masses 
were analysed by bronchoscopy with the objective to diagnose or exclude lung cancer. 
According to the gold standard, which was a histological confirmation on histological or 
cytological samples in 95.5%, 178 of the 318 (56.0%) suspicious lesions were malignant.
a) Cancer was diagnosed by bronchoscopy in only 24 of the 318 suspicious lesions. The 
overall sensitivity of bronchoscopy to detect cancer was 13.5% (24 of 178; 95% con-
fidence interval (95% CI) 9.0-19.6%), and the negative predictive value was 47.6% 
(140 of 294, 95% CI 41.8-53.5%). As no false-positive diagnoses were made, the 
specificity and positive predictive value were both 100%. The sensitivity and nega-
tive predictive value of the ancillary procedure bronchial washing were respectively 
9.3% (95% CI 5.7-14.8) and 45.9% (95% CI 40.2-51.7%), for bronchial brushing 
respectively 7.9% (95% CI 3.3-17.0%) and 41.2% (95% CI 32.4-50.6%). The sensitiv-
ity and negative predictive value for the ancillary procedures transbronchial needle 
aspiration (TBNA), transbronchial biopsy (TBB) and endobronchial biopsy (EBB) 
were respectively TBNA: 33.3% (95% CI 6.0-75.9%) and 0% (95% CI 0-6.0%); TBB: 
16.7% (95% CI 0.9-63.5%) and 44.4% (95% CI 15.3-77.3%); EBB: 45.8% (95% CI 
26.2-66.8%) and 55.2% (95% CI 36.0-73.0%).
b) Multivariate regression analyses were performed on the subset of 178 cases with 
cancer to identify predictors of a successful bronchoscopic procedure. Nodule size, 
defined as nodule diameter in mm, was a statistically significant positive predic-
tor (odds ratio 1.07 (95% CI 1.02-1.13). Further, the visibility of the lesion during 
bronchoscopy was also a statistically significant positive predictor (87.61 (95% 
CI 4.90-564.88). The following characteristics were significantly associated with a 
successful bronchoscopic procedure: nodule volume doubling time, central versus 
peripheral localisation, upper lobe localisation versus lower or middle lobe localisa-
tion, screening round, scan type, presence or absence of bronchial compression.
c) In 24 of the 178 bronchoscopies of malignant lesions, the result of the bronchoscopy 
was positive. Hence, in 154 bronchoscopic evaluations the result was false-negative, 
which corresponds with a negative predictive value of 47.6%. The diagnoses made 
based on bronchoscopy in these false-negative procedures were: aspecific inflam-
mation (27.3%), metaplasia (3.9%), fibrosis (1.3%), Aspergillus Fumigatus infection 
(0.6%), atypia (0.6%) and resolving haemorrhage (0.6%), in the remaining cases 
(65.6%) no abnormalities were detected.
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Interpretation of results
a) The overall sensitivity and negative predictive value of bronchoscopy in subjects 
with suspicious CT-detected pulmonary nodules was respectively 13.5% and 47.6%. 
As no false-positive diagnoses of cancer were made by bronchoscopy, the sensitivity 
and positive predictive value were both 100%. 
To date, the have been no other publications on the diagnostic performance 
of conventional white light bronchoscopy for diagnosing lung cancer in subjects 
with CT-detected nodules. This is probably because bronchoscopy is not routinely 
performed in other lung cancer screening trials. 
In non-screening studies, the published sensitivity of bronchoscopy varied from 
51% to 76%.42-47 Differences between these and the current study were: a smaller 
size of the lesions (2.8% >30 mm versus 48-72 mm)42,43,46,47 and a lower incidence 
of endobronchial abnormalities (7.3% versus 8-64%).43-45 The lower sensitivity in 
the current study can be explained by these differences as both nodule size and 
endobronchial visibility are independent predictors for a successful bronchoscopy 
procedure.48 
According to the guidelines that were available at the time this study was 
conducted, conventional white light bronchoscopy was only recommended for 
suspicious lesions with an air bronchogram on CT.49,50 According to the currently 
available guideline,33 conventional white light bronchoscopy is not recommended 
anymore. Only more advanced techniques such as radial endobronchial ultrasound, 
electromagnetic navigational bronchoscopy and virtual bronchoscopy navigation 
techniques are recommended for individuals who are poor candidates for transtho-
racic biopsy in case the lesion is located in proximity to a patent bronchus. 
Concluding, this study demonstrates that the routine use of conventional bron-
choscopy in the diagnostic work-up of CT-detected pulmonary nodules is not 
justified. It is highly unlikely that the yield outweighs the harms (distress and risk of 
complications) and costs (health care facilities, personnel and resources) associated 
with routine use of bronchoscopy.33 However, to determine this cost-effectiveness 
analyses including all these aspects should be performed. The use of conventional 
white light bronchoscopy in selected cases (larger nodules located in proximity to 
a patent bronchus) will result in better test characteristics, which will yield a higher 
cost-effectiveness. Nonetheless, this can also not be recommended as conventional 
white light bronchoscopy has become an outdated technique for diagnosis lung 
cancer in suspicious CT-detected nodules.
b) The size and visibility of the suspicious lesions were statistically significant predic-
tors of a true-positive result of the bronchoscopic procedure. It was estimated that 
for every millimetre increase in nodule diameter, the probability of a true-positive 
procedure will increase with 7%. Further, lesions which were visible during bron-
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choscopy had a significantly higher probability of a successful procedure compare 
to lesions not visible during bronchoscopy.
Concluding, size and visibility of suspicious CT-detected lesions are predictive of 
a true-positive bronchoscopic procedure.
c) A variety of diagnoses is made in false-negative bronchoscopic procedures. Instead 
of lung cancer, Aspergillus infection, aspecific inflammation, atypia, metaplasia, 
fibrosis and resolving haemorrhage are found in the histological or cytological sam-
ples obtained by bronchoscopy. Some of these findings, as infections or fibrosis, may 
also present as an approximately spherical opacity on CT. This demonstrates that 
lung cancer can be missed by bronchoscopy in the presence of benign abnormalities 
that could also explain the suspicious lesion opacity on CT. Such a situation bares 
the risk of a missed or delayed lung cancer diagnosis. This information, combined 
with the estimated negative predictive value of 47.6%, proofs that bronchoscopy 
is not an appropriate technique to exclude a diagnosis of lung cancer in subjects 
referred for screen-detected nodules. 
Concluding, deceitful benign diagnoses can be made by bronchoscopy in persons 
wherein the suspicious lesion is actually lung cancer. Therefore, the use of bronchos-
copy to exclude a diagnosis of lung cancer is not recommended in a lung cancer 
screening program.
Conclusion
The performance of white light bronchoscopy is not sufficient to justify routine use in 
subjects with suspicious pulmonary nodules detected in a lung cancer screening pro-
gramme.
Research question VII
Chapter 8. Evaluation of surgical procedures
Complications following lung surgery in the Dutch-Belgian randomized lung cancer 
screening trial. 
European Journal of Cardio-Thoracic Surgery
Main research question
To what extent did adverse events related to thoracic surgery, occur in participants after 
a positive screening test results?
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Sub research questions
a) How often occurred re-thoracotomy, complications, and post-operative mortality 
in participants who underwent thoracic surgery for a positive screening test result?
b) What was the length of hospital stay for lung resection performed by thoracotomy 
and video-assisted thoracoscopic surgery?
c) To what extent were surgical procedures performed for benign nodules?
Main results
In a series of 415 participants with a positive screening result in the NELSON trial, 215 
(51.8%) underwent a surgical procedure. Seventeen of these 215 participants (7.9%) only 
underwent a mediastinoscopy. The remaining 198 participants underwent lung surgery; 
in 44 (22.2%) lung surgery was preceded by a mediastinoscopy. The majority (n = 182; 
91.9%) of the lung surgeries were resections performed via a thoracotomy. 5.6% (n = 11) 
of the procedures were wedge resections performed via a video-assisted thoracoscopic 
(VATS) procedure. The remaining 2.5% (n = 5) of the procedures were initiated as VATS 
procedures, but were converted to a thoracotomy. Summarising, in 198 subjects 187 
thoracotomies and 16 VATS procedures were performed.
a) 47% (n = 88) of the thoracotomies were complicated by at least one non-life threat-
ening condition and 10% (n = 18) was complicated by at least one life threatening 
condition. In 38% (n = 6) of the VATS procedures at least one non-life threatening 
complication occurred, but no life threatening complications have been observed. 
As 5% had both minor and major complications, the proportion of participants with 
any complication was 53%. The complications caused by thoracotomy necessitated a 
re-thoracotomy in 3% and re-admission to the hospital after discharge in 5%. After 
VATS procedures, no re-thoracotomies or re-admissions occurred. There was no 
mortality within the first 30 days after thoracotomy or VATS in the NELSON trial.
b) The median length of hospital stay after thoracotomy was 13 days (range 2 to 51 
days). After a VATS procedure the median length of hospital stay was 8 days (range 
4 to 12 days). In subjects with non-life threatening complications, the length of 
hospital stay after thoracotomy was a median 15 days, ranging from 6 to 51 days and 
after VATS 9 days (range 7 to 12 days). In the case of life threatening complications 
following thoracotomy, the median length of hospital stay was 21 days, ranging 
from 8 to 51 days.
c) The resection specimens obtained by the 198 surgical procedures yielded the 
diagnosis of lung cancer in 151 (76.3%) cases. Hence, in the remaining 47 cases 
(23.7%) benign abnormalities were resected. Twenty of the 47 subjects (42.6%) who 
underwent surgery for benign disease experienced non-life threatening complica-
tions and three of the 47 subjects (6.4%) had life threatening complications. 
Chapter 11
298
Interpretation of results
a) In this study, the incidence of re-thoracotomy, complications, and mortality after 
lung surgery in the NELSON lung cancer screening trial was assessed. A few other 
lung cancer screening trials published their adverse events. One or more complica-
tions after surgery occurred in the NELSON trial in 53.% of the participants, which 
is higher than in all other screening trials: 45.0% of the participants of the U.S. 
National Lung Screening Trial (NLST)13; 33.9% of the participants of the Italian 
DANTE trial51; 25% of the participants of the Italian COSMOS lung cancer screen-
ing cohort study52; and 0% of the participants of the Danish lung cancer screening 
trial.9 However, in the incidence of  major complications,10% in the NELSON trial, 
was within the range of the other screening trials: 15.3% in the DANTE trial51; 
11.9% in the NLST13; 6% in the COSMOS trial52; and 0% in the Danish trial.9  Post-
operative mortality was 0% in the NELSON trial, which is comparable to the NLST 
(0.01% within 60 days)13, the Danish trial (0%)9 and the COSMOS trial (0%)52, only 
in the DANTE trial a higher mortality rate (5.1%) was published.51
The incidence of non-life threatening complications after thoracotomy in NEL-
SON (47%) was also high in the range of the incidences of published non-screening 
series (7% to 57%).51,53-68 However, the incidence of  life threatening complications 
after thoracotomy in the NELSON trial (10%) was low in the range (4% to 26%) 
of non-screening studies.51,53-68 The incidence of non-life threatening complications 
after VATS procedures was 38% in the NELSON trial, which is high compared to 
the range in the literature (9% to 51%).69,70 No life threatening complications have 
been observed after VATS in the NELSON trial, which is at the lower range of the 
reported incidence in the literature (0% to 12%).51,70,71 In the NELSON trial, com-
plications after thoracotomy necessitated a re-thoracotomy in 3%. The reported re-
thoracotomy rates after a thoracotomy varied from 0 to 9%.59,72 No re-thoracotomies 
after VATS were performed in the NELSON trial, while the reported re-operation 
rate after VATS varied between 1 and 5%.62,72 Finally, no post-operative mortal-
ity after respectively thoracotomy and VATS were observed in the NELSON trial, 
compared to mortality rates of  respectively 0-8%51,53-61,63-68,72-82 and 0-4%58,83 after 
thoracotomy and VATS in other studies. 
The aforementioned comparisons with other screening studies and clinical series 
can be made as this study also demonstrated that the age range and co-morbidity 
level were comparable.84 Nonetheless, the studies were quite heterogenic with 
respect to the definition, classification and methods of data collection on com-
plications. Not in all studies, a distinction was made between life threatening and 
non-life threatening complications. Moreover, some studies collected the data by 
reviewing individual patient charts, and others based on ICD-9 codes or on claims 
in Medicare files. The latter two methods result in an underestimation of complica-
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tions, especially for minor complications. Probably because all individual patient 
files were carefully evaluated in the current study, the minor complication rate 
was relatively high. As reporting major complications and mortality occurs more 
accurate than reporting minor complications, the comparisons concerning major 
complications and post-operative mortality between this study and the literature is 
more reliable. Hence, both the incidence of major complications and post-operative 
mortality were relatively low compared to clinical series, and comparable to other 
screening trials. This could probably be explained by the fact that screen-detected 
cancers, in general, are diagnosed earlier than symptom-detected lung cancers, and 
as a result the required resection of screen-detected lung cancer are more often less 
extensive.13,19,85 This is supported by the observation that pneumonectomies were 
rarely performed in the NELSON trial, while more complex resections with higher 
expected complication rates were performed in the published clinical studies.
Concluding, post-operative minor complications (47%) were more frequent in 
the NELSON than reported in the literature. The incidence of major complications 
(10%), re-thoracotomy (3%) and post-operative mortality (0%) were at the lower 
range of the reported incidences in other studies. This suggests that lung surgery for 
lung cancer detected by low-dose computed tomography is at least as safe as lung 
surgery for clinically detected lung cancer. Although the design of the current study 
does not allow drawing conclusions on comparisons between thoracotomy and 
VATS; the incidence of complications, re-operations and post-operative mortality 
were lower after VATS procedures. As this was also observed in other published 
studies, VATS may be a safer method for lung resections for screen-detected lung 
cancers, and should probably be the preferred method for those cases wherein both 
VATS and thoracotomy are appropriate. 
b) The median length of hospital stay in after thoracotomy in the NELSON trial (13 
days) was in the middle of the range reported in the literature (5 to 22 days).72,80 In 
subjects with non-life threatening complications, the length of hospital stay after 
thoracotomy was a slightly longer (median 15 days), and in the case of life threaten-
ing complications substantially longer (median 21 days). After a VATS procedure, 
the median length of hospital stay in the NELSON trial was 8 days, which is in the 
lower range of lengths of stay reported in the literature 4 to 23 days.57,72 In subjects 
with non-life threatening complications, the length of hospital stay after VATS was 
slightly longer (median 9 days).
Concluding, the length of hospital stay (median 13 days after thoracotomy and 8 
days after VATS) in the NELSON trial was comparable to the literature. Although 
the design of the current study does not allow drawing conclusions on comparisons 
between thoracotomy and VATS; the length of hospital stay was lower after VATS 
procedures, both in this study and in other published studies. Therefore, VATS may 
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be considered as the preferred method for lung resections for screen-detected lung 
cancers, for those cases wherein both methods are appropriate.
c) The 198 surgical procedures included in this study yielded the diagnosis of lung 
cancer in 151 (76.3%) cases. Hence, in the remaining 47 cases (23.7%) benign ab-
normalities were resected. Most other lung cancer screening trials reported on the 
percentage of surgeries for benign disease and the incidence in NELSON is at the 
higher range: NLST 32.2% surgeries in the absence of lung cancer,13 in the DANTE 
trial 22% of the resected nodules was benign,51 in the Danish trial this was 18.2%,9 
in the Italian MILD trial 9%86 and in the ITALUNG trial only 5.5%.87 The high 
percentage of surgeries of benign nodules in the NLST may be partly due to the vast 
proportion of the participants (39.1%) who received one or more positive screening 
result,13 due to the low specificity (73.4-83.9%) of the NLST screening algorithm.7,14 
In the NELSON trial however, the specificity of the screening algorithm is much 
higher (98.6%)23 and the proportion of subjects with a positive screening result 
much lower (6.0%).88 This suggests that the relatively high number of surgeries for 
benign nodules are not caused by the screening algorithm, but by decisions made 
during the diagnostic work-up for positive screening results. One aspect that might 
play a role is the fact that the diagnostic work-up in the NELSON trial usually only 
consisted of imaging and bronchoscopy. As a result, proof of the suspicion of lung 
cancer by biopsy was rarely obtained before surgery. The lower numbers of surgeries 
for benign nodules in the other screening trials suggests that they applied a more 
cautious approach towards suspicious CT-detected nodules. Since these studies did 
not publish on the counter side of this approach (number of additional diagnostic 
tests, months of follow-up and cancerous nodules unjustly not resected), it is not 
possible to determine whether their approach is recommendable. Nonetheless, ef-
forts should be made to investigate whether it is possible to safely reduce the number 
of surgeries for benign nodules. 
Another reason for this is the occurrence of complications in this group. Hence, 
20 of the 47 subjects (42.6%) who underwent surgery for benign disease, non-life 
threatening complications occurred and in three of the 47 subjects (6.4%) life 
threatening complications occurred. In other lung cancer screening trials that 
published on such adverse events, the incidence of complications was lower: NLST 
20.5% (from which 2.4% was minor, 7.9% was intermediate and 5.5% were major 
complications),13 DANTE trial 0%51 and COSMOS trial 0%.52 Post-operative mor-
tality did not occur after surgery for benign nodules in the NELSON trial, DANTE 
trial,51 COSMOS trial,52 and was rare in the NLST 1.2%.13
Concluding, 23.7% of the lung surgeries in the NELSON trial were performed for 
benign nodules. This percentage, as well as the incidence of complications (42.6%) is 
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relatively high compared to other screening trials. Future studies should investigate 
how to safely reduce the number of surgeries for benign nodules.
Conclusion
This study demonstrated that adverse events after thoracic surgery for positive screening 
test results were common. The incidence of minor complications was relatively high, 
while in the incidence of major complications, re-operations and post-operative mortal-
ity was relatively low. Finally, a relatively high percentage of the surgeries was performed 
for benign nodules.
Research question VIII
Chapter 9. Endpoint determination
Uniform and blinded cause of death verification in a lung cancer CT screening trial. 
Lung Cancer
Main research question
How should the endpoint verification process of the NELSON trial be designed to ensure 
uniform, objective and unbiased endpoint determination?
Sub research questions
a) How to develop a cause of death review protocol that ensures uniform, objective 
and unbiased endpoint determination?
b) How was the performance of the developed cause of death protocol compared to the 
official death certificates?
c) What were sources of disagreement between users of the developed cause of death 
protocol?
d) What were the best sources of information for a review of the cause of death of a 
participant?
Main results
a) The primary endpoint of the NELSON trial is lung cancer-specific mortality. Infor-
mation on the cause of death of the NELSON participants can be obtained from the 
death certificates, which are available from Statistics Netherlands and the Flemish 
Agency for Care and Health. Therefore, the first step in the design the endpoint 
verification process of the NELSON trial, was to perform a literature study on the 
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reliability of the use of official death certificates for endpoint verification in screen-
ing trials. 
This initial study learned that the use of death certificates for this purpose is 
debated for several reasons: sticky-diagnosis bias and slippery linkage bias,100 in-
accurate form completion and errors in encoding,101 and incorrect ante mortem 
diagnoses.102 Further, the sensitivity and specificity of the official death certificates 
for (lung) cancer death have been reported to range respectively from 84.5% to 
99.7% and from 91.3% to 99.7%.103-106 Moreover, the errors introduced by all these 
aforementioned inaccuracies are biased towards a reduction in the efficacy of 
screening.103-106
To overcome these problems clinical expert committees, reviewing the medical 
files of the deceased participants to determine the cause of death, are frequently 
employed in cancer screening trials.103-108 The additional value of such a clinical 
expert committee depends on its independence from the screening trial and the 
quality and uniformity of the review process. Therefore, predetermined criteria and 
flowcharts are often used for the evaluation of the medical files, which should be 
blinded for the participants’ identity and study group.
The next part of this study was to define the principles of the cause of death review 
process that will be used in the NELSON trial. Firstly, the definition of the primary 
cause of death to be used was adopted from the definition of the World Health 
Organisation. Next, a classification system that defines the graduation of certainty 
that lung cancer was the primary cause of death was adopted from the European 
Randomised Study of Screening for Prostate Cancer.104 
Secondly, the target population of the end point verification process was defined 
to be all participants of the NELSON trial that have ever been diagnosed with lung 
cancer. The lung cancer cases will be identified by linkages with the national cancer 
registries of the Netherlands and Belgium and by checking all official death certifi-
cates for the diagnosis lung cancer, which are obtained from Statistics Netherlands 
and the Flemish Agency for Care and Health. For all identified cases, the diagnosis 
of lung cancer will be verified in a separate verification process.
Thirdly, the data required for the endpoint verification process was defined to 
be the complete medical file from the first consultation or diagnostic test for (sus-
pected) lung cancer, until death, including autopsy report if available. 
Fourthly, the requirements for the clinical expert committee were defined to be: 
three independent experts; a pulmonologist–oncologist, a pathologist specialised in 
lung oncology and a clinical epidemiologist, who have never been employees of the 
NELSON trial.
Finally, the tools that the expert committee should use to classify the cause of 
death were designed; a flowchart and detailed list of criteria which classify the cause 
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of the death into one of the six categories defining the graduation of certainty that 
lung cancer was the primary cause of death.
b) To determine the performance of the aforementioned newly developed endpoint 
verification process compared to the official death certificates, a pilot study of fifty 
cases was conducted. When classifying the outcome of the cause of death review 
process as golden standard, the sensitivity and specificity of the death certificates 
were respectively 95.2% (95% confidence interval: 84.2-98.7%) and 62.5% (95% 
confidence interval: 30.6–86.3%).  Disagreement was observed in 10% (5 of 50 
individuals) with the following causes of death: adult respiratory distress syndrome 
after lobectomy, rupture of an abdominal aneurysm during chemotherapy, another 
malignancy besides lung cancer in two cases (breast carcinoma and acute myeloid 
leukaemia) and small cell lung carcinoma diagnosed after the person’s death by 
autopsy.
c) The agreement between the uses of the newly developed endpoint verification 
process was also investigated in the pilot study. Hence, in 76% of the cases the 
reviewers reached a concordant conclusion. In the remaining cases, the sources 
of disagreement were: significant comorbidity, multiple coinciding malignancies, 
death after an intervention and death indirectly caused by lung cancer, such as death 
due to post-obstruction pneumonia or paraneoplastic pulmonary embolism. When 
clustering all ‘definitely’ and  ‘probable’ lung cancer deaths into one group and all 
‘possible’, ‘unlikely’ and ‘definitely not’ lung cancer deaths and ‘intercurrent deaths’ 
into another, the differences were minimal; agreement in 90% (kappa of 0.65).
d) Finally, the pilot study learned that the letters of the pulmonologist were the best 
source of information for the review of the cause of death in 65% of the cases.
Interpretation of results
a) Endpoint verification of a cancer screening trial should not solely be based on the 
official death certificate because of biases, inaccuracies in diagnosing, filling in 
forms and encoding, and suboptimal sensitivity and specificity for cancer-specific 
primary cause of death. Instead, endpoint verification should be based on a cause 
of death verification process that provides a validated method and tools used by a 
committee of independent experts. The following aspects should be defined in the 
protocol: 
I) the definition of the primary cause of death
II) a classification system that defines the grade of certainty that the primary 
endpoint was the primary cause of death
III) the target population and methods to identify them within the study popula-
tion
IV) the data required for the cause of death review process
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V) requirements for the clinical expert committee
VI) tools to be used by the clinical expert committee
VII) method to evaluate or compare the cause of death verification process to the 
official death certificates
Concluding, a cause of death review protocol that ensures uniform, objective 
and unbiased endpoint determination should employ a committee of independent 
experts that use a protocol that defines the aforementioned criteria.
b) The sensitivity and specificity of the official death certificates for lung cancer specific 
mortality were 95.2% and 62.5%, respectively. Despite the lack of a ‘gold standard’ 
for the cause of death of lung cancer participants, this still demonstrates the limita-
tions of the official cause of death certification in lung cancer patients for scientific 
purposes. 
Concluding, the official death certificates probably have insufficient distinctive 
character for lung cancer-specific death for determining the primary endpoint of a 
cancer screening trial.
c) The agreement between the two users of the cause of death verification protocol 
was reasonable. Cases that resulted in disagreement between the two users in 
the pilot study had: significant comorbidity, multiple coinciding malignancies, 
intervention-related death or death indirectly caused by lung cancer. Cases with 
significant comorbidity or coinciding malignancies are well-known sources of 
disagreement,103,109 and will probably often be discussed in the expert committee 
to reach consensus. The other sources of disagreement between these two users 
indicate a lack of knowledge on complications from lung cancer treatments (such 
as surgery and chemotherapy) and indirect causes of lung cancer death (such as 
post-obstruction pneumonia and paraneoplastic syndromes). This illustrates the 
necessity of the employment of experts in the committee. 
Further, the pilot study learned that the voluntary use of a flowchart and pre-
specified criteria as an aid in the decision-making process will not always result in 
the use of these tools. Therefore, it is recommended to make the use of the flowchart 
obligatory in the decision-making process. In the NELSON trial, this will be accom-
plished by applying an electronic questionnaire with mandatory questions which 
are directly derived from the flowchart. Once the cause of death is classified using 
this electronic questionnaire, the expert has the opportunity to indicate whether he 
agrees or disagrees with the conclusion and whether he wants to discuss the case 
with the other experts or not.
Concluding, when the developed cause of death protocol is used by a clinical 
expert committee the patients with significant comorbidity and multiple coincid-
ing malignancies will probably yield disagreement. In such cases, meetings of the 
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experts should be conducted to facilitate the discussion of these cases and to reach 
consensus.
d) The item that was regarded as the best source of information for the 
cause of death review in the medical file was the letters of the pulmonologist. In the 
Netherlands and Belgium, the pulmonologist is the main caretaker of lung cancer 
patients. Therefore, the pulmonologist regularly writes letters to the other involved 
caretakers and the general practitioner of the patient, to inform them on the 
clinical findings, results from diagnostic procedures and recommendations from 
multidisciplinary meetings. Moreover, about half of the lung cancer patients die at 
the hospital, which is usually at the pulmonology department, which will result in 
an accurate documentation of the death of death of the patient in the letter of the 
pulmonologist. As autopsies are not commonly performed in the Netherlands and 
Belgium, this valuable report will rarely be available for the cause of death review 
process.
Concluding, the best source of information for the cause of death review process 
of a lung cancer screening trial are, in the Netherlands and Belgium, the letters of 
the pulmonologist.
Conclusion
To ensure uniform, objective and unbiased endpoint determination in the NELSON 
trial an independent committee of experts should perform a cause of death verification 
process. For this process, the medical files of all deceased study participants diagnosed 
with lung cancer should be blinded for the participant’s identity and study group. These 
files should be reviewed using a flowchart and detailed criteria to determine the grade of 
certainty that lung cancer was the primary cause of death. 
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GENERAL CONCLUSIONS FROM THIS THESIS
I) The screening algorithm of the NELSON trial adequately stratified participants 
according to their lung cancer risk. 
II) The screening algorithm of the NELSON trial yielded a relatively low number of 
diagnostic work-ups for positive screening test results. 
III) The screening algorithm of the NELSON trial yielded a relatively limited number of 
follow-up LCDT scans for indeterminate screening test results.
IV) The positive predictive value of screening test results in the NELSON trial com-
pared favourably to other studies, nonetheless false-positive screening test results 
are one of the most common harms of the NELSON screening algorithm.
V) The negative predictive value of screening test results was very high in the NELSON 
trial, as in other lung cancer screening studies.
VI) The sensitivity in the NELSON trial was slightly lower than in other studies, but the 
lung cancers in the screening group were diagnosed as early as in other studies.
VII) The specificity in the NELSON trial was substantially higher than in other studies, 
which is a prerequisite for cost-effectiveness.
VIII) The majority of the lung cancers not detected by low-dose CT screening were not 
preventable: some lung cancers were not missed but arose during the screening 
interval, and other lung cancers were missed due to causes that can never com-
pletely be eliminated, such as human error and non-compliance by participants. 
Preventable causes of detection failures were radiological detection and interpreta-
tion errors. 
IX) The performance of the screening strategy may be improved by reducing the num-
ber of detection and interpretation errors by increasing the radiologist’s attention 
for endobronchial lesions, bulla wall thickenings, and pleural-attached lesions.
X) The performance of the NELSON screening strategy may be improved by an effec-
tive smoking cessation program, as current smokers are at increased risk of being 
diagnosed with a lung cancer not detectable by screening.
XI) The performance of the NELSON screening strategy may be improved by using a 
nodule management protocols with thresholds for nodule size and growth based on 
the lung cancer probability of the screened individuals.
XII) The use of nodule volume in lung cancer probability-based nodule management 
protocols yields higher efficiency and less harm than the use of nodule diameter.
XIII) In the NELSON lung cancer screening trial, a relatively high number of invasive 
diagnostic procedures for benign nodules were performed.
XIV) The performance of white light bronchoscopy is not sufficient to justify routine use 
in subjects with suspicious pulmonary nodules detected in a lung cancer screening 
programme.
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XV) In the NELSON lung cancer screening trial, minor complications after surgical 
procedures was common, while major complications, re-operations and post-
operative mortality were relatively uncommon.
XVI) In the NELSON lung cancer screening trial, a relatively high percentage of the 
surgical procedures was performed for benign nodules.
XVII) Screening for lung cancer using low-dose computed tomography probably leads to 
a stage shift towards earlier diagnosis; this effect is stronger in women than in men.
XVIII) The screening strategy of the NELSON trial was capable of detecting lung cancer 
as early as in another screening trial that demonstrated a significant lung cancer 
mortality reduction.
XIX) Screening for lung cancer using low-dose computed tomography probably leads 
to a shift in histology towards detecting slower growing and more peripherally 
localised subtypes of lung cancer.
XX) The lung cancers not detected by screening had a different histopathology, with 
a higher growth rate and metastatic potential, than the lung cancers that were 
detected by screening.
XXI) The endpoint determination of lung cancer screening trials should encounter the 
grade of certainty that lung cancer was the primary cause of death of the partici-
pants. 
XXII) The endpoint determination of lung cancer screening trials should be performed 
by an independent committee of experts who review the blinded medical file of all 
deceased study participants diagnosed with lung cancer by using a flowchart and 
detailed criteria.
GENERAL RECOMMENDATIONS BASED ON THIS THESIS
I) Future studies should investigate whether the harms induced by false-positive 
screening results can be reduced by: optimising the nodule management protocol 
and the use of additional determinants to determine the screening test result, 
such as participant characteristics, radiological and other biomarkers.
II) An effective smoking cessation program should be co-implemented with CT 
screening, as current smokers have demonstrated to be at increased risk of being 
diagnosed with a lung cancer not detectable by screening.
III) Methods to increase radiologist’s attention for endobronchial lesions, bulla wall 
thickenings, and pleural-attached lesions should be developed, as this may help 
reducing the number of missed lung cancers.
IV) Lung cancer screening programs should use a nodule management protocol with 
thresholds for nodule size and growth based on lung cancer probability.
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V) Individuals without pulmonary nodules at CT screening may undergo their next 
screening after a screening interval of two years.
VI) Subjects with pulmonary nodules measuring ≤100 mm³ or ≤5 mm should not 
undergo serial follow-up CT examinations, but regular CT screening with annual 
or biannual intervals.
VII) In subjects with pulmonary nodules measuring 100-300 mm³ or 5-10 mm the 
assessment of nodule volume-doubling time by follow-up CT at short notice is 
appropriate; volume doubling times <600 days warrant diagnostic evaluation.
VIII) Subjects with pulmonary nodules measuring >300 mm³ or >10 mm should 
undergo immediate diagnostic evaluation to diagnose or exclude lung cancer.
IX) Lung cancer screening programs should use nodule volume for estimating nodule 
size and growth since it yields higher screening efficiency and less harms than the 
use of nodule diameter.
X) Future studies should assess the causes of the high rate of invasive procedures 
for benign nodules in the NELSON trial, and targeted interventions should be 
developed, evaluated and implemented.
XI) The lung cancer prediction model using nodule size and growth rate should 
be extended with individual characteristics to investigate whether lung cancer 
prediction can be improved. A validated and reliable lung cancer prediction tool 
may help identifying malignant nodules and may reduce unnecessary diagnostic 
procedures for benign nodules.
XII) Conventional white light bronchoscopy should not routinely be used in subjects 
with suspicious CT-detected pulmonary nodules, as the diagnostic yield is insuf-
ficient to outweigh harms and costs.
XIII) Lung cancer screening should be performed in hospitals offering minimal inva-
sive thoracic surgery, to limit complications and post-operative mortality both in 
individuals undergoing surgery for lung cancer and for individuals undergoing 
surgery for benign nodules.
XIV) Future studies should compare all lung cancers diagnosed in the screening group 
with all lung cancers diagnosed in the control group to determine whether LDCT 
screening led to a shift in stage or histopathology.
XV) Analysis of the difference in lung cancer mortality between the screening group 
and the control group of the NELSON trial will determine whether the observed 
favourable stage distribution of the lung cancers in the screening group yielded a 
significant lung cancer mortality reduction.
XVI) A post hoc analysis of the effectiveness of LDCT screening stratified by gender 
should be performed, as women with screen-detected lung cancer have demon-
strated to be diagnosed at more favourable cancer stages than men.
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XVII) Endpoint determination in lung cancer screening trials should encounter the 
determination of the grade of certainty that lung cancer was the primary cause of 
death of the study participants.
XVIII) Endpoint determination in lung cancer screening trials should be performed by 
an independent committee of experts who perform a blinded review of the medi-
cal file, of all deceased study participants with lung cancer by using a flowchart 
and detailed criteria.
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Summary
Part I: Introduction
Lung cancer is a major public health problem since it causes most cancer-related deaths 
worldwide. As the disease often causes no symptoms at early stages, diagnosis at advanced 
stages, wherein cure is no longer possible, is common. Improvements in lung cancer 
treatment have been made, but yielded only modest improvement in survival over the last 
decades. Continuous efforts should be made to force back exposure to causative agents of 
lung cancer, tobacco smoking in particular. However, this is not expected to reverse the 
lung cancer epidemic in the next decades. Lung cancer screening can reduce morbidity 
and mortality from lung cancer by detecting the disease at an early and curable stage. As 
this early stage is often not accompanied by any signs or symptoms, screening has to be 
applied to apparently healthy, asymptomatic persons. Unfortunately, screening exposes 
these persons to several harms: some related to the screening test itself, such as exposure 
to ionising radiation, others related to false-positive, false-negative screening test results, 
or overdiagnosis. Therefore, only lung cancer screening programs wherein benefits 
outweigh harms should be implemented. This thesis aimed to identify opportunities to 
improve the balance between benefits and harms of a screening program.
Part II: Evaluation of findings
In Chapter 2, data on screening test results and screen-detected lung cancer were used 
to determine positive predictive value and 5.5-year lung cancer probability. This study 
demonstrated that the screening algorithm of the NELSON trial adequately stratified 
participants according to their lung cancer risk. Further, the screening algorithm yielded 
a limited number of follow-up low-dose computed tomography (LDCT) and additional 
diagnostic procedures for positive screening test results. Although the predictive value 
of screening test results in the NELSON trial compared favourably to other studies, too 
many invasive diagnostic procedures were performed for false-positive screening test 
results. 
In Chapter 3, the tumour characteristics of the lung cancers detected by screening were 
analysed. Analyses showed that screening yielded a stage shift towards earlier diagnosis, 
more in women than in men; and a shift in histology towards slower growing and more 
peripherally localised subtypes of lung cancer.
In Chapter 4, the performance of the screening algorithm of the NELSON trial was 
estimated, and opportunities to improve its performance were identified. Detection rates 
and sensitivity of the NELSON screening protocol appeared to be sufficient for diag-
nosing lung cancer as early as in a lung cancer trial that reduced lung cancer mortality 
significantly. Moreover, the NELSON screening protocol yielded a very high specificity, 
which is a prerequisite for cost-effectiveness. Nonetheless, performance of the screen-
ing protocol may be improved by co-implementation of CT screening with an effective 
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smoking cessation program, and training of screening radiologists to reduce the number 
of detection and interpretation errors.
In Chapter 5, radiological causes of the failure to detect lung cancers by screening were 
investigated, and opportunities to improve performance of the screening algorithm were 
identified. This evaluation learned that the majority of the lung cancers not detected by 
low-dose CT screening were not preventable. Performance of the screening strategy may 
be improved by reducing the number of detection and interpretation errors, which may 
be achieved by increasing the radiologist’s attention for endobronchial lesions, bulla wall 
thickenings, and pleural-attached lesions.
Part III: Optimisation of screening
In Chapter 6, lung cancer probability of participants was estimated and used to design 
and evaluated nodule management protocols. The current guideline on the management 
of nodules classifies nodules <4 mm as not suspicious for lung cancer; nodules of 4 to 8 
mm as indeterminate (for which growth assessment is required: nodules with a volume 
doubling-time <400 days are subsequently classified as suspicious for lung cancer); 
and nodules ≥8 mm as suspicious for lung cancer. Analyses showed that the guideline 
performed well, but also that improvements were possible. Raising nodule size diameter 
threshold from 4 mm to 5mm and from 8 mm to 10 mm, and nodule volume doubling-
time threshold from 400 days to 600 days was estimated to yield both a higher sensitivity 
and a higher specificity. Further, a nodule management protocol using nodule volume 
thresholds of 100 mm³ and 300 mm³, and a nodule volume doubling-time threshold of 
600 days was evaluated. This protocol was estimated to yield the same sensitivity as the 
current guideline, but a substantially higher specificity. Results of this study imply that 
use of volumetry and lung cancer probability-based thresholds for nodule size and growth 
can improve lung cancer detection and reduce unnecessary follow-up CT examinations 
and invasive diagnostic procedures.
In Chapter 7, the value of white light bronchoscopy in the diagnostic work-up of suspi-
cious CT-detected nodules was determined. This study demonstrated that bronchoscopy 
could not diagnose lung cancer effectively due to insufficient sensitivity, and could not 
exclude lung cancer reliably due to deceitful benign diagnoses. Therefore, routine use of 
bronchoscopy in subjects with suspicious pulmonary nodules detected in a lung cancer 
screening programme is not recommended.
In Chapter 8, adverse events related to thoracic surgery, performed in the diagnostic 
work-up of suspicious CT-detected nodules were assessed. This study demonstrated that 
adverse events after thoracic surgery for positive screening test results were common. 
Incidence of minor complications was relatively high, while incidence of major complica-
tions, re-operations and post-operative mortality was relatively low. Finally, a relatively 
high percentage of surgeries were performed for benign nodules.
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Part IV: Evaluation of effectiveness
In Chapter 9, design and evaluation of the endpoint verification process of the NELSON 
trial was presented. This study demonstrated that an independent committee of experts 
should perform a cause of death verification process to ensure uniform, objective and 
unbiased endpoint determination. For this process, medical files of all deceased study 
participants diagnosed with lung cancer should be blinded for participant identity and 
study group. Subsequently, these files should be reviewed using a flowchart and criteria 
to determine grade of certainty that lung cancer was the primary cause of death. A pilot 
study demonstrated that this method is preferred over use of official death certificates, 
which have insufficient distinctive character for lung cancer-specific death.
Part V: Implications for implementation
In Chapter 10, currently available literature on all relevant aspects of LDCT screening for 
lung cancer was reviewed to determine whether benefits of LDCT screening outweigh 
its harms. Next, it was determined whether LDCT screening meets the World Health 
Organisation criteria for screening. This review learned that initial estimates of several 
harms and benefits of screening have been made, but substantial gaps in knowledge re-
main. Currently available evidence suggests that benefits of LDCT screening outweigh 
its harms.
In Chapter 11, the ‘General Discussion’, results of this thesis were summarised and 
discussed. The screening algorithm of the NELSON trial yielded a favourable balance 
between negative, indeterminate and positive screening test results, which led to a limited 
number of follow-up LDCT scans and diagnostic work-ups. The screening algorithm 
had a high sensitivity, which is promising for mortality analysis which is planned at ten 
years of follow-up. The screening algorithm of the NELSON trial also yielded a very high 
specificity, which is promising for the planned cost-effectiveness analysis. Lung cancers 
detected through screening were diagnosed at early stages. Moreover, the cancer stage 
distribution of lung cancers detected and missed by screening combined was also favour-
able. The majority of lung cancers missed by screening were not preventable. Nonethe-
less, performance of the screening algorithm may be improved by reducing detection 
and interpretation errors, which may be achieved by increasing the radiologist’s attention 
for endobronchial lesions, bulla wall thickenings, and pleural-attached lesions. Further, 
performance of the screening algorithm may be improved by slight adjustments of the 
thresholds for nodule size and growth rate that determine the screening test result. Ad-
ditionally, co-implementation of CT screening with an effective smoking cessation pro-
gram will also contribute to improved performance of the screening algorithm. Harms 
and costs of the screening algorithm can safely be reduced by eliminating routine use of 
bronchoscopy for suspicious screen-detected nodules from diagnostic work-up. Harms 
induced by adverse events after thoracic surgery both for lung cancer and for benign 
Chapter 12
322
nodules may be reduced by routine use of video-assisted thoracoscopic surgery.  Finally, 
effectiveness of the screening algorithm of the NELSON trial will be determined using 
the endpoint determination procedure presented in this thesis.
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Deel I: Introductie
Longkanker is een groot maatschappelijk gezondheidsprobleem doordat het wereldwijd 
één van de meest voorkomende vormen van kanker is en de meeste kanker-gerelateerde 
sterfgevallen veroorzaakt. Longkanker veroorzaakt vaak pas in een gevorderd stadium 
klachten, dit geeft een vertraging in het tijdstip waarop de diagnose wordt gesteld en 
meestal is dan geen genezing meer mogelijk is. Hoewel de behandeling van longkanker 
in de afgelopen decennia is verbeterd, heeft dit slechts geresulteerd in een minimale 
verbetering in de overleving van longkankerpatiënten. Het blijft noodzakelijk om het 
gebruik van en de blootstelling aan stoffen die longkanker veroorzaken te blijven ter-
ugdringen, dit geldt in het bijzonder voor tabaksrook. Toch is het de verwachting dat 
preventieve maatregelen op zichzelf niet afdoende zullen zijn om de longkankerepidemie 
in de komende decennia terug te dringen. Screening op longkanker kan de gezond-
heidsschade en sterfte veroorzaakt door longkanker verminderen door de ziekte in een 
vroeg en behandelbaar ziektestadium op te sporen. Aangezien het vroege stadium van 
longkanker vaak geen klachten veroorzaakt, vindt de screening plaats op schijnbaar 
gezonde personen. Deze personen, van wie slechts een deel een vroeg stadium van long-
kanker onder de leden heeft, lopen door de screening echter ook risico’s. De risico’s van 
screening zijn onder andere gerelateerd aan de screening test zelf, zoals blootstelling aan 
ioniserende straling. Daarnaast is er een kans op een fout-positieve of een fout-negatieve 
screeningtestuitslag en de kans op overdiagnose. Vanwege deze schadelijke neveneffecten 
screening is het wenselijk om alleen longkankerscreeningsprogramma’s in te voeren 
waarvan de voordelen opwegen tegen de nadelen. Het doel van dit promotieonderzoek 
was mogelijkheden identificeren die de balans tussen de voordelen en nadelen van een 
longkankerscreeningsprogramma kunnen verbeteren. 
Deel II: Evaluatie van de bevindingen
In Hoofdstuk 2, wordt beschreven hoe de screeningtestuitslagen en de door screening 
gedetecteerde longkankers werden gebruikt om de positief voorspellende waarde van de 
screeningtest te bepalen. Verder werd in dit hoofdstuk de kans op longkanker in de ko-
mende 5,5 jaar op basis van de screeningtestuitslag geschat. Dit onderzoek toonde aan dat 
het screeningprotocol van de NELSON studie goed in staat was om de studiedeelnemers 
in te delen naar hun risico op longkanker. Screening in de NELSON studie leidde boven-
dien tot een beperkt aantal vervolgscans en aanvullende diagnostische onderzoeken. In 
vergelijking met andere studies was de voorspellende waarde van een positieve screen-
ingtestuitslag hoog in de NELSON studie. Echter, er werden wel relatief meer invasieve 
diagnostische onderzoeken gedaan voor fout-positieve screeningtestuitslagen. 
In Hoofdstuk 3 werden de tumorkarakteristieken van de door screening gedetecteerde 
longkankers gepresenteerd. Analyses toonden aan dat screening heeft geleid tot de diag-
nose van longkanker in een gunstiger ziektestadium, dit effect was sterker bij vrouwen 
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dan bij mannen. Daarnaast werd aangetoond dat screening frequent leidt tot de detectie 
van traag-groeiende longkankers die zich in de buitenranden van de longen bevinden.
In Hoofdstuk 4 werden de testkarakteristieken van het screeningsprotocol van de NEL-
SON studie geschat en werden mogelijkheden om het screeningsprotocol te verbeteren 
geïdentificeerd. Het detectievermogen en de sensitiviteit van het screeningsprotocol 
bleken in staat om longkanker in een net zo’n vroeg stadium op te sporen als gepresen-
teerd in een ander longkankerscreeningsstudie waarvan de effectiviteit al is aangetoond. 
Bovendien bleek dat het screeningsprotocol van de NELSON studie een zeer hoge 
specificiteit heeft, wat een voorwaarde is voor een kosteneffectief screeningsprogramma. 
Toch kunnen de uitkomsten van het screeningsprotocol mogelijk verbeterd worden door 
gelijktijdige implementatie met een effectief stoppen-met-roken-programma en een 
trainingsprogramma voor screeningsradiologen dat het aantal detectie-, en interpreta-
tiefouten verminderd. 
In Hoofdstuk 5 werd onderzocht of er radiologische oorzaken ten grondslag lagen 
aan het missen van longkankers in de studie en of er mogelijkheden om het screening-
sprotocol te verbeteren. Dit onderzoek toonde aan dat de meerderheid van de gemiste 
longkankers niet te voorkomen was. Echter, winst valt te behalen door het verminderen 
van het aantal detectie-, en interpretatiefouten door radiologen. Deze fouten kunnen 
mogelijk verminderd worden door de aandacht van de screeningsradioloog te verhogen 
voor endobronchiale laesies, wandverdikkingen in longblazen en laesies die vastzitten 
aan de longvliezen.
Deel III: Optimalisatie van screening
In Hoofdstuk 6 werd het risico op longkanker van de studiedeelnemers geschat. Deze 
risico-inschattingen werden gebruikt om protocollen voor management van nodules te 
ontwerpen en te evalueren. De huidige richtlijn voor het management van longnodules 
classificeert nodules kleiner dan 4 mm als niet verdacht voor longkanker; nodules van 4 tot 
8 mm als onduidelijk (waarvoor bepaling van de groeisnelheid geïndiceerd is: nodules met 
een volume-verdubbelingstijd korter dan 400 dagen worden vervolgens als verdacht voor 
longkanker geclassificeerd); en nodules van 8 mm en groter als verdacht voor longkanker. 
Dit onderzoek toonde aan dat deze richtlijn voldoet, maar ook dat er mogelijkheid tot 
verbetering is. Zo zullen de sensitiviteit en specificiteit toenemen door het verhogen van 
de afkapwaarden voor nodulegrootte van 4 naar 5 mm en van 8 naar 10 mm, en de afkap-
waarde voor nodulegroei van 400 naar 600 dagen. Daarnaast is een nodulemanagement-
protocol ontworpen en geëvalueerd dat gebruik maakt van volumetrie. De afkapwaarden 
van dit protocol waren; volumes van 100mm³ en 300mm³ voor nodulegrootte, en een 
volume verdubbelingstijd van 600 dagen. Dit protocol heeft dezelfde sensitiviteit als de 
huidige richtlijn, maar een substantieel hogere specificiteit. Concluderend, het gebruik 
van volumetrie en het gebruik van afkapwaarden voor nodulegrootte en nodulegroei die 
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gebaseerd zijn op longkankerrisico kunnen longkankerdetectie verbeteren en het aantal 
onnodige CT scans en invasieve diagnostische onderzoeken verminderen.
In Hoofdstuk 7 is de waarde van bronchoscopie als diagnostisch instrument in de work-
up van verdachte longnodules vastgesteld. Dit onderzoek toonde aan dat longkanker 
niet effectief vastgesteld kon worden met bronchoscopie door onvoldoende sensitiviteit. 
Daarnaast kon longkanker niet betrouwbaar uitgesloten worden met bronchoscopie om-
dat bronchoscopie tot misleidende goedaardige diagnoses kon leiden in patiënten met 
longkanker. Kortom, het routinematig gebruik van bronchoscopie in een longkanker-
screeningsprogramma wordt op basis van dit onderzoek afgeraden. 
In Hoofdstuk 8 werden de complicaties in kaart gebracht die kunnen optreden na 
chirurgie van de long die plaats vond naar aanleiding van verdachte nodules op de 
CT-scan. Deze studie toonde aan dat complicaties na longchirurgie vaak voorkwamen. 
Vergeleken met andere studies kwamen milde complicaties relatief vaak voor in de 
NELSON studie, maar ernstige complicaties, zoals een her-operatie en postoperatieve 
sterfte kwamen relatief weinig voor. Daarnaast werd in deze studie gevonden dat er in de 
NELSON studie relatief vaak geopereerd is voor goedaardige nodules.
Deel IV: Evaluatie van effectiviteit
In Hoofdstuk 9 werd het eindpuntverificatieproces van de NELSON studie ontworpen en 
geëvalueerd. Deze studie toonde aan dat een onafhankelijke commissie van experts een 
geprotocolleerd review proces zouden moeten uitvoeren. Dit leidt tot een eenduidige, 
objectieve en betrouwbare bepaling van de eindpunten. Om de betrouwbaarheid te 
verhogen is het is belangrijk dat de medische status van alle studiedeelnemers die ooit 
gediagnosticeerd zijn met longkanker geblindeerd worden voor de identiteit en studi-
egroep van de deelnemer. En om vast te stellen of de deelnemer al dan niet overleden 
is aan longkanker moeten deze medische statussen gereviewd worden aan de hand van 
een stroomdiagram en vooraf vastgestelde criteria. De pilotstudie toonde aan dat deze 
methode te verkiezen is boven het gebruik van de officiële overlijdenscertificaten. De 
laatst genoemde heeft als nadeel dat dit onvoldoende onderscheidend vermogen voor 
longkanker-specifieke sterfte hebben.
Deel V: Implicaties voor implementatie
In Hoofdstuk 10 werd een studie gepresenteerd waarin gepubliceerde literatuur over alle 
relevante aspecten van longkankerscreening in ogenschouw werd genomen om te bep-
alen of de voordelen van longkankerscreening met CT scans opwegen tegen de nadelen. 
Vervolgens werd bepaald of longkankerscreening met CT voldoet aan de screeningscri-
teria van de Wereldgezondheidsorganisatie. Dit onderzoek toonde aan dat er voorlopige 
schattingen zijn gemaakt van de voordelen en nadelen van longkankerscreening, maar 
dat er ook nog veel onduidelijkheden zijn. Op basis van deze onvolledige informatie kan 
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slechts geconcludeerd worden dat de literatuur suggereert dat de voordelen van long-
kankerscreening opwegen tegen de nadelen.
In Hoofdstuk 11, de ‘Algemene Discussie’ werden de resultaten van dit promotieonder-
zoek samengevat en besproken. Het screeningsprotocol van de NELSON studie leverde 
een gunstige balans op tussen het aantal negatieve, twijfelachtige en positieve testuitsla-
gen, waardoor het aantal vervolgonderzoeken beperkt was. Het screeningsprotocol had 
een hoge sensitiviteit, wat veelbelovend is voor de eindanalyses naar het effect van screen-
ing op longkankersterfte. Het screeningsprotocol had ook een zeer hoge specificiteit, wat 
veelbelovend is voor de analyses naar de kosteneffectiviteit van longkankerscreening. De 
longkankers gedetecteerd door de screening werden in een vroeg ziektestadium gediag-
nosticeerd. Bovendien is ook de gecombineerde stadiumverdeling van de longkankers die 
gedetecteerd en gemist zijn door screening gunstig. De meerderheid van de oorzaken van 
het missen van longkankers in de screeningsstudie waren niet te voorkomen. Toch zou 
het screeningsprotocol verbeterd kunnen worden door een vermindering van het aantal 
detectie-, en interpretatiefouten, hetgeen bereikt zou kunnen worden door meer aan-
dacht van de radiologen voor endobronchiale laesies, wandverdikkingen in longblazen en 
laesies die vastzitten aan de longvliezen. Daarnaast kan het screeningsprotocol mogelijk 
verbeterd worden door kleine aanpassingen van de afkapwaarden voor nodulegrootte 
en de snelheid van nodulegroei die het screeningsresultaat bepalen. Implementatie van 
longkankerscreening gecombineerd met een effectief stoppen-met-roken-programma zal 
de balans tussen de voordelen en nadelen van longkanker screening verbeteren. Tijdens 
longkankerscreening lijkt geen plaats te zijn voor het routinematig toepassen van bron-
choscopie om longkanker in een nodule uit te sluiten. Door deze vorm van diagnostiek 
niet op routinebasis toe te passen zullen de kosten en de kans op nadelige effecten van de 
screening afnemen. Tenslotte zal de effectiviteit van longkankerscreening in de NELSON 
studie worden vastgesteld met het eindpuntverificatieproces dat gepresenteerd werd in 
dit proefschrift.
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Dankwoord
Er zijn een groot aantal mensen die ik wil bedanken omdat zij direct of indirect hebben 
bijgedragen aan de totstandkoming van dit proefschrift.
Prof.dr. H.J. de Koning, geachte promotor, beste Harry, je was zowel mijn promotor 
als mijn directe begeleider en daarmee de belangrijkste persoon tijdens mijn promo-
tieonderzoek. Ik ben blij dat ik bij jou, in mijn ogen dé expert in de wereld op het gebied 
van screening, mijn onderzoek heb kunnen doen. Je hebt me de vrijheid gegeven om 
mijn eigen ideeën uit te werken en me vele mogelijkheden geboden om naar interessante 
workshops, congressen en cursussen te gaan. Bedankt voor het vertrouwen dat je in me 
hebt gehad en alles wat ik van je heb geleerd.
Prof.dr. H.C. Hoogsteden, geachte promotor, beste professor Hoogsteden, hartelijk 
dank voor uw steun tijdens mijn promotie en de mogelijkheden die u me geboden heeft.
Prof.dr. M.G.M. Hunink, prof.dr. P.E. Postmus, prof.dr. H. van Swieten, prof. I.D. de 
Beaufort, geachte leden van de promotiecommissie, hartelijk dank voor uw bereidheid 
om mijn proefschrift te beoordelen en met mij hierover van gedachten te wisselen op 25 
november 2014.
Prof.dr. M. Oudkerk, geacht lid van de promotiecommissie, beste professor Oudkerk, 
hartelijk dank dat u zitting wilde nemen in de promotiecommissie en mijn proefschrift 
wilde beoordelen. Daarnaast wil ik u bedanken voor de tijd en energie die u in mijn 
artikelen heeft gestoken; met uw kritische commentaren heeft u telkens weer geprobeerd 
om het beste naar boven te halen. 
Prof.dr. K. Nackaerts, geacht lid van de promotiecommissie, beste professor Nackaerts, 
allereerst wil ik u bedanken dat u zitting wilde nemen in de promotiecommissie. Tevens 
wil ik u bedanken voor de prettige samenwerking, uw waardevolle commentaren op mijn 
manuscripten, de uitnodiging om deel te nemen aan het Leuvens Longkanker Sympo-
sium en de uitnodiging om samen het ‘priority paper evaluation’-artikel te schrijven. 
Drs. S. Silva en M.F. Jonker MSc, lieve Sonja en Marcel, ik ben blij dat jullie mij als 
paranimfen tijdens de verdediging van mijn proefschrift willen bijstaan. Als kamer-
(108)-genootjes hebben jullie me al vanaf het begin van mijn onderzoek bijgestaan; met 
verstandige adviezen, maar vooral ook met humor en een borrel op z’n tijd. Jullie hebben 
mijn promotietijd onvergetelijk gemaakt, 108 rules! ;)
Dr. E.Th. Scholten, beste Ernst, ik wil je heel erg bedanken voor je enorme bijdrage aan 
de twee artikelen over de intervalkankers (hoofdstuk 4 en 5), zonder jou waren ze er niet 
geweest. Ik vond het heel prettig om met je samen te werken en heb veel gehad aan je 
adviezen en steun. 
Dr. J. van Rosmalen, beste Joost, heel erg bedankt voor je langdurige inzet voor het 
‘lung cancer probability’-artikel (hoofdstuk 6). Dankzij jouw bewonderenswaardige ken-
nis van de biostatistiek en je flexibiliteit om dit te gebruiken om medische richtlijnen te 
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optimaliseren is ons artikel ‘Lancet Oncology’-waardig geworden. Ik wens je veel succes 
met je nu al indrukwekkende loopbaan.
Dr. R.J. van Klaveren, beste Rob, ik wil je heel erg bedanken voor je begeleiding bij het 
‘bronchoscopie’-artikel (hoofdstuk 7) en het ‘cause of death’-artikel (hoofdstuk 9). Je hebt 
me op een gedegen manier geleerd hoe onderzoek opgezet en artikelen geschreven moet 
worden. Dankzij het vertrouwen dat jij in me had, heb ik de mogelijkheid gekregen om 
dit promotieonderzoek te gaan doen. Ik vind het erg jammer dat onze samenwerking niet 
langer heeft mogen duren.
Dr. S.C. van ’t Westeinde, lieve Susan, ten eerste wil ik je bedanken voor je begeleiding 
en hulp bij mijn allereerste artikel (hoofdstuk 7). Ik heb veel van je geleerd, zowel over het 
onderzoek als over andere dingen die belangrijk zijn voor een jonge dokter. Ik ben blij dat 
we als ‘NELSON ladies’ contact zullen houden.
Dr. C.M. van der Aalst, lieve Carlijn, toen ik met mijn promotieonderzoek begon was ik 
erg blij dat je me op sleeptouw nam en me wegwijs maakte op de afdeling. Bedankt voor 
je hulp bij mijn artikelen en de zaken er om heen. Ik vond het erg gezellig met je op de 
kamer, en we zeker zullen als ‘NELSON ladies’ contact houden.
K. ten Haaf MSc, lieve Kevin, je bent een bijzondere collega voor me geweest. Je bent 
een van de meest oprechte persoon die ik ken en ik heb je humor leren waarderen. Je 
gave om me op te vrolijken hebben me door teleurstellingen en frustraties, die bij het 
promoveren horen, heen geholpen.
Drs. A.U. Yousaf - Khan, beste Uraujh, wat leuk dat je het NELSON team bent komen 
versterken. Ik vond het gezellig om met je samen te werken en ik heb er alle vertrouwen in 
dat je een straks een mooi proefschrift zult afleveren. Veel succes met je verdere loopbaan.
M.A. Quak, lieve Marianne, heel erg bedankt voor al je inspanningen voor de NELSON 
studie en de hulp bij mijn projecten.
R. Faber en F. Santegoeds, beste Roel en Frank, heel erg bedankt voor jullie inspan-
ningen om de datastromen van de NELSON studie in goede banen te leiden en voor jullie 
adviezen en hulp bij mijn projecten.
A. de Bruijn, lieve Arry, bedankt voor jouw hulp en ondersteuning die je direct en 
indirect aan de NELSON studie en mij hebt geboden. Harry boft maar met jou als sec-
retaresse.
Dr. P.A. de Jong, beste Pim, bedankt voor je nuttige commentaren op mijn artikelen en 
je belangrijke bijdrage aan de twee intervalkanker artikelen (hoofdstuk 4 en 5).
Prof.dr. J.-W.J. Lammers en prof.dr. H.J.M. Groen, hartelijk dank voor uw waardevolle 
bijdragen aan al mijn artikelen en in het bijzonder voor uw rol als expert bij de pilot-studie 
naar het evalueren van de doodsoorzaken voor het ‘cause of death’-artikel (hoofdstuk 9).
Drs. C. Weenink, Dr. E. Thunnissen, Dr. R. Vliegenthart, veel dank voor jullie bijdragen 
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